HOME@>@‹³ŽºÐ‰î@>@Œ€‹†‹ÆÑ(˜_•¶¥Šw‰ï”­•\)@>@‘“àŠw‰ï

‹³ŽºÐ‰î

‹³ŽºÐ‰î

Œ€‹†‹ÆÑ(˜_•¶¥Šw‰ï”­•\)

‘“àŠw‰ï

2018”N 2017”N 2016”N
2015”N 2014”N 2013”N
2012”N 2011”N 2010”N
2009”N 2008”N 2007”N
2006”N 2005”N  

2018”N
‘æ47‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïi2018”N2ŒŽ9“ú`10“úA’·èŽsj

    ƒƒCƒuƒjƒ“ƒOƒZƒ~ƒi[„

  1. ‰ºìG–ŸFŽ‰Ž¿ˆÙíÇf—Â̍ŐV‚Ì’mŒ©
  2. ƒYIAƒZƒbƒVƒ‡ƒ“„

  3. »‘ºTˆê˜YA²“¡Œö—YA•àV —ºA‘å’Î’mLA‹e’n‡—TAMd Elias AL-MamunAŽ… ‹œA’r“c®•œA—é–؍N‘ŸA²“¡‘åŽ÷A‘呺~ˆêA–ì–ؐ³“¹AMohammad Abdul Hai SiddiqueA‹{“c •qA‰ºìG–ŸF¶S•s‘S‚É”º‚€”x‚ŒŒˆ³Ç”­Ç‚É‚š‚¯‚éROCK1‚ÆROCK2‚Ì–ðŠ„•ª’S‚̉𖟁iÅ—DGÜŽóÜj
  4. “c’†C•œA”’ŒË ’A_ŒË–ΗYAꎓ¡‘åŽ÷AˆÉ“¡H‘ãAˆä‹‚—z—SAŠ’JãĎqA²“¡¹—¢A‰ºìG–ŸF”xzŠÂ‚š‚æ‚Ñ”x‚ŒŒˆ³Ç‚É‚š‚¯‚é“à”çˆË‘¶«‰ß•ª‹É”œ‰ž‚̏d—v«|’áŽ_‘f—U”­«”x‚ŒŒˆ³Ç‚𒆐S‚Æ‚µ‚œŒŸ“¢|iÅ—DGÜŽóÜj
  5. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j”­•\„

  6. “V…G˜aAŒ–{‘׎¡A”‘ò ‘EA‘åŽR@”nA‰F’Ë—T‹IA•œ–쓹ŠîA™àV A“y‰® ‘A²“¡ŒöˆêA{“c •jAi“¡’q•FA’r“c®•œAŒ‹{Œ’‰îA‹e’n —ƒA‰H”öŽ‹MA”’ŒË ’A‚‹Ž A‰ºìG–ŸFŠ¥“®–¬‰ßŽûk”œ‰ž‚É‚š‚¯‚éS‘ŸƒŠƒ“ƒpŠÇ‚̏d—v«|ƒuƒ^“®•šƒ‚ƒfƒ‹‚ð—p‚¢‚œŒŸ“¢|
  7. –ì–ؐ³“¹A²“¡Œö—YAH“¡ rA‘呺~ˆêA‹e’n‡—TA²“¡‘åŽ÷A»‘ºTˆê˜YA•àV —ºA‘å’Î’mLA‰ºìG–ŸF‘å“®–¬•œŠŠ‹Ø×–E‚ÌŒ`Ž¿•ÛŽ‚ð‹@˜‚Æ‚µ‚œ‹¹•”‘å“®–¬áŽ‚ÌŒ`¬‚Æ”j—ô‚ɑ΂·‚éSmgGDS ‚Ì—\–h“IŠÖ—^
  8. “›ˆä³lAŠì–Œ”üAâ—œ‚Ü‚äŽqAŒèr”ŽA’‡@ª~ŽqA²“¡Œö—YA‰ºìG–ŸAVèÍFÉŽ_‰–^ˆŸÉŽ_‰–‚Ì•s‘«‚Í‘ãŽÓÇŒóŒQAŒŒŠÇ•s‘SAS‘Ÿ“Ë‘RŽ€‚ðŽä‹N‚·‚é
  9. “›ˆä³lA¶‰z‹M–ŸAéŒË‹MŽuAâ—œ‚Ü‚äŽqA¬“cŒjŽmA‰€ ŽûãA–L•œ—R”üŽqA˜aò OlAŽR“c‘s—ºA‰ºìG–ŸA–öŒŽ‰„ÍA–˜a”ŽAŒ} Š°F’áŽ_‘f«”x‚ŒŒˆ³‚É‚š‚¯‚鍜‘NO ‡¬y‘fŒn‚Ì•ÛŒì“I–ðŠ„
  10. “›ˆä³lA‹v•Û“c—zHA–ìŒûŽ•FAâ—œ‚Ü‚äŽqAŒèr”ŽA’‡@ª~ŽqA‰ºìG–ŸA{‰ÁŒŽˆê”ŽAŠ_‰Ô ŠwF”][Ç‚É‚š‚¯‚éNO ‡¬y‘f‚Ì—LŠQ‚ȍì—pF«·‚š‚æ‚уeƒXƒgƒXƒeƒƒ“‚ÌŠÖ—^
‘æ11‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2018”N1ŒŽ20“ú`21“úA•Ÿ‰ªŽsj

    ƒ‹€ÃƒVƒ“ƒ|ƒWƒEƒ€„

  1. ‚‹Ž F“Œ“ú–{‘åkÐ‚ªzŠÂŠíŽŸŠ³‚É‹y‚Ú‚µ‚œ‰e‹¿‚Ɛ«·
  2. â“c‘וFF–«S•s‘Sf—Âɂš‚¯‚鐫·F CHART-2Œ€‹†‚©‚ç‚Ì’mŒ©
  3. ƒ—DG‰‰‘èŒó•âŒû‰‰„

  4. ‹yì‘ì–çAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VAÂ–ö ”£A”’ŒË ’A‹{“c •qA‰ºìG–ŸFSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚邪‚ñŽ€–S‹K’èˆöŽq‚Ɛ«·i—DGÜŽóÜj
  5. ŽO–ØŒi‘ŸA’†–ì œA’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA”‘ò ‘EA‰ºìG–ŸF”ñ•Ù–ŒÇ«S–[×“®Š³ŽÒ‚É‚š‚¯‚é–³ÇŒó«”][Ç‚̐«·‚ÌŒŸ“¢
  6. ç—t‹M•FA’†–ì œA’·’J•”—Y”òA–Ø‘º‹`—²A[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò ‘EA‰ºìG–ŸFS‘ŸƒTƒ‹ƒRƒCƒh[ƒVƒXŠ³ŽÒ‚É‚š‚¯‚éS‘ŸÄ“¯Šú—Ö@‚Ì—LŒø«‚ÉŠÖ‚·‚鐫·
  7. ²“¡ŒöˆêA‚‹Ž A‰H”öŽ‹MAi“¡’q•FA’r“c®•œA‹e’n —ƒAŒ–{‘׎¡A‹{“c •qAâ“c‘וFA‰ºìG–ŸF‚—î‹}«S‹Ø[ÇŠ³ŽÒ‚É‚š‚¯‚éƒvƒ‰ƒCƒ}ƒŠ[Š¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—ÃŒø‰Ê‚̐«·‚ÉŠÖ‚·‚錟“¢
  8. ®–ì —ºAŒš•”r‰îAâ“c‘וFA™‘ºGˆê˜YA²“¡Œö—YA”’ŒË ’AˆÀ’B —A–Ø‘º³lA—§–ì Ž A’†“‡O“¹A¬ŽRk‘Ÿ˜YAâV–؉ÀŽA‰ºìG–ŸF¬læ“V«SŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é”x‚ŒŒˆ³Ç‚̐«·
  9. Â–ö ”£Aâ“c‘וFAŒã‰ªL‘Ÿ˜YA”’ŒË ’A‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºìG–ŸFS•s‘S”­Ç‚ƒŠƒXƒNŠ³ŽÒ‚É‚š‚¯‚鍶Žº‹ìo—Š‚ÌŒoŽž“I•Ï‰»‚̐«·
  10. ƒƒ|ƒXƒ^[”­•\„

  11. ‰H”öŽ‹MA‚‹Ž A²“¡ŒöˆêAi“¡’q•FA’r“c®•œA‹e’n —ƒAŒ–{‘׎¡A‹{“c •qAâ“c‘וFA‰ºìG–ŸF”ñ•ÂÇ«Š¥“®–¬‚𔺂€S‹Ø[ÇiMINOCAjŠ³ŽÒ‚̗Տ°‘œ|‹{éŒ§AMI“o˜^Œ€‹†|
  12. ²“¡‰ë”VAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YAŒã‰ªL‘Ÿ˜YA”’ŒË ’A‚‹Ž A‹{“c •qA‰ºìG–ŸF‚—îS•s‘SŠ³ŽÒ‚̗Տ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq‚É‚š‚¯‚鐫·|CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  13. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VA”’ŒË ’A‚‹Ž A‹{“c •qA‰ºìG–ŸFBNP‚ÆNT-proBNP‚Ì‘ŠŠÖ‚É‚š‚¯‚鐫·
  14. Œš•”r‰îA™‘ºGˆê˜YA²“¡Œö—YAÂ–Ø—³’jAŽR–{¹DAŽ… ‹œAÖ“¡¹—˜Aì–쌀ŒåAˆÀ’B —A‰ºìG–ŸFzŠÂŠíƒRƒ“ƒTƒ‹ƒe[ƒVƒ‡ƒ“‚ªs‚í‚ê‚œ”DPÇ—á‚ÌŒŸ“¢

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2017”N
‘æ2‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï“Œ–kŽx•”’n•û‰ïi2017”N12ŒŽ3“úAå‘äŽsj

    ƒƒVƒ“ƒ|ƒWƒEƒ€„

  1. Œ–{‘׎¡A’|“à‰ëŽjA“y‰® ‘A‹e’r —ƒAì–{r•ãAŒF’J‹Iˆê˜YA‰H”öŽ‹MAi“¡’q•FA’r“c®•œA‚‹Ž AãŒŽ³”ŽAâV–؉ÀŽA‰ºìG–ŸFTAVIp‘O‚Æ–«Šú‚̍‚—îŽÒƒtƒŒƒCƒ‹•]‰¿FTAVIŒã‚¹‚ñ–Ï‚Ì—\‘ª‚Æ•af˜AŒg‚̏d—v«
  2. ƒˆê”ʉ‰‘èiŒûqj„

  3. ²“¡ŒöˆêA‰H”öŽ‹MA™àV A“y‰® ‘Ai“¡’q•FA’r“c®•œA‹e’n —ƒAŒ–{‘׎¡A‚‹Ž A‰ºìG–ŸF‰^“®•‰‰×—U”­«Š¥¹k‹·SÇ‚Ì‚P—á
  4. HŒŽŽO“ށA™‘ºGˆê˜YAÂ–Ø—³’jA™àV AŠ`‰Ô—²ºA‰ºìG–ŸAãŒŽ³”ŽFCTEPH‚ÆPAH‚ÌŠÓ•Ê‚É‚š‚¯‚éŒÄ‹CƒKƒX•ªÍ‚Ì—L—p«
  5. ™àV AÂ–Ø—³’jAHŒŽŽO“ށA®–ì —ºA_’ÍŽ–çA²“¡ —yAŽR–{¹DAŒš•”r‰îA™‘ºGˆê˜YA‰ºìG–ŸF–«ŒŒð•ÂÇ”x‚ˆ³Ç‚É‚š‚¯‚é‰^“®‘Ï—e”\‚Ɖ^“®ŽžŒŒs“®‘Ô‚ÌŒŸ“¢
  6. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA²“¡ —yA_’ÍŽ–çA®–ì —ºAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸF‰^“®•‰‰×‰ESƒJƒe[ƒ‹‚ɑ΂·‚錌s‘ԕω» \ƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚ÌŒø‰Ê”»’è‚ւ̉ž—p
  7. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  8. –x —ÇŽqA‰H”öŽ‹MA’·’J•”—Y”òAÂ–Ø—³’jA™‘ºGˆê˜YAŠìƒAƒ†ƒ~A–Ÿ’¿çŒbA—é–ØŽõŽ÷AHŒŽŽO“ށAŠ`‰Ô—²ºA‰ºìG–ŸFS•s‘SŠ³ŽÒ‚Ì“úí¶Šˆ‚É‚š‚¯‚é–â‘è“_‚‚¢‚Ä‚ÌŒŸ“¢
‘æ165‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2017”N12ŒŽ2“úAå‘äŽsj

    ƒYIAÇ—á”­•\•”–偄

  1. “y‰® ‘AŒ–{‘׎¡A‹e’n —ƒA™àV Ai“¡’q•FA’r“c®•œA‰H”öŽ‹MA‚‹Ž Aì–{r•ãAŒF’J‹Iˆê˜YAâV–؉ÀŽA–x“à‹v“¿A‰ºìG–ŸFTAVI ‚É‚æ‚èvWF ‚•ªŽq—Ê‘œ—Ê‘ÌŒ‡‘¹‚̉ü‘P‚Ɩэ׌ŒŠÇŠg’£Ç‚̏Á‘Þ‚ð”F‚ß‚œHeyde ÇŒóŒQ‚̈ê—ái—DGÜŽóÜj
  2. ƒYIAŒ€‹†”­•\•”–偄

  3. ç—t‹M•FA’†–ì œA’·’J•”—Y”òA–Ø‘º‹`—²A[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò ‘EA•Ÿ“c_“ñA‰ºìG–ŸFS‘ŸƒTƒ‹ƒRƒCƒh[ƒVƒXŠ³ŽÒ‚̐S‹ØáŠQ‚ÉŠÖ˜A‚µ‚œ¶ŽºŽûk”\‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿i—DGÜŽóÜj
  4. ƒˆê”ʉ‰‘聄

  5. Æˆä—m•ãA™‘ºGˆê˜YA²“¡ —yAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAÂ–Ø—³’jAŽR–{¹DA_’ÍŽ–çA®–ì —ºA‘å“c‰pŠöA‚£ Œ\A‰ºìG–ŸFanthracycline ŒnRŠàÜ‚É‚æ‚éS“Ő«‚Ì‘gDŠw“I•]‰¿‚É‚š‚¯‚éS‘ŸMRI ‚Ì—L—p«
  6. ²“¡ —yA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽR–{¹DAŽ… ‹œA_’ÍŽ–çA®–ì —ºAÆˆä—m•ãA²“¡Œö—YA‰ºìG–ŸF––œŒ^”x“®–¬‹·ó‚̈ê—á
  7. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DAŽ… ‹œA²“¡ —yA_’ÍŽ–çA®–ì —ºAÆˆä—m•ãAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸFƒoƒ‹[ƒ“”x“®–¬Œ`¬pŒã‚̉^“®•‰‰×‰ESƒJƒe[ƒeƒ‹ŒŸž
  8. Œš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DAŽ… ‹œA²“¡ —yA‘å’Î’mLA_’ÍŽ–çA®–ì —ºAÆˆä—m•ãA²“¡Œö—YA‰ª“cŽ“TAˆÀ’B —AHê”ü‹IA‰ºìG–ŸF¶‘Ì”xˆÚA‚ðŽ{s‚µ‚œ¬Ž™Šú”­Ç‚Ì”x“®–¬«”x‚ŒŒˆ³Ç‚Ì‚P—á
  9. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VAÂ–ö ”£A”’ŒË ’A‚‹Ž A‹{“c •qA‰ºìG–ŸFHFpEF Š³ŽÒ‚É‚š‚¯‚éŠÈ•Ö‚È—\Œã—\‘ªƒŠƒXƒNƒXƒRƒA|CHART-2 Œ€‹†‚©‚ç‚Ì•ñ|
  10. ²“¡‰ë”VAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YAÂ–ö ”£AŽO‰Y³’šAŒã‰ªL‘Ÿ˜YA”’ŒË ’A‚‹Ž A‹{“c •qA‰ºìG–ŸF‚—îŽÒS•s‘S‚̗Տ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq‚š‚æ‚ѐ«·‚ɂ‚¢‚Ä‚ÌŒŸ“¢|CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  11. ²“¡ŒöˆêA‰H”öŽ‹MA™àV A“y‰® ‘Ai“¡’q•FA’r“c®•œA‹e’n —ƒAŒ–{‘׎¡A‚‹Ž A‰ºìG–ŸF‰^“®•‰‰×—U”­«Š¥¹k«‹·SÇ‚Ì‚P—á
  12. i“¡’q•FA‚‹Ž AŒ–{‘׎¡A”’ŒË ’A‹e’n —ƒA‰H”öŽ‹MA’r“c®•œA{“c •jA™àV A“y‰® ‘AŠ’JãĎqA²“¡ŒöˆêAÆˆä—m•ãAÂ–ö ”£A‰ºìG–ŸF˜JìŽžŒ“ˆÀÃŽž‹¹’ɂ𔺂€S‹Ø‰Ë‹Ž‚ð‡•¹‚µ‚œŠ¥¹k«‹·SÇ‚̈ê—á
  13. Â–ö ”£Aâ“c‘וFAŒã‰ªL‘Ÿ˜YA”’ŒË ’A‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA‚‹Ž A‹{“c •qA‰ºìG–ŸFS•s‘SƒXƒe[ƒW‚ªS–[×“®‚Æ—\Œã‚Æ‚ÌŠÖŒW‚É‹y‚Ú‚·‰e‹¿‚Ɛ«·FCHART-2 Œ€‹†‚©‚ç‚Ì’mŒ©
  14. ’·’J•”—Y”òAŽO–ØŒi‘ŸA”‘ò ‘EA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA’†–ì œA‰ºìG–ŸFS–[×“®‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚œ‰i‹vŒ^‰º‘åÃ–¬ƒtƒBƒ‹ƒ^[—¯’uŒã‚̈ê—á
  15. ’†–ì œA’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò ‘EA‰ºìG–ŸFV‹K3D ƒ}ƒbƒsƒ“ƒOƒVƒXƒeƒ€Rhythmia ‚É‚æ‚Á‚ÄŒŸo‚³‚ê‚œ”÷¬“dˆÊ‚Ö‚ÌŽ¡—ª‘tŒ÷‚µ‚œ’ʏíŒ^S–[‘e“®Ç—á
  16. –Ø‘º‹`—²A’†–ì œA’·’J•”—Y”òAç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘ŸAŒš•”r‰îA‰ºìG–ŸFƒtƒ@ƒ[Žl’¥ÇªŽ¡pŒã‚ÌATP ŠŽŽó«S–[•p”‚ɑ΂µAƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚œˆê—á
  17. ŽO–ØŒi‘ŸA’†–ì œA’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA”‘ò ‘EA‰ºìG–ŸFƒpƒbƒ`ƒeƒXƒgŒ‹‰Ê‚ÉŠî‚«AƒSƒAƒeƒbƒNƒX‚ðŽg—p‚¹‚ž‚ÉICD Ažp‚ðŽ{s‚µ‚œ‹à‘®ƒAƒŒƒ‹ƒM[‚Ì‚P—á
  18. âV“¡Œ³ˆêAÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DAŽ… ‹œA²“¡ —yA_’ÍŽ–çA®–ì —ºAÆˆä—m•ãAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸF”][Ç‚𔭏ǂµt-PA ‚ÆŒŒð‰ñŽû—Ö@‚É‚æ‚èŒãˆâÇ‚È‚­‰ü‘P‚µ‚œDCM ‚̈êÇ—á
  19. ™àV A‹e’n —ƒA“y‰® ‘A²“¡ŒöˆêAÆˆä—m•ãAÂ–ö ”£Ai“¡’q•FA’r“c®•œA‰H”öŽ‹MA”’ŒË ’AŒ–{‘׎¡A‚‹Ž Aâ“c‘וFA‰Í’à ‘Aì–{r•ãAâV–؉ÀŽA‰ºìG–ŸF‹}«S•s‘S”­Ç‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œ‹‘卶Žº“àŒŒð‚Ì‚P—á
  20. ŽR–{¹DA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îA²“¡ —yA_’ÍŽ–çA®–ì —ºA‰ºìG–ŸF‘å“®–¬Šî•”’uŠ·Œã‚Ì”DPoŽY‚Ì‚P—á
‘æ58‰ñ“ú–{–¬ŠÇŠw‰ïŠwpW‰ïi2017”N10ŒŽ19“ú`21“úA–ŒŒÃ‰®Žsj

    ƒJCAA‘Il”­•\„

  1. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA®–ì@—ºAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚̕“I•]‰¿\’·Šú—\Œã‚ƍ‡•¹ÇiÅ—DGÜŽóÜj
  2. ƒƒ|ƒXƒ^[”­•\„

  3. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA®–ì@—ºAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸFƒoƒ‹[ƒ“”x“®–¬Œ`¬pŒã‚Ì–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚š‚¯‚é‰^“®•‰‰×‰ESƒJƒe[ƒeƒ‹
‘æ21‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2017”N10ŒŽ12“ú`14“úAH“cj

    ƒYIA Ržu‰‰ —Տ°„

  1. ²“¡ŒöˆêA‚‹Ž@A›Á@Œ³‹gA‰H”öŽ‹MA‹{“c@•qAâ“c‘וFA‰ºìG–ŸF‚—î‹}«S‹Ø[ÇŠ³ŽÒ‚É‚š‚¯‚é—ˆ‰@ŽžS•s‘S‡•¹‚Ì•p“x‚Æ—\Œã‚ÌŒoŽž“I•Ï‰»‚ÉŠÖ‚·‚錟“¢|‹{éAMI“o˜^Œ€‹†|i—DGÜŽóÜj
  2. ‰H”öŽ‹MA‚‹Ž@Aâ“c‘וFA‹{“c@•qA”’ŒË@’AŒã‰ªL‘Ÿ˜YA‰ºìG–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Œã‚ÌŽc‘¶‹·ó‚ª—\Œã‚É—^‚Š‚é‰e‹¿‚ƍ¶Žº‹ìo—Š‚Æ‚ÌŠÖ˜A
  3. ƒYIA Ržu‰‰ Šî‘b„

  4. »‘ºTˆê˜YA²“¡Œö—YAŽ…@‹œA—é–؍N‘ŸA’r“c®•œA‘呺~ˆêA‹e’n‡—TA•àV@—ºA–ì–ؐ³“¹A‰ºìG–ŸFƒ}ƒEƒX‚̈³•‰‰×S•s‘Sƒ‚ƒfƒ‹‚É‚š‚¯‚éROCK1‚ÆROCK2‚Ì–ðŠ„‚Ìˆá‚¢
  5. ƒˆê”ÊŒû‰‰„

  6. ™‘ºGˆê˜YAŽR–{¹DAÂ–Ø—³’jAŒš•”r‰îA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA®–ì—ºA²“¡Œö—YA‰ºìG–ŸFƒAƒ“ƒ_[ƒ\ƒ“Eƒtƒ@ƒuƒŠ[•a‚̐f’f‚É‚š‚¯‚錌Ÿ÷’†ƒOƒƒ{ƒgƒŠƒAƒIƒVƒ‹ƒXƒtƒBƒ“ƒSƒVƒ“‘ª’è‚Ì—L—p«
  7. ’†–ì@œA’·’J•”—Y”òA–Ø‘º‹`—²A[àV‹±”V˜NAç—t‹M•FAŽO–ØŒi‘ŸA”‘ò@‘EA‰ºìG–ŸFƒGƒ“ƒpƒOƒŠƒtƒƒWƒ““Š—^‚ªS•s‘S‰ü‘P‚É‘tŒ÷‚µ‚œ“œ”A•a‡•¹‹•ŒŒ«S‹ØÇ‚̈ê—á
  8. ®–ì@—ºAŒš•”r‰îA™‘ºGˆê˜YA²“¡Œö—YAÂ–Ø—³’jAŽR–{¹DAˆÀ’B@—A–Ø‘º³lAâV–؉ÀŽF¬læ“V«SŽŸŠ³Š³ŽÒ‚É‚š‚¯‚éHCV—z«‚̐S‹@”\‚â—\Œã‚É—^‚Š‚é‰e‹¿
  9. Œã‰ªL‘Ÿ˜YAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA”’ŒË@’A‚‹ŽA‹{“c@•qA‰ºìG–ŸFŒoŒûƒuƒhƒE“œ•‰‰×ŽŽŒ±‚Æ”÷—ʃAƒ‹ƒuƒ~ƒ“”A‚É‚æ‚閝«S•s‘SŠ³ŽÒ‚̃ŠƒXƒN•]‰¿|SUPPORTŽŽŒ±ƒTƒu‰ðÍ|
  10. ’ÒŒOØŽqAâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAˆ¢•”—Ú—žA‹yì‘ì–çA”’ŒË@’A‚‹Ž@A‹{“c@•qA‰ºìG–ŸF¶Žº‹ìo—Š‚ª’†’ö“x‚É•Û‚œ‚ê‚œS•s‘S‚̗Տ°“I“Á’¥FCHART-2Œ€‹†‚©‚ç‚Ì’mŒ©
  11. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VA”’ŒË@’A‚‹ŽA‹{“c@•qA‰ºìG–ŸF¶Žº‹ìo—Š‚Ì•Û‚œ‚ê‚œ–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚éŠÈ•Ö‚È—\Œã—\‘ªƒŠƒXƒNƒXƒRƒA |CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  12. ’|“à‰ëŽjAŒ–{‘׎¡Aì–{r•ãA“y‰®@‘A‚‹Ž@A‹{“c@•qAãŒŽ³”ŽArˆäŒ[sAâV–؉ÀŽA‰ºìG–ŸFTAVIp‘O‚Æ–«Šú‚É‚š‚¯‚鍂—îŽÒƒtƒŒƒCƒ‹•]‰¿FTAVIpŒã‚¹‚ñ–Ï‚Ì—\‘ª‚ƃtƒŒƒCƒ‹ƒKƒCƒh•af˜AŒg‚̏d—v«
  13. ‘å’Î’mLA²“¡Œö—YA–î”ö”M—TA‘呺~ˆêA‹e’n‡—TA•àV@—ºA»‘ºTˆê˜YA–ì–ؐ³“¹A‹{“c@•qA‰ºìG–ŸFƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚éS•s‘SŠ³ŽÒ‚Ì’·Šú—\Œã—\‘ª
  14. ‹yì‘ì–çAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA”’ŒË@’A‚‹ŽA‹{“c@•qA‰ºìG–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚邪‚ñŽ€–SƒŠƒXƒN‚Ì‘‰Á |CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  15. ƒƒVƒ“ƒ|ƒWƒEƒ€„

  16. Œš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DAâV“¡¹—˜Aì–쌀ŒåA–Ø‘º³lAˆÀ’B@—A²“¡Œö—YA‰ºìG–ŸFSŽŸŠ³‡•¹”DP‚ÌŒŸ“¢ |“Œ–k‘åŠw•a‰@‚ÌŒoŒ±|
  17. ƒƒ|ƒXƒ^[„

  18. ˆ¢•”—Ú—žAâ“c‘וFAŒã‰ªL‘Ÿ˜YA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VAŽO‰Y³’šA”’ŒË’A‹{“c@•qA‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚ÌŒ’NŠÇ—ˆÓŽ¯‚Æ—\Œã‚É‚š‚¯‚鐫·‚ÉŠÖ‚·‚錀‹† |CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  19. ²“¡@—yA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DAŽ…@‹œA²“¡Œö—YA•ŸŒŽ‹KŽqA‘å“c‰pŠöA‰ºìG–ŸFS‘ŸMRI‚ªf’f‚É—L—p‚Ÿ‚Á‚œSƒAƒ~ƒƒCƒh[ƒVƒX‚̈ê—á
  20. ²“¡‰ë”VAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YAŒã‰ªL‘Ÿ˜YA”’ŒË@’A‚‹ŽA‹{“c@•qA‰ºìG–ŸF‚—«S•s‘SŠ³ŽÒ‚Ì—\Œã‚š‚æ‚Ñ—\Œã‹K’èˆöŽq‚ɂ‚¢‚ā|CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  21. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VA”’ŒË@’A‚‹ŽA‹{“c@•qA‰ºìG–ŸFHFpEFABorderline HFpEFAHFrEF‚É‚š‚¯‚éBNP‚Ì—\Œã—\‘ª”\‚Ì”äŠr|CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  22. –Ø‘º‹`—²A•Ÿ“c_“ñA’†–ì@œA’·’J•”—Y”òA[àV‹±”V˜NAç—t‹M•FAŽO–ØŒi‘ŸA‡‰®‰ë•FA‰ºìG–ŸFŠŽõƒŠ[ƒh”²‹Ž‚É‚æ‚èS•s‘S‚©‚ç‚̉ü‘P‚ª‰Â”\‚Æ‚È‚Á‚œ•s®–¬ŒŽ«‰EŽºS‹ØÇ‚̈ê—á
  23. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  24. ‰ºì@G–ŸFR‹ÃŒÅ—Ö@‚É‚š‚¯‚éÅV‚Ì’mŒ©
  25. ™‘º@Gˆê˜YFfabry•a ‘Šúf’f‚Ì‚œ‚ß‚ÌŽŽ‚Ý
‘æ23‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi7ŒŽ15“ú`16“úA2017”NAŠò•ŒŽsj
  1. ˆ¢•”—Ú—žAâ“c‘וFAŽO‰Y³’šA¬–쐣„¶A’ÒŒOØŽqA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VAÂ–ö@”£AŒã‰ªL‘Ÿ˜YA”’ŒË@’A‚‹Ž@A‹{“c@•qA‰ºìG–ŸF“ú–{‚Ì–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚é‰^“®KŠµ‚Æ—\Œã‚ÉŠÖ‚·‚錀‹† -CHART-2Œ€‹†‚©‚ç‚Ì•ñ-
‘æ70‰ñ“ú–{Ž_‰»ƒXƒgƒŒƒXŠw‰ïŠwpW‰ïi2017”N6ŒŽ28“ú`29“úA‚‚­‚ÎŽsj

    ƒŒû‰‰”­•\„

  1. ‹e’n‡—TA²“¡Œö—YAMd. Elias-Al-Mamun, Mohammad Abdul Hai Siddique, ‘呺~ˆêA²“¡‘åŽ÷A–ì–ؐ³“¹A»‘ºTˆê˜YA‹{“c@•qA‰ºìG–ŸFV‹K•aˆö’`”’ƒZƒŒƒmƒvƒƒeƒCƒ“P‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\D
‘æ164‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2017”N6ŒŽ10“úA·‰ªŽsj

    ƒYIAÇ—á”­•\•”–偄i*—DGÜŽóÜj

  1. *™àVA‰H”öŽ‹MA“y‰®‘Ai“¡’q•FA‹e’n—ƒAŒ–{‘׎¡A‚‹ŽA™‘ºGˆê˜YAâ“c‘וFA‰ºìG–ŸFŠ¥¹k«‹·SÇ‚ð‡•¹‚µ‚»‚̉Á—Âɂæ‚è‰^“®‘Ï—e”\‚ª’˜–Ÿ‚ɉü‘P‚µ‚œ”ì‘åŒ^S‹ØÇ‚Ì1—á
  2. ƒYIAŒ€‹†”­•\•”–偄i*Å—DGÜŽóÜj

  3. *_’ÍŽ–çA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA®–ì—ºA@Œã‰ªL‘Ÿ˜YA²“¡Œö—YA‹{“c•qA‰ºìG–ŸF”x“®–¬«”x‚ŒŒˆ³Ç‚Ì’·Šú—\Œã‚ɑ΂·‚é‰ES‹@”\‚Ɛ«·‚ÌŠÖ˜A
  4. ƒˆê”ʉ‰‘聄

  5. ’†–쐜A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸFpŒãˆê‰ß«–[ŽºƒuƒƒbƒN‚ð’悵‚œ’†Šu•›“`“±˜H‚ð—L‚·‚éWPWÇŒóŒQ‚̈ê—á
  6. ’·’J•”—Y”òAŽO–ØŒi‘ŸA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA’†–쐜A‰ºìG–ŸF‘m–X•Ù—Ö3 Žž•ûŒü‚ɐS–[Å‘Šú‹»•±•”ˆÊ‚ð”F‚ß‚œfast/slow Œ^AVNRT ‚̈ê—á
  7. ’†–쐜A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸFReverse common AFL ‚É—ÞŽ—‚µ‚œpropagation ‚ð’悵‚œLLRA‹NŒ¹AT ‚̈ê—á
  8. ŽR–{¹DA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îA²“¡—yA_’ÍŽ–çA®–ì—ºAŒã‰ªL‘Ÿ˜YA@²“¡Œö—YA‰ºìG–ŸF“¯ˆê‰ÆŒn“àFabry •aŠ³ŽÒ‚É‚š‚¯‚é—Տ°‘œ
  9. ²“¡—yA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çA®–ì—ºA@²“¡Œö—YA•ŸŒŽ‹KŽqA‰ºì@G–ŸFSƒAƒ~ƒƒCƒh[ƒVƒX‚̊ӕʂɐS‘ŸMRI T1 ƒ}ƒbƒsƒ“ƒO‚ª—L—p‚Å‚ ‚Á‚œ‘œ”­«œ‘Žî‚̈ê—á
  10. “y‰®‘AŒ–{‘׎¡A‹e’n—ƒA™àVA‰H”öŽ‹MA‚‹ŽAì–{r•ãAŒF’J‹Iˆê˜YAâV–؉ÀŽA‰ºìG–ŸFValsalva “ŽŒa‚©‚猟“¢‚µ‚œŒoƒJƒe[ƒeƒ‹“I‘å“®–¬•Ù’uŠ·piTAVIj device ‚Ì‘I‘ð@- “–‰@‚É‚š‚¯‚éŒoŒ±-
  11. ™àVAŒ–{‘׎¡A“y‰®‘A{“c•jAi“¡’q•FA‰H”öŽ‹MA‹e’n—ƒA‚‹ŽAâ“c‘וFA‰ºìG–ŸF‰^“®—U”­«Š¥¹k‚É”º‚€–³ÇŒó«S‹Ø‹•ŒŒ‚Ì1 —á
  12. ‹e’n—ƒA“y‰®‘A™àVA{“c•jAi“¡’q•FA‰H”öŽ‹MA”’ŒË’AŒ–{‘׎¡A‚‹ŽA‰ºìG–ŸFŠ¥¹k•”ˆÊ‚̊펿“I‹·ó‚̐is‚ðOFDI ‚ÅŠÏŽ@‚Å‚«‚œ1 —á
  13. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çA®–ì—ºAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚Ì’·Šú—\Œã
  14. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çA®–ì—ºAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸFƒgƒŒƒvƒƒXƒeƒBƒjƒ‹‚ð”牺“Š—^‚Å“±“ü‚µ‚œ”x“®–¬«”x‚ŒŒˆ³Ç‚Ì5 Ç—á
  15. ®–ì—ºAŒš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA²“¡Œö—YAˆÀ’B—A¬ŽRk‘Ÿ˜YAâV–؉ÀŽA‰ºìG–ŸFBridge to candidacy ‚Æ‚µ‚Ä‘ÌŠOŽ®VAD ‚Æ”xŒŒŠÇŠg’£–ò—Ö@‚ðs‚Á‚œC³‘匌ŠÇ“]ˆÊÇ‚Ì1 —á
  16. HŽR³”NA‰Í’яA‹g‰ªˆê˜NAˆÀ’B—AŒF’J‹Iˆê˜YA‚‹ŽA™‘ºGˆê˜YAÂ–Ø—³’jAì–{r•ãA‰ºìG–ŸAâV–؉ÀŽF“–‰@‚É‚š‚¯‚éAž‚ÝŒ^¶S•â•lHS‘Ÿ50 —á‚̐¬Ñ
  17. ˆ¢•”—Ú—žAâ“c‘וFA‹{“c•qAŽO‰Y³’šAŠ}ŒŽM‘Ÿ˜YA‹yì‘ì–çA²“¡‰ë”VAÂ–ö”£AŒã‰ªL‘Ÿ˜YA”’ŒË’A‚‹ŽA‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚錒NŠÇ—ˆÓŽ¯‚Ɛ«·‚ÉŠÖ‚·‚錀‹†-CHART-2 Œ€‹†‚©‚ç‚Ì•ñ-
  18. ²“¡‰ë”VAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YAÂ–ö”£AŒã‰ªL‘Ÿ˜YA”’ŒË’A‚‹ŽA‹{“c•qA‰ºìG–ŸF‚—îŽÒS•s‘S‚̗Տ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq‚ɂ‚¢‚Ä‚ÌŒŸ“¢-CHART-2 Œ€‹†‚©‚ç‚Ì•ñ-
  19. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VAÂ–ö”£A”’ŒË’A‚‹ŽA‹{“c•qA‰ºìG–ŸFHFpEFAHFmrEFAHFrEF ‚É‚š‚¯‚éBNP ‚Ì—\Œã—\‘ª”\-CHART-2 Œ€‹†‚©‚ç‚Ì•ñ-
‘æ2‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïi2017”N6ŒŽ2`3“úAŽD–yŽsj

    ƒ”ªŠªÜŽóÜu‰‰„

  1. ²“¡Œö—YF’vŽ€«ŽŸŠ³”x‚ŒŒˆ³Ç‚Ì‘S‚­V‚µ‚¢•aˆö’`”’‚É’…–Ú‚µ‚œŽ¡—ÖòŠJ”­
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€„

  3. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV@—ºA»‘ºTˆê˜YA–ì–ؐ³“¹AMd. Elias Al-MamunAMohammad Abdul Hai SiddiqueA‰ºìG–ŸF“œ”A•aŽ¡—Öòƒƒgƒzƒ‹ƒ~ƒ“‚É‚æ‚é”x‚ŒŒˆ³ÇŽ¡—Â̊ù‘¶–òÄŠJ”­
  4. ™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çA²“¡@—yA®–ì@—ºA²“¡Œö—YA‰ºìG–ŸFCTEPH ‚É‚š‚¯‚é“à•žŽ¡—Ã
  5. ™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çAé“c—SŽqAÎˆä’q“¿A‰ºìG–ŸFäPŒŽ•aŠÖ˜A”x‚ŒŒˆ³Ç‚É‚š‚¯‚é”xŒŒŠÇŠg’£–òŽg—p‚ÌŽÀÛ
  6. Œš•”r‰îAâ“c‘וFA™‘ºGˆê˜YA®–ì@—ºAˆÀ’B@—A–Ø‘º³lA—§–ì@Ž A’†“‡O“¹A¬ŽRk‘Ÿ˜YAâV–؉ÀŽA‰ºìG–ŸF¬læ“V«SŽŸŠ³Š³ŽÒ‚Ì”x‚ŒŒˆ³Ç ] ‘œŽ{Ý“o˜^Œ€‹†‚©‚ç]
  7. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV@—ºA»‘ºTˆê˜YA–ì–ؐ³“¹AMd. Elias Al-MamunAMohammad Abdul Hai SiddiqueA‰ºìG–ŸFŒŒŽ’†ƒTƒCƒgƒJƒCƒ“‚É‚æ‚錌ŠÇ“à”çAMPK —}§‚Æ”x‚ŒŒˆ³‘£i‹@\
  8. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“„

  9. Œš•”r‰îA™‘ºGˆê˜YA_’ÍŽ–çAÂ–Ø—³’jA‰ºìG–ŸF”x‚ŒŒˆ³ÇŠ³ŽÒ‚ÉŠÖ‚·‚é‘OŒü‚«‘å‹K–ÍŽÀ‘Ô’²ž
  10. ƒ‰ï’·“Á•ÊŠé‰æ„

  11. Satoh K, Shimokawa H. Identification of Novel Therapeutic Targets for Pulmonary Arterial Hypertension.
  12. ƒYIA ƒZƒbƒVƒ‡ƒ“iŠî‘bE—DG‰‰‘èj„

  13. ²“¡‘åŽ÷A²“¡Œö—YA–î”ö”M—TAAl-Mamun Md EliasASiddique Mohammad Abdul HaiA‹e’n‡—TA‘呺~ˆêA•àV@—ºA‹{“c@•qA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚š‚¯‚éV‹K•aˆö’`”’TAFI ‚Ì‹@”\‰ðÍiYIA—DGÜŽóÜj
  14. •àV@—ºA²“¡Œö—YA‹e’n‡—TA‘呺~ˆêA²“¡‘åŽ÷AAbdul Hai Siddique MohammadAElias Al-Mamun Md.A»‘ºTˆê˜YA–ì–ؐ³“¹A‰ºìG–ŸF–ò•šƒXƒNƒŠ[ƒjƒ“ƒO‚É‚æ‚éV‹K”x‚ŒŒˆ³Ž¡—ÖòCelastamycin‚Ì”­Œ©iYIA—DGÜŽóÜj
  15. ‹e’n‡—TA²“¡Œö—YA•àV@—ºAElias-Al-Mamun Md.AAbdul Hai Siddique MohammadA‘呺~ˆêA²“¡‘åŽ÷A–ì–ؐ³“¹A‹{“c@•qA‰ºìG–ŸFV‹K•aˆö’`”’ƒZƒŒƒmƒvƒƒeƒCƒ“P ‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\iYIAÅ—DGÜŽóÜj
  16. ƒˆê”ʉ‰‘聄

  17. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV@—ºA»‘ºTˆê˜YA–ì–ؐ³“¹AMd. Elias Al-MamunAMohammad Abdul Hai SiddiqueA‰ºìG–ŸF”x“®–¬«”x‚ŒŒˆ³Ç‚É‚š‚¯‚éV‹K•aˆö’`”’ADAMTS8 ‚Ì‹@”\‰ðÍ
  18. Mohammad Abdul Hai SiddiqueA²“¡Œö—YA•àV@—ºAMd. Elias Al-MamunA‹e’n‡—TA‘呺~ˆêA²“¡‘åŽ÷A–ì–ؐ³“¹A»‘ºTˆê˜YA‘å’Î’mLA‰ºìG–ŸFDiscovery of Emetine as a Novel Therapeutic Agent for PAH
  19. –î”ö”M—TA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA²“¡Œö—YA‰ºìG–ŸF’SŠàŠ³ŽÒ‚É‚š‚¯‚é”xÇðÇ‚̋ÌŐü—nŒn‚Ì“Á’¥
  20. Md. Elias Al-MamunA²“¡Œö—YA²“¡‘åŽ÷A–î”ö”M—TAMohammad Abdul Hai SiddiqueA‹e’n‡—TA‘呺~ˆêA•àV@—ºA»‘ºTˆê˜YA–ì–ؐ³“¹A‰ºìG–ŸFRivaroxaban prevents the development of CTEPH in mice
  21. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA®–ì@—ºAŒã‰ªL‘Ÿ˜NA²“¡Œö—YA‰ºìG–ŸFƒoƒ‹[ƒ“”x“®–¬Œ`¬pŒã‚ÌCTEPH ‚É‚š‚¯‚é‰^“®•‰‰×‰ESƒJƒe[ƒeƒ‹
  22. Œš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA®–ì@—ºA²“¡Œö—YA‰ºìG–ŸFInoperable CTEPH ‚ɑ΂·‚é BPA Ž¡—Â̒·Šú—\Œã
  23. Œš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA®–ì@—ºA²“¡Œö—YAˆÀ’B@—A¬ŽRk‘Ÿ˜YAâV–؉ÀŽA‰ºìG–ŸF‘ÌŠOŽ®VAD ‚Æ”xŒŒŠÇŠg’£–ò—Ö@‚ðs‚Á‚œC³‘匌ŠÇ“]ˆÊÇ‚Ì1 —á
  24. ®–ì@—ºAŒš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA”’ˆä„ŽuA²“¡Œö—YA‰ºìG–ŸF“«Š¥¹k«‹·SÇ‚Æ’˜–Ÿ‚È”x‚ŒŒˆ³‚ð‡•¹‚µ‚œEGPA ‚Ì1 —á
  25. …àVˆ»”TA”~“à‚Ђ낊A¯Žq@Œ\A‚–ì^ˆËŽqA–Ÿ’¿çŒbAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA™‘ºGˆê˜YA‰ºìG–ŸFƒgƒŒƒvƒƒXƒ`ƒjƒ‹Ž‘±”牺“Š—^Š³ŽÒ‚Ìáu’ɂɑ΂·‚éŠÅŒìƒPƒA
  26. –î”ö”M—TA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚錌ŠÇŠg’£–ò’†Ž~‚̉e‹¿
  27. HŒŽŽO“ށA™‘ºGˆê˜YAÂ–Ø—³’jAŠ`‰Ô—²ºAãŒŽ³”ŽA‰ºìG–ŸFCTEPH ‚ÆPAH ‚ÌŠÓ•Ê‚É‚š‚¯‚éŒÄ‹CƒKƒX•ªÍ‚Ì—L—p«
  28. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA®–ì@—ºA²“¡Œö—YA‰ºìG–ŸFƒgƒŒƒvƒƒXƒeƒBƒjƒ‹‚ð”牺“Š—^‚Å“±“ü‚µ‚œ5 Ç—á
  29. ²“¡@—yA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çA®–ì@—ºA²“¡Œö—YA‘å“c‰pŠöA‰ºìG–ŸF‰EŽºŒ`‘ԕω»‚ð’·ŠúŠÏŽ@‚Å‚«‚œ“Á”­«”x“®–¬«”x‚ŒŒˆ³Ç‚Ì2 Ç—á
  30. _’ÍŽ–çA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@—yAŒã‰ªL‘Ÿ˜NA²“¡Œö—YA‹{“c@•qA‰ºìG–ŸF”x“®–¬«”x‚ŒŒˆ³Ç‚Ì’·Šú—\Œã‚ɑ΂·‚é‰ES‹@”\‚Ɛ«·‚ÌŠÖ˜A
‘æ17‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2017”N5ŒŽ19“ú`20“úA“¿“‡Žsj
  1. ˆä‹‚—z—SAŠ’JãĎqAˆÉ“¡H‘ãA“c’†C•œAÖ“¡‘åŽ÷A_ŒË–ΗYA”’ŒË@’A‰ºìG–ŸFŠ¥zŠÂ‚̍Pí«ˆÛŽ‚É‚š‚¯‚éPKG1a‚ÌŽ_‰»“IŠˆ«‰»‚̈Ӌ`‚ÌŒŸ“¢D
  2. “›ˆä³lAâ—œ‚Ü‚äŽqA•œ—Ç—YŽiA“à“c‘Ÿ˜YAŒèr”ŽA–ìŒûŽ•FA’‡@ª~ŽqA‰ºìG–ŸF2/3t“ENO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚Ì“Ë‘RŽ€‚É‚š‚¯‚鐫·D
  3. “›ˆä³lA‹v•Û“c—zHA–ìŒûŽ•FAâ—œ‚Ü‚äŽqAŒèr”ŽA’‡@ª~ŽqA‰ºìG–ŸA{‰ÁŒŽˆê”ŽAŠ_‰Ô@ŠwF”][Ç‚É‚š‚¯‚éNO‡¬y‘f‚Ì—LŠQ‚ȍì—pF«·‚š‚æ‚уeƒXƒgƒXƒeƒƒ“‚ÌŠÖ—^D
‘æ3‰ñ“ú–{S‹ØÇŒ€‹†‰ïi2017”N4ŒŽ22“úAŠò•ŒŽsj

    ƒƒVƒ“ƒ|ƒWƒEƒ€FS‹ØÇ‚̉摜f’f‚ƃoƒCƒIƒ}[ƒJ[„

  1. ™‘ºGˆê˜YAŽR–{¹DAŒš•”r‰îAÂ–Ø—³’jA–î”ö”M—TA_’ÍŽ–çA²“¡—yA®–ì—ºA‰ºìG–ŸFS‹ØÇ‚̉摜f’f‚ƃoƒCƒIƒ}[ƒJ[SFabry•a‚É‚š‚¯‚鑁Šúf’f‚Ì‚œ‚߂̉摜f’f‚ƃoƒCƒIƒ}[ƒJ[.
  2. ƒƒ|ƒXƒ^[”­•\„

  3. Œã‰ªL‘Ÿ˜YAâ“c‘וFA‹ž—ºˆêA”’ŒË’A’ÒŒOØŽqA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA‚‹ŽA‹{“c•qA‰ºìG–ŸF‰ä‚ª‘‚É‚š‚¯‚éŠg’£Œ^S‹ØÇ‚Ì—\Œã‚̉ü‘PFCHART-1/2Œ€‹†‚æ‚è.
  4. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çA®–ì—ºAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸAꎓ¡—ÁŽqA‹g’·P–ŸA–îè³‰pFƒgƒ‰ƒ“ƒXƒTƒCƒŒƒ`ƒ“Œ^ƒAƒ~ƒƒCƒh[ƒVƒX‚Ì2—á.
  5. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çA®–ì—ºA‰ºìG–ŸAHŽR³”NAì–{r•ãAâV–؉ÀŽFŒ€ÇŒ^S‹Ø‰Š‚ð‡•¹‚µ‚œ–òÜ«‰ß•qÇÇŒóŒQ‚Ì1—á.
‘æ81‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi3ŒŽ17“ú`19“úA2017”NA‹à‘òŽsj

    ƒPlenary Session„

  1. (PL03-3:Late Complications after Repair in Adult Congenital Heart Disease)Tatebe S, Sugimura K, Aoki T, Yamamoto S, Yaoita N, Kouzu K, Sato H, Satoh K, Shimokawa H. Clinical Importance of Pulmonary Hypertension in Adults with Congenital Heart Disease after Cardiac Surgery.
  2. (PL08-5:“ú–{”­‚̃rƒbƒOƒf[ƒ^‚ð—p‚¢‚œ—Տ°Œ€‹†)Shiroto T, Sakata Y, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Miura M, Nochioka K, Takahashi J, Miyata S, Shimokawa H. How can We Utilize Clinical Big Data in an Observational Study? \Lessons from the CHART-2 Study\
  3. ƒSymposium„

  4. (SY01-1:’Ž‚—ŽÐ‰ï‚É‚š‚¯‚éS•s‘S‚ÌŠÇ—EŽ¡—Ã)Takahashi J, Cui Y, Hao K, Ito K, Shimokawa H. Temporal Trends in the Prevalence and Outcomes of Heart Failure in Geriatric Patients with Acute Myocardial Infarction.
  5. (SY02-1:Vascular Biology as Interactive Science of Cardiovascular Disease)Satoh K, Sunamura S, Nogi M, Kurosawa R, Kudo S, Omura J, Kikuchi N, Sato T, Otsuki T, Suzuki K, Miura M, Aoki T, Tatebe S, Sugimura K, Sakata Y, Shimokawa H. Novel Therapeutic Targets for Cardiovascular Diseases \Rho-kinase, Cyclophilin A and Its Receptor, Basigin\
  6. (SY10-3:Molecular Basis of Cardiovascular Dysfunction in Metabolic Diseases) Godo S, Enkhjargal B, Noda K, Saito H, Shimokawa H. Importance of Endothelial Dysfunction in the Pathogenesis of Cardiovascular Insufficiency in Metabolic Disorders.
  7. (SY12-3: Understanding the Mechanism of Pulmonary Hypertension)Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, Sunamura S, Nogi M, Otsuki T, Tatebe S, Aoki T, Sugimura K, Shimokawa H. Thrombin-Activatable Fibrinolysis Inhibitor Plays a Crucial Role in The Development of Chronic Throm-boembolic Pulmonary Hypertension\A Possible Novel Therapeutic Target\
  8. (SY19-2: S‘ŸˆÚA¬ÑŒüã‚Ì‚œ‚ß‚ÌŽæ‚è‘g‚Ý)Aoki T, Sugimura K,Tatebe S, Yamamoto S, Yaoita N, Sato H, Kozu K, Satoh K, Akiyama M, Kawamoto S, Saiki Y, Shimokawa H. Pulmonary Hypertension in Potential Heart Transplant Recipients with Implantable Ventricular Assist Device.
  9. ƒSpecial Session„

  10. (SS12-5:‘å‹K–͍ЊQ‚ƏzŠÂŠí•aFŽñ“s’Œ‰ºŒ^\“ìŠCƒgƒ‰ƒt‚Ö‚Ì”õ‚Š)Takahashi J, Shimokawa H. Impact of the Great East Japan Earthquake Disaster on Cardiovascular Diseases.
  11. ƒLate Breaking Cohort Studies„

  12. (LBCS1-2:Heart Failure: Multi-organ Interaction and Treatment)Tatebe S, Sakata Y, Sugimura K, Satoh K, Shiroto T, Konno R, Adachi O, Kimura M, Tateno S, Nakajima H, Oyama K, Saiki Y, Shimokawa H. Clinical Characteristics of Adult Congenital Heart Disease in a Prospective Multicenter Cohort Study \An Initial Report from the CHART-2 Study\
  13. (LBCS2-1:Bio- and Genetic Markers for Cardiovascular Events)Odaka Y, Takahashi J, Tsuburaya R, Nishimiya K, Hao K, Matsumoto Y, Ito K, Sakata Y, Miyata S, Manita D, Hirowatari Y, Shimokawa H. Plasma Levels of Serotonin as a Novel Biomarker for Co-presence of Coronary Microvascular Dysfunction in Patient with Vasospastic Angina.
  14. (LBCS4-1:Environmental Factors of Atrial Fibrillation and Treatment)Sakata Y, Yamauchi T, Nochioka K, Shiroto T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Miura M, Takahashi J, Miyata S, Ninomiya T, Shimokawa H. Establishment of Predictive Models of New-onset Atrial Fibrillation Based on Clinical Background: Insights from the CHART-2 and the Hisayama Studies.
  15. (LBCS6-6:Advanced Vascular Interventions: Techniques and Outcomes)Aoki T, Sugimura K, Tatebe S, Yamamoto S, Yaoita N, Kozu K, Sato H, Konno R, Nochioka K, Satoh K, Shimokawa H. Long-term Beneficial Effects of Balloon Pulmonary Angioplasty on Hemodynamics and Prognosis in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension.
  16. ƒLate Breaking Cohort Studies-poster„

  17. (LBCSP2-2:Systemic Thrombosis and Treatment)Shiroto T, Sakata Y, Nochioka K, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Miura M, Takahashi J, Miyata S, Shimokawa H. Temporal Trend in Antithrombotic Therapies in Patients with Cardiovascular Diseases \Report from the CHART-2 Study\
  18. (LBCSP1-3:Risk Factor Analysis for Cardiovascular Events)Kozu K, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Sato H, Nochioka K, Satoh K, Miyata S, Shimokawa H. Long-term Prognosis of Patients with Pulmonary Hypertension for All Subtypes \A Single Center Experience\
  19. ƒJapan Heart Foundation Satoh Memorial Award Lecture„

  20. Satoh K. Development of Novel Therapies for Cardiovascular Diseases by Clinical Application of Basic Research.
  21. ƒCirculation Journal Award Session„

  22. (Clinical Investigation:Second Place)Suzuki H. Hippocampal Blood Flow Abnormality Associated with Depressive Symptoms and Cognitive Impairment in Patients with Chronic Heart Failure.
  23. ƒYoung Investigator's Award Finalists Lectures (Basic Research)„

  24. Kikuchi N, Satoh K, Omura J, Satoh T, Kurosawa R, Nogi M, Sunamura S, Otsuki T, Numano K, Yaoita N, Yamamoto S, Tatebe S, Aoki T, Sugimura K, Shimokawa H. Selenoprotein P Promotes Pulmonary Arterial Smooth Muscle Cell Proliferation and Pulmonary Arterial Hypertension.
  25. ƒYoung Investigator's Award Finalists Lectures (Clinical Research)„

  26. Odaka Y, Takahashi J, Suda A, Komatsu M, Kikuchi Y, Hao K, Matsumoto Y, Sakata Y, Miyata S, Shimokawa H. Plasma Concentration of Serotonin is a Novel Biomarker for Coronary Microvascular Dysfunction in Patients with Suspected Angina and Unobstructive Coronary Arteries.
  27. ƒYoung Investigatorfs Award for International Students Finalists Lectures„

  28. Mohammad Abdul Hai Siddique, Satoh K, Kurosawa R, Md. Elias-Al Mamun, Kikuchi N, Omura J, Sato T, Nogi M, Sunamura S, Shimokawa H. Identification of Emetine as a Novel Therapeutic Agent for Pulmonary Hypertension in Rats\Highthroughput Screening of 5,562 Compounds\
  29. ƒLuncheon Seminar„

  30. (LS67-2:zŠÂŠí“à‰Èˆã‚Ì“úíf—Âɐö‚Þˆâ“`«ŽŸŠ³)Sugimura K.ƒtƒ@ƒuƒŠ[•a‚É‚š‚¯‚鑁Šúf’fE‘ŠúŽ¡—Â̏d—v«`“–‰@@zŠÂŠí“à‰È‚É‚š‚¯‚éf’fEŽ¡—Â̎æ‚è‘g‚Ý.
  31. ƒOral Presentation (English)„

  32. (OE-063:Fontan/ACHD)Kimura Y, Fukuda K, Nakano M, Hasebe Y, Chiba T, Miki K, Tatebe S, Kimura M, Adachi O, Saiki Y, Shimokawa H. Clinical Impact of Atrioventricular Conduction Disturbance on Lethal Ventricular Arrhythmias in Patients with Total Correction of Tetralogy of Fallot.
  33. (OE-079:Angina Pectoris (Clinical) 1)Suda A, Takahashi J, Hao K, Kikuchi Y, Shindo T, Komatsu M, Odaka Y, Matsumoto Y, Sakata Y, Shimokawa H. Rho-kinase Inhibition with Intracoronary Fasudil Restores Coronary Microvascular Dysfunction in Patients with Vasospastic Angina.
  34. (OE-141:Heart Failure (Laboratory/Biomarkers)1)Otsuki T, Satoh K, Omura J, Kikuchi N, Sato T, Kurosawa R, Sunamura S, Nogi M, Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Miyata S, Shimokawa H. Plasma Levels of Cyclophilin A are Associated with Increased Mortality in Patients with Heart Failure.
  35. (OE-205:Heart Failure (Basic))Sunamura S, Satoh K, Suzuki K, Kudo S, Ikeda S, Omura J, Kikuchi N, Sato T, Kurosawa R, Nogi M, Numano K, Shimizu T, Shimokawa H. Crucial Role of ROCK1 to Maintain Cardiac Contractile Function in Response to Chronic Pressure-Overload in Mice.
  36. (OE-248:Heart Failure (Laboratory/Biomarkers) 2)Nochioka K, Sakata Y, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Miura M, Shirato T, Miyata S, Takahashi J, Shimokawa H. Incidence and Determinant Factors of Hospitalization for Worsening Heart Failure in Patients Treated with Diuretics in the CHART-2 Study.
  37. (OE-259:Pulmonary Circulation)Omura J, Satoh K, Kikuchi N, Satoh T, Kurosawa R, Nogi M, Sunamura S, Ohtsuki T, Kozu K, Suzuki K, Yaoita N, Aoki T, Tatebe S, Sugimura K, Shimokawa H. A Disintegrin and Metalloproteinase with Throm- bospondin Motifs 8 (ADAMTS8) Promotes Hypoxia-induced Pulmonary Hypertension in Mice.
  38. (OE-330:Arrhythmia, Others (Clinical/Diagnosis/Treatment)1)Nakano M, Fukuda K, Hasebe Y, Hirano M, Kimura Y, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Feasibility of Subcutaneous Implantable Cardioverter Defibrillator on the Detection Mechanisms.
  39. (OE-295:Vascular Biology)Nogi M, Satoh K, Kudo S, Omura J, Kikuchi N, Sato T, Sunamura S, Kurosawa R, Otsuki T, Suzuki K, Shimokawa H. Protective Roles of Small GTP-binding Protein GDP Dissociation Stimulator (SmgGDS) against Angiotensin II-induced Thoracic Aortic Dissection and Rupture in Mice.
  40. (OE-366:ACS/AMI (Basic))Shindo T, Ito K, Ogata T, Hatanaka K, Kurosawa R, Eguchi K, Kagaya Y, Monma Y, Shiroto T, Miyata S, Taki H, Kanai H, Shimokawa H. Molecular Mechanisms for Low-intensity Pulsed Ultrasound-induced Angiogenesis: Contribution of Mechano-transduction.
  41. ƒOral Presentation (Japanese) „

  42. (OJ-014:Heart Failure (Laboratory/Biomarkers))Kasahara S, Sakata Y, Nochioka K,Tsuji K, Onose T, Abe R, Oikawa T, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Prognostic Risk Stratification with B-type Natriuretic Peptide for HFpEF, Borderline HFpEF and HFrEF Patients \A Report from the CHART-2 Study\
  43. (OJ-053:Cardiomyopathy/Hypertrophy (Clinical))Yamamoto S, Sugimura K, Suzuki H, Tatebe S, Aoki T, Yaoita N, Sato H, Kozu K, Ota H, Takanami K, Takase K, Satoh K, Shimokawa H. Novel Diagnostic Strategy for Cardiac Involvement in Patients with Anderson-Fabry Disease.
  44. (OJ-079:Heart Failure (Pharmacology))Oikawa T, Sakata Y, Nochioka K, Tsuji K, Onose T, Abe R, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Intensity of Statin Therapy and Prognosis in Patients with Ischemic Heart Failure\A Report from the CHART-2 Study\
  45. (OJ-091:Angina Pectoris (Clinical))Odaka Y, Takahashi J, Hao K, Kikuchi Y, Suda A, Komatsu M, Matsumoto Y, Ito K, Miyata S, Sakata Y, Shimokawa H. Sustained Myocardial Ischemia in Patients with Microvascular Angina Even after Nitrate Administration.
  46. ƒFeatured Research Session„

  47. (FRS-099:Coronary Imaging)Ohyama K, Matsumoto Y, Amamizu H, Uzuka H, Nishimiya K, Morosawa S, Hirano M, Watabe H, Funaki Y, Takahashi J, Ito K, Shimokawa H. Inflammatory Changes of Perivascular Adipose Tissue in the Pathogenesis of DES-induced Hyperconstricting Responses in Pigs \Usefulness of 18F-FDG PET Imaging\
  48. (FRS-106:Pulmonary Circulation)Kurosawa R, Satoh K, Kikuchi N, Omura J, Sato T, Nogi M, Sunamura S, Suzuki K, Hai Siddique Mohammad Abdul, Shimokawa H. Celastramycin Inhibits Pulmonary Arterial Smooth Muscle Cell Proliferation and Ameliorates Hypoxia-induced Pulmonary Hypertension.

    ƒExcellent Case Presentation by Young Careers in English„

  49. (ECP2-1)Sugisawa J, Matsumoto Y, Tsuchiya S, Suda A, Shindo T, Kikuchi Y, Hao K, Takahashi J, Shimokawa H. Silent Myocardial Ischemia Associated with Exercise-Induced Coronary Artery Spasm.
  50. ƒPoster Session (English)„

  51. (PE-264:Heart Failure (Non-pharmacology) 1)Hao K, Takahashi J, Sakata Y, Miyata S, Shiroto T, Nochioka K, Yamauchi T, Tsuji K, Onose T, Oikawa T, Abe R, Sato M, Kasahara S, Shimokawa H. Prognostic Impact of Residual Coronary Artery Stenosis in Patients with Ischemic Heart Failure after Percutaneous Coronary Intervention.
  52. (PE-395:Arrhythmia, Others (Basic))Hirano M, Yamamoto H, Hasebe Y, Fukuda K, Morosawa S, Amamizu H, Oyama K, Uzuka H, Takayama K, Shimokawa H. Development of a Novel Shock Wave Catheter Ablation System\A Validation Study in Pigs in Vivo\
  53. (PE-442:Heart Failure (Basic) 2)Ogata T, Ito K, Shindo T, Hatanaka K, Kurosawa R, Eguchi K, Kagaya Y, Monma Y, Shimokawa H. Low-intensity Pulsed Ultrasound Enhances Angiogenesis and Ameliorates Contractile Cardiac Func-tion of Pressure-Overloaded Hearts in Mice.
  54. (PE-458:Heart Failure (Laboratory/Biomarkers) 2)Sato M, Sakata Y, Nochioka K, Sato K, Onose T, Tsuji K, Oikawa T, Abe R, Kasahara S, Yamauchi T, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Clinical Characteristics and Prognostic Factors of Elderly Patients with Heart Failure: A Report from the CHART-2 Study.
  55. (PE-685:Coronary Circulation/Chronic Coronary Disease (Basic/Clinical) 2)Uzuka H, Matsumoto Y, Nishimiya K, Ohyama K, Amamizu H, Morosawa S, Hirano M, Shindo T, Kikuchi Y, Hao K, Shiroto T, Ito K, Takahashi J, Fukuda K, Funaki Y, Shimokawa H. Catheter-based Renal Denervation Suppresses Coronary Hyperconstricting Responses after Drug-Eluting Stent Implantation in Pigs in Vivo \Evidence for the Kidney-Brain-Heart Axis\
  56. (PE-393:Arrhythmia, Others (Basic))Morosawa S, Yamamoto H, Hirano M, Uzuka H, Oyama K, Hasebe Y, Nakano M, Fukuda K, Shimokawa H. Impact of a New Shock Wave Catheter Ablation System on the Depth of Myocardial Lesions in Pigs in Vivo.
  57. (PE-786:Pulmonary Circulation 2)Aoki T, Sugimura K, Tatebe S, Yamamoto S, Yaoita N, Sato H, Kouzu K, Nochioka K, Satoh K, Shimokawa H. Effectiveness and Safety of Balloon Pulmonary Angioplasty in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension.
  58. ƒPoster Session (Japanese)„

  59. (PJ-219:Heart Failure, Atrial Fibrillation, and Obesity)Abe R, Sakata Y, Nochioka K, Onose T, Tsuji K, Oikawa T, Kasahara S, Sato M, Miura M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Association between Health Consciousness and Mortality in Patients with Heart Failure \A Report from the CHART-2 Study\
  60. (PJ-278:Heart Failure (Non-pharmacology))Tsuji K, Sakata Y, Nochioka K, Miura M, Onose T, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Clinical Characteristics of Heart Failure Patients with Mid-range Ejection Fraction \A Report from the CHART-2 Study\
  61. (PJ-284:Pulmonary Circulation)Sato H, Ota H, Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Kozu K, Satoh K, Shimokawa H. Balloon Pulmonary Angioplasty Improves Biventricular Functions in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension.
  62. (PJ-285:Pulmonary Circulation)Tanaka S, Sato S, Kajitani S, Ikumi Y, Ito A, Saito H, Godo S, Shiroto T, Shimokawa H. Roles of Endothelium-Dependent Hyperpolarization in Pulmonary Microcirculation in Mice \Implications for Pulmonary Hypertension\
  63. (PJ-242: Ventricular Arrhythmia (Clinical/Diagnosis/Treatment)2)Hasebe Y, Fukuda K, Nakano M, Hirano M, Kimura Y, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Impact of Enlarged Left Ventricular Dimension on Ventricular Fibrillation Event in Patients with Ischemic Cardiomyopathy and Implantable Cardioverter Defibrillator.
  64. (PJ-290:ACS/AMI (Clinical/Treatment) 1)Cui Y, Hao K, Takahashi J, Miyata S, Shindo T, Kikuchi Y, Matsumoto Y, Ito K, Sakata Y, Shimokawa H. Temporal Trends in Emergency Care and Outcomes of Geriatric Patients with Acute Myocardial Infarction in Japan.
  65. (PJ-311:Gender Differences)Onose T, Sakata Y, Nochioka K, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Miyata S, Takahashi J, Shimokawa H. Sex Differences in Post-traumatic Stress Disorder in Cardiovascular Patients after the Great East Japan Earthquake \The CHART-2 Study\
  66. (PJ-346:Arrhythmia, Others (Clinical/Diagnosis/Treatment)3)Miki K, Fukuda K, Nakano M, Hasebe Y, Hirano M, Kimura Y, Chiba T, Fukasawa K, Morosawa S, Shimokawa H. Impact of Types of Atrial Fibrillation on Characteristics of Silent Brain Infarcts in Patients with Non-valvular Atrial Fibrillation.
  67. (PJ-673:Cardiac Arrest/Resuscitation)Komatsu M, Takahashi J, Hao K, Kikuchi Y, Odaka Y, Suda A, Matsumoto Y, Sakata Y, Miyata S, Shimokawa H. Long-term Prognosis of Out-of-hospital Cardiac Arrest Survivors with Vasospastic Angina \An Update\
  68. (CP-236:ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Eg‘ÌŠˆ“®6)Takeuchi M, Matsumoto Y, Kawamoto S, Takahashi J, Aoki T, Sugimura K, Miyata S, Kozuki M, Arai H, Saiki Y, Shimokawa H. ŒoƒJƒe[ƒeƒ‹‘å“®–¬•Ù—¯’up‚ɑ΂·‚éŒp‘±“I‚ȃtƒŒƒCƒ‹ƒKƒCƒh‚̃ŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚́ApŒã‰ñ•œƒŒƒxƒ‹‚ð—\‘ª‚µAÝ‘îŠú‚ÌQOL ‚ƃtƒŒƒCƒ‹‚ð‰ü‘P‚·‚é.
‘æ46‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïi2ŒŽ10“ú`11“úA2017”NA“ß”eŽsj

    ƒƒVƒ“ƒ|ƒWƒEƒ€FS–¬ŠÇì“®•šŽ¿‚Ì‹Ž“n‚µŒ€‹†„

  1. ²“¡Œö—YA‰ºìG–ŸF”x‚ŒŒˆ³Ç‚̐V‹K•aˆö’`”’‚É’…–Ú‚µ‚œ‘Šúf’f–@‚ƐV‹KŽ¡—ÖòŠJ”­‚̉”\«
  2. ƒYIAƒZƒbƒVƒ‡ƒ“„

  3. •àV —ºFV‹K”x‚ŒŒˆ³ÇŽ¡—ÖòƒZƒ‰ƒXƒgƒ‰ƒ}ƒCƒVƒ“‚Ì”­Œ©
  4. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  5. –ì–ؐ³“¹A²“¡Œö—YAH“¡ rA‘呺~ˆêA‹e’n‡—TA²“¡‘åŽ÷A»‘º Tˆê˜YA•àV —ºA‘å’Î’mLAÀ–ì˜a•FA—é–؍N‘ŸA‰ºìG–ŸFƒAƒ“ƒWƒIƒeƒ“ƒVƒ“2ŽhŒƒ‚ł̃}ƒEƒX‚Ì‹¹•”‘å“®–¬‰ð—£‚š‚æ‚Ñ‹¹•”‘å“®–¬áŽƒ‚ƒfƒ‹‚É‚š‚¯‚éSmall GTP-binding Protein GDP Dissociation Stimulator‚Ì•ÛŒì“I‚È–ðŠ„
  6. »‘º Tˆê˜YA²“¡Œö—YA—é–؍N‘ŸAH“¡ rA‘呺~ˆêA‹e’n‡—TA²“¡‘åŽ÷A•àV —ºA–ì–ؐ³“¹A‘å’Î’mLAÀ–ì˜a•FA‰ºìG–ŸFƒ}ƒEƒX‚̈³•‰‰×S•s‘Sƒ‚ƒfƒ‹‚É‚š‚¯‚éROCK1‚É‚æ‚éS‹@”\ˆÛŽ‹@\
  7. ²“¡‘åŽ÷A²“¡Œö—YA–î”ö” M—TA‹e’n‡—TA‘呺~ˆêA•àV —ºAMd. Elias Al-MamunAMohammad Abdul Hai SiddiqueA™‘º Gˆê˜YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚š‚¯‚éV‹K•aˆö’`”’TAFI‚Ì‹@”\‰ðÍ
  8. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV —ºAÀ–ì˜a•FA_’ÍŽ–çAÂ–Ø—³’jAŒš•”r‰îA™‘º Gˆê˜YA‰ºìG–ŸFADAMTS8‚Í”x‚ŒŒˆ³‚É‚š‚¯‚é”xŒŒŠÇƒŠƒ‚ƒfƒŠƒ“ƒO‚ƉES•s‘S‚𑝈«‚³‚¹‚é
  9. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  10. ‰ºì G–ŸFŽ‰Ž¿ˆÙíÇŽ¡—Â̍ŋ߂̐i•à
‘æ10‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2017”N1ŒŽ28`29“úA–ŒŒÃ‰®j

    ƒÅ—DG‰‰‘èÜ„

  1. {“c@•jA‚‹Ž@A‰H”öŽ‹MAi“¡’q•FA¬Œ^‹±A¬‘é—I“ñAŒ–{‘׎¡Aâ“c‘וFA‰ºìG–ŸFŠ¥¹k«‹·SÇŠ³ŽÒ‚É‚š‚¯‚銥”÷¬ŒŒŠÇ‹@”\ˆÙí‚̐«·‚ɂ‚¢‚Ä‚ÌŒŸ“¢.
  2. ƒ—DG‰‰‘èŒó•â„

  3. ‹yì‘ì–çAâ“c‘וFAŒã‰ªL‘Ÿ˜YA¬–쐣„¶A’ҁ@ŒOØŽqAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA”’ŒË@’A‹{“c@•qA‰ºìG–ŸFS‹Ø[ÇŠ³ŽÒ‚Ì—\Œã‚ɑ΂·‚éƒXƒ^ƒ`ƒ“Ž¡—Ẩe‹¿‚Ì’j—·.
  4. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YA¬–쐣„¶Aˆ¢•”—Ú—žA‹yì‘ì–çA”’ŒË@’A‹{“c@•qA‰ºìG–ŸF¶Žº‹ìo—Š‚ª–«S•s‘SŠ³ŽÒ‚ÌBNP’l‚Æ—\Œã‚Æ‚Ì‘ŠŠÖ‚É‹y‚Ú‚·‰e‹¿‚Ɛ«·FCHART-2Œ€‹†‚©‚ç‚Ì•ñ.
  5. _’ÍŽ–çA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA²“¡@ꡁAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‹{“c@•qF’PˆêŽ{Ý‚É‚š‚¯‚é”x‚ŒŒˆ³Ç‘S—Տ°•ª—Þ‚Ì’·Šú—\Œã‚ÌŒŸ“¢.
  6. ƒƒVƒ“ƒ|ƒWƒEƒ€FzŠÂŠíŽŸŠ³‚É‚š‚¯‚鐫·‚Æ‚»‚̑Ήž„

  7. ‚‹Ž@A‰ºìG–ŸFŠ¥zŠÂ‹@”\ˆÙí‚É‚š‚¯‚鐫·.
  8. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  9. ’ҁ@ŒOØŽqAâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA¬–쐣„¶A‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA”’ŒË@’A‹{“c@•qA‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚̍¶Žº‹ìo—Š‚ÌŒoŽž•Ï‰»‚Ɛ«·@\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  10. ›Á@Œ³‹gA‰H”öŽ‹MA‚‹Ž@A‹{“c@•qAi“¡’q•FA‹e’n@—ƒAŒ–{‘׎¡Aâ“c‘וFA‰ºìG–ŸF‚—îS‹Ø[ÇŠ³ŽÒ‚ÌŠ³ŽÒ”wŒi‚Ɖ@“àŽ€–S—Š‚É‚š‚¯‚鐫·‚ɂ‚¢‚Ä‚ÌŒŸ“¢.
  11. ŽO–ØŒi‘ŸA•Ÿ“c_“ñA’†–ì@œA’·’J•”—Y”òA•œ–쓹ŠîA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA”‘ò@‘EA‰ºìG–ŸFS–[×“®Š³ŽÒ‚Ì•aŠú‚É‚æ‚鍶SŽšŒŒ—¬‘¬“x’ቺ—\‘ªˆöŽq‚̐«·‚ÉŠÖ‚·‚錟“¢.

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2016”N(*µ‘ҍu‰‰j
‘æ1‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï“Œ–kŽx•”’n•û‰ïi2016”N12ŒŽ4“úAå‘äj

    ƒˆê”ʉ‰‘èiŒûqj„

  1. ˆÉ“¡CA‰ºìG–ŸAãŒŽ³”ŽFS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚̈ãŽt‘²‘OE‘²Œã‹³ˆç‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²žŒ‹‰Ê
  2. ƒˆê”ʉ‰‘èiŒûqj„

  3. [àV‹±”V˜NA•Ÿ“c_“ñA’†–쐜A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FAŽO–ØŒi‘ŸA‰ºìG–ŸFS–[×“®‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‰^“®‘Ï—e”\‚É—^‚Š‚é—L—p«‚ɂ‚¢‚Ä
  4. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  5. ™àVAŠ`‰Ô—²ºA{“c•jAi“¡’q•FA‰H”öŽ‹MA‹e’n—ƒAŒ–{‘׎¡A‚‹ŽAâ“c‘וFA‰ºìG–ŸF•ÂÇ«“®–¬d‰»Ç‚ɑ΂·‚é‰^“®—Ö@ŒãA•às‹——£‚̉„’·‚É‚æ‚è‹·S’É‚ªŒ°Ý‰»‚µAŒŒsÄŒš‚ðŽ{s‚µ‚œ‚P—á
  6. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  7. HŒŽŽO“ށA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA’|“à‰ëŽjAŠ`‰Ô—²ºA‰ºìG–ŸAãŒŽ³”ŽF”x“®–¬‹·ó‚É‚æ‚é”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒJƒe[ƒeƒ‹Ž¡—ÂƕÀs‚µAˆÀ‘S‚ɉ^“®—Ö@‚ðŽ{s‚µ‚œ1—á
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€„

  9. ’|“à‰ëŽjAŒ–{‘׎¡A‰ºìG–ŸFzŠÂŠíf—Âɂš‚¢‚ătƒŒƒCƒ‹‚ð‚Ç‚Ì‚æ‚€‚ɍŽ•ž‚·‚é‚©|S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì–ðŠ„|
‘æ163‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2016”N12ŒŽ3“úAå‘äj

    ƒYIAÇ—á”­•\•”–偄i*Å—DGÜŽóÜj

  1. *®–ì—ºAŒš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çA‰H”öŽ‹MA‚‹ŽA’†–쐜A•Ÿ“c_“ñA‰ºìG–ŸA”’ˆä„ŽuAÎˆä’q“¿A™‰Y‹v•qA’†“ˆ@‘s‘ŸFSŽº×“®‚Å”­Ç‚µŠ¥¹k«‹·SÇ‚Æ”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚œDŽ_‹…«‘œ”­ŒŒŠÇ‰Š«“÷‰èŽîÇiEGPAj‚Ì‚P—á
  2. ƒYIAŒ€‹†”­•\•”–偄i*Å—DGÜŽóÜj

  3. *’ÒŒOØŽqAâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA¬–쐣„¶Aˆ¢•”—Ú—žA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA”’ŒË’A‚‹ŽA‹{“c•qA‰ºì@G–ŸF–«S•s‘SŠ³ŽÒ‚É‚š‚¢‚趎º‹ìo—Š‚̕ω»‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿ |CHART-2 Œ€‹†‚©‚ç‚Ì•ñ|
  4. ƒˆê”ʉ‰‘聄

  5. ²“¡ŒöˆêA˜Q‘Ő¬lA™]³A‘ëˆä’šA‹ž—ºˆêA‰Á“¡“ցA‰ºìG–ŸFÁ‰»ŠÇoŒŒŠ³ŽÒ‚ªŽó‚¯‚Ä‚¢‚œRŒŒð—Ö@‚Æ‚»‚Ì——R
  6. ²“¡—yA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çA®–ì—ºA²“¡Œö—YA‰ºìG–ŸF‘å“®–¬•Ù“ñë•Ù‚É‚æ‚é‘å“®–¬•Ù•Âœ•s‘SÇ‚ƍ¶Žºãk–§‰»áŠQ‚ª‡•¹‚µ‚œˆê—á
  7. ‚–Ø—S‰îAH“¡rA”·Œ’ˆê˜YA£ì«lA‘ŠàVŒ’‘Ÿ˜YAŽR–{‹`lA™³•¶A‰ºìG–ŸFdÇ‘å“®–¬•Ù‹·óÇ‚ɑ΂·‚é‹Ù‹}ƒoƒ‹[ƒ“Šg’£p‚̗Տ°¬Ñ
  8. “y‰®‘AŒ–{‘׎¡A‚‹ŽA™‘ºGˆê˜YA‹e’n—ƒA‰H”öŽ‹MAi“¡’q•FA{“c•jA™àVA‰ºìG–ŸAŒF’J‹Iˆê˜YAì–{r•ãAâV–؉ÀŽF’áS‹@”\‚𔺂Á‚œdÇ‘å“®–¬•Ù‹·óÇ‚ɐlHS”xƒTƒ|[ƒg‰º‚Å TAVI ‚ðŽ{s‚µ‚œ 2 —á
  9. _’ÍŽ–çAÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸF—¯’u‚©‚ç 1 ”N‚ðŒo‚Ä IVC filter ‚𔲋Ž‚µ‚œ 1 —á
  10. ”·Œ’ˆê˜YA£ì«lAH“¡rA‚–Ø—S‰îA‘ŠàVŒ’‘Ÿ˜YAŽR–{‹`lA™³•¶A‰ºìG–ŸF”DP 37 T‚Å‚­‚à–Œ‰ºoŒŒ‚𔭏ǂµAS•s‘S‚ð‡•¹AS‹@”\’ቺ‚ª‘J‰„‚µ‚œ 1 —á
  11. {“c•jA‚‹ŽA‰H”öŽ‹MA‹e’n—ƒAi“¡’q•FA™àVAŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFŠ¥¹k‚É‚æ‚é”ñ•ÂÇ«Š¥“®–¬S‹Ø[Ç (MINOCA) ‚ª‹^‚í‚ê‚œˆê—á
  12. ™àVA‰H”öŽ‹MA{“c•jA›ÁŒ³‹gAi“¡’q•FA‹e’n—ƒAŒ–{‘׎¡A‚‹ŽAˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºì@G–ŸF¶‰ñùŽ}‘€Ž}‚ðÓ”C•a•Ï‚Æ‚·‚é‹}«S‹Ø[Ç‚É“û“ª‹Ø’f—ô‚ð‡•¹‚µ‚œ‚P—á
  13. Š’JãĎqA‹e’n—ƒA“y‰®‘A™àVA{“c•jA›ÁŒ³‹gAi“¡’q•FA‰H”öŽ‹MAŒ–{‘׎¡A‚‹ŽAˆÉ“¡Œ’‘ŸA‰ºìG–ŸFbó‘B‹@”\˜ŽiŽž‚ÉŠ¥¹k‚É‚æ‚éSŽº×“®‚𔭏ǂµ‚œˆê—á
  14. ç—t‹M•FA•Ÿ“c_“ñA’†–쐜A’·’J•”—Y”òA•œ–쓹ŠîA–Ø‘º‹`—²A[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸFƒfƒoƒCƒXŠŽõ‚𗈂µƒŒ[ƒU[ƒŠ[ƒh”²‹Ž‚š‚æ‚є牺Až‚ÝŒ^œ×“®ŠíAž‚ݏp‚ðŽ{s‚µ‚œ“Á”­«SŽº×“®Ç—á
  15. ’†–쐜A•Ÿ“c_“ñA’·’J•”—Y”òA•œ–쓹ŠîA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸF‰EŽº“û“ª‹Ø‹NŒ¹SŽº•p”‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚œ•s®–¬ŒŽ«‰EŽºS‹ØÇÇ—á
  16. £ì«lAH“¡rA”·Œ’ˆê˜YA‚–Ø—S‰îA‘ŠàVŒ’‘Ÿ˜YAŽR–{‹`lA™³•¶A‰ºìG–ŸFSŒ¹«Çð‚ð 2 “x‹N‚±‚µ‚œS–[×“®‚̈ê—á
  17. ŽO–ØŒi‘ŸA•Ÿ“c_“ñA’†–쐜A’·’J•”—Y”òA•œ–쓹ŠîA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA”‘ò‘EA‰ºìG–ŸF‘OŽž_‚ÌŒŽˆö‚Æ‚µ‚ĐSŽº•p”‚ƐS–[•p”‚ÌŠÓ•Ê‚ªd—v‚Å‚ ‚Á‚œƒtƒ@ƒ[Žl’¥ÇpŒã‚Ì‚P—á
  18. [àV‹±”V˜NA•Ÿ“c_“ñA’†–쐜A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FAŽO–ØŒi‘ŸA‰ºìG–ŸF”­ì«S–[×“®Š³ŽÒ‚̉^“®‘Ï—p”\‚ƃJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚é“Ž’²—¥ˆÛŽ‚ÌŠÖ˜A
  19. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸAHŽR³”NAì–{r•ãAâV–؉ÀŽFA‚Šž‚ÝŒ^•â•lHS‘Ÿ‘•’…Š³ŽÒ‚É‚š‚¯‚é”x‚ŒŒˆ³Ç‚ÉŠÖ‚·‚錟“¢
  20. ”—“c‚Ý‚­AÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çA²“¡—yAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸFÄ”­«ŠŽõ«S“à–Œ‰Š‚̈ê—á
  21. H“¡rAŽR–{‹`lA£ì«lA”·Œ’ˆê˜YA‚–Ø—S‰îA‘ŠàVŒ’‘Ÿ˜YA™³•¶A‰ºìG–Ÿ FSFA ‚ÌŒŒð«•ÂÇ‚É‚š‚¯‚錌ð—n‰ð—Ö@‚𕹗p‚µ‚œ 2-step EVT –@‚ÌŒŸ“¢
  22. H“¡rAŽR–{‹`lA£ì«lA”·Œ’ˆê˜YA‚–Ø—S‰îA‘ŠàVŒ’‘Ÿ˜YA™³•¶A‰ºìG–ŸFOPTIMO Sheathless ƒJƒe[ƒeƒ‹‚Ì•¹—p‚É‚Ä SFA ‚̃Xƒeƒ“ƒg“àŒŒð«•ÂÇ‚ÌŠ®‘SŒŒsÄŒš‚ɐ¬Œ÷‚µ‚œˆê—á
  23. ²“¡‰ë”VAâ“c‘וFAŒã‰ªL‘Ÿ˜YA²“¡Œª“ñ˜YA¬–쐣„¶A’ÒŒOØŽqA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YAŽR“à‹BA”’ŒË’A‚‹ŽA‰ºìG–ŸA‹{“c•qF‚—îŽÒS•s‘S‚̗Տ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq‚ɂ‚¢‚Ä‚ÌŒŸ“¢ |CHART-2 Œ€‹†‚©‚ç‚Ì•ñ|
  24. _’ÍŽ–çAÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡—yA²“¡Œö—YA‰ºìG–ŸFƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚ðˆÀ‘S‚ÉŽ{s‚Å‚«‚œƒnƒCƒŠƒXƒN’†•Œ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̈ê—á
  25. ˆ¢•”—Ú—žAâ“c‘וFAŽO‰Y³’šA¬–쐣„¶A’ÒŒOØŽqAŠ}ŒŽM‘Ÿ˜YA‹yì‘ì–çA²“¡‰ë”VAŒã‰ªL‘Ÿ˜YA”’ŒË’A‚‹ŽA‰ºìG–ŸA‹{“c•qF“ú–{‚Ì–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚錒NˆÓŽ¯‚ƐS•s‘S“ü‰@‚ÉŠÖ‚·‚錀‹† |CHART-2 Œ€‹†‚©‚ç‚Ì•ñ|
  26. ¬–쐣„¶Aâ“c‘וFAŒã‰ªL‘Ÿ˜YA”’ŒË’A’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA‚‹ŽA‰ºìG–ŸA‹{“c•qFS•s‘SŠ³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚Ì—\Œã‚ւ̉e‹¿ |CHART-2Œ€‹†‚æ‚è|
  27. Œã‰ªL‘Ÿ˜YAâ“c‘וFA¬–쐣„¶A’ÒŒOØŽqA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA”’ŒË’A‚‹ŽA‰ºìG–ŸA‹{“c•qF–«S•s‘S‚̐S•s‘S“ü‰@D”­ŽžŠúEŠëŒ¯ˆöŽqFCHART-2 Œ€‹†
‘æ13‰ñ“ú–{zŠÂŠíŠÅŒìŠw‰ïŠwpW‰ïi2016”N10ŒŽ22“úAå‘äj

    ƒ“Á•Êu‰‰„

  1. *‰ºìG–ŸFzŠÂŠíŠÅŒì‚É‚š‚¯‚éƒn[ƒgƒ`[ƒ€‚̏d—v«
‘æ57‰ñ “ú–{–¬ŠÇŠw‰ï‘‰ïi2016”N10ŒŽ13`15“úA“ޗǁj

    ƒˆê”ʉ‰‘è@Œûq„

  1. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA²“¡—yA_’ÍŽ–çA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éBPA‚̍‡•¹Ç‚Æ—\Œã‚ÌŒŸ“¢
  2. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[„

  3. _’ÍŽ–çAÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡—yA‰ºìG–ŸFƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚ªˆÀ‘S‚ÉŽ{s‚Å‚«‚œƒnƒCƒŠƒXƒN’†•Œ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̈ê—á
‘æ20‰ñ“ú–{S•s‘SŠw‰ïi2016”N10ŒŽ7`9“úAŽD–yj

    ƒ“Á•ÊŠé‰æ2 “Á”­«S‹ØÇ’²žŒ€‹†”ǁEŠg’£‘Š”ì‘åŒ^S‹ØÇ“o˜^ŠÏŽ@Œ€‹†”Ǎ‡“¯¬‰Ê•ñ `S‹ØÇŒ€‹†‚̍őOü`i“Á”­«S‹ØÇ’²žŒ€‹†”Ç / Šg’£‘Š”ì‘åŒ^S‹ØÇ“o˜^ŠÏŽ@Œ€‹†”Ç / ‘æ20‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïj„

  1. ‰ºìG–ŸFTrends in Clinical Characteristics, Treatments and Prognosis in Patients with Dilated Cardiomyopathy in Japan -Epidemiologic Insights from the CHART Studies-
  2. ƒYIA Ržu‰‰ —Տ°2„

  3. ’ÒŒOØŽqAâ“c‘וFAŽO‰Y³’šA‹{“c•qAŒã‰ªL‘Ÿ˜YAŽR“à‹BA¬–쐣„A”’ŒË’A‚‹ŽA‰ºìG–ŸF¶Žº‹ìo—Š‚ª•Û‚œ‚ê‚œS•s‘SŠ³ŽÒ‚̗Տ°Šw“I“Á’¥‚ɂ‚¢‚ā@-CHART-2Œ€‹†‚©‚ç‚Ì’mŒ©-
  4. ƒƒVƒ“ƒ|ƒWƒEƒ€4 ‹•ŒŒ«S•s‘S‚ÌŽ¡—Ð헪„

  5. ‰H”öŽ‹MA‚‹ŽA‹{“c•qAâ“c‘וFA‰ºìG–ŸF‹•ŒŒ«S•s‘SŠ³ŽÒ‚É‚š‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Œã‚ÌŽc‘¶‹·ó‚ª—\Œã‚É—^‚Š‚é‰e‹¿
  6. ƒƒVƒ“ƒ|ƒWƒEƒ€6 •â•lHS‘Ÿ‚Ì–â‘è“_‚ðl‚Š‚遄

  7. Â–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡Œö—YAHŽR³”NAì–{r•ãAÖ–؉ÀŽA‰ºìG–ŸFSŽº•â•ƒfƒoƒCƒXŽg—pŠ³ŽÒ‚É‚š‚¯‚é”x‚ŒŒˆ³Ç‚ÌŒŸ“¢
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€14 S•s‘S‚̃oƒCƒIƒ}[ƒJ[„

  9. ²“¡Œö—YA—é–؍N‘ŸA‘å’Î’mLA»‘ºTˆê˜YAH“¡rA’r“c®•œAŽ…‹œA‰ºìG–ŸFS•s‘S‚̐V‚µ‚¢ƒoƒCƒIƒ}[ƒJ[: Cyclophilin A‚ÆBasigin -Šî‘bŒ€‹†‚̗Տ°‰ž—p-
  10. ƒƒVƒ“ƒ|ƒWƒEƒ€16 S–[×“®‡•¹S•s‘SŠ³ŽÒ‚Ì–â‘è“_‚ÆŽ¡—Ð헪„

  11. ŽR“à‹BAâ“c‘וFA¬–쐣„¶A’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA²“¡‰ë”VA‹{“c•qA‰ºìG–ŸF–«S•s‘S‚É‚š‚¯‚éS–[×“®”­ÇŒã‚ÌŒo‰ßŽžŠÔ‚Æ—\Œã‚ւ̉e‹¿‚Æ‚ÌŠÖ˜A‚ÌŒŸ“¢FCHART-2Œ€‹†‚©‚ç‚Ì’mŒ©
  12. ƒƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€5 “ú–{E‰¢BE•Ä‘S•s‘SŠw‰ï@‡“¯ƒVƒ“ƒ|ƒWƒEƒ€„

  13. â“c‘וFA‰ºìG–ŸFHeart Failure Pandemic : Lessons from Japan's Experience
  14. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“3 V‚œ‚ȐS•s‘SŽ¡—ÊJ”­Œ€‹†iŠî‘bA—Տ°A‰uŠwŒ€‹†‚Ì—§ê‚©‚çj„

  15. â“c‘וFA‰ºìG–ŸFV‚œ‚ȐS•s‘SŽ¡—ÊJ”­Œ€‹†:‰uŠwŒ€‹†‚Ì—§ê‚©‚ç -‘æ“ñŽŸ“Œ–k–«S•s‘S“o˜^Œ€‹†‚©‚ç‚Ì’mŒ©-
  16. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[13 ƒtƒ@ƒuƒŠ[•af—Â̎ÀÛ`‚»‚ÌŽæ‚è‘g‚݂ɂ‚¢‚ā`„

  17. ™‘ºGˆê˜YFƒtƒ@ƒuƒŠ[•a‚É‚š‚¯‚鑁ŠúŒŸžEf’fEŽ¡—Â̏d—v«@`ƒtƒ@ƒuƒŠ[•a‘΍ô‚̏d“_ƒ|ƒCƒ“ƒg`
  18. ƒˆê”ÊŒû‰‰6 ‹•ŒŒ«ŽŸŠ³1„

  19. ‹yì‘ì–çAâ“c‘וFAŽR“à‹BA’ÒŒOØŽqA¬–쐣„¶AŠ}ŒŽM‘Ÿ˜YA”’ŒË’A‚‹ŽA‹{“c•qA‰ºìG–ŸFƒXƒ^ƒ`ƒ“‚ª‹•ŒŒ«S•s‘SŠ³ŽÒ‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢@-CHART-2 Œ€‹†‚É‚š‚¯‚é–òÜ‹­“x•Ê‚ÌŒŸ“¢-
  20. ƒˆê”ÊŒû‰‰11 ‰æ‘œf’f„

  21. ŽR–{¹DA—é–؏G–ŸA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽO‰Y³’šA–î”ö”M—TA‚˜QŒ’‘Ÿ˜YA‚£Œ\A‰ºìG–ŸFFabry•aŠ³ŽÒ‚É‚š‚¯‚éS‹ØMIBGƒVƒ“ƒ`ƒOƒ‰ƒtƒB[‚Ì—L—p«
  22. ƒˆê”ÊŒû‰‰12 ƒoƒCƒIƒ}[ƒJ[3„

  23. ‘å’Î’mLA²“¡Œö—YA‘呺~ˆêA‹e’nM—TA²“¡‘åŽ÷A»‘ºTˆê˜YA™‘ºGˆê˜YAŒš•”r‰îA‹{“c•qA‰ºìG–ŸFŒŒŸ÷’†ƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚éS•s‘SŠ³ŽÒ‚Ì’·Šú—\Œã—\‘ª
  24. ƒˆê”ÊŒû‰‰13 •Ù–ŒÇ1„

  25. ’|“à‰ëŽjAŒ–{‘׎¡Aì–{r•ãAŒF’J‹Iˆê˜YAŽO‰Y³’šA™‘ºGˆê˜YA‚‹ŽAÖ–؉ÀŽAãŒŽ³”ŽA‰ºìG–ŸFSƒŠƒn‚Í‘å“®–¬•Ù‹·óÇ‚ɑ΂·‚é‘Sg–ƒŒ‰ºTAVIŒã‚ɒቺ‚·‚ég‘Ì‹@”\‚ð‰ü‘P‚·‚éFƒtƒŒƒCƒ‹•]‰¿‚̏d—v
  26. ƒˆê”ÊŒû‰‰26 CRT„

  27. ç—t‹M•FA•Ÿ“c_“ñA’†–쐜A’·’J•”—Y”òA•œ–쓹ŠîA–Ø‘º‹`—²A[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸF–{–M‚É‚š‚¯‚éCRTƒy[ƒVƒ“ƒO•”ˆÊ‚É‚æ‚é—Տ°Œø‰Ê‚ÉŠÖ‚·‚錟“¢
  28. ƒƒ|ƒXƒ^[6 S‹Ø‰Ši1j-Ç—á•ñ„

  29. ®–ì—ºAÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA_’ÍŽ–çAHŽR³”NAÖ–؉ÀŽA‰ºìG–ŸFƒƒLƒVƒŒƒ`ƒ“‚É‚æ‚é–òÜ«‰ß•qÇÇŒóŒQiDIHSj‚ÉŒ€ÇŒ^S‹Ø‰Š‚𕹔­‚µ‚œˆê—á
  30. ƒE ƒ|ƒXƒ^[9 Šî‘bŒ€‹†4„

  31. »‘ºTˆê˜YA²“¡Œö—YA—é–؍N‘ŸA’r“c®•œA‘呺~ˆêA‹e’n‡—TA²“¡‘åŽ÷A–ì–ؐ³“¹AŽ…‹œA‰ºìG–ŸFƒ}ƒEƒX‚̈³•‰‰×S•s‘Sƒ‚ƒfƒ‹‚É‚š‚¯‚éROCK1‚É‚æ‚éS‹@”\ˆÛŽ‹@\
  32. ƒE ƒ|ƒXƒ^[13 International3„

  33. Š}ŒŽM‘Ÿ˜YAâ“c‘וFAŽR“à‹BA¬–쐣„¶A’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çA”’ŒË’A‹{“c•qA‰ºìG–ŸFHFpEF‚ÆHFrEF‚É‚š‚¯‚éBNP‚Ì“¯“™‚È—\Œã—\‘ªŒø‰Ê -CHART-2Œ€‹†‚©‚ç‚Ì•ñ-
‘æ1‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïi2016”N10ŒŽ1`2“úA“Œ‹žj

    ƒYIA ƒZƒbƒVƒ‡ƒ“„

  1. ‘呺 ~ˆêA²“¡ Œö—YA‹e’n ‡—TA²“¡ ‘åŽ÷A•àV —ºAÂ–Ø —³’jAŒš•” r‰îA™‘º Gˆê˜YA¯ì NA‰ª“c Ž“TA‰ºì G–ŸFAMPK ‚Ì”x‚ŒŒˆ³Ç”­Ç‚ɑ΂·‚é—}§‹@\‚̉𖟁i—DGÜŽóÜj
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€3 ‹­”çÇ‚É‚æ‚é”x‚ŒŒˆ³Ç‚Ì–â‘è“_if’fAŽ¡—ÁA“W–]j„

  3. é“c —SŽqAÎˆä —IãāA¯ —z‰îA“¡“c —mŽqA”’ˆä „ŽuA“¡ˆä ”ŽŽiA™‘º Gˆê˜YA‰ºì G–ŸAÎˆä ’q“¿A’£‘Ö G˜YF‹­”çÇ‚ƃVƒF[ƒOƒŒƒ“ÇŒóŒQ‡•¹”x“®–¬«”x‚ŒŒˆ³Ç‚ÌŽ¡—Ã
  4. ƒƒVƒ“ƒ|ƒWƒEƒ€6 PH ‚ɑ΂·‚éÅVŠî‘bŒ€‹†‚̐¬‰Ê„

  5. ²“¡ Œö—YA‹e’n ‡—TA‘呺 ~ˆêA²“¡ ‘åŽ÷A•àV —ºAŒš•” r‰îA™‘º Gˆê˜YA¯ì NA‰ª“c Ž“TA‰ºì G–ŸF”x“®–¬«”x‚ŒŒˆ³Ç‚̐V‹K•aˆö’`”’”­Œ©‚ƐV‹KŽ¡—Öò’Tõ
  6. ƒƒVƒ“ƒ|ƒWƒEƒ€7 ”x“®–¬Œ`¬‚Ì‚·‚ׂā„

  7. ™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽR–{ ¹DA–î”ö” M—TA—é–Ø G–ŸA_’à Ž–çA²“¡ —yA²“¡ Œö—YA‰ºì G–ŸFOCT guided BPA
  8. ƒˆê”ʉ‰‘è2 Ç—á•ñ1„

  9. ‹e’n —ƒAŽR–{ ¹DA™‘º Gˆê˜YAÈÀ ‚肱A‘å–{ ‰pŽŸ˜YA“n•” Œ«A‚‹Ž Ž–ŸAŒˆä Š²”VAŒã“¡ •q˜aA‰ºì G–ŸF––œŒŒŠ²×–EˆÚA‚É‚æ‚è”x‚ŒŒˆ³‚ª‰ü‘P‚µ‚œPOEMS ÇŒóŒQ‚Ì‚P—á
  10. ƒˆê”ʉ‰‘è3 —Տ°Œ€‹†1„

  11. Â–Ø —³’jA™‘º Gˆê˜YAŒš•” r‰îAŽR–{ ¹DA–î”ö” M—TA_’à Ž–çA²“¡ Œö—YAHŽR ³”NAì–{ r•ãAâV–Ø ‰ÀŽA‰ºì G–ŸFA‚Šž‚ÝŒ^•â•lHS‘Ÿ‘•’…Š³ŽÒ‚É‚š‚¯‚é”x‚ŒŒˆ³Ç‚ÉŠÖ‚·‚錟“¢
  12. ƒˆê”ʉ‰‘è5 ”x‚ŒŒˆ³E”xzŠÂ‚ÌŠî‘b„

  13. •àV —ºA²“¡ Œö—YA‹e’n ‡—TA‘呺 ~ˆêA²“¡ ‘åŽ÷AMohammad Abdul Hai SiddiqueA Md. Elias Al-MamunAŒš•” r‰îAÂ–Ø —³’jA™‘º Gˆê˜YA‰ºì G–ŸF‰»‡•šƒXƒNƒŠ[ƒjƒ“ƒO‚É‚æ‚éV‹K”x‚ŒŒˆ³ÇŽ¡—Öò‚ÌŠJ”­
  14. ‹e’n ‡—TA²“¡ Œö—YA‘呺 ~ˆêA²“¡ ‘åŽ÷A•àV —ºA–ì–Ø ³“¹AŒš•” r‰îAÂ–Ø —³’jA™‘º Gˆê˜YA‰ºì G–ŸFV‹K•aˆö’`”’ƒZƒŒƒmƒvƒƒeƒCƒ“P ‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\
  15. ²“¡ ‘åŽ÷A²“¡ Œö—YA–î”ö” M—TA‹e’n ‡—TA‘呺 ~ˆêA•àV —ºAMd. Elias Al-MamunA Mohammad Abdul Hai SiddiqueA™‘º Gˆê˜YA‰ºì G–ŸFV‹K•aˆö’`”’TAFI ‚É‚æ‚閝«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì”­Ç‹@\
  16. ƒˆê”ʉ‰‘è6 ŠO‰ÈŽ¡—ÁiPEAA”xˆÚAjE‚»‚Ì‘Œ„

  17. HŒŽ ŽO“ށA™‘º Gˆê˜YAÂ–Ø —³’jAŠ`‰Ô —²ºAˆÉ“¡ CAãŒŽ ³”ŽA‰ºì G–ŸFCTEPH ‚ɑ΂·‚éŒÄ‹CƒKƒX•ªÍ‚ð—p‚¢‚œ”ñNP“I‚ȏdÇ“x•]‰¿–@
  18. —é–Ø G–ŸA™‘º Gˆê˜YAŒš•” r‰îAÂ–Ø —³’jA‰ºì G–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³ÇiCTEPHj‚Æ“‡Žž’²Ç‚ÌŠÖ˜A
  19. ƒˆê”ʉ‰‘è9 ”x‚ŒŒˆ³Ç‚Æ–òÜ„

  20. ®–ì —ºAÂ–Ø —³’jA™‘º Gˆê˜YAŒš•” r‰îAŽR–{ ¹DA–î”ö” M—TA²“¡ —yA_’à Ž–çA²“¡ Œö—YA‰ºì G–ŸF“–‰@‚É‚š‚¯‚éƒgƒŒƒvƒƒXƒeƒBƒjƒ‹‚ÌŽg—pŒoŒ±
  21. ƒˆê”ʉ‰‘è10 Ç—á•ñ2„

  22. –î”ö” M—TA™‘º Gˆê˜YAÂ–Ø —³’jAŽO‰Y ³’šAŒš•” r‰îAŽR–{ ¹DA²“¡ Œö—YA‰ºì G–ŸF‘O–э׌ŒŠÇ«”x‚ŒŒˆ³Ç‚©‚çŒã–э׌ŒŠÇ«”x‚ŒŒˆ³Ç‚Æ‚È‚Á‚œ‚P—á
  23. ƒˆê”ʉ‰‘è11 –«”xŒŒðÇðÇ ”x‚ŒŒˆ³Ç„

  24. _’à Ž–çA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA–î”ö” M—TA—é–Ø G–ŸA‹{“c •qA‰ºì G–ŸFCTEPH ‚̃oƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ä‚ÌŒŒŸ÷Cyclophilin A ”Z“x‚Ì—L—p«
  25. Â–Ø —³’jA™‘º Gˆê˜YAŒš•” r‰îAŒã‰ª L‘Ÿ˜NAŽR–{ ¹DA–î”ö” M—TA²“¡ —yA_’à Ž–çA²“¡ Œö—YA‰ºì G–ŸF”ñŽèp“K‰ž‚ÌCTEPH Ç—á‚ɑ΂·‚éBPA ‚Ì’·Šú—\Œã‚ÆŽüpŠú‡•¹Ç
‘æ64‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2016”N9ŒŽ23`25“úA“Œ‹žj

    ƒ“Á•ÊŠé‰æ1 Žc‘¶ƒŠƒXƒNŒž­‚Ì‚œ‚߂̐V‚œ‚ȃoƒCƒIƒ}[ƒJ[’T‚µ„

  1. ²“¡Œö—YFLDL-C‚Ɉˑ¶‚µ‚È‚¢‘S‚­V‚µ‚¢V‹K•aˆö’`”’‚ƃoƒCƒIƒ}[ƒJ[‚̗Տ°‰ž—p
  2. ƒ“Á•ÊŠé‰æ5 S‘Ÿ•a—Տ°Œ€‹†‚̐V‚µ‚¢•ûŒü«‚ðl‚Š‚遄

  3. â“cN•FF‘æ“ñŽŸ“Œ–k–«S•s‘S“o˜^iCHART-2jŒ€‹†‚ÌŒ»ó‚Æ“W–]
  4. ƒ“Á•ÊŠé‰æ9 kÐ‚ƐSŒŒŠÇŽŸŠ³F‚»‚̑΍ô‚ÆŽÀ‘H„

  5. Â–Ø —³’jF“Œ“ú–{‘åkÐ‚©‚çŠw‚ñ‚Ÿ‚±‚Æ
  6. ƒ“Á•ÊŠé‰æ10 “ú–{‚ÌACS“o˜^Œ€‹†‚ÌŒ»ó‚©‚玟‚ÌŽž‘ã‚ց„

  7. ‚‹Ž A‰H”ö Ž‹MA›Á Œ³‹gAˆÉ“¡ Œ’‘ŸAâ“c ‘וFA‰ºì G–Ÿ F ‹}«S‹Ø[Ç”­Ç—Š‹y‚щ@“àŽ€–S—Š‚Ì‹ß”N‚É‚š‚¯‚éŒo”N•Ï‰»\Miyagi AMI Registry Studyi1985-2014j‚©‚ç‚Ì•ñ\
  8. ƒ“Á•ÊŠé‰æ14 ICT‚ðŠˆ—p‚µ‚œƒrƒbƒOƒf[ƒ^‚©‚ç‚Ì’mŽ¯‚̐¶¬F‰ä‘‚ÌŒ»ó‚Ɖۑ聄

  9. ’†ŽR ‰ë°A‰ºìG–ŸFf—Ïî•ñƒXƒgƒŒ[ƒW•W€‹K–ñSS-MIX2‚ð—p‚¢‚œƒrƒbƒOƒf[ƒ^ŽûW‚É‚š‚¯‚錻ó‚Æ–â‘è“_
  10. ƒƒVƒ“ƒ|ƒWƒEƒ€3 S–[×“®ƒAƒuƒŒ[ƒVƒ‡ƒ“‚̃Xƒgƒ‰ƒeƒW[‚Æ’·Šú—\Œã„

  11. [àV ‹±”V˜NA•Ÿ“c _“ñA’†–ì œA‹ß“¡ ³‹PA£ì «lAç—t ‹M•FAŽO–Ø Œi‘ŸA‰ºì G–Ÿ FS–[×“®ƒAƒuƒŒ[ƒVƒ‡ƒ“Œã‚Ì“Ž’²—¥ˆÛŽ‚ª‰^“®‘Ï—p”\‚É—^‚Š‚é—L—p«
  12. ƒƒVƒ“ƒ|ƒWƒEƒ€8 S‹Ø‹•ŒŒ‚ð‚Ç‚€•]‰¿‚µAŽ¡—Âɔœ‰f‚³‚¹‚é‚©„

  13. ¬‘é —I“ñA‚‹Ž Aš¢’J —²Ž¡A ‰H”ö Ž‹MAŒ‹{ Œ’‰îA{“c •jA¬Œ ^‹±AŒ–{ ‘׎¡A ˆÉ“¡ Œ’‘ŸA‰ºì G–ŸFŠ¥”÷¬ŒŒŠÇáŠQ‚ÆŒŒŸ÷ƒZƒƒgƒjƒ“”Z“x
  14. ƒƒVƒ“ƒ|ƒWƒEƒ€13 “ñŽŸ«S‹ØÇ‚̐f’f‚̐i•à`ƒCƒ[ƒWƒ“ƒO‚ƃoƒCƒIƒ}[ƒJ[`„

  15. ŽR–{ ¹DA™‘º Gˆê˜YA—é–Ø G–ŸAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šA–î”ö” M—TA²“¡ —yA_’à Ž–çA²“¡ Œö—YA‚˜Q Œ’‘Ÿ˜YA‰ºì G–ŸFFabry•aŠ³ŽÒ‚É‚š‚¯‚é‰æ‘œf’f‚ƃoƒCƒIƒ}[ƒJ[
  16. ƒƒVƒ“ƒ|ƒWƒEƒ€15 “ú–{‚©‚ç”­M‚·‚é”x‚ŒŒˆ³f—Á„

  17. ²“¡ Œö—YA™‘º Gˆê˜YAŒš•” r‰îAÂ–Ø —³’jA–î”ö” M—TA‘呺 ~ˆêA‹e’n ‡—TA²“¡ ‘åŽ÷A•àV —ºA–ì–Ø ³“¹A»‘º Tˆê˜YA_’à Ž–çA‰ºì G–ŸF”x‚ŒŒˆ³Ç‚Ì‘S‚­V‚µ‚¢•aˆö’`”’‚É’…–Ú‚µ‚œ‘Šúf’f‚ÆŽ¡—ÖòŠJ”­‚̉”\«
  18. ƒŽRŒû“O‚ÆŠw‚ԏzŠÂŠí•a‚̍ŋ߂̎¡—ÃPart III ”x‚ŒŒˆ³„

  19. ²“¡ Œö—YA–î”ö” M—TA‘呺 ~ˆêA‹e’n ‡—TA²“¡ ‘åŽ÷A•àV —ºAŽR–{ ¹DAÂ–Ø —³’jAŒš•” r‰îA™‘º Gˆê˜YA‰ºì G–ŸF”x‚ŒŒˆ³Ç‚̍ŐV‚Ì–ò•šŽ¡—Âƍ¡Œã‚ÌŽ¡—ÖòŠJ”­
  20. ƒJCC-ACCƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€ Current and Future in TAVI and BRS in US and Japan„

  21. ‚‹Ž FAn Excellent Experience of the ACC Leadership Training Program yReport-ACC Leadership training programz
  22. ƒ“ú–{S‘Ÿ•aŠw‰ïE“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€ S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ŃtƒŒƒCƒ‹‚ðŽ•ž‚µ‚æ‚€„

  23. ’|“à ‰ëŽjAŒ–{ ‘׎¡AX M–FA‚‹Ž A™‘º Gˆê˜YAŽO‰Y ³’šAì–{ r•ãAŒF’J ‹Iˆê˜YAãŒŽ ³”ŽAâV–Ø ‰ÀŽA‰ºì G–ŸFŒoƒJƒe[ƒeƒ‹‘å“®–¬•Ù—¯’up‚É‚š‚¯‚éS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“\—Šw—Ö@Žm‚Ì—§ê‚©‚çuƒtƒŒƒCƒ‹v‚ð”FŽ¯‚µ‘Ήž‚·‚éd—v«\
  24. ƒƒtƒ@ƒCƒA[ƒTƒCƒhƒVƒ“ƒ|ƒWƒEƒ€6 Š¥¹k‚̍ŐV’mŒ©„

  25. ‘åŽR @”nFŠ¥“®–¬‰ßŽûk”œ‰ž‚É‚š‚¯‚銥“®–¬ŽüˆÍŽ‰–b‘gD‚Ì–ðŠ„\Š¥“®–¬ŠO–Œ‘€‚É’–Ú‚µ‚ā\
  26. ƒˆê”ʉ‰‘è@Œû‰‰ S•s‘S@”ñ–ò•š“I—Ö@A•a‘ԁ„

  27. ”öŒ` „AˆÉ“¡ Œ’‘ŸAi“¡ ’q•FA”©’† ˜a–ŸA]Œû ‹v”üŽqA‘ë G•¶A‹àˆä _A‰ºì G–ŸF’áo—̓pƒ‹ƒX”g‚ð—p‚¢‚œ’Ž‰¹”gŒŒŠÇV¶—Ö@‚́Aˆ³•‰‰×S•s‘Sƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚š‚¢‚āAS‹@”\’ቺ‚ð—}§‚·‚é
  28. ƒˆê”ʉ‰‘è@Œû‰‰ •Ù–ŒÇ2„

  29. ‚–Ø —S‰îA™ ³•¶AH“¡ rA”· Œ’ˆê˜YA“ñ•r ‘Ÿ˜YA£ì «lA‘ŠàV Œ’‘Ÿ˜YAŽR–{ ‹`lA‰ºì G–ŸFdÇ‘å“®–¬•Ù‹·óÇ‚ɑ΂·‚éƒoƒ‹[ƒ“Šg’£p‚̗Տ°¬Ñ
  30. ƒˆê”ʉ‰‘è@Œû‰‰ ‹~‹}E“Ë‘RŽ€EŽ©—¥_ŒoEƒXƒgƒŒƒXESg„

  31. ¬–쐣 „¶Aâ“c ‘וFAŽR“à ‹BA’Ò ŒOØŽqA‹yì ‘ì–çAŠ}ŒŽ M‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸFSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚ÌŒoŽž•Ï‰»‚Æ—\Œã‚É‹y‚Ú‚·‰e‹¿\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  32. ƒˆê”ʉ‰‘è@Œû‰‰ ’·Šú—\Œã—\‘ªˆöŽq„

  33. ‘å’Î ’mLA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA–î”ö” M—TA—é–Ø G–ŸA²“¡ —yA_’à Ž–çA“ñ•r ‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸFŒŒŸ÷’†Cyclophilin A‚É‚æ‚銥“®–¬ŽŸŠ³‚Ì’·Šú—\Œã—\‘ª
  34. ƒˆê”ʉ‰‘è@Œû‰‰ ’·Šú—\Œã—\‘ªˆöŽq„

  35. ‘å’Î ’mLA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA–î”ö” M—TA—é–Ø G–ŸA²“¡ —yA_’à Ž–çA“ñ•r ‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸFŒŒŸ÷’†Adipsin”Z“x‚É‚æ‚銥“®–¬ŽŸŠ³‚Ì’·Šú—\Œã—\‘ª
  36. ƒˆê”ʉ‰‘è@Œû‰‰ S•s‘SE‚»‚Ì‘Œ„

  37. Š}ŒŽ M‘Ÿ˜YAâ“c ‘וFAŽR“à ‹BA¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žA‹yì ‘ì–çA²“¡ ‰ë”VA‚‹Ž A‹{“c •qA‰ºì G–ŸFHFpEFŠ³ŽÒ‚É‚š‚¯‚éBNP’l‚Æ—\Œã‚Æ‚ÌŠÖ˜A‚ÍHFrEFŠ³ŽÒ‚Æ“¯“™‚Å‚ ‚é
  38. ƒˆê”ʉ‰‘è@Œû‰‰ S•s‘SE‚»‚Ì‘Œ„

  39. ¬–쐣 „¶Aâ“c ‘וFAŽR“à ‹BA’Ò ŒOØŽqA‹yì ‘ì–çAŠ}ŒŽ M‘Ÿ˜YA‚‹Ž A‹{“c •qA ‰ºì G–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  40. ƒˆê”ʉ‰‘è@Œû‰‰ S•s‘SE‚»‚Ì‘Œ„

  41. ŽR“à ‹BAâ“c ‘וFA‚“c „A‹{“c •qAŽO‰Y ³’šA’A–Ø šáˆê˜YA¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žA‹yì ‘ì–çAŠ}ŒŽ M‘Ÿ˜YAŒã‰ª L‘Ÿ˜YA ‚‹Ž A‰ºì G–ŸF–«S•s‘SŠ³ŽÒ‚Ì—\Œã‚É‚š‚¯‚鍶Žº‹ìo—Š‚Æ•nŒŒ‚̘AŠÖ‚̉e‹¿‚ÌŒŸ“¢\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  42. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ S•s‘S‚Ì—\Œã—\‘ª„

  43. Š}ŒŽ M‘Ÿ˜YAâ“c ‘וFA’A–Ø šáˆê˜YAŽR“à ‹BA¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žA‹yì ‘ì–çA‚‹Ž A‹{“c •qA‰ºì G–ŸF–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚éV‚µ‚¢—\Œã—\‘ªƒŠƒXƒNƒXƒRƒA
  44. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ S•s‘S‚Ì—\Œã—\‘ª„

  45. ŽR“à ‹BAâ“c ‘וFA”’ŒË ’A¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žA‹yì ‘ì–çAŠ}ŒŽ M‘Ÿ˜YA²“¡ ‰ë”VAŒã‰ª L‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸFS•s‘SƒnƒCƒŠƒXƒNÇ—á‚É‚š‚¯‚éS–[×“®‚Ì—\Œã‚ւ̉e‹¿‚Æ”­Ç—\‘ªƒŠƒXƒNƒXƒRƒA‚ÌŒŸ“¢\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  46. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ S•s‘S‚Ì—\Œã—\‘ª„

  47. ‹yì ‘ì–çAâ“c ‘וFAŽO‰Y ³’šA’A–Ø šáˆê˜YAŽR“à ‹BA¬–쐣 „¶A’Ò ŒOØŽqAŠ}ŒŽ M‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸFƒXƒ^ƒ`ƒ“‚Ì–òÜ‹­“x‚ªS‹Ø[ÇŠ³ŽÒ‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢ \ CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  48. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ Ç—á•ñ@S“à–Œ‰Š„

  49. –î”ö” M—TA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA—é–Ø G–ŸA²“¡ Œö—YA ‰ºì G–ŸFBartonella quintanaŠŽõ‚É”º‚€ŠŽõ«S“à–Œ‰Š‚̈ê—á
  50. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ Ç—á•ñ@S“à–Œ‰Š„

  51. –î”ö” M—TA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA—é–Ø G–ŸA²“¡ Œö—YA‰ºì G–ŸFBartonella quintanaŠŽõ‚É”º‚€ŠŽõ«S“à–Œ‰Š‚̈ê—á
  52. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ •s®–¬Eƒy[ƒXƒ[ƒJ[‚ƐSƒGƒR[„

  53. ŽO–Ø Œi‘ŸA•Ÿ“c _“ñA’†–ì œA‹ß“¡ ³‹PA£ì «lA•œ–ì “¹ŠîA[àV ‹±”V˜NA”‘ò ‘EA‰ºì G–ŸFS–[×“®Š³ŽÒ‚É‚š‚¯‚鍶SŽšŒŒ—¬‘¬“x’ቺ‚ÌŠñ—^ˆöŽq‚ÌŒŸ“¢
  54. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ S•s‘S@—\‘ªˆöŽq2„

  55. ç—t ‹M•FA’†–ì œA‹ß“¡ ³‹PA£ì «lA•œ–ì “¹ŠîA[àV ‹±”V˜NAŽO–Ø Œi‘ŸA”‘ò ‘EA•Ÿ“c _“ñA‰ºì G–ŸFS‘ŸÄ“¯Šú—Ö@iCRTj‚̍¶Žº4‹ÉƒŠ[ƒh‚É‚š‚¯‚é—LŒø«‚š‚æ‚ѐSŒŒŠÇƒCƒxƒ“ƒg‚ÉŠÖ‚·‚錟“¢
  56. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ CTPEHE”xŒŒð„

  57. Œš•” r‰îA™‘º Gˆê˜YAÂ–Ø —³’jAŽO‰Y ³’šAŽR–{ ¹DA–î”ö” M—TA—é–Ø G–ŸA²“¡ —yA_’à Ž–çA²“¡ Œö—YA‰ºì G–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚Ì’·Šú—\Œã‰ü‘PŒø‰Ê
‘æ22‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2016”N7ŒŽ16“ú`17“úA“Œ‹žj

    ƒƒVƒ“ƒ|ƒWƒEƒ€9FŠî‘bŒ€‹†‚ð—\–hS‘Ÿ•aŠw‚Ì–¢—ˆ‚ÉŠˆ‚©‚·„

  1. Œ–{‘׎¡A‹ààV³”́A‰F’Ë—T‹IA‰ºìG–ŸFS‹Ø[ÇŒã‚̍œ‚̕ω»‚Ɖ^“®—Ö@‚É‚æ‚é‰î“üŒø‰ÊF“®•šƒ‚ƒfƒ‹‚ð—p‚¢‚œSEœŠÖ˜Ai‘æ13‰ñ–Ø‘º“oÜiŠw‰ïÜjŽóÜj
  2. ƒYIAƒZƒbƒVƒ‡ƒ“„

  3. ’|“à‰ëŽjAŒ–{‘׎¡Aì–{r•ãAXM–FAŒF’J‹Iˆê˜YAˆÉ“¡Œ’‘ŸAâ“c‘וFAãŒŽ³”ŽAâV–؉ÀŽA‰ºìG–ŸF‘å“®–¬áŽE‰ð—£‚ɑ΂·‚ép‘O‚©‚ç‚̌ċzƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÍŽüpŠúŒÄ‹zŠí‡•¹Ç‚ðŒž­‚·‚éiÅ—DGÜŽóÜj
  4. ’A–Øšáˆê˜YAâ“c‘וFA•Ÿ–{‹`OA–î–ì‰ë•¶A–啶r–ŸA‘ã“c_”VAˆÀ“c‘A‰ºìG–ŸFS•s‘SŠ³ŽÒ‚š‚æ‚уnƒCƒŠƒXƒNŒQ‚É‚š‚¯‚é‰^“®‘jŠQˆöŽq‚ÌŒŸ“¢|‘S‘‘œŽ{Ý‹€“¯ƒRƒz[ƒgŒ€‹†‚æ‚èi—DGÜŽóÜj
  5. ƒƒVƒ“ƒ|ƒWƒEƒ€4F”x‚ŒŒˆ³Ç‚ɑ΂·‚éS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“„

  6. HŒŽŽO“ށA™‘ºGˆê˜YAÂ–Ø—³’jAŠ`‰Ô—²ºAXM–FAˆÉ“¡CA‰ºìG–ŸAãŒŽ³”ŽF–«ŒŒðÇð«”x‚ŒŒˆ³‚ɑ΂·‚éŒÄ‹CƒKƒX•ªÍ‚ð—p‚¢‚œ”ñNP“I‚ȏdÇ“x•]‰¿–@
‘æ162‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2016”N6ŒŽ4“úA·‰ªj

    ƒYIAÇ—á”­•\•”–偄

  1. ŽO–ØŒi‘ŸA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA£ì«lA•œ–쓹ŠîAç—t‹M•FA[àV‹±”V˜NA”‘ò@‘EA‰ºìG–ŸF•s®–¬ŒŽ«‰EŽºS‹ØÇ‚̗Տ°‘œ‚ɍ“Ž—‚µ‚œSƒTƒ‹ƒRƒCƒh[ ƒVƒX‚Ì‚P—á
  2. ƒYIAŒ€‹†”­•\•”–偄i–Å—DGÜŽóÜj

  3. ¬‘é—I“ñA‚‹Ž@Aš¢’J—²Ž¡A‰H”öŽ‹MAŒ‹{Œ’‰îA{“c@•jA¬Œ^‹±AŒ–{‘׎¡A ˆÉ“¡Œ’‘ŸA‰ºìG–ŸFŒŒŸ÷ƒZƒƒgƒjƒ“”Z“x‚ÍŠ¥”÷¬ŒŒŠÇáŠQ‚𔜉f‚·‚é
  4. ƒˆê”ʉ‰‘聄

  5. ‚ŒŽ^ŒáA‰Í’Á@‘AHŽR³”NAì–{r•ãAâV–؉ÀŽAÂ–Ø—³’jA™‘ºGˆê˜YA‰ºìG–ŸFR‘ÌŠÖ˜AŒ^‹‘â”œ‰žiAMRj‚ð‡•¹‚µ‚œS‘ŸˆÚA‚̈ê—á
  6. {“c@•jAŒ‹{Œ’‰îAš¢’J—²Ž¡A‰H”öŽ‹MAŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸA²“¡‰pºAXìF‘¥AŠC–ì—Ï–ŸFHybridŽèpŽº‚É‚š‚¢‚ďW–ñ“I‰Á—Âð—v‚µ‚œu‚œ‚±‚‚ڌ^S‹ØÇv‚̈ê—á
  7. ›Á@Œ³‹gA‰H”öŽ‹MAŒ‹{Œ’‰îAš¢’J—²Ž¡AŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFSƒTƒ‹ƒRƒCƒh[ƒVƒX‚ÉŠ¥¹k«‹·SÇ‚ð‡•¹‚µ‚œ2Ç—á
  8. Š}ŒŽM‘Ÿ˜YAâ“c‘וFA’A–Ø‘sˆê˜YAŽR“à@‹BA¬–쐣„¶A’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çA‚‹Ž@A‰ºìG–ŸA‹{“c@•qF–«S•s‘SŠ³ŽÒ‚ÌŠÈ•Ö‚È—\Œã—\‘ªƒŠƒXƒNƒX ƒRƒA‚ÌŠJ”­
  9. ˆ¢•”—Ú—žAâ“c‘וFAŽO‰Y³’šAŽR“à@‹BA¬–쐣„¶A’ÒŒOØŽqA ‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YAŒã‰ªL‘Ÿ˜YA‚‹Ž@A‰ºìG–ŸA‹{“c@•qF“ú–{‚Ì–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚éÝ‘NŠÇ—‚Æ—\Œã‚ÉŠÖ‚·‚錀‹†|CHART-2Œ€‹†‚©‚ç‚Ì•ñ|
  10. ’ÒŒOØŽqAâ“c‘וFAŽO‰Y³’šAŒã‰ªL‘Ÿ˜YA ’A–Ø‘sˆê˜YAŽR“à@‹BA¬–쐣„¶Aˆ¢•”—Ú—žA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA‚‹Ž@A‰ºìG–ŸA‹{“c@•qF¶Žº‹ìo—Š‚ª’ቺ‚µ‚œS•s‘S‚ƍ¶Žº‹ìo—Š‚ª•Û‚œ‚ê‚œS•s‘S‚̗Տ°Šw“I“Á’¥‚É‚š‚¯‚鍷|CHART-2Œ€‹†‚Ì’mŒ©|
  11. ’†–ì@œA•Ÿ“c_“ñA’·’J•”—Y”òA–Ø‘º‹`—²A•œ–쓹ŠîA[àV‹±”V˜NAç—t‹M•FAŽO–ØŒi‘ŸA”‘ò@‘EA‰ºìG–ŸFƒtƒ@ƒ[Žl’¥ÇpŒã‚ÌPVC‚ɑ΂µA‘å“®–¬Š¥ë‚©‚ç‚Ì’Ê“d‚ª—LŒø‚Å‚ ‚Á‚œˆê—á
  12. [àV‹±”V˜NA’†–ì@œA‹ß“¡³‹PA£ì«lAç—t‹M•FAŽO–ØŒi‘ŸA•Ÿ“c_“ñA‰ºìG–ŸFJ wave‚ÌŠÖ˜A‚ªŽŠŽ‚³‚ê‚éSŽº×“®”­ì‚ð‹N‚±‚µ‚œŽá”NBrugadaÇŒóŒQ‚̈ê—á
  13. ’†–ì@œA•Ÿ“c_“ñA’·’J•”—Y”òA–Ø‘º‹`—²A•œ–쓹ŠîA[àV‹±”V˜NAç—t‹M•FAŽO–ØŒi‘ŸA”‘ò@‘EA‰ºìG–ŸFì“®Šm”FƒeƒXƒg‚É‚æ‚è“K³‚ÈICDÝ’肪‰Â”\‚Å‚ ‚Á‚œ•ÂÇ«”ì‘åŒ^S‹ØÇ‚Ì1—á
  14. ç—t‹M•FA•Ÿ“c_“ñA’†–ì@œA’·’J•”—Y”òA•œ–쓹ŠîA[àV‹±”V˜NA–Ø‘º‹`—²AŽO–ØŒi‘ŸA”‘ò@‘EA‰ºìG–ŸFŠ¥¹k«‹·SÇ‚ÌŠÖ—^‚ª‹^‚í‚ê‚éSŽº×“®‚ɑ΂µ‚ÄS-ICDAž‚Ý‚ðŽ{s‚µ‚œ1—á
  15. ™àV@AŒš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡@—yA_’ÍŽ–çA²“¡Œö—YA‰ºìG–ŸF”œ•œ‚·‚é”sŒŒÇ«”xÇð‚ÅŽèpŽ¡—ÂƂȂÁ‚œVSD‡•¹ŠŽõ«S“à–Œ‰Š‚Ì1—á
  16. Œš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡@—yA_’ÍŽ–çA²“¡Œö—YA‰ºìG–ŸA¬ŽRk‘Ÿ˜YA’†Œé•¶AXè—TŽqA‰ª“cŽ“WAˆÀ’B@—AâV–؉ÀŽFBMPR2ˆâ“`Žq•ÏˆÙ‚ªf’f‚³‚ê‚œASD‡•¹”x“®–¬«‚ŒŒˆ³Ç‚Ì1—á
  17. –î”ö”M—TA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽO‰Y³’šAŽR–{¹DA—é–؏G–ŸA²“¡Œö—YA‰ºìG–ŸF‹}‘¬‚ɐis‚µ‚œ‹­”çÇ‚É”º‚€”x‚ŒŒˆ³Ç‚Ì1—á
  18. Â–Ø—³’jA™‘ºGˆê˜YA—é–؏G–ŸAŽO‰Y³’šAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@—yA_’ÍŽ–çA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Æ“‡Žž’²Ç‚ɂ‚¢‚Ä‚ÌŒŸ“¢
  19. ‚‹ŽA‰ºìG–ŸF‰ä‚ª‘‚Ì–x«S•s‘SŠ³ŽÒ‚É‚š‚¢‚ĐS–[×“®‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿| CHART-2Œ€‹†‚©‚ç‚Ì•ñˆê
  20. ¬–쐣„¶Aâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA’A–Ø‘sˆê˜YAŽR“à‹BA’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA‹{“c@•qA‚‹ŽA‰ºìG–ŸFSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚Ì’nˆæ•Ê‚É‚š‚¯‚éŒoŽž•Ï‰»‚ÌŒŸ“¢
  21. _’ÍŽ–çAÂ–Ø—³’jA™‘ºGˆê˜YAŽO‰Y³’šAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡—yA²“¡Œö—YA‰ºìG–ŸF––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•a•ÏŒ`‘ԁ[OFDI‚É‚æ‚錟“¢[
‘æ2‰ñ“ú–{S‹ØÇŒ€‹†‰ïi2016”N5ŒŽ14“úAŒ–{Žsj

    ƒƒVƒ“ƒ|ƒWƒEƒ€FS‹ØÇ‚̉摜f’f„

  1. £ì«lA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA•œ–쓹ŠîAç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘ŸA”‘ò@‘EA‰ºìG–ŸFRecent progress in the management of cardiac sarcoidosis.
  2. ƒˆê”ÊŒû‰‰„

  3. Œ“‡«ŽmAŒŠì^‘Ÿ˜YA–k•—­ŽjA•Ÿ“cŒbˆêA’|Î‹±’mA‰ºìG–ŸAÖ“¡”\•FA“›ˆä—T”VF‚킪‘‚ÌŠg’£‘Š”ì‘åŒ^S‹ØÇ‚ð‘ΏۂƂµ‚œ‘œŽ{Ý“o˜^ŠÏŽ@Œ€‹†.
  4. ƒƒ|ƒXƒ^[”­•\„

  5. ™àV@A‰H”öŽ‹MAŒ‹{Œ’‰îAŽR–{¹DAš¢’J—²Ž¡AŒ–{‘׎¡A™‘ºGˆê˜YA‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFFabry•a‚ÉŠ¥¹k«‚ð‡•¹‚µ‚œˆê—á.
  6. ŽO–ØŒ[‘ŸA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA£ì«lA•œ–쓹ŠîAç—t‚•FA[àV‹±”V˜NA‰ºìG–ŸF•s®–¬ŒŽ«‰EŽºS‹ØÇ‚Æ‚ÌŠÓ•Ê‚É‹ê—¶‚µ‚œSƒTƒ‹ƒRƒCƒh[ƒVƒX‚̈ê—á.
  7. _’ÍŽ–çA—é–؏G–ŸAŒŽRC•œA²“¡@ꡁA–î”ö”M—TAŽR–{¹DA‰H”öŽ‹MAŽO‰Y³’šAÂ–Ø—³’jAŒ–{‘׎¡A™‘ºGˆê˜YAÂ–ؐ³ŽuA‰ºìG–ŸF‘œ”­«d‰»Ç‚Ì”]Š²•a•Ï‚É‚æ‚é‚œ‚±‚‚ڐS‹ØÇ‚̈ê—á.
  8. Œ‹{Œ’‰îAŒ–{‘׎¡A‰H”öŽ‹MAš¢’J—²Ž¡A‚‹Ž@AˆÉ“¡Œ’‘ŸA“n粗ŽHA¯ì@NA‰ª“cŽ“TA‰ºìG–ŸF•ÂÇ«”ì‘åŒ^S‹ØÇ‚É‚œ‚±‚‚ڐS‹ØÇ‚𕹔­‚µ‚œ”xˆÚAÇ—á.
“Œ–k‘åŠw‘åŠw‰@ˆãŠwŒnŒ€‹†‰È•‘®‘n¶‰ž—pˆãŠwŒ€‹†ƒZƒ“ƒ^[ 2016ƒVƒ“ƒ|ƒWƒEƒ€i2016”N3ŒŽ22“úAå‘äŽsj
  1. ‰ºìG–ŸFƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`•”–åÐ‰î.
  2. ‰ºìG–ŸFæiˆã—ÊJ”­ƒRƒAƒZƒ“ƒ^[.
‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2016”N3ŒŽ18“ú`20“úAå‘äj

    ƒCongress Chairperson's Lecture„

  1. Shimokawa H. The Past, Present and Future of Cardiovascular Medicine in Japan\Lessons from the Great East Japan Earthquake\Circ J. 2016, 80(Suppl. I):I-3
  2. ƒPlenary Session„

  3. (PL01:Creating New Trends for Diagnosis and Treatment of Heart Failure\Integration of Basic Science, Clinical Research and Medical Practice\) Suzuki H, Matsumoto Y, Sumiyoshi A, Kaneta T, Ota H, Yoshikawa T, Sugimura K, Aoki T, Tatebe S, Miura M, Takahashi J, Satoh K, Miyata S, Ito K, Furukawa K, Fukumoto Y, Arai H, Yanai K, Kawashima R, Taki Y, Shimokawa H. Emerging Role of the Heart-Brain Axis via the Hippocampus in the Pathogenesis of Heart Failure. Circ J. 2016, 80(Suppl. I):I-29
  4. (PL03:The Great East Japan Earthquake: What We Learned in the past 5 Years and Future Perspectives) Aoki T, Sugimura K, Nakano M, Hao K, Onose T, Takahashi J, Fukuda K, Sakata Y, Shimokawa H. Lessons from the Great East Japan Earthquake Disaster. Circ J. 2016, 80(Suppl. I):I-40
  5. Yasuda S, Tahara Y, Miyamoto Y, Nishimura K , Takegami M, Ogawa H, Hirata K, Morino Y, Nakamura M, Takeishi Y, Shimokawa H, Naito H. Survey of Emergencies Adapting Business Continuity Plan for (non) Disaster-Base Hospitals; Report from Ministry of Health, Labour and Welfare Grant-in-Aid Investigators. Circ J. 2016, 80(Suppl. I):I-45
  6. (PL05:Treatment Paradigm of Coronary Artery Disease: 20 Years From Now!!) Hao K, Takahashi J, Sai G, Miyata S, Nishimiya K, Tsuburaya R, Matsumoto Y, Ito K, Sakata Y, Shimokawa H. Temporal Trends in the Incidence and Mortality of AMI for 30 Years \A Report from the Miyagi AMI Registry Study\ Circ J. 2016, 80(Suppl. I):I-53
  7. (PL07:Let's Discuss the Near Future of Cardiovascular Medicine)Ito K, Shindo T, Hatanaka K, Ogata T, Kurosawa R, Eguchi K, Kagaya Y, Nishimiya K, Tsuburaya R, Hao K, Taki H, Matsumoto Y, Takahashi J, Kanai H, Shimokawa H. Non-invasive Angiogenic Therapies with Acoustic Waves for Cardiovascular Diseases \Promising Approaches for the Future\ Circ J. 2016, 80(Suppl. I):I-68
  8. (PL08:Progress and Future in Pulmonary Hypertension Clinic) Satoh K, Sato T, Kikuchi N, Omura J, Kurosawa R, Suzuki K, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Miura M, Yaoita N, Fukumoto Y, Miyata S, Nakamura K, Ito H, Kadomatsu K, Shimokawa H. Cyclophilin A and Its Receptor Basigin Promote Vascular Smooth Muscle Proliferation and Pulmonary Hypertension \Possible Novel Therapeutic Target Pathway\ Circ J. 2016, 80(Suppl. I):I-76
  9. (PL09:Gender-Specific Medicine in Cardiovascular Disease\Up to Date\)Tsuji K, Sakata Y, Miura M, Miyata S, Nochioka K, Tadaki S, Ushigome R, Yamauchi T, Sato K, Onose T, Abe R, Oikawa T, Kasahara S, Takahashi J, Shimokawa H. Sex Differences in the Clinical Characteristics and Prognosis of Heart Failure with Preserved Ejection Fraction \Insights from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-85
  10. ƒSymposium„

  11. (SY02:Diagnosis and Treatment Using Recently Developed and Emerging Devices) Chiba T, Nakano M, Fukuda K, Kondoh M, Segawa M, Hirano M, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Impacts of Quadripolar Left Ventricular Lead and Left Ventricular Reverse Remodeling in Patients with Cardiac Resynchronization Therapy. Circ J. 2016, 80(Suppl. I):I-110
  12. (SY05:Frontline of CTEPH Practice in Japan in 2016) Yaoita N, Satoh K, Sato T, Kikuchi N, Omura J, Kurosawa R, Nogi M, Otsuki T, Kouzu K, Numano K, Suzuki K, Sunamura S, Tatebe S, Aoki T, Sugimura K, Horiuchi H, Shimokawa H. Crucial Role of Thrombin-Activated Fibrinolysis Inhibitor in the Pathogenesis of Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-131
  13. (SY07:Unsolved Issues in Heart Failure with Preserved Ejection Fraction (HFpEF) Based on Cohort Studies and Clinical Trials) Miura M, Sakata Y, Ushigome R, Tsuji K, Sato K, Tadaki S, Yamauchi T, Onose T, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Perspectives of Medical Therapies for Heart Failure with Preserved Ejection Fraction \Lessons from the CHART Studies and the SUPPORT Trial\ Circ J. 2016, 80(Suppl. I):I-145
  14. (SY10:New Strategy for the Secondary Prevention after Acute Coronary Syndrome Based on Cohort Studies) Oikawa T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Abe R, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Prognostic Impacts of Statins after Myocardial Infarction in the CHART-2 Study\A Validation Analysis of the gFire and Forgeth Theory\ Circ J. 2016, 80(Suppl. I):I-165
  15. (SY15:Bioresorbable Scaffolds (BRS) in Current and Future) Nishimiya K, Matsumoto Y, Uzuka H, Amamizu H, Oyama K, Hirano M, Shindo T, Tsuburaya R, Takahashi J, Ito K, Shimokawa H. Beneficial Effects of Novel Bioresorbable Polymer Coating on Enhanced Coronary Vasoconstricting Responses after Drug-Eluting Stent Implantation in Pigs in Vivo. Circ J. 2016, 80(Suppl. I):I-195
  16. (SY19:How Do We Establish Usefulness of Left Ventricular Assist Device in Japan?) Akiyam Ma, Fujiwara H, Katahira S, Kumagai K, Aoki T, Sugimura K, Fukuda K, Takahashi J, Kawamoto S, Shimokawa H, Saiki Y. Patient Selection for Mechanical Circulatory Support: A Single Center Review of 39 Patients. Circ J. 2016, 80(Suppl. I):I-224
  17. (SY20:Functional Impairment of Coronary Arteries; Clinical Implications and Further Evaluation)Tsuburaya R, Takahashi J, Nakamura A, Nozaki E, Sugi M, Yamamoto Y, Hiramoto T, Horiguchi S, Inoue K, Gotoh T, Katoh A, Shinozaki T, Miyata S, Yasuda S, Shimokawa H. Beneficial Effects of Long-acting Nifedipine on Coronary Vasomotion Abnormalities after Drug-Eluting Stent Implantation \The NOVEL Study\ Circ J. 2016, 80(Suppl. I):I-230
  18. (SY22:The Role of Heart Team Approach for Patients with CVD; Prevention to Rehabilitation)Kajikawa A, Miura M, Tanaka H, Saito Y, Suzuki H, Kakihana T, Takeuchi M, Syojima K, Myochin C, Kondoh M, Hao K, Sugimura K, Shimokawa H. Importance of Evidence-Based Approach for Heart Team in Heart Failure Practice. Circ J. 2016, 80(Suppl. I):I-244
  19. (SY24:How Should We Design and Conduct Sensible Clinical Research in Japan?) Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. The CHART-2 (Chronic Heart Failure Analysis and Registry in the Tohoku District-2) Study \Working Model of Observational Study in Japan\ Circ J. 2016, 80(Suppl. I):I-256
  20. (SY27:Mechanisms of Atherosclerosis in Metabolic Syndrome: From Bench to Bedside) Noda K, Fukumoto Y, Saito H, Godo S, Tsutsui M, Shimokawa H. Crucial Role of Rho-kinase in the Pathogenesis of Metabolic Syndrome \Suppression of Endothelial Nitric Oxide Synthase and AMP-activated Protein Kinase. Circ J. 2016, 80(Suppl. I):I-277
  21. ƒSpecial Session„

  22. (SS01:Let's Learn Medical Statistics in 3 Days! ‡@) Miyata S. Let's Learn Medical Statistics in 3 Days! ‡@ Circ J. 2016, 80(Suppl. I):I-288
  23. (SS04:Editors-in-Chief of the Top Medical Journals) Shimokawa H. Circulation Journal. Circ J. 2016, 80(Suppl. I):I-301
  24. (SS05:Let's Learn Medical Statistics in 3 Days! ‡A) Miyata S. Let's Learn Medical Statistics in 3 Days! ‡A Circ J. 2016, 80(Suppl. I):I-308
  25. (SS06:Novel Therapeutic Targets in Cardiovascular Disease)Satoh K, Suzuki K, Sunamura S , Otsuki T, Shimizu T, Ikeda I, Aoki T, Tatebe S, Sugimura K, Shimokawa H. Crucial Roles of Rho-kinase, Cyclophilin A and Its Receptor, Basigin, for Cardiac Hypertrophy, Fibrosis and Failure\Novel Therapeutic Targets of Heart Failure\ Circ J. 2016, 80(Suppl. I):I-310
  26. (SS07:Heart Failure Pandemic: An Emerging Agenda in the Super-aged Society) Miura M, Sakata Y, Miyata S, Ushigome R, Sato K, Tadaki S, Yamauchi T, Tsuji K, Onose T, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Shimokawa H. Current Status and Future Perspectives of Chronic Heart Failure in Japan \Lessons from the CHART Studies\ Circ J. 2016, 80(Suppl. I):I-318
  27. (SS08:30th Anniversary of NO Research: What Have We Learned and Where to Go) Tsutsui M, Shimokawa H, Yanagihara N, Mukae H, Otsuji Y. Circ J. Diverse Roles of NO Synthases \ Lessons from Genetically Modified Mice \ Circ J. 2016, 80(Suppl. I):I-324
  28. (SS09:Development of Non-invasive Therapy for Cardiovascular Diseases)Matsubara T, Ito K, Shimokawa H. Cardiac Shock Wave Therapy. Circ J. 2016, 80(Suppl. I):I-329
  29. Ito K, Shindo T, Kanai H, Shimokawa H. A New Angiogenic Therapy Using Low-intensity Pulsed Ultrasound for Angina Pectoris. Circ J. 2016, 80(Suppl. I):I-330
  30. (SS14:Let's Learn Medical Statistics in 3 Days! ‡B)Miyata S. Let's Learn Medical Statistics in 3 Days! ‡B Circ J. 2016, 80(Suppl. I):I-354
  31. (SS15:Large-scale Disasters and Cardiovascular Disease)Aoki T, Sugimura K, Nakano M, Hao K, Nihei T, Onose T, Takahashi J, Fukuda K, Sakata Y, Shimokawa H . Cardiovascular Diseases after the Great East Japan Earthquake Disaster \ Risk Factor for Cardiovascular Diseases. Circ J. 2016, 80(Suppl. I):I-357
  32. (SS17:Information and Communication Technology Will Launch a New Era in Cardiovascular Medicine)Ito K, Takahashi J, Hao K, Inoue K, Hiramoto T, Shimokawa H. A Prehospital 12-lead Electrocardiogram Transmission System in Emergency Cardiovascular Care in Miyagi. Circ J. 2016, 80(Suppl. I):I-371
  33. (SS18:Importance of Cardio-Oncology)Sugimura K, Yaoita N, Shimokawa H. Pulmonary Vascular Diseases in Patients with Malignancy. Circ J. 2016, 80(Suppl. I):I-377
  34. ƒESC-JCS Joint Symposium„

  35. (ESC-JCS JS:Coronary Microvascular Dysfunction Revisited)Takahashi J, Odaka Y, Shimokawa H. Plasma Serotonin Level is a Novel Biomarker for Presence of Coronary Microvascular Dysfunction in Patients with Unobstructive Coronary Artery Disease. Circ J. 2016, 80(Suppl. I):I-384
  36. ƒRound Table Discussion„

  37. (RT04:Management of Heart Failure Patients in the Highly Aged Society in Japan) Sakata Y, Miura M, Sato K, Tadaki S, Ushigome R, Yamauchi T, Miyata S, Takahashi J, Shimokawa H. Clinical Characteristics Treatments and Prognosis of Elderly Patients with Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-424
  38. (RT08:The Present Situation of Sudden Cardiac Death and the Role of ICDs in Japan)Fukuda K. Satake H, Sakata Y, Miyata S, Nakano M, Kondo M, Segawa M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Current Status of Sudden Cardiac Death with Implantable Cardioverter-Defibrillator in Patients with Chronic Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-444
  39. ƒTopic„

  40. (TP02:Clinical Practice of Right Heart Failure)Tatebe S, Sugimura K, Aoki T, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kozu K, Satoh K, Shimokawa H. Pathophysiology and Treatment of Right Heart Failure in Patients with Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-479
  41. (TP07:The Vascular Adventitia: An Active Participant in Vessel Pathogenesis from the gOutside inh)Nishimiya K, Matsumoto Y, Takahashi J, Uzuka H, Wang H, Tsuburaya R, Hao K, Ohyama K, Odaka Y, Miyata S, Ito K, Shimokawa H. Enhanced Adventitial Vasa Vasorum Formation in Patients with Vasospastic Angina \Assessment with Optical Frequency Domain Imaging\ Circ J. 2016, 80(Suppl. I):I-516
  42. (TP08:Implication of Frailty and Sarcopenia in Cardiology Practice)Matsumoto Y, Takeuchi M, Mori N , Takahashi J, Sugimura K, Miura M, Kumagai K, Kawamoto S, Furukawa K, Arai H, Saiki Y, Kohzuki M, Shimokawa H. Important Roles of Frailty Assessment and Rehabilitation for the Elderly Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. Circ J. 2016, 80(Suppl. I):I-521
  43. ƒMeet the Expert„

  44. (ME01:Therapeutic Strategy for Brugada Syndrome)Nakano M, Fukuda K, Kondo M, Segawa M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Overview of Brugada Syndrome \Epidemiology and Diagnosis\ Circ J. 2016, 80(Suppl. I):I-542
  45. Matsumoto Y, Takeuchi M, Mori N, Takahashi J, Sugimura K, Miura M, Kumagai K, Kawamoto S, Furukawa K, Arai H, Saiki Y, Kohzuki M, Shimokawa H. Roles of Transcatheter Aortic Valve Replacement and Cardiac Rehabilitation for the Elderly Patients with Aortic Stenosis. Circ J. 2016, 80(Suppl. I):I-550
  46. (ME04:Balloon Pulmonary Angioplasty: Recent Advances of Management for Patients with Chronic Thromboembolic Pulmonary Hypertension)Sugimura K, Aoki T, Miura M, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kozu K, Satoh K, Shimokawa H . Efficacy and Safety of Balloon Pulmonary Angioplasty in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-559
  47. (ME05:Use of Bio-makers in the Cardiovascular Medicine)Satoh K, Otsuki T, Shimokawa H. Cyclophilin A: A Novel Biomarker for Patients with Coronary Artery Disease. Circ J. 2016, 80(Suppl. I):I-562
  48. (ME10:Diagnosis of Vasospastic Angina)Tsuburaya R, Takahashi J, Nishimiya K, Hao K, Matsumoto Y, Shimokawa H. Coronary Hyperconstricting Response Induced by a Drug-eluting Stent as a Remaining Important Issue Even in the Second Generation Era \ Beneficial Effects of Long-acting Nifedipine. Circ J. 2016, 80(Suppl. I):I-593
  49. ƒMorning Lecture„

  50. (ML22:Management of Chronic Tromboembolic Pulmonary Hypertension)Sugimura K, Shimokawa H. Management of Chronic Tromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-618
  51. ƒLate Breaking Clinical Trials/Cohort Studies„

  52. (LBCT/LBCS I:Coronary Artery Disease)Oikawa T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Abe R, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Prognostic Impact of Statin Intensity in Patients with Ischemic Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-627
  53. (LBCT/LBCS II:Arrhythmia, Hypertension)Ikeda T, Ogawa H, Atarashi H, Inoue H, Uchiyama S, Kitazono T, Yamashita T, Shimizu W, Kaikita K, Kamouchi M, Fukuda K, Matsui K, Shimokawa H. Effectiveness and Safety of Rivaroxaban in Patients with Non-Valvular Atrial Fibrillation \The Second Report from the EXPAND Study\ 11 Circ J. 2016, 80(Suppl. I):I-632
  54. (LBCT/LBCS III:Intervention)Tsuburaya R, Takahashi J, Nakamura A, Nozaki E, Sugi M, Yamamoto Y, Hiramoto T, Horiguchi S, Inoue K, Gotoh T, Katoh A, Shinozaki T, Miyata S, Yasuda S, Shimokawa H. Beneficial Effects of Long-acting Nifedipine on Coronary Vasomotion Abnormalities after Drug-Eluting Stent Implantation \The NOVEL Study\ Circ J. 2016, 80(Suppl. I):I-639
  55. (LBCT/LBCS IV:Heart Failure)Miura M, Sakata Y, Miyata S, Tadaki S, Ushigome R, Sato K, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Shimokawa H. Beneficial Effect of Additive Use of Olmesartan to Beta-Blockers in Hypertensive Patients with Heart Failure with Preserved Ejection Fraction. Circ J. 2016, 80(Suppl. I):I-643
  56. Sugimura K, Miura M, Aoki T, Tatebe S, Yamamoto S, Suzuki H, Yaoita N, Kouzu K, Miyata S, Sakata Y, Shimokawa H. Prognostic Impact of Furosemide in Chronic Heart Failure\A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-645
  57. Kotooka N, Sato Y, Mizuno A, Eguchi K, Inomata T, Yamamoto K, Tsutsui H, Masuyama T, Kitakaze M, Inoue T, Shimokawa H, Shin-Ichi Momomura, Yoshihiko Seino, Koichi Node. Home Telemonitoring Study for Japanese Patients with Heart Failure (HOMES-HF). Circ J. 2016, 80(Suppl. I):I-647
  58. ƒFeatured Research Session„

  59. (FRS05:Heart Failure, Treatment)Suda A, Takahashi J, Hao K, Sakata Y, Miyata S, Miura M, Shimokawa H. Prognostic Impacts of Revascularization Strategy and Residual Coronary Stenosis in Patients with Ischemic Heart Failure. Circ J. 2016, 80(Suppl. I):I-688
  60. (FRS06:Heart Failure, Basic and Cardiac Function)Suzuki K, Satoh K, Ikeda S, Sunamura S, Otsuki T, Sato T, Kikuchi N, Omura J, Kurosawa R, Nogi M, Numano K, Sugimura K, Aoki T, Tatebe S, Miyata S, Mukherjee R, Francis G Spinale, Kadomatsu K, Shimokawa H. Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure-Overload in Mice. Circ J. 2016, 80(Suppl. I):I-695
  61. (FRS13:Coronary Artery Disease, Treatment)Uzuka H, Matsumoto Y, Nishimiya K, Amamizu H, Ohyama K, Hirano M, Hao K, Tsuburaya R, Ito K, Takahashi J, Shimokawa H. Catheter-based Renal Denervation Suppresses Coronary Hyperconstricting Responses after Drug-eluting Stent Implantation in Pigs in Vivo. Circ J. 2016, 80(Suppl. I):I-733
  62. Hatanaka K, Ito K, Shindo T, Ogata T, Kurosawa R, Kagaya Y, Eguchi K, Shimokawa H. Molecular Mechanisms of Angiogenic Effects of Low-energy Shock Wave Therapy: Potential Involvement of Mechanotransduction Pathways. Circ J. 2016, 80(Suppl. I):I-734
  63. (FRS14:Cardiovascular Disease, Preventive Medicine)Kasahara S, Sakata Y, Miura M, Ushigome R, Sato K, Tadaki S, Onose T, Tsuji K, Yamauchi T, Abe R, Oikawa T, Takahashi J, Miyata S, Shimokawa H. The Risk Score to Predict Long-term Prognosis of Patients with Chronic Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-739
  64. Yamauchi T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Clinical Backgrounds and Prognostic Impacts of New Onset Atrial Fibrillation \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-742
  65. (FRS19:Heart Failure, Pulmonary Hypertension)Kikuchi N, Satoh K, Omura J, Sato T, Kurosawa R, Nogi M, Otsuki T, Numano K, Kouzu K, Suzuki K, Sunamura S, Tatebe S, Aoki T, Sugimura K, Shimokawa H. Selenoprotein P Promotes Vascular Smooth Muscle Cell Proliferation and Pulmonary Hypertension \A Possible Novel Therapeutic Target\ Circ J. 2016, 80(Suppl. I):I-769
  66. Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, Sunamura S, Nogi M, Suzuki K, Shimokawa H. nvolvement of Thrombin Activatable Fibrinolysis Inhibitor in the Pathogenesis of Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-771
  67. Tsutsui M, Ishida M, Noguchi K, Shimokawa H. Protective Role of Myelocytic Nitric Oxide Synthases in Hypoxic Pulmonary Hypertension in Mice. Circ J. 2016, 80(Suppl. I):I-773
  68. ƒYoung Investigator's Award Finalists Lectures (Clinical Research)„

  69. Suzuki H, Matsumoto Y, Ota H, Sugimura K, Takahashi J, Ito K, Miyata S, Furukawa K, Arai H, Fukumoto Y, Taki Y, Shimokawa H. Hippocampus Abnormalities are Associated with Depressive Symptoms and Cognitive Impairment in Patients with Chronic Heart Failure. Circ J. 2016, 80(Suppl. I):I-841
  70. Nishimiya K, Matsumoto Y, Takahashi J, Uzuka H, Wang H, Tsuburaya R, Hao K, Ohyama K, Odaka Y, Miyata S, Ito K, Shimokawa H. Enhanced Adventitial Vasa Vasorum Formation in Patients with Vasospastic Angina \Assessment with Optical Frequency Domain Imaging\ Circ J. 2016, 80(Suppl. I):I-844
  71. ƒYoung Investigator's Award Finalists Lectures (Basic Research) )„

  72. Godo S, Sawada A, Saito H, Ikeda S, Enkhjargal B, Suzuki K, Tanaka S, Shimokawa H. Disruption of Physiological Balance between Nitric Oxide and Endothelium-dependent Hyperpolarization Impairs Cardiovascular Homeostasis in Mice. Circ J. 2016, 80(Suppl. I):I-846
  73. ƒOral Presentation (English)„

  74. (OE07:ACS/AMI, Basic)Shindo T, Ito K, Ogata T, Hatanaka K, Kurosawa R, Eguchi K, Kagaya Y, Hanawa K, Aizawa K, Shirato T, Miyata S, Taki H, Hasegawa H, Kanai H, Shimokawa H. Low-intensity Pulsed Ultrasound Enhances Angiogenesis and Ameliorates Left Ventricular Dysfunction in a Mouse Model of Acute Myocardial Infarction. Circ J. 2016, 80(Suppl. I):I-894
  75. (OE12:ACS/AMI, Clinical/Pathophysiology 1)Nihei T, Yamamoto Y, Kudo S, Hanawa K, Hasebe Y, Takagi Y, Minatoya Y, Sugi M, Shimokawa H. Impact of the Fukushima Daiichi Nuclear Power Plant Disaster on Acute Myocardial Infarction in Iwaki City. Circ J. 2016, 80(Suppl. I):I-923
  76. (OE17:Heart Failure, Basic 1)Mukaiyama Y, Matsuhashi T, Kikuchi K, Shima H, Takeuchi Y, Mishima E, Akiyama Y, Suzuki C, Suzuki T, Aoki T, Ito S, Nakada K, Hayashi K, Osaka H, Abe T. Mitochonic Acid MA-5 Binds to Mitochondria and Ameliorates Mitochondrial Disease Cardiac Myocyte Damage. Circ J. 2016, 80(Suppl. I):I-950
  77. (OE32:Atherosclerosis, Clinical 1) Otsuki T, Satoh K, Sugimura K Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kouzu K, Nihei T, Takahashi J, Miyata S, Shimokawa H. Prognostic Impacts of Plasma Levels of Cyclophilin A in Patients with Coronary Artery Disease. Circ J. 2016, 80(Suppl. I):I-1043
  78. (OE38:Preventive Medicine/Epidemiology/Education 2)Onose T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Abe R, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Temporal Changes in Post-Traumatic Stress Disorder after the Great East Japan Earthquake \A Report from the CHART-2 Study\Circ J. 2016, 80(Suppl. I):I-1076
  79. (OE39:Ventricular Arrhythmia 4)Nakano M, Fukuda K, Kondoh M, Segawa M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S , Shimokawa H. Effectiveness of Radiofrequency Catheter Ablation on Premature Ventricular Contraction-Triggered Ventricular Fibrillation in Patients with Idiopathic Ventricular Fibrillation. Circ J. 2016, 80(Suppl. I):I-1082
  80. (OE44:Heart Failure, Basic 2) Sunamura S, Satoh K, Suzuki K, Ikeda S, Omura J, Kikuchi N, Sato Th, Kurosawa R, Nogi M, Numano K, Shimizu T, Shimokawa H . Crucial Role of ROCK1 to Maintain Contractile Function in Response to Pressure-Overload in Mice. Circ J. 2016, 80(Suppl. I):I-1114
  81. (OE48:Atherosclerosis, Clinical 2) Otsuki T, Satoh K, Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kouzu K, Nihei T, Takahashi J, Miyata S, Shimokawa H . Prognostic Impacts of Plasma Levels of Adipsin in Patients with Coronary Artery Disease. Circ J. 2016, 80(Suppl. I):I-1139
  82. (OE59:CTEPH BPA)Kozu K, Satoh K, Sugimura K, Aoki T, Miura M, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Otsuki T, Sato H, Miyata S, Shimokawa H. Plasma Cyclophilin A as a Useful Biomarker for the Effects of Percutaneous Transluminal Pulmonary Angioplasty in Patients with CTEPH. Circ J. 2016, 80(Suppl. I):I-1202
  83. Aoki T, Sugimura K, Miura M, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kouzu K, Satoh K, Shimokawa H. Effects of Percutaneous Transluminal Pulmonary Angioplasty on Oxygenation Capacity in Patients with Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-1203
  84. ƒOral Presentation (Japanese) „

  85. (OJ01:ACS/AMI, Clinical/Treatment)Kagaya Y, Ito K, Takahashi J, Matsumoto Y, Tsuburaya R, Hao K, Nishimiya K, Shindo T, Ogata T, Kurosawa R, Eguchi K, Hatanaka K, Miyata S, Shimokawa H. Low-energy Cardiac Shock Wave Therapy Ameliorates Left Ventricular Remodeling in Patients with Acute Myocardial Infarction. Circ J. 2016, 80(Suppl. I):I-1225
  86. (OJ04:Ventricular Arrhythmia, Conduction Block)Segawa M, Fukuda K, Nakano M, Kondoh M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Prognostic Impacts of Corticosteroid Therapy in Cardiac Sarcoidosis Patients with Advanced Heart Block. Circ J. 2016, 80(Suppl. I):I-1243
  87. (OJ07:Preventive Medicine/Epidemiology/Education)Oikawa T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Abe R, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. LDL-independent Beneficial Prognostic Impacts of Statins in Patients with Old Myocardial Infarction \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-1256
  88. (OJ12:Pulmonary Circulation)Omura J, Satoh K, Kikuchi N, Sato T, Kurosawa R, Nogi M, Otsuki T, Kouzu K, Suzuki K, Sunamura S, Tatebe S, Aoki T, Sugimura K, Shimokawa H . Disruption of Endothelial AMP-activated Protein Kinase Worsens Hypoxia-induced Pulmonary Hypertension in Mice. Circ J. 2016, 80(Suppl. I):I-1291
  89. (OJ18:Intravascular Imaging)Ohyama K, Matsumoto Y, Amamizu H, Uzuka H, Nishimiya K, Hao K, Tsuburaya R, Takahashi J, Shimokawa H . Increased Coronary Perivascular Adipose Tissue Volume in Patients with Vasospastic Angina\Correlations with Adventitial Vasa Vasorum Formation and Rho-kinase Activity\ Circ J. 2016, 80(Suppl. I):I-1326
  90. (OJ30:Coronary Artery Disease, Clinical)Nishimiya K, Wang H, Matsumoto Y, Takahashi J, Uzuka H, Hao K, Tsuburaya R, Amamizu H, Ohyama K, Masayasu Komatsu, Odaka Y, Ito K, Shimokawa H. Association of Enhanced Adventitial Vasa Vasorum Formation with Atherosclerotic Changes Adjacent to Myocardial Bridge \An Optical Frequency Domain Imaging Study\ Circ J. 2016, 80(Suppl. I):I-1395
  91. Yada T, Shimokawa H, Gotoh M, Ogasawara Y, Kajiya F. Important Role of Endogenous H2O2 during Reactive Hyperemia in Dogs in Vivo \An Infrared Fluorescence Microscope Study\ Circ J. 2016, 80(Suppl. I):I-1397
  92. (OJ40:Cost-health Care System) Nakayama M, Takehana K, Kohro T, Shimokawa H, IHE-J Cardiology Technical Committee. Japanese Circulation Society Releases the Standard Export Data Format for Standardized Structured Medical Information Exchange Extended Storage. Circ J. 2016, 80(Suppl. I):I-1457
  93. (OJ43:Heart Failure, Treatment 3)Miura M, Sakata Y, Miyata S, Sato K, Ushigome R, Tadaki S, Yamauchi T, Tsuji K, Onose T, Oikawa T, Kasahara S, Abe R, Nochioka K, Takahashi J, Shimokawa H. Prognostic Impacts of Supplemental Use of Angiotensin Receptor Blocker Olmesartan with a Special Reference to Left Ventricular Ejection Fraction. Circ J. 2016, 80(Suppl. I):I-1473
  94. ƒPoster Session (English)„

  95. (PE043:Metabolic Disorder 1)Tadaki S, Sakata Y, Miura Y, Fukumoto Y, Miura T, Yano M, Kadokami T, Daida H, Kitakaze M, Shimokawa H. Prognostic Impacts of Metabolic Syndrome in Patients with Chronic Heart Failure\A Report from the Multicenter Prospective Cohort Study\ Circ J. 2016, 80(Suppl. I):I-1759
  96. (PE044:Stroke)Tsutsui M, Kubota H, Noguchi K, Ishida M, Shimokawa H, Ohya Y. Complete Disruption of All Nitric Oxide Synthases Markedly Reduces Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Mice. Circ J. 2016, 80(Suppl. I):I-1767
  97. (PE085:Preventive Medicine/Epidemiology/Education 1)Abe R, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Assessment of Self-care Behavior in Patients with Chronic Heart Failure \A Report from the CHART Study\ Circ J. 2016, 80(Suppl. I):I-2039
  98. (PE089:Atrial/Supraventricular Arrhythmia, Clinical/Treatment 10)Fukasawa K, Fukuda K, Nakano M, Kondoh M, Segawa M, Hirano M, Chiba T, Miki K, Morosawa S, Shimokawa H. Impact of Sinus Rhythm Maintenance with Atrial Fibrillation Ablation on Exercise Tolerance. Circ J. 2016, 80(Suppl. I):I-2063
  99. (PE098:Cardiomyopathy 2)Segawa M, Fukuda K, Nakano M, Kondoh M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H . Improved Long-term Prognosis of Patients with Cardiac Sarcoidosis in the Present Era. Circ J. 2016, 80(Suppl. I):I-2115
  100. (PE099:Heart Failure, Prognosis)Kasahara S, Sakata Y, Miura M, Ushigome R, Sato K, Tadaki S, Onose T, Tsuji K, Yamauchi T, Abe R, Oikawa T, Takahashi J, Miyata S, Shimokawa H. B-Type Natriuretic Peptide Predicts Long-term Prognosis of Patients with Chronic Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-2122
  101. (PE107:Preventive Medicine/Epidemiology/Education 2)Tadaki S, Sakata Y, Miura Y, Fukumoto Y, Yano M, Kadokami T, Yasuda S, Daida H, Shimokawa H. Prognostic Impacts of Factors Interfering Daily Exercise in Patients with Chronic Heart Failure \A Multicenter Prospective Cohort Study\ Circ J. 2016, 80(Suppl. I):I-2180
  102. (PE117:Pulmonary Circulation 1)Hidenobu Takagi, Ota H, Sugimura K, Shimokawa H, Takase K. Clinical Severity of Chronic Thromboembolic Pulmonary Hypertension: Assessment on Lung Perfused Blood Volume Images Acquired by Dual-energy CT. Circ J. 2016, 80(Suppl. I):I-2241
  103. ƒPoster Session (Japanese)„

  104. (PJ019:Arrhythmia, Clinical/Diagnosis/Treatment 3)Hasebe Y, Kudo S, Nihei T, Hanawa K, Takagi Y, Minatoya Y, Yamamoto Y, Sugi M, Shimokawa H. Current Status of Triplet Therapy in Patients with Atrial Fibrillation Undergoing Coronary Angioplasty with Drug-eluting Stent in the NOAC Era. Circ J. 2016, 80(Suppl. I):I-2425
  105. (PJ029:Heart Failure, Prognosis)Tsuji K, Sakata Y, Miura M, Miyata S, Nochioka K, Tadaki S, Ushigome R, Sato K, Yamauchi T, Onose T, Abe R, Kasahara S, Takahashi J, Shimokawa H. Different Clinical Characteristics between HFpEF and HFrEF \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-2492
  106. (PJ042:CTEPH BPA)Yaoita N, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Miura M, Satoh K, Shimokawa H. Influence of Discontinuation of Medications after Successful Percutaneous Transluminal Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-2574
  107. Sato H, Ota H, Sugimura K, Aoki T, Miura M, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Kouzu K, Satoh K, Takase K, Shimokawa H. Percutaneous Transluminal Pulmonary Angioplasty Improves Biventricular Functions and Pulmonary Flow in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-2576
  108. (PJ044:Heart Failure, Treatment 1)Sugimura K, Miura M, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Sato H, Miyata S, Sakata Y, Shimokawa H. Prognostic Effect of Diuretics for Japanese Patients with Chronic Heart Failure\A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-2588
  109. (PJ066:Heart Failure, Pathophysiology)Sato K, Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Clinical Characteristics and Prognostic Factors of Elderly Patients with Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-2729
  110. (PJ070:Arrhythmia, Clinical/Diagnosis/Treatment 8)Hirano M, Yamamoto H, Hasebe Y, Fukuda K, Amamizu H, Morosawa S, Oyama K, Uzuka H, Takayama K, Shimokawa H. Development of a Novel Shock Wave Catheter Ablation System \A Preclinical Validation Study\ Circ J. 2016, 80(Suppl. I):I-2762
  111. (PJ079:Vascular Biology 1)Saito H, Sato S, Itoh A, Ikumi Y, Tanaka S, Godo S, Ida T, Fujii S, Akaike T, Shimokawa H. Important Roles of Endothelial Caveolin-1 in Maintaining Microvascular Homeostasis \Possible Protective System against Nitrative Stress\ Circ J. 2016, 80(Suppl. I):I-2820
  112. (PJ094:Thromboembolism/Antithrombotic Therapy/Thrombolysis 4)Miki K, Fukuda K, Nakano M, Kondo M, Segawa M, Hirano M, Chiba T, Morosawa S, Fukasawa K, Shimokawa H. Effectiveness and Safety of NOACs in Atrial Fibrillation Patients Undergoing Ablation Therapy with a Special Reference to Left Atrial Function. Circ J. 2016, 80(Suppl. I):I-2920
  113. (PJ107:Preventive Medicine/Epidemiology/Education 3)Ushigome R, Sakata Y, Miyata S, Miura M, Sato K, Tadaki S, Yamauchi T, Tsuji K, Onose T, Oikawa T, Abe R, Nochioka K, Shimokawa H. Temporal Changes in Sex Differences in Clinical Profiles of Patients with Symptomatic Heart Failure \A Report from the CHART Studies\ Circ J. 2016, 80(Suppl. I):I-3005
  114. (PJ108:Congenital Heart Disease/Kawasaki's Disease)Kondo M, Fukuda K, Nakano M, Segawa M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Impact of Prolonged QRS Duration for Tachyarrhythmic Events in Adult Patients with Postoperative Tetralogy of Fallot. Circ J. 2016, 80(Suppl. I):I-3011
‘æ207‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2016”N2ŒŽ29“úAå‘äŽsj
  1. ™àVAŒ‹{Œ’‰îA‰H”öŽ‹MAš¢’J—²Ž¡AŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF‹}«S‹Ø[ÇŽ¡—ÃŒã‚ɃwƒpƒŠƒ“‹Nˆö«ŒŒ¬”ÂŒž­ÇiHITj‚É‚æ‚鈟‹}«ƒXƒeƒ“ƒgŒŒðÇiSATj‚ðŒJ‚è•Ô‚µ‚œ1—á.
‘æ39‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï“Œ–k’n•û‰ïi2016”N2ŒŽ13“úAå‘äŽsj
  1. ™àVAŒ‹{Œ’‰îA‰H”öŽ‹MAš¢’J—²Ž¡AŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF‹}«S‹Ø[ÇŽ¡—ÃŒã‚ɃwƒpƒŠƒ“‹Nˆö«ŒŒ¬”ÂŒž­ÇiHITj‚É‚æ‚鈟‹}«ƒXƒeƒ“ƒgŒŒðÇiSATj‚ðŒJ‚è•Ô‚µ‚œ1—á.
  2. {“c•jA‚‹Ž@A_ŒË–ΗYA‹{ì”T—ŽqAŒ‹{Œ’‰îA‰H”öŽ‹MAš¢’J—²Ž¡AŒ–{‘׎¡A‹vŽu–{–ÎŽ÷A‰ºìG–ŸFŠO«‚­‚à–Œ‰ºoŒŒ‚Æ‹}«S‹Ø[Ç‚ð‡•¹‚µ‚œˆê—á.
‘æ45‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïŠwpW‰ïi2016”N2ŒŽ5`6“úA“¿“‡Žsj
  1. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV@—ºA_’ÍŽ–çAÂ–Ø—³’jAŒš•”r‰îA™‘ºGˆê˜YA‰ºìG–ŸF”x“®–¬ŒŒŠÇ“à”çAMPK‚Í”x‚ŒŒˆ³Ç‚̐is‚ð—}§‚·‚é.
  2. ‘å’Î’mGA²“¡Œö—YA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îA“ñ•r‘Ÿ˜YA‚‹Ž@A‹{“c@•qA‰ºìG–ŸFƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚銥“®–¬ŽŸŠ³‚Ì’·Šú—\Œã—\‘ª.
‘æ9‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2016”N1ŒŽ30“ú`31“úAŽD–yŽsj

    ƒÅ—DG‰‰‘èÜ„

  1. ’ҁ@ŒOØŽqAâ“c‘וFAŽO‰Y³’šA’A–Ø‘sˆê˜YAŽR“à@‹BA¬–쐣„¶Aˆ¢•”—Ú—žAŒã‰ªL‘Ÿ˜YA‚‹Ž@A‹{“c@•qA‰ºìG–ŸF‚킪‘‚É‚š‚¯‚鍶Žº‹ìo—Š‚ª•Û‚œ‚ê‚œS•s‘SŠ³ŽÒ‚̗Տ°“I“Á’¥‚É‚š‚¯‚鐫·@\CHART-2Œ€‹†‚©‚ç‚Ì’mŒ©\
  2. ƒÅ—DG‰‰‘èÜ„

  3. ›Á@Œ³‹gA‰H”öŽ‹MA‚‹Ž@AˆÉ“¡Œ’‘ŸA‹{“c@•qAŒ‹{Œ’‰îAš¢’J—²Ž¡AŒ–{‘׎¡Aâ“c‘וFA‰ºìG–ŸF‹}«S‹Ø[Ç”­Ç—Š‹y‚щ@“àŽ€–S—Š‚ÌŒo”N•Ï‰»‚̐«·‚ÉŠÖ‚·‚錟“¢@\Miyagi AMI Registry‚©‚ç‚Ì•ñ\
  4. ƒˆê”ʉ‰‘聄

  5. ŽR–{¹DA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jAŽO‰Y³’šA—é–؏G–ŸA‰ºìG–ŸFƒtƒ@ƒuƒŠ[•a‚É‚š‚¯‚éƒwƒeƒÚ‡‘̏—«Š³ŽÒ‚̃XƒNƒŠ[ƒjƒ“ƒO.
  6. ç—t‹M•FA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA£ì«lA•œ–쓹ŠîA[àV‹±Žj˜NAŽO–ØŒi‘ŸA”‘ò@‘EA‰ºìG–ŸF—ŒSŽº‚؁[ƒVƒ“ƒO‚É‚æ‚鍶Žºk¬Œø‰Ê‚ƐSŒŒŠÇƒCƒxƒ“ƒg‚ÌŠÖ˜A‚É‚š‚¯‚鐫·‚ÌŒŸ“¢.
  7. ŽO–ØŒi‘ŸA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA£ì«lA•œ–쓹ŠîAç—t‹M•FA[àV‹±Žj˜NA”‘ò@‘EA‰ºìG–ŸFS–[×“®‚Ì”xÃ–¬Šu—£p‘Ώۊ³ŽÒ‚É‚š‚¯‚鍶–[‚̍\‘¢“I‚š‚æ‚Ñ‹@”\“I•Ï‰»‚̐«·.
  8. ¬–쐣„¶Aâ“c‘וFA‹{“c@•qAŽO‰Y³’šA’A–Ø‘sˆê˜YAŽR“à@‹BA’ҁ@ŒOØŽqAˆ¢•”—Ú—žAŒã‰ªL‘Ÿ˜YA‚‹Ž@A‰ºìG–ŸFSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚ÌŒo”N•Ï‰»‚Ɛ«·@\CHART-2Œ€‹†‚©‚ç\
  9. ’A–Ø‘sˆê˜YAâ“c‘וFA•Ÿ–{‹`OA–î–ì‰ë•¶A–åãr–ŸA‘ã“c_”VAˆÀ“c@‘A‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚š‚æ‚Ñ‚»‚̃nƒCƒŠƒXƒNŒQ‚É‚š‚¯‚é‰^“®‘jŠQˆöŽq‚̐«·‚ÌŒŸ“¢@\‘S‘‘œŽ{Ý‹€“¯ƒRƒz[ƒgŒ€‹†‚æ‚è\
  10. Œš•”r‰îA™‘ºGˆê˜YAÂ–Ø—³’jAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡@ꡁA_’ÍŽ–çA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³ÇŠ³ŽÒ‚̐«·‚É‚æ‚é—\Œã‚ÌŒŸ“¢.

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2015”N
‘æ161‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2015”N12ŒŽ5“úAå‘äj

    ƒYIAŒ€‹†”­•\•”–偄i–—DGÜŽóÜj

  1. _’ÍŽ–çA—é–؏G–ŸA²“¡—yA–î”ö”M—TAŽR–{¹DA‰H”öŽ‹MAŽO‰Y³’šAŒš•”r‰îAÂ–Ø—³’jAŒ–{‘׎¡A™‘ºGˆê˜YA‰ºìG–ŸF‘œ”­«d‰»Ç‚Ì”]Š²•a•Ï‚É‚æ‚é‚œ‚±‚‚ڐS‹ØÇ‚̈ê—á
  2. ƒYIAÇ—á”­•\•”–偄i–—DGÜŽóÜj

  3. £ì«lA•Ÿ“c_“ñA’†–쐜A‹ß“¡³‹PA•œ–쓹•æAç—t‹M•FA[’˱”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸFS‘ŸƒTƒ‹ƒRƒCƒh[ƒVƒX‚É‚š‚¯‚éƒXƒeƒƒCƒhŽ¡—ÊJŽnŒã‚̐SŽº«•s®–¬‚ÌŒoŽž“I“Á’¥‚Ɖe‹¿ˆöŽq‚ÉŠÖ‚·‚錟“¢
  4. ƒˆê”ʉ‰‘聄

  5. ŽR–{¹DA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽO‰Y³’šA—é–؏G–ŸA–î”ö”M—TA²“¡—yA²“¡Œö—YA‰ºìG–ŸF“–‰È‚É‚š‚¯‚éFabry•a‚̐f—Âɂ‚¢‚Ä
  6. ’†–쐜A•Ÿ“c_“ñA‹ß“¡³‹PA£ì«lA•œ–쓹•æAç—t‹M•FA[•Y‹±”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸFƒsƒ‹ƒWƒJƒCƒjƒh“Š—^‚ŏoŒ»‚µ‚œ’x‰„“dˆÊ‚Ö‚ÌRFCA‚ª—LŒø‚Å‚ ‚Á‚œ‚ƍl‚Š‚ç‚ê‚éBrugadaÇŒóŒQÇ—á
  7. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–쐜A£ì«lA•œ–쓹ŠîAç—t‹M•FA[’˱”V˜NAŽO–ØŒi‘ŸA”‘ò‘EA‰ºìG–ŸF¶”xÃ–¬‹€’ÊŠ²‚ð—L‚µCryoballoonablationŽ{sŒã‚ɍĔ­‚ð”F‚ß‚œ”­ì«S–[×“®‚̈ê—á
  8. ‹yì‘ì–çAâ“c‘וFA’A–Ø‘sˆê˜YA‹ž—ºˆêA²“¡Œª“ñ˜YAŽR“à‹BA’ÒŒOØŽqA¬–쐣„¶Aˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YAŒã‰ªL‘Ÿ˜YA‚‹ŽAŽO‰Y³’šA‹{“c•qA‰ºìG–ŸF6ƒXƒ^ƒ`ƒ“‹­“x‚ªS‹Ø[ÇŠ³ŽÒ‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢| CHART-2Œ€‹†‚æ‚è[
  9. {“c•jA_ŒË–ΗYA‚‹ŽAŒ‹{Œ’‰îA‰H”öŽ‹MAš¢’J—²Ž¡AŒ–{‘׎¡A‰ºìG–ŸFŠO«‚­‚à–Œ‰ºoŒŒ‚Æ‹}«S‹Ø[Ç‚ð‡•¹‚µ‚œˆê—á
  10. ‰Á‰ê’J—T‘ŸAˆÉ“¡Œ’‘ŸA‚‹ŽAŒ–{‘׎¡A‰€’J—²Ž¡A‰H”öŽ‹MAŒ‹{Œ’‰îAi“¡’q•FA”öŒ`„A•àV—ºA]Œû‹v”üŽqA”©’†˜a–ŸA‹{“c•qA‰ºìG–ŸF‹}«S‹Ø[ÇŒã‚̍¶ŽºƒŠƒ‚ƒfƒŠƒ“ƒO‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Â̌ø‰Ê
  11. ‰H”öŽ‹MAŒ‹{Œ’‰îAŽR–{¹DA‰€’J—²Ž¡AŒ–{‘׎¡A™‘ºGˆê˜YA‚‹ŽAˆÉ“¡Œ’‘ŸA‰ºìG–ŸFFabry•a‚ÉŠ¥Šlk«‹·SÇ‚ð‡•¹‚µ‚œˆê—á
  12. [àV‹±”V˜NAŒ—’J—²Ž¡A‚‹ŽA{“c•jAŒ‹{Œ’‰îA‰H”öŽ‹MAŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸF”ñS‘ŸŽèp’†‚É”­Ç‚µ‚œ–òÜ—noƒXƒeƒ“ƒg—¯’uŒãˆŸ‹}«ƒXƒeƒ“ƒgŒŒðÇ‚̈ê—á
  13. “n•”Œ«A‹e’n—ƒAŽuŠ™@‘ñA‘哹Ž›”ò—Y”nA‰Á“¡d•FA‚‹ŽŽ–ŸA‹Ê“c–F–ŸA•Ÿˆäº’jA–îì@—F•ÛAŒˆäŠ²”VAŒã“¡•q˜aAŽR–{¹DA™‘ºGˆê˜YA‰ºìG–ŸF‰Â‹t«‚̍¶ŽºáŠQ‚ð‚«‚œ‚µ”x‚ŒŒˆ³‚ð‡•¹‚µ‚œPOEMSÇŒóŒQ‚Ì1—á
  14. ‘å]’@Â–Ø—³’jA_’ÍŽ–çA—é–؏G–ŸAŽR–{¹DAŽO‰Y³’šAŒš•”r‰îA™‘ºGˆê˜YA‰ºìG–ŸFŠO‰È“IŒŒð“Eœp‚ŗǍD‚ÈŒo‰ß‚ª“Ÿ‚ç‚ê‚œ”xÇðÇ‚̈ê—á
  15. —é–؏G–ŸA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA‰ºìG–ŸF“‡Žž’²Ç‚ð”wŒi‚ɍRƒŠƒ“Ž‰Ž¿R‘̏njóŒQ‚Å”­Ç‚µ‚œ”xÇðÇ‚̈ê—á
  16. ŽR“à‹BAâ“c‘וFA’A–Ø‘sˆê˜YA‹ž—ºˆêA²“¡Œª“ñ˜YA¬–쐣„¶A’ÒŒOØŽqAˆ¢•”—Ú—žAŠ}ŒŽM‘Ÿ˜YA‹yì‘ì–çAŒã‰ªL‘Ÿ˜YA‹{“c•qAŽO‰Y³’šA‚‹ŽA‰ºìG–ŸF‰ä‚ª‘‚Ì–x«S•s‘SŠ³ŽÒ‚É‚š‚¢‚ĐS–[×“®‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿| CHART-2Œ€‹†‚©‚ç‚Ì•ñˆê
  17. ¬–쐣„¶Aâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’š@’A–Ø‘sˆê˜YAŽR“à‹BA’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çAŠ}ŒŽM‘Ÿ˜YA‹{“c@•qA‚‹ŽA‰ºìG–ŸFSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚Ì’nˆæ•Ê‚É‚š‚¯‚éŒoŽž•Ï‰»‚ÌŒŸ“¢
  18. _’ÍŽ–çAÂ–Ø—³’jA™‘ºGˆê˜YAŽO‰Y³’šAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡—yA²“¡Œö—YA‰ºìG–ŸF––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•a•ÏŒ`‘ԁ[OFDI‚É‚æ‚錟“¢[
‘æ56‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi2015”N10ŒŽ29“ú`31“úA“Œ‹žj
  1. ¬‘é—I“ñA‚‹Ž@A{“c@•jA¬Œ^‹±AŒ‹{Œ’‰îA‰H”öŽ‹MA‰~’J—²Ž¡AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFŠ¥”÷¬zŠÂáŠQ‚ÆŒŒ’†ƒZƒƒgƒjƒ“‚ÌŠÖ˜A‚ÌŒŸ“¢.
  2. _’ÍŽ–çAÂ–Ø—³’jA™‘ºGˆê˜YAŽO‰Y³’šAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•a‘ÔŒ`¬@\OFDI‚É‚æ‚錟“¢\
  3. Â–Ø—³’jA™‘ºGˆê˜YAŽO‰Y³’šAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA—é–؏G–ŸA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³ÇŠ³ŽÒ‚É‚š‚¯‚éŒo”ç“I”x“®–¬Šg’£p‚ÌŽ_‘f‰»”\‚Ö‚ÌŒø‰Ê.
‘æ19‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2015”N10ŒŽ22`24“úA‘åãj

    ƒYIARžu‰‰FŠî‘bŒn„iYIAŽóÜj

  1. Suzuki K, Satoh K, Omura J, Sato T, Kudo S, Otsuki T, Shimokawa H. Basigin promotes cardiac fibrosis and failure in response to chronic pressure-overload in mice
  2. ƒYIARžu‰‰F—Տ°Œn„iFinalistj

  3. Otsuki T, Satoh K, Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Miyata S, Shimokawa H. Prognostic impacts of plasma levels of cyclophilin A in patients with heart failure
  4. ƒ“Á•ÊŠé‰æ3F“ú–{E‰¢BE•Ä‘S•s‘SŠw‰ï‡“¯ƒVƒ“ƒ|ƒWƒEƒ€„

  5. Sakata Y, Shimokawa H. Temporal trends in clinical profiles of symptomatic heart failure in Japan@- A report from the CHART Studies -
  6. ƒ“Á•ÊŠé‰æ4F“ú–{EŠØ‘S•s‘SŠw‰ï‡“¯ƒVƒ“ƒ|ƒWƒEƒ€„

  7. Sakata Y, Shimokawa H. Differences in clinical characteristics and prognosis between HFpEF and HFrEF@-A report from the CHART-2 Study-
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€4FS•s‘S‚É‚š‚¯‚é‹@”\•]‰¿|Žûk‹@”\EŠg’£‹@”\E‰ES‹@”\|„

  9. ²“¡@—yA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA²“¡Œö—YA‘å“c‰p‹PA‰ºìG–ŸFS‘ŸMRI‚ð—p‚¢‚œ–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚ÌŒø‰ÊŒŸ“¢
  10. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“4FƒTƒ‹ƒRƒCƒh[ƒVƒXS‹ØÇ‚É”º‚€––ŠúS•s‘S‚ɑ΂·‚鎡—Á„

  11. £ì«lA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA•œ–쓹ŠîAç—t‹M•FAŽO–ØŒi‘ŸA”‘ò@‘EA[àV‹±”V˜NA‰ºìG–ŸASƒTƒ‹ƒRƒCƒh[ƒVƒX––ŠúS•s‘S‚É‚š‚¯‚鍡Œã‚̉ۑè
  12. ƒƒ[ƒNƒVƒ‡ƒbƒv1FHFpEF‚̐f’f‚ÆŽ¡—Á„

  13. ’ÒŒOØŽqAâ“c‘וFAŽO‰Y³’šAŒã‰ªL‘Ÿ˜YA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹Ž@A‹{“c@•qA‰ºìG–ŸF‰ä‚ª‘‚É‚š‚¯‚鍶Žº‹ìo—Š‚ª•Û‚œ‚ê‚œS•s‘SŠ³ŽÒ‚Ì—\Œã‚ÆŽ¡—à -CAHRT-2Œ€‹†‚©‚ç‚Ì•ñ-
  14. ƒƒ[ƒNƒVƒ‡ƒbƒv6FS•s‘SŠî‘bŒ€‹†‚̍őOü„

  15. Sato K, Suzuki K, Sunamura S, Otsuki T, Shimizu T,Ikeda S, Aoki T, Tatebe S, Sugimura K, Shimokawa H. Crucial roles of Rho-kinase, cyclophilin A and its receptor, basigin, for cardiac hypertrophy, fibrosis and failure -novel therapeutic targets-
  16. ƒƒ[ƒNƒVƒ‡ƒbƒv7F¬læ“V«SŽŸŠ³––ŠúŠ³ŽÒ‚ÌŠÇ—„

  17. Tatebe S, Sugimura K, Aoki T, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Sato K, Shimokawa H. Current status of the management for adult congenital heart disease associated with end-stage pulmonary arterial hypertension
  18. ƒƒ[ƒNƒVƒ‡ƒbƒv9F‘å‹K–ÍŒ€‹†@|ƒŒƒWƒXƒgƒŠŒ€‹†‚Æ‘OŒü‚«Š„‚è•t‚¯ŽŽŒ±|„

  19. Miura M, Sakata Y, Miyata S, Tadaki S, Ushigome R, Yamauchi T, Sato K, Nochioka K, Takahashi J, Shimokawa H. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartaniSUPPORTjtrial
  20. Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Tsuji K, Onose T, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. The chronic heart failure analysis and registry in the Tohoku District-2iCHART-2jStudy as a model of Japanese observational study
  21. ƒƒn[ƒgƒ`[ƒ€ƒVƒ“ƒ|ƒWƒEƒ€2FS•s‘S•a‘ÔƒXƒe[ƒW•Ê‚̉h—{ŠÇ—„

  22. “c’†—T”üAŽO‰Y³’šAâ“c‘וFA™‘ºGˆê˜YA‹ß“¡³‹PA‰H”öŽ‹MA¯“‡˜a¢A—é–ØŽõŽ÷AŠ`‰Ô—²ºA‰ºìG–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚éCONUTƒXƒRƒA‚É‚æ‚é‰h—{•]‰¿‚Ì—L—p«
  23. ƒƒn[ƒgƒ`[ƒ€ƒVƒ“ƒ|ƒWƒEƒ€3FS•s‘SƒPƒA‚É‚š‚¯‚闝‘z“I‚Ȉã—Ðê–åEƒ`[ƒ€iIPWj‚ð\’z‚·‚é‚ɂ́H„

  24. ŠìƒAƒ†ƒ~AŽO‰Y³’šA™‘ºGˆê˜YA‹ß“¡³‹PA‰H”öŽ‹MA¯“‡˜a¢A—é–ØŽõŽ÷AŠ`‰Ô—²ºA“c’†—T”üA‰ºìG–ŸF“–‰@‚É‚š‚¯‚éƒn[ƒgƒ`[ƒ€‚Ì—§‚¿ã‚°‚ÌŒ»ó‚Ɖۑè
  25. ƒƒn[ƒgƒ`[ƒ€ƒVƒ“ƒ|ƒWƒEƒ€6F‚—îŽÒS•s‘SŠ³ŽÒ‚ɑ΂·‚éƒAƒvƒ[ƒ`@|ƒtƒŒƒCƒ‹A”F’mÇA‘ŸŠíáŠQ|„

  26. ²“¡Œª“ñ˜YAâ“c‘וFA‹{“c@•qAŽO‰Y³’šA‹ž—ºˆêA’A–Ø‘sˆê˜YA¬–쐣„¶A’ҁ@ŒOØŽqAŽR“à@‹BA‰ºìG–ŸF ‚—îŽÒS•s‘SŠ³ŽÒ‚É‚š‚¯‚é‰îŒì•K—v“x‚š‚æ‚щh—{ó‘Ô‚Ì•]‰¿‚Ƒ΍ô‚̏d—v«: CHART-2Œ€‹†‚©‚ç‚Ì•ñ
  27. ƒˆê”ÊŒû‰‰2F“ñŽŸ«S‹ØÇi1j`SƒTƒ‹ƒRƒCƒh[ƒVƒX`„

  28. Segawa M, Fukuda K, Nakano M, Kondo M, Hirano M, Chiba T, Miki K, Morosawa S, Fukazawa K, Shimokawa H. The significance of advanced heart block in patients with cardiac sarcoidosis
  29. ƒˆê”ÊŒû‰‰10F‚œ‚±‚‚ڐS‹ØÇ„

  30. Suzuki H, Matsumoto Y, Sugimura K, Takahashi J, Fukumoto Y, Shimokawa H. Evidence for brain activation in patients with Takotsubo cardiomyopathy -A new finding of cardio-cerebral connection-
  31. Kochi R, Aoki T, Sugimura K, Tatebe S, Miura M, Yaoita N, Takahashi J, Matsumoto Y, Satou K, Shimokawa H. Takotsubo cardiomyopathy in a case of recurrent pheochromocytoma
  32. ƒˆê”ÊŒû‰‰15F–«S•s‘Si‚Pj„

  33. Yamauchi T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Tsuji K, Miyata S, Shimokawa H. Prognostic impact of de-novo atrial fibrillation in patients with chronic heart failure - A report from the CHART-2 Study-
  34. ƒˆê”ÊŒû‰‰18FS•s‘SES”ì‘å‚Ì•ªŽq‹@\i‚Pj„

  35. Sunamura S, Satoh K, Suzuki K, Omura J, Kikuchi N, Satoh T, Kurosawa R, Kudo S, Ikeda S, Shimokawa H. ROCK1 plays a crucial role to maintain cardiac function in response to pressure-overload in mice
  36. ƒˆê”ÊŒû‰‰35F“ñŽŸ«S‹ØÇi3j`”ì‘åŒ^`„

  37. Nakano M, Fukuda K, Kondo M, Segawa M, Hirano M, Chiba T, Fukazawa K, Miki K, Morosawa S, Shimokawa H. Implantable cardioverter defibrillator for primary prevention properly perminated ventricular tachycardia in patient with cardiac fabry disease
  38. ƒˆê”ÊŒû‰‰37F–«S•s‘Si3j„

  39. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Sato K, Yamauchi T, Onose T, Shimokawa H. Temporal trends in drug therapies and clinical outcomes in patients with symptomatic heart failure: Lessons from the CHART Studies
  40. ƒƒ|ƒXƒ^[6F‰æ‘œf’f„

  41. Obe H, Suzuki H, Ota H, Aoki T, Sugimura K, Matsumoto Y, Kushimoto S, Shimokawa H. Cardiac magnetic resonance as an alternative diagnostic method for Takotsubo cardiomyopathy in a patient with allergy to iodine contrast media
  42. ƒƒ|ƒXƒ^[9F—˜”AÜŽ¡—Á„

  43. Sugimura K, Miura M, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Satoh K, Miyata S, Sakata Y, Shimokawa H. Prognostic impacts of diuretics in Japanese patients with chronic heart failure
‘æ4‰ñ “ú–{”xzŠÂŠw‰ïE‘æ3‰ñ“ú–{”x‚ŒŒˆ³Šw‰ïŠwpW‰ïi10ŒŽ3“ú`4“úA2015”NA“Œ‹žj

    ƒYIAƒZƒbƒVƒ‡ƒ“„

  1. ²“¡@‘åŽ÷A²“¡@Œö—YA–î”ö”@M—TA‹e’n@‡—TA‘呺@~ˆêA•àV@—ºA™‘º@Gˆê˜YA’†‘º@ˆê•¶AˆÉ“¡@_A‰ºì@G–ŸFTEPH ‚É‚š‚¯‚éV‹K•aˆö’`”’ TAFI ‚ÌŠî‘b“I E —Տ°“I‹@”\‰ðÍ.
  2. “n糁@—ŽHA¯ì@NAˆÀ’B@—AVˆäì@O“¹AŒ“c@ˆÀŽjA–ì“c@‰ëŽjAŒš•”@r‰îA™‘º@Gˆê˜YA‰ºì@G–ŸAÄ–؁@‰ÀŽA‰ª“c@Ž“TF“V«SŽŸŠ³‚ÉŠÖ˜A‚µ‚œ”x‚ŒŒˆ³Ç‚ɑ΂·‚é”xˆÚA.
  3. ƒƒVƒ“ƒ|ƒWƒEƒ€2F‰ES•s‘S‚̃Cƒ[ƒWƒ“ƒO„

  4. Œš•”@r‰îA™‘º@Gˆê˜YAÂ–؁@—³’jAŽO‰Y@³’šAŽR–{@¹DA–î”ö”@M—TA —é–؁@G–ŸA²“¡@—yA_’Á@Ž–çA²“¡@Œö—YA‰ºìG–ŸFOCT‚É‚æ‚éPH‚̐f’f.
  5. ƒƒVƒ“ƒ|ƒWƒEƒ€6FTEPH ––œŒ^‚ɑ΂·‚éƒoƒ‹[ƒ“Šg’£p‚̐¬Ñ‚Æ–â‘è“_ /CTEPH ‚ɑ΂·‚é PEA‚š‚æ‚Ñ EPA ‚Ì’†ŠúE‰“Šu¬Ñ„

  6. ™‘º@Gˆê˜YAÂ–؁@—³’jAŽO‰Y@³’šAŒš•”@r‰îAŽR–{@¹DA–î”ö”@M—TA —é–؁@G–ŸA²“¡@—yA²“¡@Œö—YA‰ºì@G–ŸF“–‰@‚É‚š‚¯‚é PTPA ‚̐¬Ñ‚Æ–â‘è
  7. ƒƒVƒ“ƒ|ƒWƒEƒ€8F”x‚ŒŒˆ³Ž¡—Öò‚Ì”xŒŒŠÇˆÈŠO‚ւ̍ì—p‚ð‰î‚µ‚œ”x‚ŒŒˆ³•a‘Ô‰ü‘P‚̉”\«„

  8. ²“¡@Œö—YA‰ºì@G–ŸFƒTƒCƒNƒƒtƒBƒŠƒ“ A ‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\‚Æ‚»‚̗Տ°‰ž—p.
  9. ƒˆê”ʉ‰‘聄

  10. ‘呺@~ˆêA²“¡@Œö—YA‹e’n@‡—TA²“¡@‘åŽ÷A•àV@—ºA_’Á@Ž–çAÀ–ì@˜a•FAÂ–؁@—³’jAŒš•”@r‰îA™‘º@Gˆê˜YA‰ºì@G–ŸF”x“®–¬ŒŒŠÇ“à”ç AMPK ‚Í”x‚ŒŒˆ³Ç‚̐is‚ð—}§‚·‚é.
  11. À–ì@˜a•FA²“¡@Œö—YA‘å’΁@’mLA‹e’n@‡—TA‘呺@~ˆêA²“¡@‘åŽ÷A•àV@—ºAÂ–؁@—³’jAŒš•”@r‰îA™‘º@Gˆê˜YA‰ºì@G–ŸFPH Š³ŽÒ‚ÌŒŒŸ÷’†ƒTƒCƒNƒƒtƒBƒŠƒ“ A ‚ƉŠÇ«ƒTƒCƒgƒJƒCƒ“‚Ì‘ŠŠÖ.
  12. •àV@—ºA²“¡@Œö—YA‹e’n@‡—TA‘呺@~ˆêA²“¡@‘åŽ÷A–ì–؁@³“¹AÀ–ì@˜a•FAMohammad SiddiqueAElias Al-MamunA™‘º@Gˆê˜YA‰ºì@G–ŸF‰»‡•šƒXƒNƒŠ[ƒjƒ“ƒO‚É‚æ‚éV‹K”x‚ŒŒˆ³ÇŽ¡—Öò‚ÌŠJ”­.
  13. Œš•”@r‰îA™‘º@Gˆê˜YAÂ–؁@—³’jAŽO‰Y@³’šAŽR–{@¹DA–î”ö”@M—TA—é–؁@G–ŸA²“¡@—yA²“¡@Œö—YA‰ºì@G–ŸFDiastolic pulmonary gradient ‚É‚æ‚é Group2 PH Š³ŽÒ‚Ì—\Œã—\‘ª.
  14. ‹e’n@‡—TA²“¡@Œö—YA‘呺@~ˆêA²“¡@‘åŽ÷A•àV@—ºA–ì–؁@³“¹A‘å’΁@’mLAŒš•”@r‰îAÂ–؁@—³’jA™‘º@Gˆê˜YA‰ºì@G–ŸFV‹K•aˆö’`”’ƒZƒŒƒmƒvƒƒeƒCƒ“ P ‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\
  15. Â–؁@—³’jA™‘º@Gˆê˜YAŽO‰Y@³’šAŒš•”@r‰îA–î”ö”@M—TA—é–؁@G–ŸA²“¡@—yA_’Á@Ž–çA²“¡@Œö—YA‰ºì@G–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚š‚¯‚é OFDI ‚ð—p‚¢‚œ•a•ÏŒ`‘Ô‚ÌŠÏŽ@.
  16. –î”ö”@M—TA²“¡@Œö—YA²“¡@‘åŽ÷A™‘º@Gˆê˜YAÂ–؁@—³’jAŽO‰Y@³’šAŒš•”@r‰îA•Ÿ–{@‹`OA‰ºì@G–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•aˆö‚É‚š‚¯‚é TAFI ‚ÌŠÖ—^.
  17. Â–؁@—³’jA™‘º@Gˆê˜YAŽO‰Y@³’šAŒš•”@r‰îAŽR–{@¹DA–î”ö”@M—TA—é–؁@G–ŸA²“¡@—yA²“¡@Œö—YA‰ºì@G–ŸFCTEPH‚É‚š‚¯‚éŒo”ç“I”x“®–¬Šg’£p‚̌ċz‹@”\‚Ö‚ÌŒø‰Ê.
  18. ²“¡@Œö—YA™‘º@Gˆê˜YAÂ–؁@—³’jAŒš•”@r‰îAŽO‰Y@³’šA–î”ö”@M—TA—é–؁@G–ŸAŽR–{@¹DA_’Á@Ž–çA‘å’΁@’mLA‰ºì@G–ŸFŒŒŸ÷’†ƒTƒCƒNƒƒtƒBƒŠƒ“ A ‚Í PTPA Ž¡—Â̗LŒø«‚𔜉f‚·‚é.
  19. ²“¡@—yA‘å“c@‰pŠöA™‘º@Gˆê˜YAÂ–؁@—³’jAŒš•”@r‰îAŽO‰Y@³’šAŽR–{@¹DA–î”ö”@M—TA—é–؁@G–ŸA²“¡@Œö—YA‰ºì@G–ŸFS‘Ÿ MRI ‚ð—p‚¢‚œŒo”ç“I”x“®–¬Œ`¬p‚ÌŒø‰ÊŒŸ“¢.
  20. ŽO‰Y@³’šA™‘º@Gˆê˜YAÂ–؁@—³’jAŒš•”@r‰îAŽR–{@¹DA–î”ö”@M—TA
  21. —é–؁@G–ŸA²“¡@—yA²“¡@Œö—YA‰ºì@G–ŸFƒCƒ}ƒ`ƒjƒu“Š—^‚É‚æ‚è’·Šú¶‘¶‚ª“Ÿ‚ç‚ê‚œ”xÃ–¬•ÂÇ«ŽŸŠ³‚̈ê—á.
  22. —é–؁@G–ŸA™‘º@Gˆê˜YAÂ–؁@—³’jAŒš•”@r‰îAŽO‰Y@³’šAŽR–{@¹DA–î”ö”@M—TA²“¡@Œö—YA‹vŽu–{@¬Ž÷A‰ºì@G–ŸF“‡Žž’²Ç‚É”º‚€RƒŠƒ“Ž‰Ž¿R‘̏njóŒQ‚Å”­Ç‚µ‚œ”xÇðÇ‚̈ê—á.
  23. ¯Žq@Œ\A™‘º@Gˆê˜YAŽO‰Y@³’šA‹g“c@KŽ}AŽ›Œ@Œb”üA¯“‡@˜a¢A–Ÿ’¿@çŒbA—é–؁@ŽõŽ÷AŠ`‰Ô@—²ºA‰ºì@G–ŸF”x“®–¬«”x‚ŒŒˆ³ÇŠ³ŽÒ‚ɑ΂·‚éƒ`[ƒ€ˆã—Ã.
‘æ63‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2015”N9ŒŽ18`20“úA‰¡•lj

    ƒƒVƒ“ƒ|ƒWƒEƒ€1FŒŒŠÇ‹@”\•]‰¿‚ÌŒ»ó‚Ɖۑ聄

  1. Œ‹{ Œ’‰îAŒ–{ ‘׎¡A‰F’Ë —T‹IA‘åŽR @”nAi“¡ ’q•FA•œ–ì “¹ŠîA¬‘é —I“ñA‰H”ö Ž‹MAš¢’J —²Ž¡A‚‹Ž AˆÉ“¡ Œ’‘ŸA‰ºì G–ŸFŠ¥“®–¬¹k‚É‚š‚¯‚銥“®–¬ƒCƒ[ƒWƒ“ƒO‚̏d—v«
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€2F‹}«Š¥ÇŒóŒQ‚̐f—Â̐i•à|‚³‚ç‚È‚é—\Œã‚̉ü‘P‚ÉŒü‚¯‚ā|„

  3. ‰H”ö Ž‹MA‚‹Ž AˆÉ“¡ Œ’‘ŸA‹{“c •qA›Á Œ³‹gAŒ‹{ Œ’‰îAš¢’J —²Ž¡AŒ–{ ‘׎¡Aâ“c ‘וFA‰ºì G–ŸF‹}«S‹Ø[Ç‚Ì”­Ç—Š‚Ɖ@“àŽ€–S—Š‚Ì‹ß”N‚É‚š‚¯‚éŒo”N•Ï‰»\MIYAGI-AMI Registry Study‚©‚ç‚Ì•ñ\
  4. ƒƒVƒ“ƒ|ƒWƒEƒ€3FS‘Ÿ“Ë‘RŽ€‚Ì—\’m‚Æ—\–h‚̍őOü„

  5. ²’| —m”VA•Ÿ“c _“ñAâ“c ‘וFA‹{“c •qA’†–ì œA‹ß“¡ ³‹PA•œ–ì “¹ŠîA£ì «lA‰ºì G–ŸF–{–M–«S•s‘SŠ³ŽÒ‚̐S‘Ÿ“Ë‘RŽ€‚ɑ΂·‚éˆêŽŸ—\–h–Ú“I‚̐A‚Šž‚ÝŒ^œ×“®Ší‚ÌŒ»ó\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  6. ƒƒVƒ“ƒ|ƒWƒEƒ€4FŠó­SŒŒŠÇŽŸŠ³‚ðŒ©’Œ‚·„

  7. ™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šA–î”ö” M—TA²“¡ —yA²“¡ Œö—YA‰ºì G–ŸF“–‰@‚É‚š‚¯‚éFabry•af—Â̌»ó
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€5FV‚œ‚ȃGƒrƒfƒ“ƒX‚ÉŠî‚­kÐŽžzŠÂŠíŽŸŠ³‚Ì—\–h‚ÆŠÇ—F‹}«Šú‚©‚疝«Šú‚ց„

  9. ‚‹Ž A‰ºì G–ŸF‘åkÐ‚ƐS•s‘S ¬–쐣 „¶Aâ“c ‘וFAŒã‰ª L‘Ÿ˜YA‹{“c •qAŽO‰Y ³’šA’A–Ø šáˆê˜YA‹ž —ºˆêAŽR“à ‹BA²“¡ Œª“ñ˜YA’Ò ŒOØŽqAˆ¢•” —Ú—žA‚‹Ž A‰ºì G–ŸFSŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚Æ‚»‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  10. ƒƒVƒ“ƒ|ƒWƒEƒ€8FS•s‘S‘ˆ«‚ð‚à‚œ‚ç‚·”ñS‘ŸˆöŽqi”]A”xj„

  11. ŽR“à ‹BAâ“c ‘וFA‚“c „A‹{“c •qAŽO‰Y ³’šA’A–Ø ‘sˆê˜YA‹ž —ºˆêA²“¡ Œª“ñ˜YA¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žAŒã‰ª L‘Ÿ˜YA‚‹Ž A‰ºì G–ŸF–«S•s‘SŠ³ŽÒ‚Ì—\Œã‚ɑ΂·‚é•nŒŒ‚̉e‹¿‚ÌŒŸ“¢\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  12. ƒƒVƒ“ƒ|ƒWƒEƒ€9F‰uŠwŒ€‹†‚ðzŠÂŠíŽŸŠ³—\–h‚ÉŠˆ‚©‚·„

  13. â“c ‘וFAŽO‰Y ³’šA’A–Ø ‘sˆê˜YA‹ž —ºˆêA²“¡ Œª“ñ˜YAŽR“à ‹BA¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žAŒã‰ª L‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸF‰ä‚ª‘‚É‚š‚¯‚閝«S•s‘S‘å‹K–ÍŠÏŽ@Œ€‹†FCHART-2Œ€‹†
  14. ƒƒVƒ“ƒ|ƒWƒEƒ€14FSŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é“œ”A•a‚ÌŠÇ—„

  15. ŽO‰Y ³’šAâ“c ‘וFA‹{“c •qA’A–Ø ‘sˆê˜YA‹ž —ºˆêAŽR“à ‹BA²“¡ Œª“ñ˜YA¬–쐣 „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žAŒã‰ª L‘Ÿ˜YA‚‹Ž A‰ºì G–ŸF‹•ŒŒ«/”ñ‹•ŒŒ«S•s‘S‚É‚š‚¯‚é“œ”A•a‚Ì—\Œã‚ւ̉e‹¿\tÇ‚ÌŠÏ“_‚©‚ç‚̍lŽ@\
  16. ƒ“ú–{S‘Ÿ•aŠw‰ïE“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€FS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚©‚çƒtƒŒƒCƒ‹‚ðl‚Š‚遄

  17. Œ–{ ‘׎¡A’|“à ‰ëŽjA‚‹Ž A™‘º Gˆê˜YAŽO‰Y ³’šAãŒŽ ³”ŽA‰ºì G–ŸFŒoƒJƒe[ƒeƒ‹‘å“®–¬•Ù—¯’up‚É‚š‚¯‚éS‘ŸƒŠƒnƒrƒŠ‚Ì–ðŠ„`ƒtƒŒƒCƒ‹iFrailtyj‚Ì”FŽ¯‚ƌċzE‰^“®‹@”\ŠÇ—‚̏d—v«`
  18. ƒ—DG‰‰‘èƒZƒbƒVƒ‡ƒ“iˆãŽtj„

  19. š¢’J —²Ž¡A‚‹Ž A’†‘º –Ÿ_A–ìè ‰p“ñA™ ³•¶AŽR–{ ‹`lA•œ–{ “N–çA–xŒû ‘Aˆäã Š°ˆêAŒã“¡ •q˜aA‰Á“¡ “ցAŽÂè ‹BA‰ºì G–ŸF’·ŽžŠÔì—pŒ^ƒjƒtƒFƒWƒsƒ“‚É‚æ‚é–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚ÌŒŒŠÇ•ÛŒìŒø‰ÊFNOVELŽŽŒ±
  20. ƒŽáŽèÇ—áPresenterÜF”ñNP“I‰æ‘œf’f„

  21. ‘åç³ Š°KA—é–Ø G–ŸA‘å“c ‰pŠöAÂ–Ø —³’jA™‘º Gˆê˜YAŒ–{ ‘׎¡A‹vŽu–{ ¬Ž÷A‰ºì G–ŸF“®–¬ƒKƒX”]ÇðÇ‚ɍ‡•¹‚µ‚œ‚œ‚±‚‚ڐS‹ØÇ‚Ì1—áFƒˆ[ƒh‘¢‰eÜƒAƒŒƒ‹ƒM[Ç—á‚É‚š‚¯‚éS‘ŸMRI‚Ì—L—p«
  22. ƒƒ‚[ƒjƒ“ƒOƒŒƒNƒ`ƒƒ[3F–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚ÌŠ¥¹k‚ÆŒŒŠÇ‹@”\•ÛŒìí—ª„

  23. ‚‹Ž F–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚ÌŠ¥¹k‚ÆŒŒŠÇ‹@”\•ÛŒìí—ª
  24. ƒƒtƒ@ƒCƒA[ƒTƒCƒhƒVƒ“ƒ|ƒWƒEƒ€6FŠ¥¹k‚̍ŐV’mŒ©„

  25. Œ‹{ Œ’‰îFŠ¥¹k«‹·SÇ‚É‚š‚¯‚éŠO–ŒVasa vasorum‚ÌŠÖ—^`Optical frequency domain imagingiOFDIj‚ð—p‚¢‚œŒŸ“¢`
  26. ƒˆê”ʉ‰‘èFŒû‰‰„

  27. –î”ö” M—TA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŽO‰Y ³’šAŒš•” r‰îA‰ºì G–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•aˆö‚É‚š‚¯‚éTAFI‚Ì–ðŠ„‚Æ‚»‚Ì‹@”\“IˆÓ‹`
  28. ‘å’Î ’mLA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA–î”ö” M—TA—é–Ø G–ŸA²“¡ —yA_’à Ž–çA“ñ•r ‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸFŒŒŸ÷’†ƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚銥“®–¬ŽŸŠ³‚Ì’·Šú—\Œã—\‘ª
  29. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  30. ²“¡ Œª“ñ˜YAâ“c ‘וFA‹{“c •qAŽO‰Y ³’šA‹ž —ºˆêA’A–Ø šáˆê˜YA¬–쐣 „¶A’Ò ŒOØŽqAŽR“à ‹BAˆ¢•” —Ú—žAŒã‰ª L‘Ÿ˜YA‚‹Ž A‰ºì G–ŸF‰ä‚ª‘‚É‚š‚¯‚鍂—îŽÒS•s‘S‚̗Տ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq: ‘æ“ñŽŸ“Œ–k–«S•s‘S“o˜^(CHART-2)Œ€‹†‚©‚ç‚Ì•ñ
  31. ‹ž —ºˆêAâ“c ‘וFA‹{“c •qAŽO‰Y ³’šA’A–Ø šáˆê˜YA²“¡ Œª“ñ˜YAŽR“à ‹BA¬–쐣 „¶A’Ò ŒOØŽqA‹yì ‘ì–çAŠ}ŒŽ M‘Ÿ˜YAŒã‰ª L‘Ÿ˜YA‚‹Ž A‰ºì G–ŸF‰ä‚ª‘‚̏nj󐫖«S•s‘Sf—Â̕ϑJ‚Ɛ«·FCHARTŒ€‹†‚©‚ç‚Ì•ñ
  32. ›Á Œ³‹gA‰H”ö Ž‹MA‚‹Ž AˆÉ“¡ Œ’‘ŸA‹{“c •qAŒ‹{ Œ’‰îAš¢’J —²Ž¡AŒ–{ ‘׎¡Aâ“c ‘וFA‰ºì G–ŸF‹}«S‹Ø[Ç”­Ç—Š‹y‚щ@“àŽ€–S—Š‚Ì”N‘ã•ÊŒo”N•Ï‰»‚ÌŒŸ“¢\Miyagi AMI Registry Study‚©‚ç‚Ì•ñ
  33. Â–Ø —³’jA™‘º Gˆê˜YAŽO‰Y ³’šAŒš•” r‰îA–î”ö” M—TA²“¡ —yA²“¡ Œö—YA‰ºì G–ŸFŒo”ç“I”x“®–¬Šg’£p‚Í–«ŒŒðÇð«”x‚ŒŒˆ³Š³ŽÒ‚É‚š‚¢‚ÄŒŒs“®‘ԂɉÁ‚Š‚ÄŽ_‘f‰»‚à‰ü‘P‚·‚é
  34. ²“¡ —yA‘å“c ‰pŠöA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’šAŽR–{ ¹DA–î”ö” M—TA²“¡ Œö—YA‰ºì G–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚ÌŒø‰ÊŒŸ“¢
  35. ’†–ì œA•Ÿ“c _“ñA‹ß“¡ ³‹PA£ì «lA•œ–ì “¹ŠîAç—t ‹M•FA‰ºì G–ŸFICDƒŠ[ƒh‚̕ύX‚ª—LŒø‚Å‚ ‚Á‚œ‚œ×“®è‡’l‚ð’悵‚œBrugadaÇŒóŒQ‚̈ê—á
  36. “c’† û€˜NAÂ–Ø —³’jA™‘º Gˆê˜YAŒš•” r‰îAŽO‰Y ³’šA–î”ö” M—TA²“¡ —yA‰ºì G–ŸF‘œŠj‹×–E‚ð”F‚ß‚œŒ€ÇŒ^S‹Ø‰Š‚̈ê—á
  37. £ì «lA•Ÿ“c _“ñAÂ–Ø —³’jA’†–ì œA‹ß“¡ ³‹PA•œ–ì “¹ŠîA™‘º Gˆê˜YA‰ºì G–ŸFPETAMRIŽž‘ã‚É‚š‚¢‚ăKƒŠƒEƒ€ƒVƒ“ƒ`‚ªSƒTƒ‹ƒRƒCƒh[ƒVƒXf—Âɉʂœ‚·–ðŠ„
  38. Œš•” r‰îA™‘º Gˆê˜YAÂ–Ø —³’jAŽO‰Y ³’šA–î”ö” M—TA—é–Ø G–ŸA²“¡ —yA²“¡ Œö—YA‰ºì G–ŸFDiastolic pulmonary gradient‚ð—p‚¢‚œpost-capillary PHŠ³ŽÒ‚Ì—\Œã—\‘ª
‘æ21‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2015”N7ŒŽ18`19“úA•Ÿ‰ªŽsj

    ƒYIA session„

  1. ‹ààV³”́AŒ–{‘׎¡AŠÝ–{ŒõŽiAAxel LinkeA‰ºìG–ŸFƒgƒŒƒbƒhƒ~ƒ‹‰^“®—Ö@‚͐S‹Ø[ÇŒã‚̍œ–§“x’ቺ‚ð—\–h‚·‚é@\S‹Ø[Çƒ}ƒEƒXƒ‚ƒfƒ‹‚Å‚ÌŒŸ“¢\iÅ—DGÜŽóÜj
  2. ƒˆê”ʉ‰‘èFŒû‰‰„

  3. ‰H”öŽ‹MAŒ–{‘׎¡AX@M–FAŒ‹{Œ’‰îA‰~’J—²Ž¡A‚‹Ž@AˆÉ“¡Œ’‘ŸAâ“c‘וFAãŒŽ³”ŽA‰ºìG–ŸFŠ¥¹k«‹·SÇŠ³ŽÒ‚ɑ΂·‚éƒJƒ‹ƒVƒEƒ€hR–ò‚̉^“®‘Ï—e”\‰ü‘PŒø‰Ê‚ɂ‚¢‚Ä‚ÌŒŸ“¢
  4. ’A–Ø‘sˆê˜YAâ“c‘וFA•Ÿ–{‹`OA–î–ì‰ë•¶A–åãr–ŸA‘ã“c_”VAˆÀ“c@‘A‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚š‚æ‚уnƒCƒŠƒXƒNŒQ‚É‚š‚¯‚ég‘ÌŠˆ“®‚Ɖ^“®‘jŠQˆöŽq‚ÌŒŸ“¢@\‘S‘‘œŽ{Ý‹€“¯ƒRƒz[ƒgŒ€‹†‚æ‚è[
  5. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  6. ŽO‰Y³’šA™‘ºGˆê˜YAŒš•”r‰îAÂ–Ø—³’jA–î”ö”M—TA²“¡@ꡁA“c’†—T”üAŠìƒAƒ†ƒ~A²X–Ø•S‡‰ÔAŠ`‰Ô—²ºA—é–ØŽõŽ÷A²“¡Œö—YA‰ºìG–ŸFS•s‘SŽè’ ‚ðŽg—p‚µŠO—ˆ‚ÅŒo‰ßŠÏŽ@‚µ‚œŠg’£Œ^S‹ØÇ‚É‚æ‚édÇS•s‘S‚̈ê—á.
‘æ15‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2015”N6ŒŽ26`27“úA–L’†Žsj

    ƒYIA session„

  1. Ö“¡‘åŽ÷A²“¡¹—¢A“c’†C•œA_ŒË–ΗYA‰ºìG–ŸFŒŒŠÇ“à”ç‚É‚š‚¯‚éCaveolin-1/“à”çŒ^ˆêŽ_‰»’‚‘f‡¬y‘f•¡‡‘Ì‚ÌŒ`¬‚ªEDH‚ð‰î‚µ‚œ”÷¬zŠÂ‚̍Pí«‚̈ێ‚ɏd—v‚Å‚ ‚é.i—DGÜŽóÜj
  2. ƒˆê”ʉ‰‘èFŒû‰‰„

  3. “›ˆä³lA“à“c‘Ÿ˜YA’J–{º‰pA‰ºìG–ŸA–öŒŽ‰„ÍA”ö’ҁ@–LA“c‘º‰ëmFƒCƒ‹ƒxƒTƒ‹ƒ^ƒ“‚ƃAƒ€ƒƒWƒsƒ“‚Ì•¹—p“Š—^‚Í2/3t“ENOSsŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚é‹}«S‹Ø[Ç‚Ì”­Ç‚ð’˜–Ÿ‚É—}§‚·‚é.
  4. ¶‰z‹M–ŸAéŒË‹MŽuA“›ˆä³lA–˜a”ŽAÎ–{—TŽmAŽR“c‘‘—ºA–L•œ—R”üŽqA‰ºìG–ŸA–öŒŽ‰„ÍAŒ}@Š°FNO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚é’áŽ_‘f«”x‚ŒŒˆ³Ç.
  5. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  6. _ŒË–ΗYAÖ“¡‘åŽ÷A“c’†C•œA²“¡¹—¢A‰ºìG–ŸF“à”çˆË‘¶«’oŠÉ”œ‰ž‚É‚š‚¯‚éNO‚ÆEDHF‚̐¶—“Iƒoƒ‰ƒ“ƒX‚̏d—v«.
  7. ²’|—m•œA²“¡Œö—YAŠC–@N—TArˆä—zˆêA‰ºìG–ŸFäNã÷Žûk’oŠÉ‹@\‚É‚š‚¯‚éŠeŽíNOŽY¶‡¬y‘f‚Ì‹@”\“I–ðŠ„•ª’S.
  8. –î“c–L—²A‰ºìG–ŸA—§‰Ô”Ž”VA¬Š}ŒŽN•vFƒCƒk¶‘Ì“à“œ”A•a«Š¥”÷¬‘€•›ŒŒŠÇ‚É‚š‚¢‚ĉߎ_‰»…‘f‚É‚æ‚銥”÷¬‘€•›ŒŒŠÇŠg’£‚́AŠ¥“®–¬•ÂÇŽž‚ÌNO‚É‚æ‚錌ŠÇ“à”çáŠQ‚ð‘㏞‚·‚é.
  9. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  10. ‰ºìG–ŸFd—v«‚𑝂·S•s‘S‚̐f—Ã.
‘æ205‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2015”N6ŒŽ20“úAå‘äŽsj
  1. ŽR–{—ŽˆêA‹vŽu–{¬Ž÷A—é–؏G–ŸA‰ºìG–ŸFSepsis-induced encephalopathy‚É‚æ‚é‘J‰„«ˆÓŽ¯áŠQ‚ð’悵‚œŠŽõ«S“à–Œ‰Š‚Ì1—á.
  2. “c’†Œ’ŽqAóÀŒhˆê˜YA‹vŽu–{¬Ž÷A—é–؏G–ŸA’†–ì@œA™‘ºGˆê˜YAâ“c‘וFA‰ºìG–ŸF“ª•”ŠO‚É‚æ‚éR‹ÃŒÅ—Ö@’†’fŒã‚É”­Ç‚µ‚œ‘œ”­ÇðÇ‚Ì1—á.
  3. ˆÉ“¡‚ä‚«‚́A‘å粊°KA‹vŽu–{¬Ž÷A—é–؏G–ŸAŒš•”r‰îAÂ–Ø—³’jA™‘ºGˆê˜YA‰ºìG–ŸF‘–Œ‰Š‚É‚Í”­Ç‚µ‚œ”x‰Š‹…‹Û‚É‚æ‚銎õ«S“à–Œ‰Š‚Ì1—á.
‘æ160‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2015”N6ŒŽ6“úA·‰ªŽsj

    ƒYIAÇ—á”­•\•”–偄

  1. ²“¡@—yAŽO‰Y³’šA™‘ºGˆê˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡Œö—YA‰ºìG–ŸFƒCƒ}ƒ`ƒjƒu“Š—^‚É‚æ‚è’·Šú¶‘¶‚ª“Ÿ‚ç‚ê‚œ”xÃ–¬•ÂÇ«ŽŸŠ³‚̈ê—á.
  2. ƒYIAÇ—á”­•\•”–偄i–Å—DGÜŽóÜj

  3. ¬–쐣„¶Aâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA’A–Ø‘sˆê˜YA‹ž@—ºˆêAŽR“à@‹BA²“¡Œª“ñ˜YA’ҁ@ŒOØŽqAˆ¢•”—Ú—žA‚‹Ž@A‹{“c@•qA‰ºìG–ŸFS‘Ÿ•aŠ³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚ÌŒoŽž•Ï‰»‚Æ—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢.
  4. ƒˆê”ʉ‰‘聄

  5. Â–Ø—³’jA™‘ºGˆê˜YAŽO‰Y³’šAŒš•”r‰îA–î”ö”M—TA²“¡@—yA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Š³ŽÒ‚É‚š‚¢‚ÄŒo”ç“I”x“®–¬Šg’£p‚ÍŒŒs“®‘ԂɉÁ‚Š‚ÄŽ_‘f‰»‚à‰ü‘P‚³‚¹‚é.
  6. ŒÃ’m—ŽŽO˜YAÂ–Ø—³’jA™‘ºGˆê˜YAŒš•”r‰îAŽO‰Y³’šA–î”ö”M—TA²“¡@—yA‚‹Ž@AŒ–{‘׎¡A‰H”öŽ‹MA²“¡Œö—YA‰ºìG–Ÿ: ‚œ‚±‚‚ڌ^S‹ØÇ—l‚ÌŽûkáŠQ‚𗈂œ‚µ‚œŠŒF×–EŽî‚̈ê
  7. Œ‹{Œ’‰îA‰H”öŽ‹MAš¢’J—²Ž¡AŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸA“n粗ŽHA¯ì@NA‰ª“c@Ž“TF•ÂÇ«”ì‘åŒ^S‚É‚œ‚±‚‚ڌ^S‹ØÇ‚𕹔­‚µ‚œ”xˆÚAÇ—á.
  8. š¢’J@—²Ž¡A‚‹Ž@AŒ‹{Œ’‰îA‰H”öŽ‹MAŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–Ÿ:“ûŽ_ƒAƒVƒh[ƒVƒX‚ð‡•¹‚µ‚œ”ñST ãžŒ^S‹Ø[Ç‚̈ê—á.
  9. “c’†Œ’ŽqAóÀŒhˆê˜YA‹vŽu–{¬Ž÷A—é–؏G–ŸA’†–ì@œA™‘ºGˆê˜YAâ“c‘וFA‰ºìG–Ÿ: “ª•”ŠOŒã‚̍R‹ÃŒÅ—Ö@’†’f‚É‚æ‚è‘Sg«ÇðÇ‚𔭏ǂµ‚œS–[×“®‚̈ê—á.
  10. ŽRè—ŽˆêA‹vŽu–{¬Ž÷A—é–؏G–ŸA‰ºìG–ŸFSepsis-induced encepharopathy ‚É‚æ‚è‘J‰„«ˆÓŽ¯áŠQ‚ð’悵‚œŠŽõ«S“à–Œ‰Š‚̈ê—á.
  11. ˆÉ“¡‚ä‚«‚́A‘å糊°KA‹vŽu–{¬Ž÷A—é–؏G–ŸAŒš•”r‰îAÂ–Ø—³’jA™‘ºGˆê˜YA‰ºìG–Ÿ: ×‹Û«‘–Œ‰Š‚É‚Ä”­Ç‚µ‚œ”x‰Š‹…‹Û‚É‚æ‚銎õ«S“à–Œ‰Š‚Ì1—á.
  12. ’A–Øšáˆê˜YAâ“c‘וFAŽO‰Y³’šA‹ž—ºˆêA²“¡Œª“ñ˜YA¬–쐣„¶AŽR“à@‹BA’ҁ@ŒOØŽqAˆ¢•”@—Ú—žA‹{“c@•qA‰ºìG–ŸF–«S•s‘S‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚̈Ӌ`‚ÌŒŸ“¢\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  13. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–ì@œA£ì«lA•œ–쓹ŠîAç—t‹M•FA‰ºìG–ŸF‰“Šuƒ‚ƒjƒ^ƒŠƒ“ƒOƒVƒXƒeƒ€‚É‚æ‚èICDƒVƒ‡ƒbƒNì“®•s‘S‚𑁊ú‚ɐf’f‚Å‚«‚œŠg’£Œ^S‹ØÇ‚̈ê—á.
  14. ’†–ì@œA•Ÿ“c_“ñA‹ß“¡³‹PA£ì«lA•œ–쓹ŠîAç—t‹M•FA‰ºìG–Ÿ: High DFT‚ð’悵AICDƒŠ[ƒh‚̕ύX‚ª—LŒø‚Å‚ ‚Á‚œBrugada ÇŒóŒQ‚̈ê—á.
  15. ç—t‹M•FA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA£ì«lA•œ–쓹ŠîA‰ºìG–ŸF‘å“®–¬‰EŠ¥ë‚©‚ç‚Ì’Ê“d‚ª—LŒø‚Å‚ ‚Á‚œ‰EŽº—¬o˜H‚ÌExit ‚ð‚à‚—¬o˜H‹NŒ¹PVC ‚̈ê—á.
  16. •Ð•œW‘Ÿ˜YAHŽR³”NA‰Í’Á@‘A‚ŒŽ^ŒáA“n粍W—CA“¡ŒŽ‰p‹LAˆÀ’B@—AŒF’J‹Iˆê˜YAì–{r•ãAâV–؉ÀŽA™‘ºGˆê˜YA‰ºìG–ŸF‘ÌŠOŽ®VAD ‚©‚çAžŒ^VAD ‚Öconversion ‚µ‚œÇ—á‚ÌŒŸ“¢.
  17. HŽR³”NA•Ð•œW‘Ÿ˜YA‰Í’Á@‘A“n粍W—CA‚ŒŽ^ŒáA“¡ŒŽ‰p‹LAˆÀ’B@—AŒF’J‹Iˆê˜YAì–{r•ãAâV–؉ÀŽAÂ–Ø—³’jA•Ÿ“c_“ñA‚‹Ž@A™‘ºGˆê˜YA‰ºìG–ŸFŠg’£‘Š”ì‘åŒ^S‹ØÇ‚ɑ΂·‚é‹@ŠB“I•â•zŠÂŽ¡—Â̎¡—Ð헪‚ÌŒŸ“¢.
‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2015”N4ŒŽ24“ú`26“úA‘åãj

    ƒSpecial Session„

  1. (SS05:The Prediction for the Future in the Large-scale Registry of Cardiovascular Disease) Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Tsuji K, Abe R, Nochioka K, Miyata S, Takahashi J, Shimokawa H. Perspectives from the chronic heart failure analysis and registry in the Tohoku District 2 (CHART-2) Study. Circ J 79(Suppl. I):I-47,2015.
  2. (SS09:Rapid Development of Antithrombotic Therapy: Current Status and Future Directions) Fukuda K , Ogawa H, Hirotsug A, Inoue H, Uchiyama S, Kitazono T, Ikeda T, Kaikita K, Kamouchi M, Matsui K, Shimokawa H. Effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation@\First report from the EXPAND study\ Circ J79(Suppl. I):I-74,2015.
  3. (SS10:Therapeutic Strategies of Coronary Artery Disease from the Point of View of Vasomotion and Microvascular Function) Kensuke Nishimiya1 ,Yasuharu Matsumoto1 , Uzuka H1 , Oyama K1 , Tomohiko Shindo1 , Ryuji Tsuburaya1 , Takashi Shiroto1 , Takahashi J , Kenta Ito1 , Hatsue Ishibashi-Ueda2 , Satoshi Yasuda3 , Hiroaki Shimokawa. Involvement of Rho-Kinase pathway in the pathogenesis of coronary hyperconstricting responses after drug-eluting stents implantation. Circ J 79(Suppl. I):I-78,2015.
  4. ƒPlenary Session„

  5. (PL01: New Multi-Modality Cardiovascular Imaging and the Dedicated Management of Diseases) Ota H, Sugimura K, Nochioka K, Tatebe S, Yamamoto S, Miura M, Satoh K, Shimokawa H. 4D flow MRI for pulmonary hypertension: an imaging tool to monitor mean pulmonary arterial pressure. Circ J 79(Suppl. I):I-99,2015.
  6. (PL02:Explore the Japanese Style Clinical Investigation beyond the Global Trends) Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Onose T, Tsuji K, Abe R, Miyata S, Takahashi J, Shimokawa H. The chronic heart failure analysis and registry in the Tohoku District-2 (CHART-2) Study: A model case of Japanese observational study. Circ J 79(Suppl. I):I-101,2015.
  7. ƒSymposium„

  8. (SY03:Novel and Advanced Therapy against Acute Coronary Syndrome\From Bench to Bedside\) Ito K, Takahashi J, Matsumoto Y, Tsuburaya R, Hao K, Nishimiya K, Kagaya Y, Shindo T, Ogata T, Kurosawa R, Shimokawa H. Low-energy cardiac shock wave therapy suppresses left ventricular remodeling after acute myocardial infarction\From bench to bedside\ Circ J 79(Suppl. I):I-176,2015.
  9. (SY10:The Importance of the Right Ventricle in Adult Congenital Heart Disease\Physiological Properties, Diagnosis, and Management of Right Heart Failure in ACHD\) Fujiwara J, Onuma H, Funamizu Y, Tatebe S, Sugimura K, Sakata Y, Saijoh Y, Shimokawa H. Echocardiographic evaluation of right ventricular dysfunction in adult patients with Tetralogy of Fallot. Circ J 79(Suppl. I):I-218,2015.
  10. (SY13:Recent Progress in Pulmonary Hypertension) Aoki T, Tatebe S, Sugimura K, Nochioka K, Miura M, Yamamoto S, Yaoita N, Sato H, Satoh K, Shimokawa H. Importance of acute hemodynamic responses to inhaled nitric oxide in patients with pulmonary hypertension due to left heart disease. Circ J 79(Suppl. I):I-243,2015.
  11. (SY15:Prevention and Control of Cardiovascular Disease: the WHO Global Strategy) Tadaki S, Sakata Y, Miura M, Miura Y, Fukumoto Y, Miura T, Kadokami T, Daida H, Kitakaze M, Shimokawa H. Prognostic impacts of physical activity in patients with chronic heart failure. A multicenter prospective cohort study. Circ J 79(Suppl. I):I-255,2015.
  12. (SY20:Diagnosis and Treatment of Functional Angina Pectoris\Insight into Vasospasm and Microvascular Disease) Takahashi J, Nihei T, Odaka Y, Tsuburaya R, Hao K, Nishimiya K, Matsumoto Y, Ito K, Shimokawa H. Prognostic impact of Rho-kinase activity in circulating leukocytes of patients with vasospastic angina. Circ J 79(Suppl. I):I-288,2015.
  13. ƒESC-JCS Joint Symposium„

  14. (ESC:Coronary Vasomotion Abnormalities) Takahashi J, Tsuburaya R, Nishimiya K, Matsumoto Y, Shimokawa H. Coronary vasomotion abnormalities induced by drug-eluting stents. Circ J 79(Suppl. I):I-327,2015.
  15. ƒRound Table Discussion„

  16. (RT05:The Current Status and Future Perspective of Acute Cardiovascular Care: the Evolving Real World Evidence from Nation-wide Registry Studies) Takahashi J, Hao K, Ito K, Sakata Y, Shimokawa H. Trends in the emergency care of AMI in Japan\A report from the Miyagi AMI registry study\Circ J 79(Suppl. I):I-381,2015.
  17. ƒTopic„

  18. (TP05:Diagnosis and Treatment of Chronic Thromboembolic Pulmonary Hypertension after an Advent and Development of Balloon Pulmonary Angioplasty) Sugimura K, Aoki T, Tatebe S, Miura M, Yaoita N, Sato H, Kato T, Satoh K, Shimokawa H. Usefulness of optical coherence tomography imaging in management of chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-431,2015.
  19. ƒLate Breaking Clinical Trials„

  20. (LBCT4) Sakata Y, Shiba N, Takahashi J, Miyata S, Nochioka K, Miura M, Takada T, Shimokawa H. Impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: A report from the SUPPORT Trial. Circ J 79(Suppl. I):I-592,2015.
  21. ƒLate Breaking Cohort Studies„

  22. (LBCS1) Onose T, Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Tsuji K, Abe R, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Adverse prognostic impacts of post-traumatic stress disorder in patients with cardiovascular disease after the Great East Japan Earthquake. Circ J 79(Suppl. I):I-597,2015.
  23. ƒYoung Investigator's Award Finalists Lectures (Clinical Research)„

  24. (YIA-C-3) Satake H, Fukuda K, Sakata Y, Miyata S, Nakano M, Kondo M, Hasebe Y, Segawa M, Shimokawa H. Current status of primary prevention of sudden cardiac death with implantable cardioverter-defibrillator in patients with chronic heart failure\A report from the CHART-2 Study\ Circ J 79(Suppl. I):I-625,2015.
  25. ƒYoung Investigator's Award for International Students Finalists Lectures„

  26. (I-YIA-2) Elias-Al-Mamun M, Satoh K, Tanaka S, Shimizu T, Nergui S, Miyata S, Fukumoto Y, Shimokawa H. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension through synergistic inhibition of Rho-kinase. Circ J 79(Suppl. I):I-632,2015.
  27. ƒFeatured Research Session„

  28. (FRS-009) Satoh K , Sugimura K , Aoki T, Nochioka K, Tatebe S, Yamamoto S, Miura M, Shimizu T, Ikeda S, Yaoita N, Kudo S, Suzuki K, Omura J, Kikuchi N, Satoh T, Kurosawa R, Sunamura S, Nogi M, Shimokawa H. Plasma Cyclophilin A as a useful biomarker for effective percutaneous transluminal pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-650,2015.
  29. (FRS-126) Nihei T, Takahashi J, Miyata S, Odaka Y, Nishimiya K, Hao K, Tsuburaya R, Matsumoto Y, Ito K, Sakata Y, Shimokawa H. Combined Japanese Coronary Spasm Association risk score and Rho-kinase activity provide useful risk stratification in patients with vasospastic angina. Circ J 79(Suppl. I):I-791,2015.
  30. ƒOral Presentation (English)„

  31. (OE-033:Heart Failure (Basic) and Translational Science) Suzuki K, Satoh K, Sunamura S, Omura J, Kikuchi N, Satoh T, Kurosawa R, Kudo S, Ikeda S, Shimokawa H. Basigin promotes cardiac fibrosis and failure in response to chronic pressure-overload in mice. Circ J 79(Suppl. I):I-824,2015.
  32. (OE-254:Intravascular Imagings OCT/OFDI) Nishimiya K, Matsumoto Y, Takahashi J, Kato T, Oyama K, Uzuka H, Odaka Y, Nihei T, Hao K, Tsuburaya R, Ito K, Shimokawa H. Enhanced adventitial vasa vasorum formation in patients with vasospastic angina\Assessment with optical frequency domain imaging\Circ J 79(Suppl. I):I-1044,2015.
  33. (OE-307: Cardiomyopathy/Hypertrophy (Basic)) Kudo S, Satoh K, Suzuki K, Sunamura S, Nogi M, Kikuchi N, Ohmura J, Ikeda S, Shimokawa H. Crucial role of SmgGDS in the inhibitory effects of statins on cardiac hypertrophy and fibrosis in mice. Circ J 79(Suppl. I):I-1097,2015.
  34. (OE-347:Pulmonary Circulation) Omura J, Satoh K, Kikuchi N, Satoh T, Kurosawa R, Suzuki K, Shimokawa H. Endothelial cell-specific AMPK deletion accelerates hypoxia-induced pulmonary hypertension in mice in vivo. Circ J 79(Suppl. I):I-1137,2015.
  35. (OE-350:Pulmonary Circulation) Satoh K, Suzuki K, Omura J, Kikuchi N, Satoh T, Sunamura S, Kurosawa R, Nogi M, Shimizu T, Ikeda S, Yaoita N, Kudo S, Aoki T, Sugimura K, Shimokawa H. Plasma levels of Cyclophilin A correlate with circulating inflammatory cytokines in patients with pulmonary hypertension. Circ J 79(Suppl. I):I-1140,2015.
  36. (OE-352:Pulmonary Circulation) Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, Sunamura S, Suzuki K, Kudo S, Shimokawa H. Thrombin activatable fibrinolysis inhibitor plays a crucial role in the pathogenesis of chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-1142,2015.
  37. (OE-358:Prevention/Epidemiology) Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Sato K, Yamauchi T, Onose T, Tsuji K, Takahashi J, Shimokawa H. Recent trends in clinical characteristics, management and prognosis in patients with symptomatic heart failure\The CHART Studies\ Circ J 79(Suppl. I):I-1148,2015.
  38. ƒOral Presentation (Japanese) „

  39. (OJ-009:Heart Failure (Diagnosis)) Miura M, Sakata Y, Miyata S, Nochioka K, Ushigome R, Tadaki S, Yamauchi T , Sato K, Onose T, Tsuji K, Abe R, Takahashi J, Shimokawa H. Prognostic impact of diabetes mellitus in patients with chronic heart failure\With special references to ischemic heart disease and nephropathy\Circ J 79(Suppl. I):I-1210,2015.
  40. (OJ-012:Heart Failure (Diagnosis)) Yamauchi T, Sakata Y, Miyata S, Nochioka K, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Tsuji K, Takahashi J, Shimokawa H. Prognostic impacts of anemia in patients with CHF with a special reference to background\A report from the CHART-2 Study\ Circ J 79(Suppl. I):I-1213,2015.
  41. (OJ-137: Heart Failure (Basic) and Translational Science) Kanazawa M, Matsumoto Y, Takahshi K, Suzuki H, Nishimiya K, Shimokawa H. Post-infarction heart failure reduces bone mineral density and strength in apolipoprotein E-deficient mice. Circ J 79(Suppl. I):I-1336,2015.
  42. (OJ-158:Coronary Circulation/Chronic Coronary Disease (Basic/Clinical)) Odaka Y, Takahashi J, Tsuburaya R, Nihei T, Nishimiya K, Hao K, Matsumoto Y, Ito K, Hirowatari Y, Shimokawa H. Plasma level of serotonin is a novel biomarker for coronary microvascular dysfunction in patient with vasospastic angina. Circ J 79(Suppl. I):I-1357,2015.
  43. (OJ-180: Vascular Disease (Therapy)) Shindo T, Ito K, Ogata T, Hatanaka K, Kurosawa R, Kagaya Y, Hanawa K, Aizawa K, Hasegawa H, Kanai H, Shimokawa H. Low-intensity pulsed ultrasound improves left ventricular dysfunction in a porcine model of chronic myocardial ischemia\Potential involvement of mechanotransduction\Circ J 79(Suppl. I):I-1379,2015.
  44. (OJ-254: Pulmonary Circulation) Yaoita N, Taiju Sato , Satoh K, Sugimura K, Tatebe S, Yamamoto S, Aoki T, Miura M, Horiuchi H, Fukumoto Y, Shimokawa H. Involvement of thrombin-activated fibrinolysis inhibitor in chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-1453,2015.
  45. (OJ-269:Prevention/Epidemiology) Sato K, Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Onose T, Tsuji K, Abe R, Nochioka K, Miyata S, Shimokawa H. The risk score for the three-year mortality in Japanese patients with aortic stenosis@\A report from the CHART-2 Study\ Circ J 79(Suppl. I):I-1468,2015.
  46. ƒPoster Session (English)„

  47. (PE-212:Coronary Circulation/Chronic Coronary Disease (Basic/Clinical)) Uzuka H, Matsumoto Y, Nishimiya K, Oyama K, Hirano M, Ogata T, Shindo T, Hanawa K, Hasebe Y , Hao K, Tsuburaya R, Ito K, Takahashi J, Shimokawa H. Possible involvement of adventitial vasavasorum and sympathetic nerves in coronary hyperconstricting responses after drug-eluting stent implantation in pigs in vivo. Circ J 79(Suppl. I):I-1704,2015.
  48. (PE-226:Cardiomyopathy/Hypertrophy (Clinical)) Segawa M, Fukuda K, Nakano M, Kondo M, Satake H, Hirano M, Shimokawa H. Time-course and influencing factors of ventricular tachy-arrhythmias after introduction of steroid therapy in cardiac sarcoidosis. Circ J 79(Suppl. I):I-1718,2015.
  49. (PE-522:Vascular Biology) Godo S, Ikeda S, Saito H, Suzuki K, Tanaka S, Ito A, Shimokawa H. Disruption of physiological balance between nitric oxide and endothelium-derived hyperpolarizing factor causes impairment of cardiovascular homeostasis in mice in vivo. Circ J 79(Suppl. I):I-2014,2015.
  50. (PE-695:Prevention/Epidemiology) Hao K, Takahashi J, Ito K, Sai G, Miyata S, Nishimiya K, Tsuburaya R, Matsumoto Y, Sakata Y, Shimokawa H. Recent trends in the incidence and mortality of acute myocardial infarction\ A report from the MIYAGI-AMI Registry Study\Circ J 79(Suppl. I):I-2187,2015.
  51. (PE-711:Pulmonary Circulation) Aoki T, Sugimura K, Nochioka K, Tatebe S, Miura M, Yamamoto S, Yaoita N, Sato H, Satoh K, Shimokawa H. Effects of PTPA on respiratory functions in patients with chronic thromboembolic pulmonary hypertension\Possible importance of intra-pulmonary shunt\Circ J 79(Suppl. I):I-2203,2015.
  52. (PE-713:Pulmonary Circulation) Sato H1, Miura M, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Ota H, Satoh K, Shimokawa H. Usefulness of cardiac MRI for evaluating the effectiveness of percutaneous transluminal pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-2205,2015.
  53. ƒPoster Session (Japanese)„

  54. (PJ-103:Autonomic Nervous System and Stress-Psychosomatic Medicine) Suzuki H, Satoh K, Tatebe S, Matsumoto Y, Kondo M, Nakano M, Fukuda K, Watanuki S, Hiraoka K, Tashiro M, Shimokawa H. Evidence for activation of cerebral autonomic center in response to cardiac electrical stimulation in humans\New finding of cardio-cerebral connection\Circ J 79(Suppl. I):I-2326,2015.
  55. (PJ-103: Cardiac Arrest/Resuscitation/Cardiopulmonary/Critical Care/ACLS) Komatsu M, Takahashi J, Nakano M, Kondo M, Tsuburaya R, Hao K, Nishimiya K, Nihei T, Matsumoto Y, Ito K, Fukuda K, Shimokawa H. Usefulness of dual-induction tests for coronary artery spasm and lethal ventricular arrhythmias in patients surviving out-of-hospital cardiac arrest. Circ J 79(Suppl. I):I-2410,2015.
  56. (PJ-508:Pulmonary Circulation) Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Sato H, Satoh K, Shimokawa H. Effectiveness of vasodilator therapy for patients with inoperable chronic thromboembolic pulmonary hypertension in prior to percutaneous transluminal pulmonary angioplasty. Circ J 79(Suppl. I):I-2731,2015.
  57. (PJ-525:Arrhythmia, Others (Clinical/Diagnosis/Treatment)) Nakano M, Fukuda K, Kondo M, Satake H, Segawa M, Hirano M, Chiba T, Shimokawa H. Usefulness of late potentials for risk stratification in patients with type 2 brugada electrocardiogram. Circ J 79(Suppl. I):I-2748,2015.
  58. (PJ-655:Pulmonary Circulation) Sato H, Tatebe S, Sugimura K, Aoki T, Miura M, Yaoita N, Nochioka K , Yamamoto S, Satoh K, Shimokawa H. Current status of the treatment for adult congenital heart disease associated with pulmonary arterial hypertension. Circ J, 79(Suppl. I):I-2878,2015.
  59. (PJ-734: Cost-health Care System/DPC/Laws) Nakayama M, Takehana K, Takeda K, Kohro T, Shimokawa H. Report data format of medical examination in cardiology should be standardized for standardized structured medical information exchange extended storage. Circ J 79(Suppl. I):I-2957,2015.
“ú–{“à‰ÈŠw‰ï–k—€Žx•”‘æ64‰ñ¶ŠU‹³ˆçu‰‰‰ïi2015”N3ŒŽ8“úA‹à‘òŽsj
  1. ‰ºìG–ŸFŠ¥¹k«‹·SÇ‚̍ŋ߂̒mŒ©.
‘æ204‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2015”N2ŒŽ21“úAå‘äŽsj
  1. Š™“c—TŠîA—é–؏G–ŸA‰ºìG–ŸA–쑺—º‰îA“ü–ìŽ÷”üA‹vŽu–{–ÎŽ÷F‹}«–ò•š’†“Å‚É‚æ‚é––œ_ŒoáŠQ‚©‚ç’·Šú“I‚ȐlHŒÄ‹zŠíˆË‘¶‚ɊׂÁ‚œ‚P—á.
  2. ²“¡@ꡁAÂ–Ø—³’jA–î”ö”M—TAŽR–{¹DAŒš•”r‰îAŽO‰Y³’šA²“¡Œö—YA™‘ºGˆê˜YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç—á‚ÉŒo”ç“I”x“®–¬Šg’£p‚ðŽ{s‚µ”x“®–¬úE‚𗈂µ‚œ2 Ç—á.
  3. “c’†Ë˜NAŒ‹{Œ’‰îA¬Œ^‹±A‚‹Ž@Aš¢’J—²Ž¡A‰H”öŽ‹MAŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸFƒXƒeƒƒCƒh•â[ŠJŽnŒã‚ÉŠ¥¹k«‹·SÇ”­ì‚ð”F‚ß‚œACTH’P“ÆŒ‡‘¹Ç‚Ì1—á.
‘æ44‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïŠwpW‰ïi2015”N2ŒŽ6`7“úA‚Œj

    ƒŠî’²u‰‰„

  1. ‰ºìG–ŸFzŠÂŠí•a‚̃gƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`.
  2. ƒYIA„

  3. –î”ö”M—TA²“¡‘åŽ÷A²“¡Œö—YA™‘ºGˆê˜YA‘呺~ˆêA•Ÿ–{‹`OA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̐V‹K•aˆö’`”’TAFI‚Ì”­Œ©‚Æ‚»‚Ì‹@”\“IˆÓ‹`.
  4. ƒYIAÅIŒó•â„

  5. H“¡@rA²“¡Œö—YA—é–؍N‘ŸA»‘ºTˆê˜YA–ì–ؐ³“¹A“c’†^ˆêA“ì@’B˜YA‹e’n‡—TA‘呺~ˆêA’r“c®•œA‰ºìG–ŸFƒXƒ^ƒ`ƒ“‚É‚æ‚é‘œ–Ê“IŒø‰Ê‚ÌŒŽˆö’`”’SmgGDS‚Ì“¯’è‚Æ‚»‚̐S”ì‘åEüˆÛ‰»‚Ì—}§‹@\.
  6. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  7. ²“¡Œö—YA—é–؍N‘ŸA‘呺~ˆêA‹e’nM—TA²“¡‘åŽ÷A•àV@—ºA–î”ö”M—TA™‘ºGˆê˜YA•Ÿ–{‹`OA’†‘ºˆê•¶AˆÉ“¡@_A‰ºìG–ŸFƒTƒCƒNƒƒtƒBƒŠƒ“AŽó—e‘ÌBasigin‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\.
‘æ8‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2015”N1ŒŽ31“ú`2ŒŽ1“úA“¿“‡j

    ƒƒVƒ“ƒ|ƒWƒEƒ€1FŠef—ÉȂɂš‚¯‚鐫·ˆãŠw‚̐i•à„

  1. ‰ºì G–ŸFzŠÂŠí“à‰È—̈æ‚É‚š‚¯‚鐫·ˆãŠw‚̐i•à
  2. ƒÅ—DG‰‰‘聄

  3. ‰H”ö Ž‹MA‚‹Ž AˆÉ“¡ Œ’‘ŸA›Á Œ³‹gA‹{“c •qAŒ‹{ Œ’‰îAš¢’J —²Ž¡AŒ–{ ‘׎¡Aâ“c ‘וFA‰ºì G–ŸF‹}«S‹Ø[Ç”­Ç—Š‚Ɖ@“àŽ€–S—Š‚ÌŒo”N•Ï‰»‚É‚š‚¯‚鐫·‚ÌŒŸ“¢ -MIYAGI-AMI Registry Study‚©‚ç‚Ì•ñ-
  4. ƒ—DG‰‰‘èŒó•â„

  5. ’Ò ŒOØŽqAâ“c ‘וFAŽO‰Y ³’šA’A–Ø ‘sˆê˜YA‹ž —ºˆêAŽR“à ‹BA²“¡ Œª“ñ˜YA¬–쐣 „¶Aˆ¢•” —Ú—žAŒã‰ª L‘Ÿ˜YA‚‹Ž A‹{“c •qA‰ºì G–ŸF¶ŽºŽûk”\‚ª•Û‚œ‚ê‚œS•s‘SŠ³ŽÒ‚É‚š‚¯‚鐫·|CHART-2Œ€‹†‚É‚š‚¯‚é’mŒ©|
  6. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  7. Â–Ø —³’jAÂ–Ø—³’jA™‘ºGˆê˜YA£ì«lA–î”ö”M—TAŒš•”r‰îAŽO‰Y³’šA²“¡@—yA²“¡Œö—YA•Ÿ“c_“ñA‰ºìG–ŸFSƒTƒ‹ƒRƒCƒh[ƒVƒX‚̗Տ°“I“Á’¥‚̐«·‚ÉŠÖ‚·‚錟“¢
  8. ’A–Ø šáˆê˜YAâ“c ‘וFA•Ÿ–{ ‹`OAŽO‰Y r˜YA–åã r–ŸA‘ã“c _”VA–k•— ­ŽjA‰ºì G–ŸF–«S•s‘SŠ³ŽÒ‚É‚š‚¢‚ăƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿‚Ɛ«·
  9. ¬–쐣 „¶Aâ“c ‘וFA‹{“c •qAŽO‰Y ³’šA’A–Ø ‘sˆê˜YA‹ž —ºˆêAŽR“à ‹BA²“¡ Œª“ñ˜YA‚‹Ž AŒã‰ª L‘Ÿ˜YA‰ºì G–ŸFSŒŒŠÇ•aŠ³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐŒã‚̐S“IŠOŒãƒXƒgƒŒƒXáŠQ‚Ɛ«·|CHART-2Œ€‹†‚©‚ç‚Ì•ñ|

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2014”N
‘æ55‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi2014”N10ŒŽ30“ú`11ŒŽ1“úA‘q•~j
  1. ˆÉ“¡Œ’‘ŸA‚‹Ž@AŒ–{‘׎¡A‰~’J—²Ž¡A‰H”öŽ‹MAŒ‹{Œ’‰îA“ñ•r‘Ÿ˜YA‰ºìG–ŸF’áo—Í‘ÌŠOÕŒ‚”gŽ¡—ÁFSŒŒŠÇŽŸŠ³‚ɑ΂·‚éV‚µ‚¢”ñNP«ŒŒŠÇV¶—Ö@.
  2. »‘ºTˆê˜YAŽO‰Y³’šA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚ƉEŽº‹@”\‚ÉŠÖ‚·‚錟“¢.
‘æ18‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2014”N10ŒŽ10`12“úA‘åãj

    ƒƒVƒ“ƒ|ƒWƒEƒ€6FS•s‘S‚É‚š‚¯‚éŠÏŽ@Œ€‹†„

  1. Sakata Y, Nochioka K, Miura M, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Miyata S, Shimokawa H. The Chronic Heart Failure Analysis and Registry in the Tohoku District) Study.
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€22FzŠÂŠí—̈æ‚É‚š‚¯‚éƒrƒbƒOƒf[ƒ^‚̍ì‚è•û„

  3. Shimokawa H. Large-scale registry study with chronic heart failure -Lessons from the CHART-2 Study-
  4. ƒYIARžu‰‰FŠî‘bŒnF—DGÜŽóÜ„

  5. Ikeda S, Satoh K, Kikuchi N, Miyata S, Suzuki K, Omura J, Shimizu T, Fukumoto Y, Sakata Y, Shimokawa H. Crucial role of Rho-kinase in pressure overload-induced right ventricular hypertrophy and dusfunction in mice.
  6. ƒYIARžu‰‰F—Տ°ŒnF—DGÜŽóÜ„

  7. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Sato K, Yamauchi T, Tsuji K, Shimokawa H. Recent trends in clinical outcomes and prognostic factors in patients with dilated cardiomyopathy -The CHART Studies-
  8. ƒˆê”ʉ‰‘聄

  9. “¡ŒŽ~ŽqA‘åÀG˜aA‘D…N—zAˆÉ“¡‹I•FAŽO–؁@rAŒš•”r‰îA™‘ºGˆê˜YAâ“c‘וFAŒžŠ–F•¶A‰ºìG–ŸFSƒGƒR[‚ð—p‚¢‚œƒtƒ@ƒ[Žl’¥Ç‚š‚æ‚Ñ”x‚ŒŒˆ³Ç—á‚É‚š‚¯‚é‰EŽº‹@”\’ቺ‹@˜‚Ì”äŠr.
  10. Yamauchi T, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Shimokawa H. Differences in clinical characteristics of anemic patients with chronic heart failure between ischemic and dilated cardiomyopathy -The CHART-2 Study-
  11. Sato K, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Ushigome R, Yamauchi T, Shimokawa H. Three-year mortality and prognostic predictors in patients with aortic stenosis -A report from the CHART-2 Study-
  12. Onose T, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Shimokawa H. Post-traumatic stress disorder after the Great East Japan Earthquake in patients with heart failure -A report from the CHART-2 Study-
  13. Aoki T, Sugimura K, Yaoita N, Yamamoto S, Tatebe S, Miura M, Nochioka K, Sato H, Satoh K, Shimokawa H. Effects of conventional medical therapy prior to percutaneous transluminal pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension.
  14. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H. Prognostic impacts of aldosterone antagonists in patients with heart failure with preserved ejection fraction -A report from the CHART-2 Study-
  15. Tadaki S, Sakata Y, Fukumoto Y, Miura T, Kadokami T, Daida H, Kitakaze M, Shimokawa H. Prognostic impact of physical activity level in patients with chronic heart failure -A multicenter prospective cohort study-
  16. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[”­•\„

  17. Sato H, Aoki T, Miura M, Yaoita N, Yamamoto S, Tatebe S, Nochioka K, Satoh K, Sugimura K, Shimokawa H. Two cases of pulmonary hypertension associated with portosystemic shunt.
  18. Aoki T, Sugimura K, Nochioka K, Tatebe S, Yamamoto S, Miura M, Satoh K, Akiyama M, Saiki Y, Shimokawa H. Impact of implantable ventricular assist devices on long-term prognosis of patients with advanced heart failure.
  19. Sato H, Aoki T, Sugimura K, Nochioka K, Tatebe S, Yamamoto S, Miura M, Yaoita N, Satoh K, Shimokawa H. A case of successful immunosuppressive therapy for chronic myocarditis.
‘æ2‰ñ“ú–{”x‚ŒŒˆ³Šw‰ïE‘æ3‰ñ“ú–{”xzŠÂŠw‰ïŠwpW‰ïi2014”N10ŒŽ3`4“úA“Œ‹žj

    ƒƒVƒ“ƒ|ƒWƒEƒ€1F“ú–{‚©‚琢ŠE‚ÉŒü‚¯‚Ä”x‚ŒŒˆ³Ç‚ÌŠî‘bŒ€‹†‚ð‚Ç‚€”­M‚µ‚Ä‚¢‚­‚©H„

  1. •Ÿ–{‹`OA‰ºìG–ŸF”x‚ŒŒˆ³Ž¡—Âɂš‚¯‚éRhoƒLƒi[ƒ[‘jŠQ–ò‚Ö‚ÌŠú‘ҁFŠî‘b`—Տ°.
  2. ƒƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€1FCTEPH„

  3. ŽO‰Y³’šA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éPTPA‚̉EŽº‹@”\‚ÉŠÖ‚·‚錟“¢.
  4. Œš•”r‰îA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF”x“®–¬ƒoƒ‹[ƒ“Œ`¬p‚ªCTEPHŠ³ŽÒ‚Ì‘ãŽÓEt‹@”\‚Ö‹y‚Ú‚·‰e‹¿.
  5. ƒƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€3FŠî‘b„

  6. ²“¡Œö—YA—é–؍N‘ŸA‘呺~ˆêA‹e’n‡—SA–î”ö”M—TA™‘ºGˆê˜YA•Ÿ–{‹`OA’†‘ºˆê•¶AˆÉ“¡@_A‰ºìG–ŸFBasigin‚ÍŒŒŠÇ•œŠŠ‹Ø×–E‘B‚𑣐i‚µ”x‚ŒŒˆ³Ç‚ðˆ«‰»‚³‚¹‚é.
  7. ƒˆê”ʉ‰‘聄

  8. ™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽR–{¹DAŽO‰Y³’šA–î”ö”M—TA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸFŒã–э׊ǐ«”x‚ŒŒˆ³Ç‚ɑ΂·‚éˆêŽ_‰»’‚‘f”xŒŒŠÇ”œ‰žŽŽŒ±‚̈Ӌ`.
  9. –î”ö”M—TA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸFŒŽ”­«’_`«ŠÌd•Ï‚̐¶‘̊̈ڐAŒã‚É”­Ç‚µ‚œ”x‚ŒŒˆ³Ç‚̈ê—á.
  10. ‘Ձ@“NᩁA™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽR–{¹DAŽO‰Y³’šA–î”ö”M—TA²“¡Œö—YA‰ºìG–ŸFOCT‚ŃŠƒo[ƒXƒŠƒ‚ƒfƒŠƒ“ƒO‚ð”F‚ß‚œ”x“®–¬«”x‚ŒŒˆ³Ç‚̈ê—á.
  11. ŽO•r@‘zAé“c—SŽqA“n•”@—ŽAŠ›ì—R‹NŽqA“¡“c—mŽqA“¡ˆä”ŽŽiAÖ“¡^ˆê˜YAÎˆä’q“¿A‰ºìG–ŸA’£‘֏G˜YF–Ɖu—}§—Ö@‚ª‘tŒ÷‚µ‚œ‹­”çÇE‹«ŠEŒ^”x“®–¬«”x‚ŒŒˆ³Ç‚Ì1—á.
  12. ²“¡@ꡁAŽO‰Y³’šA–î”ö”M—TAŽR–{¹DAŒš•”r‰îAÂ–Ø—³’jAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA™‘ºGˆê˜YA‰ºìG–ŸF–å–¬\‘åzŠÂƒVƒƒƒ“ƒg‚É”º‚€”x‚ŒŒˆ³Ç‚Ì2Ç—á.
‘æ62‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2014”N9ŒŽ26`28“úAå‘äjiŽåÃj

    ƒ‰ï’·u‰‰„

  1. ‰ºìG–ŸF–Ú‚ÉŒ©‚Š‚È‚¢‚à‚Ì‚Ì‘åØ‚³
  2. ƒA Year in Cardiology --The EHJ Perspective/The 62nd Annual Japanese College Scientific Session of Cardiology„

  3. Shimokawa H : Conclusion.
  4. ƒ“Á•ÊŠé‰æ6F”x‚ŒŒˆ³f—Â̐i•à„

  5. •Ÿ–{‹`OA‰ºìG–ŸF”x‚ŒŒˆ³Ç‚̐V–ò‚Ö‚ÌŠú‘Ò.
  6. ƒ“Á•ÊŠé‰æ8F“ú–{‚̗Տ°Œ€‹†‚ÌŒ»ó‚Æ“W–]„

  7. â“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹Ž@A‰ºìG–ŸF“Œ–k–«S•s‘S“o˜^iCHART-2jŒ€‹†‚ÌŒ»ó‚Æ“W–].
  8. ƒ“Á•ÊŠé‰æ9FInternational Symposium on Coronary Vasomotion Abnormalities„

  9. Shimokawa H. Importance of coronary vasomotion abnormalities.
  10. ƒ“Á•ÊŠé‰æ10FzŠÂŠí—̈æ‚É‚š‚¯‚é”ñi’ájNP«Ž¡—Â̐i•à„

  11. ˆÉ“¡Œ’‘ŸA‰ºìG–ŸFdÇ‹·SÇ‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Â̊J”­.
  12. ŒŒŽ—²•vA‹à’J–@”EA‰ºìG–ŸAˆÉ“¡Œ’‘ŸF’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Á@-ÎìŒ§—§’†‰›•a‰@‚É‚š‚¯‚鎡—ÃŒoŒ±-
  13. ƒƒVƒ“ƒ|ƒWƒEƒ€10FdÇS•s‘S‚ÌŽ¡—Â̐i•à„

  14. HŽR³”NAHê”ü‹IA‰Í’Á@‘Aì–{r•ãAŒã‰ªL‘Ÿ˜YA™‘ºGˆê˜YA•Ÿ“c_“ñAÖ–؉ÀŽA‰ºìG–ŸFAž‚ÝŒ^•â•lHS‘ŸŽ¡—Â̌»‹µFAž‚ÝŒãÄ“ü‰@‚ð—v‚·‚鎡—Â̌»ó‚Ƒ΍ô.
  15. ƒƒVƒ“ƒ|ƒWƒEƒ€11FAdult Congenital Heart Disease (ACHD)‚̐f—Â̐i•à„

  16. Œš•”r‰îA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAŽR–{¹DA²“¡Œö—YAˆÀ’B@—A‰ª“cŽ“TA–Ø‘º³lAHê”ü‹IAÖ–؉ÀŽA‹ß“¡@‹uA‰ºìG–ŸF”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚œACHDf—Â̎¡—Ð헪.
  17. ƒƒVƒ“ƒ|ƒWƒEƒ€12FS•s‘SŠ³ŽÒ‚ɑ΂·‚é‘œ–Ê“IƒAƒvƒ[ƒ`„

  18. â“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹Ž@A‰ºìG–ŸFÇ—á”wŒi‚ðl—¶‚µ‚œS•s‘S‚ւ̃Aƒvƒ[ƒ`FCHART-2Œ€‹†‚Ì’mŒ©‚©‚ç.
  19. ƒƒVƒ“ƒ|ƒWƒEƒ€13FV‹KŒoŒûR‹ÃŒÅ–ò(NOAC)‚ð‚Ç‚€Žg‚¢‚±‚È‚·‚©„

  20. •Ÿ“c_“ñA¬ì‹v—YAV@”ŽŽŸAˆäã@”ŽA“àŽR^ˆê˜YA–k‰€F¬A’r“cF“¿AŠC–kKˆêAŠ›‘Ő³_AŒˆä–M•FA‰ºìG–ŸF”ñ•Ù–ŒÇ«S–[×“®Š³ŽÒ‚ɑ΂·‚郊ƒo[ƒƒLƒTƒoƒ““o˜^ŠÏŽ@Œ€‹†EXPAND Study“o˜^Ç—á‚Ì”wŒiˆöŽq.
  21. ƒƒVƒ“ƒ|ƒWƒEƒ€17F–«ŽŸŠ³E¶ŠˆKŠµ•a‚ð‡•¹‚µ‚œSŽŸŠ³Š³ŽÒ‚ÌŠÇ—„

  22. ŽO‰Y³’šAâ“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹Ž@A‰ºìG–ŸF‹•ŒŒ«/”ñ‹•ŒŒ«S•s‘S‚É‚š‚¯‚é“œ”A•a‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÉŠÖ‚·‚錟“¢.
  23. ƒƒrƒWƒ…ƒAƒ‹ƒ[ƒNƒVƒ‡ƒbƒv4F”x‚ŒŒˆ³‚ðf‚遄

  24. ‘Ÿ“cGŠöA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DAŽO‰Y³’šA‰ºìG–ŸF4D flow MRI (3D phase contrast MRI)‚É‚š‚¯‚é”x“®–¬“àvortex flow‚Æ”x‚ŒŒˆ³Ç‚Æ‚ÌŠÖ˜A.
  25. ™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DAŽO‰Y³’šA–î”ö”M—TA²“¡@—yA²“¡Œö—YA‰ºìG–ŸF”x‚ŒŒˆ³Ç‚̐f’f‚ÆŽ¡—Âɂš‚¯‚éŒõŠ±Â’f‘w–@‚Ì—L—p«.
  26. ƒƒƒfƒBƒJƒ‹ƒXƒ^ƒbƒtƒZƒbƒVƒ‡ƒ“1F“dŽqƒJƒ‹ƒeŽž‘ã‚̃NƒŠƒjƒJƒ‹ƒpƒX„

  27. ‰~’J—²Ž¡A’†ŽR‰ë°A‘Ÿ“c—L‰ÀAŒã‰ªL‘Ÿ˜YA’†–ì@œA™‘ºGˆê˜YA‚‹Ž@A•Ÿ“c_“ñA‰ºìG–ŸF“dŽqƒJƒ‹ƒeŽž‘ã‚̃NƒŠƒjƒJƒ‹ƒpƒX`“dŽqƒJƒ‹ƒe“±“üˆÚsŠú‚É‚š‚¯‚é–â‘è“_.
  28. ƒ“ú–{S‘Ÿ•aŠw‰ïE“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€„

  29. Œ–{‘׎¡A‹ààV³”́A’|“à‰ëŽjA‰H”öŽ‹MA‰ºìG–ŸF‘å“®–¬•Ùd‰»ÇE‹·óÇ‚ɑ΂·‚é‰^“®—Ö@‚Í—LŒø‚©‹ÖŠõ‚©H
  30. ƒ—DG‰‰‘èƒZƒbƒVƒ‡ƒ“EŒû‰‰„

  31. ãâ—T[AŒŒŽ—²•vA‘å–쑏ŒbA•Ð“cŒ\ˆêA‹à’J–@”EAˆÉ“¡Œ’‘ŸA‰ºìG–ŸFdÇ‹•ŒŒ«SŽŸŠ³Š³ŽÒ‚̉^“®‘Ï—e”\‚ɑ΂·‚é’áo—͏Ռ‚”gŽ¡—Â̌ø‰Ê.
  32. ƒƒ‚[ƒjƒ“ƒOƒŒƒNƒ`ƒƒ[11„

  33. •Ÿ“c_“ñA‰ºìG–ŸF¬nŠú‚ðŒ}‚Š‚œS–[×“®ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Ã.
  34. ƒˆê”ʉ‰‘èEŒû‰‰„

  35. “ñ•r‘Ÿ˜YA‚‹Ž@A¬‘é—I“ñAŒ‹{Œ’‰îA‰H”öŽ‹MA‰~’J—²Ž¡AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚ɃXƒeƒ“ƒg—£’f‚ð‚«‚œ‚µŠ¥“®–¬áŽ‚ðŒ`¬‚µ‚œŽá”Nìè•aŒãˆâÇ‚̈ê—á.
  36. ’A–Ø‘sˆê˜YAâ“c‘וFA•Ÿ–{‹`OAŽO‰Yr˜YA–åãr–ŸA‘ã“c_”VA–k•—­ŽjA‰ºìG–ŸF–«S•s‘S‚š‚æ‚Ñ‚»‚̃nƒCƒŠƒXƒNÇ—á‚É‚š‚¯‚ég‘ÌŠˆ“®‚Ɖ^“®‘jŠQˆöŽq‚ÌŒŸ“¢@-‘S‘‘œŽ{Ý‹€“¯ƒRƒz[ƒgŒ€‹†-
  37. ŽR“à@‹BAâ“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c@„A’A–Ø‘sˆê˜YA‹ž—ºˆêA‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚Ì—\Œã‚ɑ΂·‚é•nŒŒ‚̉e‹¿‚ÌŒŸ“¢ -CHART-2Œ€‹†‚©‚ç‚Ì•ñ-
  38. ™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘Ÿ˜YAŽR–{¹DAŽO‰Y³’šAÂ–Ø—³’jA–î”ö”M—TA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸFŒã–э׊ǐ«”x‚ŒŒˆ³Ç‚É‚š‚¯‚éˆêŽ_‰»’‚‘f‹z“ü”xŒŒŠÇ”œ‰žŽŽŒ±‚É‚æ‚錟“¢.
  39. Œ‹{Œ’‰îAŒ–{‘׎¡A‰F’Ë—T‹IAi“¡’q•FA’·’J•”—Y”òA“ñ•r‘Ÿ˜YA‰H”öŽ‹MA‰~’J—²Ž¡A‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFOptical Frequency Domain Imaging (OFDI)‚É‚æ‚銥“®–¬ŠO–ŒVasa Vasorum‚̐¶‘Ì“à‰æ‘œ•]‰¿.
  40. Œ‹{Œ’‰îAŒ–{‘׎¡A‚‹Ž@A‰F’Ë—T‹IA¬‘é—I“ñA“ñ•r‘Ÿ˜YA‰H”öŽ‹MA‰~’J—²Ž¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFŠ¥¹k«‹·SÇ‚Ì•a‘Ô‚É‚š‚¯‚銥“®–¬ŠO–ŒVasa Vasorum‚ÌŠÖ—^-ŒõŠ±Â’f‘w‰æ‘œ(OFDI)‚ð—p‚¢‚œ—Տ°“IŒŸ“¢-
  41. ‰H”öŽ‹MA‚‹Ž@AÂ–Ø—³’jA‹{“c@•qA“ñ•r‘Ÿ˜YAŒ‹{Œ’‰îA‰~’J—²Ž¡AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF“Œ“ú–{‘åkÐŒã‚É”F‚ß‚ç‚ê‚œS”x’âŽ~Ç—á‚Ì‘‰Á‚ÉŠÖŒW‚·‚éˆöŽq‚ÌŒŸ“¢.
  42. ‰~’J—²Ž¡A‚‹Ž@A“ñ•r‘Ÿ˜YAŒ‹{Œ’‰îA‰H”öŽ‹MA”’ŒË@’AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFd“xt‹@”\áŠQ—á‚É‚š‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Œã‚̐t‹@”\ˆ«‰»‚ɑ΂·‚é—\–h“IŒŒ‰t“§Í‚ÌŒø‰Ê‚ÉŠÖ‚·‚錟“¢.
  43. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–ì@œA’·’J•”—Y”òA²’|—m”VA£ì«lA•œ–쓹ŠîA‰ºìG–ŸF‹·‚¢QRS•‚ð’悵‚Ä‚¢‚œ‚ªCRT‚ª’˜Œø‚µSˆÚA‚ð‰ñ”ð‚Å‚«‚œ‰Æ‘°«Šg’£Œ^S‹ØÇ‚̈ê—á.
  44. “ñ•r‘Ÿ˜YA‚‹Ž@A¬‘é—I“ñAŒ‹{Œ’‰îA‰H”öŽ‹MA‰~’J—²Ž¡AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸFŠ¥¹k«‹·SÇ‚Ì’·Šú—\Œã—\‘ª‚É‚š‚¯‚éRhoƒLƒi[ƒ[Šˆ«‚Ì—L—p«.
  45. ¬‘é—I“ñA‰~’J—²Ž¡A‚‹Ž@A“ñ•r‘Ÿ˜YAŒ‹{Œ’‰îA‰H”öŽ‹MAŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAœA“n—SŽjA‰ºìG–ŸFŠ¥”÷¬ŒŒŠÇ¹k‚ÆŒŒ’†ƒZƒƒgƒjƒ“‚ÌŠÖ˜A‚ÌŒŸ“¢.
  46. ŽO‰Y³’šA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA–î”ö”M—TA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚̉EŽº‹@”\‚É‹y‚Ú‚·Œø‰Ê‚ÉŠÖ‚·‚錟“¢.
  47. ‹ž—ºˆêAâ“c‘וFAŒã‰ªL‘Ÿ˜YA‹{“c@•qAŽO‰Y³’šA‚“c„ŽjA’A–Ø‘sˆê˜YAŽR“à@‹BA‰ºìG–ŸF–{–M‚É‚š‚¯‚édÇS•s‘S‚̗Տ°”wŒi‚Æ—\Œã‚ÌŽž‘ã“I•Ï‘JFCHARTŒ€‹†‚©‚ç‚Ì’mŒ©.
  48. ‚ŒK—uŽqAŽMˆä³‹`AŒ³ŽR’åŽqA’Ŗ쌛“ñA‰Í‡GŽ÷AˆÉ“¡@‘nA‰iŒŽNbA‚“c‰À‘ãŽqA‹{é‰èˆßŽqA¬£Š°”VA‰œ‘º‰ë“¿A‘ºŒ@’AˆÉ“¡Œ’‘ŸA‰ºìG–ŸA”öès—YFdÇS‹Ø‹•ŒŒ‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—ÂÌCT perfusion‚É‚æ‚錟“¢.
  49. ‰H”öŽ‹MA‚‹Ž@AˆÉ“¡Œ’‘ŸA‹{“c@•qAâ“c‘וFA“ñ•r‘Ÿ˜YAŒ‹{Œ’‰îA‰~’J—²Ž¡AŒ–{‘׎¡AˆÀ“c@‘A‰ºìG–ŸF‹}«S‹Ø[ÇŠ³ŽÒ‚É‚š‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“–¢Ž{s—á‚Ì“Á’¥@\‹{éŒ§S‹Ø[Ç‘΍ô‹Š‹c‰ï‚©‚ç‚Ì•ñ\
  50. ‚–Ø—S‰îA™@³•¶A–ì–ؐ³“¹A]Œû‹v”üŽqA›Á@Œ³‹gA”·@Œ’ˆê˜YA–©’J@–LAŒË“c@’ŒAŽR–{‹`lA‰ºìG–ŸFˆÙŽí‚Ì–òÜ—no«ƒXƒeƒ“ƒg‚ð‘g‚ݍ‡‚킹‚œŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‚̗Տ°¬Ñ‚ÌŒŸ“¢.
  51. ŒŒŽ—²•vAˆÀ“c•q•FAŽO—ÖŒ’“ñAˆäã@ŸA–ð“c—m•œA–û”ö@‹œAŒˆä’¶A“Œ@Œc”V‰îA‹à’J–@”EAˆÉ“¡Œ’‘ŸA‰ºìG–ŸFdÇ‹•ŒŒ«SŽŸŠ³‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Â̗Տ°Œø‰Ê‚Æ“à”ç×–E‹@”\‚ւ̉e‹¿.
  52. ‰®•~@“µAŒŒŽ—²•vA‹à’J–@”EAˆÉ“¡Œ’‘ŸA‰ºìG–ŸAŽÄ“c—R”üŽqFdÇ‹•ŒŒ«SŽŸŠ³‚ɑ΂·‚é’áo—͏Ռ‚”gŽ¡—ÑOŒã‚É‚š‚¯‚é‚€‚ó‘Ԃ̕ω»‚ɂ‚¢‚Ä.
  53. ƒƒ|ƒXƒ^[”­•\„

  54. –î“c–L—²A‰ºìG–ŸAŒã“¡^ŒÈAŠ’J•¶•FF¶‘Ì“àƒCƒk‹}«Š¥“®–¬•ÂÇŽžA‘€•›ŒŒs˜H‚Ì“à”ç—R—ˆ‰ß•ª‹ÉˆöŽqA‰ßŽ_‰»…‘f‚É‚æ‚錌ŠÇŠg’£‚́A“œ”A•a«Š¥”÷¬ŒŒŠÇ“à”çáŠQ‚ð‘㏞‚·‚é.
  55. –©’J@–LA–ì–ؐ³“¹A]Œû‹v”üŽqA›Á@Œ³‹gA”·@Œ’ˆê˜YA‚–Ø—S‰îAŒË“c@’ŒAŽR–{‹`lA™@³•¶A‰ºìG–ŸFDrug Eluting Balloon Šg’£’ŒŒã‚Ì‹»–¡[‚¢OFDI‰æ‘œ.
  56. ]Œû‹v”üŽqAŽR–{‹`lA–ì–ؐ³“¹A›Á@Œ³‹gA”·@Œ’ˆê˜YA‚–Ø—S‰îA–©’J@–LAŒË“c@’ŒA™@³•¶A‰ºìG–ŸF‰EŠ¥“®–¬CTO•a•Ï‚ɑ΂µ‚ÄCART–@‚É‚æ‚é‹Uo‚ւ̃Xƒeƒ“ƒg—¯’uŒãA–«Šú‚ɃXƒeƒ“ƒgŠO^oÄŠJ’Ê‚ð”F‚ß‚œ‚ƍl‚Š‚ç‚ê‚é1—á.
  57. ’†–ì@œA•Ÿ“c_“ñA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA£ì«lA•œ–쓹ŠîA‰ºìG–ŸFType 2 BrugadaS“d}Š³ŽÒ‚̃ŠƒXƒN‘w•Ê‰»‚É‚š‚¯‚éLate potentials‚Ì—L—p«.
  58. Œš•”r‰îA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽO‰Y³’šAŽR–{¹DA–î”ö”M—TA²“¡@ꡁA‰ºìG–ŸFS‘ŸˆÚA“o˜^\¿“K‰žŠO‚Æ”»’f‚µ‚œ•s‰Â‹t“IŠÌüˆÛÇ‚ð‡•¹‚µ‚œƒtƒ@ƒ[Žl’¥ÇS“àC•œpŒã‚Ì1—á.
  59. ŽO‰Y—²‰îA—é–؏G–ŸAŒ–{‘׎¡A”öè@‘ׁA‰H”öŽ‹MA‰~’J—²Ž¡A‚‹Ž@AˆÉ“¡Œ’‘ŸAˆÉ“¡’å‰ÃA‰Á‰ê’J@–LA‹vŽu–{¬Ž÷A‰ºìG–ŸFƒvƒ‰ƒ“ƒ}[•a‚ɍ‡•¹‚µ‚œ‚œ‚±‚‚ڌ^S‹ØÇ‚Ì1—á.
  60. ŽR–{‹`lA–ì–ؐ³“¹A]Œû‹v”üŽqA›Á@Œ³‹gA”·@Œ’ˆê˜YA‚–Ø—S‰îA–©’J@–LAŒË“c@’ŒA™@³•¶A‰ºìG–ŸFCoronary CTO•a•Ï‚ÌPCI‚É‚š‚¯‚éRendez-vous–@‚̍lŽ@
  61. –©’J@–LA–ì–ؐ³“¹A]Œû‹v”üŽqA›Á@Œ³‹gA”·@Œ’ˆê˜YA‚–Ø—S‰îAŒË“c@’ŒA™@³•¶A‰ºìG–ŸFCART–@‚É‚ÄRCA-CTO‚ÌPCI‚ðs‚¢Septal Rupture‚𗈂µ‚œ1—á‚Æ‚»‚Ì’·ŠúŒo‰ß.
  62. £ì«lA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸFdÇS•s‘S‚ð’悵‚œ•p”—U”­«S‹ØÇ‚Ì2—á.
  63. Â–Ø—³’jA™‘ºGˆê˜YA–î”ö”M—TAŽR–{¹DAŒš•”r‰îAŽO‰Y³’šAŒã‰ªL‘Ÿ˜YA²“¡@ꡁA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚é–ò•š—Ö@‚ÌŒø‰Ê.
  64. •œ–쓹ŠîA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA£ì«lA‰ºìG–ŸFS–[‘e×“®‚Ö‚Ì–[ŽºŒ‹ßECTIƒAƒuƒŒ[ƒVƒ‡ƒ“‚ªS•s‘SƒRƒ“ƒgƒ[ƒ‹‚É‘tŒ÷‚µ‚œCRT-DA‚Šž‚ÝŒã‚ÌŠg’£Œ^S‹ØÇ‚̈ê—á.
  65. •Ÿˆä—æ–µA—é–؏G–ŸA‹{ì”T—ŽqA‰““¡’q”VA‹à“c•ü—mA™‘ºGˆê˜YAŒ–{‘׎¡A‰Á‰ê’J@–LA‹vŽu–{¬Ž÷A‰ºìG–ŸFL”͈͔MŠ³ŽÒ‚É”­Ç‚µ‚œŠg’£Œ^S‹ØÇ‚̈ê—á.
  66. ŽO‰Y’ŒWA—é–؏G–ŸA‘OàVãđŸA¬扑’m–ŸA•Ÿ“c_“ñA‰Á‰ê’J@–LA‹vŽu–{¬Ž÷A‰ºìG–ŸF‰ESŒnS“à–Œ‰Š‚ð‡•¹‚µAƒy[ƒXƒ[ƒJ[—¯’u‚ðs‚í‚È‚©‚Á‚œèò‘¹‚É‚æ‚éS’âŽ~‚̈ê—á.
  67. ²“¡@ꡁAÂ–Ø—³’jA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DAŽO‰Y³’šA–î”ö”M—TA²“¡Œö—YA‰ºìG–ŸF–«S‹Ø‰Š‚ɖƉu—}§—Ö@‚ª’˜Œø‚µ‚œˆê—á.
‘æ203‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2014”N9ŒŽ6“úAH“cj
  1. ’†‘º‹M•jCŒš•”r‰îC™‘ºGˆê˜YCŒã‰ªL‘Ÿ˜YCŽO‰Y³’šCŽR–{¹DC–î”ö”M—TC²“¡@—yC²“¡Œö—YC‰ºìG–ŸFOFDI (ŒõŽü”g”—̈æ‰æ‘œ) ‚É‚æ‚èŠÏŽ@‚µ‚Š‚œŒŒŠÇ‰Š‚É”º‚€”x“®–¬‹·ó‚Ì1—á
‘æ29‰ñ“ú–{•s®–¬Šw‰ïE‘æ31‰ñ“ú–{S“dŠw‰ï‡“¯Šwp‘å‰ïi2014”N7ŒŽ22“ú`25“úA“Œ‹žj

    ƒSpecial symposium: Digital recording of ECG data„

  1. Nakayama M, Shimokawa H. Practical issues in the development of cardiovascular disease databases for cardiovascular disease.
  2. ƒRegular papers„

  3. Kondo M, Fukuda K, Nakano M, Hasebe Y, Satake H, Hirano M, Shimokawa H. The significance of the QRS duration for arrhythmic events in postoperative Tetralogy of Fallot.
  4. Nakano M, Fukuda K, Kondo M, Hasebe, Y, Satake H, Hirano M, Shimokawa H. Late potentials could be markers for high-risk patients with type 2 Brugada electrocardiogram.
‘æ20‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2014”N7ŒŽ19“ú`20“úA‹ž“sj

    ƒƒVƒ“ƒ|ƒWƒEƒ€7FƒnƒCƒuƒŠƒbƒhS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“FƒfƒoƒCƒX‘S·Žž‘ã‚Å‚Ì‚ ‚è•û„

  1. ˆÉ“¡Œ’‘ŸAŒ–{‘׎¡A‚‹Ž@A‰ºìG–ŸF’áo—Í‘ÌŠOÕŒ‚”gŽ¡—ÂƐS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“.
  2. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“2FV‚œ‚ȗ̈æ‚ւ̐S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“FÌ‚̏펯‚͍¡‚Ì”ñíŽ¯„

  3. Œ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF‘å“®–¬•Ùd‰»ÇE‹·óÇ‚ɑ΂·‚é‰^“®—Ö@‚ÌŒø‰Ê‚Æ‹ÖŠõ.
  4. ƒˆê”ʉ‰‘èFŒû‰‰„

  5. ŽO‰Y³’šAâ“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹Ž@A‰ºìG–ŸFSŒŒŠÇ•aŠ³ŽÒ‚É‚š‚¯‚é‰îŒì—\–h•K—vó‘Ô‚Í—\Œã•s—Ç‚ÆŠÖ˜A‚·‚é@--CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  6. ’A–Ø‘sˆê˜YAâ“c‘וFA•Ÿ–{‹`OAŽO‰Yr˜YA–åãr–ŸA‘ã“c_”VA–k•—­ŽjA‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚ég‘ÌŠˆ“®—ʂ̈Ӌ`‚ÌŒŸ“¢.
  7. ’|“à‰ëŽjAŒ–{‘׎¡A’‡•y‚¿‚ÁA²“¡–[˜YAX@M–FAˆä“c‰ëËAŒ”ö—@ŽuAˆÉ“¡Z‹PA‘’ÍKOA‰Í’Á@‘AÖ“¡•ŽuAˆÀ’B@—AHŽR³”NAŒF’J‹Iˆê˜YA–{‹g’ŒFAì–{r•ãAˆÉ“¡@CAãŒŽ³”ŽAÖ–؉ÀŽA‰ºìG–ŸF‘å“®–¬áŽ‚𒆐S‚Æ‚µ‚œ‘匌ŠÇŽŸŠ³‚̏p‘OŒÄ‹zƒŠƒn‚͈À‘S‚ÉŽÀŽ{‰Â”\‚Å‚ ‚èICUÝŽºEpŒãÝ‰@“ú”‚ð’Zk‚·‚é.
  8. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  9. ’|“à‰ëŽjAŒ–{‘׎¡A–x“cˆêŽ÷AŠ`‰Ô—²ºA–îŒût…AX@M–FAˆä“c‰ëËAˆÉ“¡Z‹PA‰Í’Á@‘AHŽR³”NAŒF’J‹Iˆê˜YAˆÉ“¡Œ’‘ŸAì–{r•ãAˆÉ“¡@CAãŒŽ³”ŽAÖ–؉ÀŽA‰ºìG–ŸF“ñŠú“I‘匌ŠÇ’uŠ·pŒã‚̑ޏk‚ÉŽŠ‚Á‚œÇ—á@\p‘OŒã‚̌ċzƒŠƒn‚𒆐S‚Æ‚µ‚œ—Šw—Ö@‰î“ü\
‘æ202‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2014”N6ŒŽ21“úAå‘äj
  1. ŽO‰Y—²‰îA—é–؏G–ŸAŒ–{‘׎¡A”öè@‘ׁA‰H”öŽ‹MA‚‹Ž@AˆÉ“¡’å‰ÃA‰Á‰ê’J@–LA‹vŽu–{–ÎŽ÷A‰ºìG–ŸFƒvƒ‰ƒ“ƒ}[•a‚ɍ‡•¹‚µ‚œ‚œ‚±‚‚ڌ^S‹ØÇ‚Ì1—á.
  2. ŽO‰Y’ŒWA—é–؏G–ŸA‘OàVãđŸA¬‰º’m–ŸA•Ÿ“c_“ñA‰Á‰ê’J@–LA‹vŽu–{–ÎŽ÷A‰ºìG–ŸFS’âŽ~E‰ESŒnS“à–Œ‰Š‚ð‡•¹‚µ‚œèò‘¹‚Ì1—á.
  3. ŽO‰Y³’šA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DA‰Á“¡@‹A²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éOCT‚ð—p‚¢‚œŒo”ç“I”x“®–¬Œ`¬p‚Ì—L—p«.
‘æ158‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2014”N6ŒŽ7“úA·‰ªj

    ƒÇ—á”­•\•”–åYIAF—DGÜŽóÜ„

  1. ’·’J•”—Y”òA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸFSŽº’†Šu‹NŒ¹SŽº•p”‚ÌŽ¡—Âɓïa‚µ‚œƒ‰ƒ~ƒ“A/C ˆâ“`ŽqŠÖ˜A‰Æ‘°«Šg’£Œ^S‹ØÇ‚̈ê–UŒŸ—á.
  2. ƒŒ€‹†”­•\•”–åYIAF—DGÜŽóÜ„

  3. ŽR“à@‹BAâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêA‚‹Ž@A‰ºìG–ŸA‹{“c@•qF–«S•s‘SŠ³ŽÒ‚Ì—\Œã‚É‹y‚Ú‚·•nŒŒ‚̉e‹¿‚ƍ¶Žº‹ìo—Š‚ÌŠÖ˜A\CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  4. ƒˆê”ʉ‰‘聄

  5. HŽR³”NA‰Í’Á@‘A‘’ÍKOAì–{r•ãAâV–؉ÀŽAŒã‰ªL‘Ÿ˜YA™‘ºGˆê˜YA•Ÿ“c_“ñA‰ºìG–ŸF“–‰@‚É‚š‚¯‚éAž‚ÝŒ^•â•lHS‘ŸŽ¡—Â̐¬Ñ.
  6. •Ð•œW‘Ÿ˜YAHŽR³”NA‰Í’Á@‘AŒF’J‹Iˆê˜YAì–{r•ãAÖ–؉ÀŽA™‘ºGˆê˜YA‰ºìG–ŸF‹}‘¬‚ÈLVAD ‘•’…‚Å‹~–œ‚µ‚œS‹ØÇ‹}«‘ˆ«‚Ì1—á
  7. “ñ•r‘Ÿ˜YA‚‹Ž@Aš¢’J—²Ž¡A‰H”öŽ‹MAŒ‹{Œ’‰îA¬‘é—I“ñAŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸFŠ¥“®–¬ƒXƒeƒ“ƒg”j‘¹‚ªŠ¥“®–¬áŽŒ`¬‚ÉŠÖ—^‚µ‚œŽá”Nìè•aŒãˆâÇ‚̈ê—á.
  8. ‰H”öŽ‹MA‚‹Ž@A“ñ•r‘Ÿ˜YAŒ‹{Œ’‰îAš¢’J—²Ž¡AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸFŠ¥¹k«‹·SÇ‚ÌŠÓ•Ê‚ª—L—p‚Å‚ ‚Á‚œŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‚É‚æ‚銮‘SŒŒsÄŒšŒã‚Ì1—á.
  9. ŽR“à—I•œAš¢’J—²Ž¡A“ñ•r‘Ÿ˜YAŒ‹{Œ’‰îA‰H”öŽ‹MAŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF–òÜ•‰‰×S‹ØŒŒ—¬ƒVƒ“ƒ`‚É‚Ä—z«ŠŒ©‚ð’悵‚œŠ¥¹k«‹·SÇ‚̈ê—á.
  10. •œ–쓹ŠîA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA‰ºìG–ŸFS–[‘e×“®‚ɑ΂·‚éCTIƒuƒƒbƒNƒ‰ƒCƒ“ì¬‚š‚æ‚Ñ–[ŽºŒ‹ßƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚œCRT-DˆÚAŒã‚ÌDCM‚̈ê—á.
  11. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–ì@œA’·’J•”—Y”òA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸF“àèòÃ–¬ƒAƒvƒ[ƒ`‚ª—LŒø‚Å‚ ‚Á‚œŽOë•Ù—Ö‹NŒ¹SŽº«ŠúŠOŽûk‚̈ê—á.
  12. ’†–ì@œA•Ÿ“c_“ñA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸFLate potential‚Ítype2ƒuƒ‹ƒKƒ_S“d}Š³ŽÒ‚̃ŠƒXƒN‘w•Ê‰»‚É—L—p‚ȉ”\«‚ª‚ ‚é.
  13. –î”ö”M—TAŽO‰Y³’šA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”@r‰îAŽR–{¹DA‰ºìG–ŸA“¡ˆä”ŽŽiAÎˆä’q“¿F¬‡«Œ‹‡‘gD•a‚É”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚œˆê—á.
  14. Â–Ø—³’jA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAŒš•”r‰îAŽR–{¹DA²“¡Œö—YA‰ºìG–Ÿ:––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚Ì—L—p«.
‘æ14‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2014”N5ŒŽ16`17“úA²‰êj

    ƒƒVƒ“ƒ|ƒWƒEƒ€1FNOƒVƒOƒiƒŠƒ“ƒO‚ÌŽž‹óŠÔÝŒv‚É‚æ‚éSzŠÂƒ_ƒCƒiƒ~ƒYƒ€‚Ì“‡“I—‰ð„

  1. “›ˆä³lA‰ºìG–ŸA–öŒŽ‰„ÍA”ö’ҁ@–LFzŠÂŠíE‘ãŽÓ«ŽŸŠ³‚É‚š‚¯‚é“àˆö«‚š‚æ‚ÑŠOˆö«NOŽY¶Œn‚Ì–ðŠ„.
  2. ƒYIAƒZƒbƒVƒ‡ƒ“FÅ—DGÜŽóÜ„

  3. _ŒË–ΗYAÖ“¡‘åŽ÷A’r“c®•œAàV“cˆŒŽqABudbazar EnkhjargalA‰ºìG–ŸF“à”çˆË‘¶«’oŠÉ”œ‰ž‚É‚š‚¯‚éNO‚ÆEDHF‚̃oƒ‰ƒ“ƒX‚͐SŒŒŠÇŒn‚̍Pí«ˆÛŽ‚ɏd—v‚Å‚ ‚é.
  4. ƒˆê”ʉ‰‘èFŒû‰‰„

  5. ²“¡Œö—YA—é–؍N‘ŸA‘呺~ˆêA‹e’n‡—TA™‘ºGˆê˜YA’†‘ºˆê•¶AˆÉ“¡@_A–双Œ’Ž¡A‰ºìG–ŸFBasigin promotes vascular smooth muscle proliferation and pulmonary hypertension.
  6. “à“c‘Ÿ˜YAŒÃ–ì—R”üA’J–{º‰pA‰ºìG–ŸA‘剮—S•ãA–öŒŽ‰„ÍA”ö’ҁ@–LF‘n–ò‚ÉŽ‘‚·‚鎩‘R”­Ç‹}«S‹Ø[Çƒ‚ƒfƒ‹‚ÌŠJ”­F2/3t“Etriple NOSs-/-ƒ}ƒEƒX.
  7. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  8. –î“c–L—²A‰ºìG–ŸA•œŒ@CAŒã“¡^ŒÈA¬Š}ŒŽN•vAŠ’J•¶•FFƒCƒk¶‘Ì“à‹}«Š¥“®–¬•ÂÇŽžA‰ßŽ_‰»…‘f‚É‚æ‚銥”÷¬‘€•›ŒŒs˜HŠg’£‚́A“œ”A•a«Š¥”÷¬ŒŒŠÇ“à”çáŠQ‚ð‘㏞‚·‚é.
  9. Ö“¡‘åŽ÷A_ŒË–ΗYAàV“cˆŒŽqABudbazar EnkhjargalA‰ºìG–ŸF”÷¬ŒŒŠÇ‚É‚š‚¢‚Ä“à”çˆË‘¶«‰ß•ª‹ÉiEDHj”œ‰ž‚ª˜Ži‚µ‚Ä‚¢‚镪Žq‹@˜‚ÌŒŸ“¢.
‘æ51‰ñ“ú–{—Տ°•ªŽqˆãŠw‰ïŠwpW‰ïi2014”N4ŒŽ11“úA“Œ‹žj

    ƒƒVƒ“ƒ|ƒWƒEƒ€2F‰ä‚ª‘‚É‚š‚¯‚éƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`‚ÌŒ»ó‚Æ‚±‚ê‚©‚ç‚̉ۑ聄

  1. ‰ºìG–ŸF“Œ–k‘åŠw‚É‚š‚¯‚éƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`.
‘æ78‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2014”N3ŒŽ21“ú`23“úA“Œ‹žj

    ƒPlenary Session„

  1. (PL01:Coronary Revascularization Based on Evidence Based Medicine-ComparingPCI and CABG-Reality and Ideal) Takahashi J, Sakata Y, Miyata S, Nochioka K, Miura M, Takada T, Shimokawa H. Prognostic impacts of revascularization strategy and residual coronary stenosis in patients with ischemic heart failure. Circ J. 78(Suppl. I):I-56,2014.
  2. (PL05:Current Status and Management of Cardiac Failure, Arrhythmias, Pulmonary Hypertension and Sudden Death in Adults with Congenital Heart Disease) Tatebe S, Fukumoto Y, Sugimura K, Nochioka K, Miura M, Yamamoto S, Shimokawa H. Adult patients with congenital heart disease as an emerging population in cardiovascular medicine. Circ J. 78(Suppl. I):I-75,2014.
  3. ƒSymposium„

  4. (SY01:Coronary Circulation Revisited: Pathogenesis of Myocardial Ischemia and Its Evaluation) Nishimiya K, Matsumoto Y, Takahashi J, Uzuka H, Shindo T, Hanawa K, Hasebe Y, Nihei T, Hao K, Tsuburaya R, Shiroto T, Ito K, Ishibashi-ueda H, Yasuda S, Shimokawa H. Important role of the adventitia in the pathogenesis of coronary hyperconstricting responses after drug-eluting stent implantation in pigs in vivo. Circ J. 78(Suppl. I):I-100,2014.
  5. (SY07:EBM in Hypertension) Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Ushigome R, Yamauchi T, Shimokawa H. Clinical significance of low diastolic blood pressure in development of de-novo heart failure \A report from the CHART-2 Study\ Circ J. 78(Suppl. I):I-137,2014.
  6. (SY09:Frontiers of Coronary Imaging Modalities) Matsumoto Y, Nishimiya K, Tanaka A, Taruya A, Takahashi J, Shindo T, Hanawa K, Hasebe Y, Tsuburaya R, Shirato T, Ito K, Yasuda S, Shimokawa H. Usefulness of micro-CT and optical coherence tomography for vasa vasorum imaging in porcine coronary arteries with stent implantation. Circ J. 78(Suppl. I):I-148,2014.
  7. (SY11:Clinical Network and Disease Registry for Cardiovascular Disease) Sakata Y, Nochioka K, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Miyata S, Shimokawa H. Experience and perspectives from the chronic heart failure analysis and registry in the Tohoku District 2 (CHART-2) Study. Circ J. 78(Suppl. I):I-161,2014.
  8. (SY15:Treatment Strategy of CKD: Collaboration by Cardiologists and Nephrologists) Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H. Prognostic impact of subclinical albuminuria in chronic heart failure \A report from the CHART-2 Study\ Circ J. 78(Suppl. I):I-184,2014.
  9. (SY17:New Treatment Methods Expected for Pulmonary Hypertension) Sugimura K, Tatebe S, Fukumoto Y, Nochioka K, Yamamoto S, Miura M, Kimio Satoh, Shimokawa H. Reactive post-capillary pulmonary hypertension as a new therapeutic target for left heart disease. Circ J. 78(Suppl. I):I-193,2014.
  10. ƒYoung Investigator's Award for International Students Finalists Lectures„

  11. Nergui S, Fukumoto Y, Do.e Z, Nakajima S, Shimizu T, Ikeda S, Elias-Al-Mamun M, Shimokawa H. Molecular and cellular mechanisms of right ventricular remodeling in pulmonary hypertension. Circ J. 78(Suppl. I):I-516,2014.
  12. ƒFeatured Research Session„

  13. Nihei T, Takahashi J, Kikuchi Y, Hao K, Takagi Y, Tsuburaya R, Shirato T, Yoshitaka Itoh, Matsumoto Y, Nakayama M, Ito K, Shimokawa H. Circadian variation of Rho-kinase activity in circulating leukocytes in patients with vasospastic angina. Circ J. 78(Suppl. I):I-597,2014.
  14. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Takada T, Tadaki S, Yamauchi T, Shimokawa H. Improved long-term prognosis of patients with dilated cardiomyopathy\A report from the CHART Studies\ Circ J. 78(Suppl. I): I-549,2014.
  15. ƒOral Presentation (English)„

  16. Nakayama M, Takehana K, Shimokawa H. Data transition platforms in hospital information system should be established to construct database with information communication technology. Circ J. 78(Suppl. I):I-856,2014.
  17. Satoh K, Fukumoto Y, Sugimura K, Aoki T, Nochioka K, Tatebe S, Yamamoto S, Miura M, Shimizu T, Ikeda S, Yaoita N, Minami T, Miyata S, Suzuki K, Omura J, Kikuchi N, Nakamura K, Ito H, Kadomatsu K, Shimokawa H. Basigin promotes inflammation and pulmonary hypertension through synergistic cooperation with extracellular Cyclophilin A. Circ J. 78(Suppl. I):I-1066,2014.
  18. Suzuki K, Satoh K, Ikeda S, Kadomatsu K, Shimokawa H. Basigin promotes cardiac fibrosis and failure in pressure-overload-induced cardiac hypertrophy in mice. Circ J. 78(Suppl. I):I-1020,2014.
  19. ƒOral Presentation (Japanese)„

  20. Godo S, Saito H, Ikeda S, Sawada A, Shiroto T, Enkhjargal B, Shimokawa H. Importance of the physiological balance between nitric oxide and endotheliumderived hyperpolarizing factor in vascular homeostasis in mice. Circ J. 78(Suppl. I):I-1149,2014.
  21. Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Ushigome R, Yamauchi T, Shimokawa H. U-Shaped relationship between left atrial diameter and prognosis of patients with heart failure with preserved ejection fraction \The CHART-2 Study\ Circ J. 78(Suppl. I):I-1266,2014.
  22. ƒPoster Session (English)„

  23. Al-mamun E, Satoh K, Tanaka S, Shimizu T, Nergui S, Miyata S, Fukumoto Y, Shimokawa H. Combination therapy with fasudil and sildenafil exerts synergistic effects through inhibition of Rho-kinase in pulmonary hypertension. Circ J. 78(Suppl. I):I-1831,2014.
  24. Hao K, Takahashi J, Ito K, Miyata S, Sakata Y, Nihei T, Tsuburaya R, Shirato T, Matsumoto Y, Nakayama M, Yasuda S, Shimokawa H. Characteristics of patients with acute myocardial infarction who did not undergo primary percutaneous coronary intervention \A Report from MIYAGI-AMI Registry\ Circ J. 78(Suppl. I):I-2038,2014.
  25. Nakano M, Fukuda K. Wakayama Y, Kondoh M, Hasebe Y, Satake H, Shimokawa H. Clinical characteristics of J wave in patients with Brugada syndrome. Circ J. 78(Suppl. I):I-1413,2014.
  26. Tsuburaya R, Takahashi J, Hao K, Shirato T, Matsumoto Y, Ito K, Nakayama M, Shimokawa H. Beneficial effects of a single prophylactic hemodialysis on renal function worsening after percutaneous coronary intervention in patients with severe CKD. Circ J. 78(Suppl. I):I-1796,2014.
  27. ƒPoster Session (Japanese)„

  28. Abe Y, Ito K, Hao K, Hanawa K, Shindo T, Nishimiya K, Hasebe Y, Yamamoto H, Satoh K, Kawakami K, Shimokawa H. Extracorporeal low-energy shock wave therapy improves left ventricular remodeling and reduces inflammatory responses after acute myocardial infarction in rats. Circ J. 78(Suppl. I):I-2399,2014.
  29. Hanawa K, Ito K, Aizawa K, Shindo T, Nishimiya K, Hasebe Y, Tsuburaya R, Hasegawa H, Yasuda S, Kanai H, Shimokawa H. Low-intensity pulsed ultrasound induces angiogenesis and ameliorates left ventricular dysfunction in a porcine model of chronic myocardial ischemia. Circ J. 78(Suppl. I):I-2578,2014.
  30. Hasebe Y, Yamamoto H, Fukuda K, Nishimiya K, Hanawa K, Shindo T, Hirano M, Kondoh M, Nakano M, Wakayama Y, Shimokawa H. Development of a novel shock wave catheter ablation system \A feasiblity study in pigs in vivo\ Circ J. 78(Suppl. I):I-2718,2014.
  31. Ikeda S, Satoh K, Fukumoto Y, Suzuki K, Shimizu T, Shimokawa H. Crucial role of Rho-kinase in pressure-overload myocardial hypertrophy in mice \Comparison between the left and right ventricles\ Circ J. 78(Suppl. I):I-2612,2014.
  32. Kondo M, Fukuda K, Wakayama Y, Nakano M, Hasebe Y, Satake H, Shimokawa H. Different characteristics of postoperative atrial tachyarrhythmias between congenital and non-congenital heart disease. Circ J. 78(Suppl. I):I-2871,2014.
  33. Miura M, Sugimura K, Nochioka K, Tatebe S, Yamamoto S, Hiramoto T, Inoue K, Tamaki K, Shimokawa H. Prognostic impact of acid-base balance on admission in acute heart failure syndrome\A report from the Tohoku Acute Failure Registry\ Circ J. 78(Suppl. I):I-2463,2014.
  34. Satake H, Fukuda K, Wakayama Y, Nakano M, Kondoh M, Hasebe Y, Hirano M, Shimokawa H. Papillary muscles as an important site of origin of lethal ventricular tachyarrhythmias \Usefulness of the new intra-cardiac echo system\ Circ J. 78(Suppl. I):I-2744,2014.
  35. Shiroto T, Takahashi J, Takagi Y, Tsuburaya R, Matsumoto Y, Nakayama M, Ito K, Kondoh M, Nakano M, Wakayama Y, Fukuda K, Yasuda S, Shimokawa H. Prognostic importance of dual-induction tests for coronary artery spasm and ventricular arrhythmias in patients surviving out-of-hospital cardiac arrest. Circ J. 78(Suppl. Ij :I-2284,2014.
  36. Suzuki H, Matsumoto Y, Ota H, Sugimura K, Takahashi J, Ito K, Furukawa K, Fukumoto Y, Arai H, Takahashi S, Taki Y, Shimokawa H. Decreased activity of the hippocampus is associated with depression in heart failure patients \Brain Investigation in Heart Failure Trial (B-HeFT)\ Circ J. 7(8 Suppl. I):I-2867,2014.
  37. Tadaki S, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Takada T, Ushigome R, Yamauchi T, Shimokawa H. Accumulation of metabolic disorders is a cardiovascular risk in patients with central obesity \The CHART-2 Study\ Circ J. 78(Suppl. I):I-2346,2014.
  38. Tatebe S, Fukumoto Y, Sugimura K, Nochioka K, Miura M, Yamamoto S, Satoh K, Shimokawa H. Percutaneous transluminal pulmonary angioplasty ameliorates metabolic and renal dysfunctions associated with hemodynamic improvement in patients with chronic thromboembolic pulmonary hypertension. Circ J. 78(Suppl. I):I-2825,2014.
  39. Yaoita N, Fukumoto Y, Horiuchi H, Shimokawa H. Involvement of thrombinactivated fibrinolysis inhibitor in chronic thromboembolic pulmonary hypertension. Circ J. 78(Suppl. I):I-2478,2014.
•œ¬25”N“x•¶•”‰ÈŠwÈ‹Ž“n‚µŒ€‹†‰Á‘¬ƒlƒbƒgƒ[ƒNƒvƒƒOƒ‰ƒ€i2014”N2ŒŽ28“úA“Œ‹žj
  1. ‰ºìG–ŸFˆãH˜AŒg‚ðŠî”Õ‚Æ‚µ‚œƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`‹’“_Œ`¬
‘æ4‰ñ‹Ž“n‚µŒ€‹†‰Á‘¬ƒlƒbƒgƒ[ƒNƒvƒƒOƒ‰ƒ€‰^‰cˆÏˆõ‰ïi2014”N2ŒŽ27“úA“Œ‹žj
  1. ‰ºìG–ŸF“Œ–k”­‚̈ã—Ë@ŠíŠJ”­‹’“_
‘æ201‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2014”N2ŒŽ15“úAå‘äj
  1. —L’|G”üC‰Á‰ê’J–LC—é–؏G–Ÿ, ‰~’J—²Ž¡, Œ–{‘׎¡, ‚‹Ž@, ˆÉ“¡Œ’‘Ÿ, ‰ºìG–Ÿ, H“¡‘å‰î, ‹vŽu–{¬Ž÷FlHS”xŠÇ—‚ð—v‚µ‚œ’á‘̉·—Ö@‚É‚æ‚éS‹@”\’ቺ‚Ì1—á
  2. ŽO‰Y’ŒW,ŽO‰Y³’š, ™‘ºGˆê˜Y, Œã‰ªL‘Ÿ˜Y, Œš•”r‰î, ŽR–{¹D, ‰ºìG–ŸF•â•zŠÂ‚ð—v‚µ‚œdÇS•s‘S‚ɃwƒpƒŠƒ“—U”­«ŒŒ¬”ÂŒž­Ç‚ð‡•¹‚µ‚œ2Ç—á‚ÌŒŸ“¢
  3. •Ÿˆä—æ–µC‰Á‰ê’J–LC—é–؏G–Ÿ, ™‘ºGˆê˜Y, ‰ºìG–Ÿ, ‹{ì”T—Žq, ‹vŽu–{¬Ž÷FL”͈͔MŠ³ŽÒ‚É”­Ç‚µ‚œŠg’£Œ^S‹ØÇ‚Ì1—á
‘æ35‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï“Œ–k’n•û‰ïi2014”N2ŒŽ15“úAŒSŽRj
  1. ‚‹Ž@C‰H”öŽ‹MCˆÉ“¡Œ’‘ŸC‹{“c@•qCâ“c‘וFC“ñ•r‘Ÿ˜YC‰~’J—²Ž¡CŒ–{‘׎¡CˆÀ“c@‘C‰ºìG–ŸF“Œ“ú–{‘åkÐŒã‚ɉü‘P‚ð”F‚ß‚œ‹}«S‹Ø[ÇŠ³ŽÒ‚ɑ΂·‚é‹~‹}ˆã—Ñ̐§‚ɂ‚¢‚Ä‚ÌŒŸ“¢@\‹{éŒ§S‹Ø[Ç‘΍ô‹Š‹c‰ï‚©‚ç‚ÌŒŸ“¢\
‘æ43‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïi2014”N2ŒŽ15`16“úA_ŒËj

    ƒƒVƒ“ƒ|ƒWƒEƒ€F“®–¬d‰»‚̍ŐV’mŒ©„

  1. ²“¡Œö—YC‰ºìG–ŸFƒTƒCƒNƒƒtƒBƒŠƒ“A ‚É‚æ‚é“®–¬d‰»‚Ì”­Ç‹@\‚ƐV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ẳ”\«
  2. ƒˆê”ʉ‰‘聄

  3. ’r“c®•œC²“¡Œö—YC•Ÿ–{‹`OCŽ…@‹œC‹{“c@•qC—é–؍N‘ŸC‹e’n‡—TC‘呺~ˆêC‰ºìG–ŸF¶Žº‚ƉEŽº‚̈³•‰‰×‚ɑ΂·‚é—U“±ˆâ“`Žq‚ÌŽž‹óŠÔ“I·ˆÙ‚ƐS”ì‘åES•s‘S‚Ì”­Ç‹@\
  4. —é–؍N‘ŸC²“¡Œö—YC’r“c®•œC–双Œ’Ž¡C‰ºìG–ŸFƒ}ƒEƒXˆ³•‰‰×ƒ‚ƒfƒ‹‚É‚š‚¢‚ÄBasigin‚͐S‘Ÿ‚̐üˆÛ‰»CS•s‘S‚Ì‘ˆ«‚ÉŠñ—^‚·‚é
‘æ14‰ñ“®–¬d‰»‹³ˆçƒtƒH[ƒ‰ƒ€ in Sendaii2014”N2ŒŽ2“úAå‘äj
  1. ‰ºìG–ŸF“Œ“ú–{‘åkÐ‚ƐSŒŒŠÇƒCƒxƒ“ƒg
‘æ7‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2014”N1ŒŽ31“ú`2ŒŽ1“úA“Œ‹žj

    ƒ‹³ˆçu‰‰„

  1. ‰ºìG–ŸFzŠÂŠíŽŸŠ³‚Ɛ«·
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€„

  3. ŽR“à@‹BAâ“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêA‚‹Ž@A‰ºìG–ŸF–{–M‚ÌStage C/DS•s‘S‚Ì”wŒiAŽ¡—ÁA’·Šú—\Œã‚É‚š‚¯‚鐫·.
  4. ƒˆê”ʉ‰‘è/ƒ|ƒXƒ^[”­•\„

  5. ’A–Ø‘sˆê˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjA‹{“c@•qA‰ºìG–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚̈Ӌ`‚Ɛ«·‚ÌŒŸ“¢.
  6. ’·’J•”—Y”òA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸF’ʏíŒ^S–[‘e“®‚̗Տ°“I“Á’¥‚É‚š‚¯‚鐫·‚ÉŠÖ‚·‚錟“¢.
  7. ‰H”öŽ‹MA‚‹Ž@AÂ–Ø—³’jA‹{“c@•qA‰~’J—²Ž¡A”’ŒË@’AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸAâ“c‘וFA‰ºìG–ŸF“Œ“ú–{‘åkÐŒã‚É”F‚ß‚ç‚ê‚œS”x’âŽ~Ç—á‚Ì‘‰Á‚ÉŠÖ‚·‚鐫·‚ÌŒŸ“¢.
  8. ŽR–{¹DA™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA²“¡Œö—YA‰ºìG–ŸF¶SŽŸŠ³‚É”º‚€Œã–э׊ǐ«”x‚ŒŒˆ³Ç‚É‚š‚¯‚錌s“®‘Ô“I’j—·‚ÌŒŸ“¢.
‘æ24‰ñ“ú–{‰uŠw‰ïŠwpW‰ïi2014”N1ŒŽ23`25“úAå‘äj
  1. ‹ž—ºˆêCâ“c‘וFCŒã‰ªL‘Ÿ˜YC‹{“c@•qCŽO‰Y³’šC‚“c„ŽjC’A–Ø‘sˆê˜YCŽR“à@‹BC‰ºìG–ŸFŠg’£Œ^S‹ØÇ‚Ì“Á’¥‚Æ‚»‚Ì—\Œã‚ÌŽž‘ã“I•Ï‘JFCHART-1Œ€‹†‚ÆCHART-2Œ€‹†‚Ì”äŠr
  2. ‚“c„ŽjCâ“c‘וFC‹{“c@•qC‚‹Ž@CŒã‰ªL‘Ÿ˜YCŽO‰Y³’šC’A–Ø‘sˆê˜YC‹ž—ºˆêCŽR“à@‹BC‰ºìG–ŸFS•s‘S”­ÇƒnƒCƒŠƒXƒNŠ³ŽÒ‚É‚š‚¯‚éV‹KS•s‘S”­Ç‹K’èˆöŽq@\CHART-2Œ€‹†\

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2013”N
‘æ157‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2013”N12ŒŽ7“úAå‘äj

ƒYIAÇ—á”­•\•”–偄

  1. ‘呺~ˆêA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽO‰Y³’šAŽR–{¹DA²“¡Œö—YA‰ºìG–ŸF–«Šˆ“®«Epstein-BarrƒEƒCƒ‹ƒXŠŽõÇ‚ɍ‡•¹‚µ‚œ”x‚ŒŒˆ³Ç‚Éä`‘ÑŒŒŠ²×–EˆÚA‚ª’˜Œø‚µ‚œˆê—á.iÅ—DGÜŽóÜj
  2. ƒYIAŒ€‹†”­•\•”–偄

  3. Œã‰ªL‘Ÿ˜YAâ“c‘וFAŽO‰Y³’šA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‹{“c@•qA‰ºìG–ŸFŠg’£Œ^S‹ØÇŽ¡—ЬÑ‚ÌŽž‘ã“I•Ï‘J‚ÌŒŸ“¢FCHARTŒ€‹†‚Ì’mŒ©‚æ‚è.iÅ—DGÜŽóÜj
  4. ƒˆê”ʉ‰‘聄

  5. —L’|G”üA‰Á‰ê’J@–LA—é–؏G–ŸAš¢’J—²Ž¡A”’ŒË@’AŒ–{‘׎¡A‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸA‘呺@‘ñAH“¡‘å‰îA“ü–ì“c@’A‹vŽu–{¬Ž÷F’á‘̉·—Ö@’†‚ɐS‹@”\’ቺ‚ð‚«‚œ‚µAŒo”ç“IlHS”x‚É‚æ‚éŠÇ—‚ð—v‚µ‚œˆê—á.
  6. ”öŒ`@„A”’ŒË@’Aš¢’J—²Ž¡AŒ–{‘׎¡Aâ“c‘וFAˆÉ“¡Œ’‘ŸA¬‘é@—I“ñA‚‹Ž@A‰ºìG–ŸF”­Ç‹}«Šú‚É‘œŽ}Š¥“®–¬¹k‚ª—U”­‚³‚ê‚œ‚œ‚±‚‚ڌ^S‹ØÇ‚̈ê—á.
  7. •Ð•œW‘Ÿ˜YAHŽR³”NA×ŽRŸŠ°A‰Í’Á@‘AŒF’J‹Iˆê˜YA–{‹g’ŒFAì–{r•ãAâV–؉ÀŽAŽO‰Y³’šAŒã‰ªL‘Ÿ˜YA™‘ºGˆê˜YA‚‹Ž@A•Ÿ“c_“ñA‰ºìG–ŸF’°ŠÇ‹•ŒŒ‚𕹔­‚µ‚œŒ€ÇŒ^S‹Ø‰Š2Ç—á.
  8. ¬‘é—I“ñA‚‹Ž@AˆÉ“¡Œ’‘ŸAŒ–{‘׎¡A”’ŒË@’Aš¢’J—²Ž¡A‰H”öŽ‹MA‰ºìG–ŸFŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“’†‚ɐ¶‚¶‚œSlow flow‚ÉRhoƒLƒi[ƒ[‘jŠQ–ò‰–Ž_ƒtƒ@ƒXƒWƒ‹Š¥’‚ª—LŒø‚Å‚ ‚Á‚œˆê—á.
  9. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–ì@œA’·’J•”—Y”òA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸFS–[•p”‚ð‡•¹‚µ‚“x–[ŽºƒuƒƒbƒN‚ð‚«‚œ‚µ‚œƒtƒ@ƒ[Žl’¥ÇpŒã‚̈ê—á.
  10. âV“¡ˆ»ŽqAš¢’J—²Ž¡A‚‹Ž@AˆÉ“¡ˆ€„A‰H”öŽ‹MA”’ŒË@’AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸF‘å“®–¬‰ŠÇŒóŒQ‚ð”wŒi‚Æ‚µ‚œ¶Š¥“®–¬ŽåŠ²•”‚Ì‹·ó•a•Ï‚É‚æ‚è‹}«S‹Ø[Ç‚𔭏ǂµ‚œŽá”N—«‚Ì1—á.
  11. ²’|—m”VA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA’·’J•”—Y”òA•œ–쓹ŠîA‰ºìG–ŸF‘å“®–¬–³Š¥ë‚©‚çKent ‘©‚Ì—£’f‚ɐ¬Œ÷‚µ‚œ–[Žº‰ñ‹A«•p”‚̈ê—á.
  12. ²“¡‘åŽ÷C“¡“c@‰›CŽRŒû“WŠ°C”öã‹IŽqCÎ’ˁ@‹CŽÂè@‹BF–«S•s‘SŠ³ŽÒ‚̐¶ŠUÄ“ü‰@‰ðÍ.
  13. ’|“à@’qA•Ÿ“c_“ñA’†–ì@œA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA•œ–쓹ŠîA‰ºìG–ŸFSŽº•p”‚ðŒ_‹@‚ɐf’f‚ÖŽŠ‚Á‚œSƒtƒ@ƒuƒŠ[•a‚̈ê—á.
  14. ’†–ì@œA•Ÿ“c_“ñA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA•œ–쓹A‰ºìG–ŸF‰EŽº—¬o˜HS“à–Œ‘€‚ُ̈í’x‰„“dˆÊ‚ɑ΂·‚éRFCA‚ªVF”­ì—}§‚É—LŒø‚Å‚ ‚Á‚œBrugadaÇŒóŒQ‚̈ê—á.
  15. ’·’J•”—Y”òA•œ–쓹ŠîA²’|—m”VA‹ß“¡³‹PA’†–ì@œA•Ÿ“c_“ñA‰ºìG–ŸFŒã’†ŠuKent‘©‚ɑ΂µ‚ÄŠ¥óÃ–¬“Ž“à‚Å‚Ì’Ê“d‚É‚æ‚莡—Âɐ¬Œ÷‚µ‚œƒnƒCƒŠƒXƒN‹U«SŽº•p”‚Ì2—á.
  16. –x“cˆêŽ÷A’|“à‰ëŽjAˆÉ“¡‘å—ºAŠ`‰Ô—²ºA²“¡–[˜YA‚‹ŽŽìAX@M–FAˆÉ“¡@CAãŒŽ³”ŽA™‘ºGˆê˜YA‰ºìG–ŸFŠÔŸ[“IƒgƒŒ[ƒjƒ“ƒO‚É‚æ‚è‰^“®‘Ï—e”\‚̉ü‘P‚ª“Ÿ‚ç‚ê‚œ–«S•s‘Sˆê—á.
  17. ŽO‰Y’ŒWAŽO‰Y³’šA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸAHŽR³”NAâV–؉ÀŽF–„‚ߍž‚ÝŒ^•â•lHS‘Ÿ‚É‚Ä‹~–œ‚µ‚Š‚œ‘ŸŠí•s‘S‚𗈂µ‚œdÇS•s‘S‚̈ê—á.
  18. ŽR“à@‹BAš¢’J—²Ž¡A‚‹Ž@A‰H”öŽ‹MA”’ŒË@’AŒ–{‘׎¡AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFìè•aŒãˆâÇ‚É‚æ‚銥“®–¬‹·ó‚ɑ΂µŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—ÂðŽ{s‚µ‚œŽá”NŽÒ‚Ì2—á.
  19. ŽR“à—I•œA‰Á‰ê’J@–LA—é–؏G–ŸA™‘ºGˆê˜YA‰ºìG–ŸA‘OàVãđŸA‹{ì”T—ŽqAŒÃì@@A²“¡•—gA‹vŽu–{¬Ž÷A²’|—¥ŽqA‘Šêß–çF‘œŒ`Ÿøo«g”Á‚ð‡•¹‚µ‚œS‹Ø‰Š‚̈ê—á.
  20. ŽR–{¹DA™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‰ºìG–ŸF¬l‚Ì––œ«”x“®–¬‹·óÇ‚Ì1—á.
‘æ36‰ñ“ú–{•ªŽq¶•šŠw‰ïi2013”N12ŒŽ3`6“úA_ŒËj

ƒƒ[ƒNƒVƒ‡ƒbƒv„

  1. ’†ŽR‰ë°C‹{“c •qC‰ºìG–ŸF—Տ°ˆã‚É‚Æ‚Á‚Ä•K—v‚ȃoƒCƒIƒCƒ“ƒtƒHƒ}ƒeƒBƒVƒƒƒ“E“Œvê–å‰Æ
“ú–{“à‰ÈŠw‰ïŠwpW‰ï‘æ41‰ñ“à‰ÈŠw‚Ì“W–]i2013”N12ŒŽ1“úAå‘äj

ƒ“Œ“ú–{‘åkÐ‚©‚çŠw‚Ô“à‰ÈŽŸŠ³@`“Á’¥A‘ΉžA—\–h`„

  1. ‰ºìG–ŸFzŠÂŠíŽŸŠ³.
‘æ17‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2013”N11ŒŽ28“ú`30“úA‘å‹{j

ƒESC-HFA/JHFSƒWƒ‡ƒCƒ“ƒgƒZƒbƒVƒ‡ƒ“„

  1. Shimokawa H. Changing heart failure management in Japan --Report from CHART Studies-
  2. ƒ“Á•ÊŠé‰æFÐŠQ‚ƐS•s‘S„

  3. Nochioka K, Sakata Y, Miyata S, Takahashi J, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Shimokawa H. Longitudinal study of post-traumatic stress disorder after the Great East Japan Earthquake Disaster in cardiovascular disease patients -The CHART Study-
  4. ƒYIAF—Տ°Œ€‹†•”–偄

  5. Nochioka K, Sakata Y, Miyata S, Takahashi J, Miura M, Takada T, Tadaki S, Ushigome R, Shimokawa H. Prognsotic impact of statin in Japanese patients with heart failure with preserved ejection frcation --A report from the CHART-2 Study-i—DGÜŽóÜj
  6. Suzuki H, Matsumoto Y, Takahashi J, Tsuburaya R, Sugimura K, Ito K, Fukumoto Y, Shimokawa H. Interactions between the heart and the brain in heart failure patients assessed by MRI -Interim results from the B-HeFT Study-iÅ—DGÜŽóÜj
  7. ƒŒû‰‰”­•\„

  8. Hao K, Takahashi J, Miyata S, Sakata Y, Tsuburaya R, Shiroto T, Matsumoto Y, Ito K, Yasuda S, Shimokawa H. Emergency care of acute myocardial infarction during the Great East Japan Earthquake Disaster -Report from the Miyagi AMI Registry Study-
  9. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Takahashi J, Shimokawa H. Prognostic impact of urine protein in diabetic patients with ischemic heart failure -A report from the CHART-2 Study-
  10. Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Shimokawa H. Different impact of anemia in chronic heart failure with preserved vs. reduced ejection fraction --A report from the CHART-2 Study-
  11. Tatebe S, Fukumoto Y, Sugimura K, Nochioka K, Miura M, Yamamoto S, Shimokawa H. Percutaneous transluminal balloon angioplasty improves metabolic and renal dysfunctions associated with hemodynamic improvement in patients with chronic thromboembolic pulmonary hypertension.
  12. ƒƒ|ƒXƒ^[”­•\„

  13. Nakano M, Fukuda K, Wakayama Y, Kondo M, Hasebe Y, Satake H, Shimokawa H. MIBI scintigraphy could be useful to identify heart failure patients with narrow QRS who respond to cardiac resynchronization therapy.
  14. Satoh T, Fujita H, Yamaguchi N, Onoue N, Ishizuka T, Shinozaki T. When rehospitalization due to chronic heart failure occurs during life time?
  15. Takada N, Sugimura K, Fukumoto Y, Nochioka K, Tatebe S, Yamamoto S, Miura M, Satoh K, Shimokawa H. Triglyceride deposit cardiomyovasculopathy with severe heart failure.
  16. Yamamoto S, Matsumoto Y, Fukumoto Y, Nochioka K, Miura M, tatebe S, Sugimura K, Suzuki T, Shimokawa H. Potential involvement of functional tricuspid regurgitation in the diagnostic errot to assess pulmonary arterial pressure by Doppler echocardiography.
‘æ33‰ñˆã—Ïî•ñŠw˜A‡‘å‰ïE‘æ14‰ñ“ú–{ˆã—Ïî•ñŠw‰ïŠwp‘å‰ïi2013”N11ŒŽ21`23“úA_ŒËj

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“„

  1. ’†ŽR‰ë°FƒAƒŒƒ‹ƒM[î•ñ‚Ì•W€‰»‚ð‚ß‚Ž‚µ‚ā@\ƒAƒŒƒ‹ƒM[î•ñ‚Ì‹€—L‚ɂ͉œ‚ª•K—v‚©\‘S‘ƒAƒ“ƒP[ƒg’²ž‚æ‚è.
‘æ28‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ïi2013”N10ŒŽ17`18“úA–‹’£j
  1. ŠÚ“c@‘C›–쐰•vC¬àV_ŽiC”ª”ŠŒ’ˆê˜YCŽR‰®œŽiCˆÉ“¡Œ’‘ŸC‰ºìG–ŸCˆä”ó‰h“ñFÒ‘‘¹‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Á@\ƒAƒƒfƒBƒjƒA‚Ö‚ÌŒø‰Ê‚ÌŒŸ“¢\.
  2. ”ª”ŠŒ’ˆê˜YC›–쐰•vC¬àV_ŽiCŠÚ“c‘CŽR‰®œŽiCˆÉ“¡Œ’‘ŸC‰ºìG–ŸCˆä”ó‰h“ñF‹}«ŠúÒ‘‘¹‚É‚š‚¯‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—ÂÌVEGF ”­Œ»‘£iE‰^“®‹@”\‰ü‘PŒø‰Ê.
‘æ54‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi2013”N10ŒŽ10“ú`12“úA“Œ‹žj

ƒ–¬ŠÇê–åˆã‹³ˆçƒZƒbƒVƒ‡ƒ“„

  1. ‰ºìG–ŸF–¬ŠÇf—Â̓W–].
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€2F”x‚ŒŒˆ³‚ÌŽ¡—Â̍őOü@–ò•šŽ¡—ÂƐNPŽ¡—Á„

  3. Œã‰ªL‘Ÿ˜YA™‘ºGˆê˜YA•Ÿ–{‹`OAŒš•”r‰îAŽR–{¹DAŽO‰Y³’šA²“¡Œö—YA‰ºìG–ŸFdÇ–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚鎡—Ð헪.
  4. ƒƒ|ƒXƒ^[”­•\„

  5. –î”ö”M—TA‘Ձ@“NA•Ÿ–{‹`OAŒš•”r‰îA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŽR–{¹DAŽO‰Y³’šA²“¡Œö—YA‰ºìG–ŸF”x“®–¬ƒŠƒ‚ƒfƒŠƒ“ƒO‚Í”x‚ŒŒˆ³”­Ç‘O‚©‚çoŒ»‚·‚éFŒõŠ±Â’f‘w–@‚ð—p‚¢‚œŒŸ“¢.
‘æ21‰ñ“ú–{ŒŒŠÇ¶•šˆãŠw‰ïŠwpW‰ïi2013”N9ŒŽ26`28“úA–L’†j

ƒ‰ï’·µ‘ҍu‰‰„

  1. ‰ºìG–ŸFŒŒŠÇ•a‚̐¬ˆö‚É‚š‚¯‚éRho-kinase‚̈Ӌ`@-Š¥¹kƒ‚ƒfƒ‹‚©‚ç—Տ°‰ž—p‚Ü‚Å-
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€F‘å“®–¬ŽŸŠ³‚É‚š‚¯‚édanger signal‚ƉŠÇ„

  3. ²“¡Œö—YA‰ºìG–ŸF‘å“®–¬ŽŸŠ³‚É‚š‚¯‚édanger signal.
‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2013”N9ŒŽ20`22“úAŒF–{j

ƒzŠÂŠíƒ^ƒCƒ€ƒgƒ‰ƒxƒ‹ƒtƒH[ƒ‰ƒ€„

  1. ‰ºìG–ŸFŠ¥“®–¬¹k\“®•šƒ‚ƒfƒ‹‚ÌŠJ”­‚©‚番Žq‹@\‚̉𖟂܂Ł\
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€1FˆÀ’芥“®–¬ŽŸŠ³‚ɑ΂·‚鎡—Ð헪„

  3. ‚‹Ž@Aâ“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjAŽÄ@MsA‰ºìG–ŸF‹•ŒŒ«–«S•s‘S‚É‚š‚¯‚銥“®–¬ŒŒsÄŒšp‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿.
  4. ƒƒVƒ“ƒ|ƒWƒEƒ€2F“œ”A•aŠ³ŽÒ‚̐SŽŸŠ³Ž¡—ÂÌevidence„

  5. ŽO‰Y³’šAâ“c‘וFAŒã‰ªL‘Ÿ˜YA‚“c„ŽjA’A–Ø‘sˆê˜YA‹{“c@•qA‚‹Ž@A‰ºìG–ŸF“œ‘ãŽÓˆÙí‚ð—L‚·‚é‹•ŒŒ«S•s‘SÇ—á‚Ì—\Œã—\‘ª‚É‚š‚¯‚é”A’`”’•]‰¿‚̈Ӌ`.
  6. ƒƒVƒ“ƒ|ƒWƒEƒ€5F‚—îŽÒS•s‘SŽ¡—Â̌»ó‚Æ“W–]„

  7. â“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjA‚‹Ž@A‰ºìG–ŸF–{–M‚É‚š‚¯‚鍂—îŽÒS•s‘SÇ—á‚̗Տ°“I“Á’¥.
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€12FS•s‘S‚É‚š‚¯‚éŽûk•s‘S‚ÆŠg’£•s‘S‚̃gƒsƒbƒNƒX„

  9. ‚“c„ŽjAâ“c‘וFA‹{“c@•qA‚‹Ž@AŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA’A–Ø‘sˆê˜YA‰ºìG–ŸFŽûk”\‚̒ቺ‚µ‚œS•s‘S‚ÆŽûk”\‚Ì•ÛŽ‚³‚ê‚œS•s‘SŠ³ŽÒ‚É‚š‚¯‚éS””‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚Ì”äŠr.
  10. ƒƒVƒ“ƒ|ƒWƒEƒ€13F––œŒŒŠÇŽŸŠ³Ž¡—Â̍őOü„

  11. ˆÉ“¡Œ’‘ŸA‹Ú‘ò@ŒºA‰Í‘ºŒ\ˆê˜YA²“¡@¬A‰ºìG–ŸF‰ºŽˆ––œ“®–¬ŽŸŠ³‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Ã.
  12. ƒƒrƒWƒ…ƒAƒ‹ƒ[ƒNƒVƒ‡ƒbƒv3„

  13. ‘Ձ@“NA•Ÿ–{‹`OAŒš•”r‰îA™‘ºGˆê˜YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽR–{¹DA–î”ö”M—TA‰ºìG–ŸF”x“®–¬ƒŠƒ‚ƒfƒŠƒ“ƒO‚Í”x‚ŒŒˆ³”­Ç‘O‚©‚çoŒ»‚·‚éFOCT‚ð—p‚¢‚œŒŸ“¢.
  14. ƒƒƒfƒBƒJƒ‹ƒXƒ^ƒbƒtƒZƒbƒVƒ‡ƒ“4FƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Âɂš‚¯‚郁ƒfƒBƒJƒ‹ƒXƒ^ƒbƒt‚̘AŒg„

  15. ¯@^—R”üA•Ÿ“c_“ñA‰ºìG–ŸA‘å—¢‚é‚èFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Âɍۂµ•K—v‚Æ‚³‚ê‚éŠÅŒìŽÀ‘H‚Ì—v‘f.
  16. ƒYIAƒZƒbƒVƒ‡ƒ“„

  17. ‰H”öŽ‹MA‚‹Ž@AˆÉ“¡Œ’‘ŸA‹{“c@•qAâ“c‘וFA“ñ•r‘Ÿ˜YAš¢’J—²Ž¡A”’ŒË@’AˆÉ“¡ˆ€„AŒ–{‘׎¡A’†ŽR‰ë°AˆÀ“c@‘A‰ºìG–ŸFEmergency care of acute myocardial infarction and the Great East Japan Earthquake Disaster.
  18. ƒˆê”ÊŒû‰‰‰‰‘聄

  19. ²’|—m”VA•Ÿ“c_“ñA‹ß“¡³‹PA’†–ì@œA’·’J•”—Y”òAŽáŽR—TŽiA™‘ºGˆê˜YAŽÂè@‹BA‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚鐇–°ŒÄ‹záŠQ‚Æ’vŽ€“I•s®–¬ƒCƒxƒ“ƒg‚Ì”­¶‚ÌŒŸ“¢.
  20. ’A–Ø‘sˆê˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjA‹{“c@•qA‰ºìG–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚̈Ӌ`‚ÌŒŸ“¢.
  21. Œš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YAŽáŽR”ü“ÞŽqAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAŽR–{¹DA‰Á‰ê’J@–LA‰ºìG–ŸF‰EŽºFDGŽæž‚ݘŽi‚Í”x‚ŒŒˆ³Š³ŽÒ‚Ì’·Šú—\Œã‚ð—\‘ª‚·‚é.
  22. “ñ•r‘Ÿ˜YA‚‹Ž@A‹e’r@—ƒA‰H”öŽ‹MAŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFŠ¥¹k«‹·SÇŠ³ŽÒ‚É‚š‚¯‚éRhoƒLƒi[ƒ[Šˆ«‚Ì“ú“à•Ï“®F––œŒŒ”’ŒŒ‹…RhoƒL ƒi[ƒ[Šˆ«‚ÉŠî‚­ŒŸ“¢.
  23. ƒÇ—áŒû‰‰”­•\„

  24. ™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DAŽO‰Y³’šA²“¡Œö—YA‰ºìG–ŸF–«Šˆ“®«Epstein-BarŠŽõÇ‚ɍ‡•¹‚µ‚œ”x‚ŒŒˆ³Ç‚̈ê—á.
  25. ™‘ºGˆê˜YA•Ÿ–{‹`OAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DAŽO‰Y³’šA‰ºìG–ŸFŒõŠ±Â’f‘w–@ŽOŽŸŒ³\’z‘œ‚É‚æ‚è”x“®–¬•a•Ï‚ð•]‰¿‚µ“Ÿ‚œ–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̈ê—á.
  26. ƒÇ—áƒ|ƒXƒ^[”­•\„

  27. Œ–{‘׎¡AâV“¡ˆ»ŽqAˆÉ“¡ˆ€„A‰~’J—²Ž¡AˆÉ“¡Œ’‘ŸA™‘ºGˆê˜YA‚‹Ž@A‰ºìG–ŸFIgGŠÖ˜AŽŸŠ³‚ɍ‡•¹‚µ‚œŠ¥¹k«‹·SÇ‚Ì1—á.
  28. ƒ‰ŠúŒ€Cˆã§—ãÜ@ƒ|ƒXƒ^[„

  29. ‘å’Î’mGAŒš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAŽR–{¹DA‰ºìG–ŸFƒ_ƒTƒ`ƒjƒuŽ¡—Ã’†‚É”x“®–¬«”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚œ‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚Ì1—á.
‘æ5‰ñ“Œ–k—Տ°•s®–¬Œ€‹†‰ïŠwpW‰ïi2013”N9ŒŽ14“úAŽRŒ`j
  1. ‹ß“¡³‹PC•Ÿ“c_“ñCŽáŽR—TŽiC’†–ì@œC’·’J•”—Y”òC²’|—m”VC‰ºìG–ŸFŽOë•Ù—ÖˆâŽc‚Ɖº‘åÃ–¬ŠÔ‚Ì‹¬•”‚ª‰ñ˜H‚̈ꕔ‚ÉŠÖ—^‚µ‚œFontanpŒãS–[•p”‚̈ê—á.
‘æ200‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2013”N8ŒŽ31“úAÂXj
  1. —L’|G”üCš¢’J—²Ž¡CŽR“à@‹BC‰H”öŽ‹MC”’ŒË@’CŒ–{‘׎¡C‚‹Ž@C’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‰ºìG–ŸFìè•aŒãˆâÇ‚É‚æ‚銥“®–¬‹·ó‚ɑ΂µŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—ÂðŽ{s‚µ‚œ2—á.
  2. ›ŒŽÍlC™‘ºGˆê˜YC‹e’n‡—TC•Ÿ–{‹`OCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽO‰Y³’šCŽR–{¹DC–î”ö”M—TC‰ºìG–ŸFf’f‚Ü‚Å‚ÉŽžŠÔ‚ð—v‚µ‚œŽá”N”­Ç“Á”­«”x“®–¬«”x‚ŒŒˆ³Ç‚Ì1—á.
‘æ19‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2013”N7ŒŽ13“ú`14“úAå‘äj

ƒƒVƒ“ƒ|ƒWƒEƒ€4FdÇS•s‘S‚ɑ΂·‚é•ïŠ‡“IƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚̐i•à„

  1. ˆÉ“¡Œ’‘ŸA‰ºìG–ŸF’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Ã.
  2. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“3F‘å‹K–͍ЊQ‚©‚ç‚Ì‹³ŒP‚Ɖۑ聄

  3. •Ÿ–{‹`OAÂ–Ø—³’jA‰ºìG–ŸF‘åkÐ‚É‚š‚¯‚éS•s‘S‚Ì‘‰Á‚Æ‚»‚̑΍ô.
  4. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“4FS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚̈ã—ÐE‘²‘OE‘²Œã‹³ˆç‚ÌŒ»ó‚Ɖۑ聄

  5. ˆÉ“¡@CA•Ÿ–{‹`OA‰ºìG–ŸAãŒŽ³”ŽFS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‘²‘OE‘²Œã‹³ˆç‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²žŒ‹‰Ê‚Æ“Œ–k‘åŠw‚ÌŒ»ó.
  6. ƒ‹³ˆçƒZƒbƒVƒ‡ƒ“6„

  7. ˆÉ“¡Œ’‘ŸFPCI‚̐i•à
  8. ƒ‚æ‚­‚í‚©‚ézŠÂŠíŒŸžm1„

  9. ’†–ì@œA•Ÿ“c_“ñAŽáŽR—TŽiA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VAƒ‚ƒnƒƒhƒAƒuƒfƒ‹ƒVƒƒƒtƒB[A‰ºìG–ŸFS•s‘Sf’fEŽ¡—Âɂš‚¯‚éBNP‚Ì–ðŠ„.
  10. ƒ‚æ‚­‚í‚©‚ézŠÂŠíŒŸžm3„

  11. •Ÿ“c_“ñFQRS”gŒ`‚Ì–¡•û
  12. ƒ‚æ‚­‚í‚©‚ézŠÂŠíŒŸžm4„

  13. ™‘ºGˆê˜YA•Ÿ–{‹`OA‰ºìG–ŸFzŠÂŠíf—Âɂš‚¯‚鋹•”ƒŒƒ“ƒgƒQƒ“ŽÊ^‚Ì“Ç‚Ý•û.
  14. ƒ‚æ‚­‚í‚©‚ézŠÂŠíŒŸžm6„

  15. Œ–{‘׎¡FS‘ŸƒJƒe[ƒeƒ‹ŒŸž
  16. ƒYIAƒZƒbƒVƒ‡ƒ“„

  17. ‚“c„ŽjAâ“c‘וFA‹{“c@•qA‚‹Ž@AŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA’A–Ø‘sˆê˜YA‰ºìG–ŸFSŒŒŠÇ•aŠ³ŽÒ‚É‚š‚¢‚ĉîŒì‚ª•K—v‚Æ‚È‚é—vˆö‚ɂ‚¢‚Ä‚ÌŒŸ“¢@|CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
  18. ƒˆê”ʉ‰‘èFŒû‰‰”­•\„

  19. ‚‹Ž@“wA‘å–î“à@–LA–k‘ºKŽqA”‘qŽu•ÛA¯Žq‹v”üŽqA‹g“c˜aŽqA•Ÿ–{‹`OAŒ–{‘׎¡AãŒŽ³”ŽA‰ºìG–ŸF‹}«S•s‘S‚É‚š‚¯‚éS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ƒvƒƒOƒ‰ƒ€“±“ü‘OŒã‚Ì”äŠrŒŸ“¢.
  20. ’|“à‰ëŽjAŒ–{‘׎¡A’‡•yçA“쓇‘å•ãAV‘‰xOA’Ø“c@‹BA˜a’n‘וFA–”é“ŽqA‚‹Ž•‘ŽqA²“¡–[˜YAX@M–FAŽRŒû‘fŽjAŽRçŒõOAˆä“c‰ëËA•Ÿ–{‹`OAŒF’J‹Iˆê˜YAì–{r•ãAãŒŽ³”ŽAâV–؉ÀŽA‰ºìG–ŸF‘å“®–¬áŽ‚𒆐S‚Æ‚µ‚œ‘匌ŠÇŽŸŠ³‚̏p‘OŒÄ‹zƒŠƒn‚͈À‘S‚ÉŽÀŽ{‰Â”\‚Å‚ ‚é@|ŒŒˆ³‘ª’艺‚Ì‹C“¹ƒNƒŠƒAƒ‰ƒ“ƒX—ûK\
  21. ’A–Ø‘sˆê˜YAâ“c‘וFAŒã‰ªL‘Ÿ˜YA‚‹Ž@AŽO‰Y³’šA‚“c„ŽjA‹{“c@•qA‰ºìG–ŸF‚—îS•s‘SŠ³ŽÒ‚É‚š‚¯‚é”]‘²’†Šù‰‚Ì—\Œã‚ւ̉e‹¿‚ÉŠÖ‚·‚錟“¢@|CHART-2‚©‚ç‚Ì•ñ\
  22. ŽO‰Y³’šAâ“c‘וFA‹{“c@•qA‚‹Ž@AŒã‰ªL‘Ÿ˜YA‚“c„ŽjA’A–Ø‘sˆê˜YAŽÄ@MsA‰ºìG–ŸFSŒŒŠÇ•a‚Ì—\Œã‚É‚š‚¯‚é‰îŒì—\–h‚̏d—v«@|CHART-2Œ€‹†‚©‚ç‚Ì•ñ\
‘æ22‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi2013”N7ŒŽ11-13“úA_ŒËj

ƒƒVƒ“ƒ|ƒWƒEƒ€4FDES —¯’uŒãƒXƒpƒXƒ€FŒ»ó‚Ƒ΍ô„

  1. Nishimiya K, Matsumoto Y, Takahashi J, Tsuburaya R, Ito Y, Shiroto T, Ito K, Yasuda S, Shimokawa H. New generation biolimus A9-eluting stents suppress coronary hyperconstricting responses after stent implantations through Rho-kinase pathway inhibition in pigs in vivo.
  2. Yasuda S, Aizawa K, Takahashi J, Shimokawa H. Rho-kinase involvement in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents in patients with coronary artery disease.
‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwpW‰ïi2013”N7ŒŽ4-6“úA“Œ‹žj
  1. Kondo M, Fukuda K, Wakayama Y, Nakano M, Hasebe Y, Kanawa A, Satake H, Shimokawa H. The importance of low voltage area in right atrium as the mechanisms of atrial tachycardia in postoperative Tetralogy of Fallot.
  2. Nakano M, Fukuda K, Wakayama Y, Kondo M, Hasebe Y, Kanawa A, Satake H, Shafee MB, Shimokawa H. Catheter ablation to premature ventricular contraction originated from tricuspid valvular annulus suppresses ventricular fibrillation in Brugada syndrome.
‘æ13‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2013”N6ŒŽ28“ú`29“úA“ß”ej

ƒƒVƒ“ƒ|ƒWƒEƒ€2F“à”ç‹@”\Œ€‹†‚̍ŋ߂̐i•à„

  1. ²“¡Œö—YA•Ÿ–{‹`OA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‚–Ø—S‰îA‰~’J—²Ž¡AˆÉ“¡ˆ€„A’†ŽR‰ë°A•“cŽç•FA‚‹Ž@AˆÉ“¡Œ’‘ŸAˆÀ“c@‘A‰ºìG–ŸFƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚éSŒŒŠÇ•a‘£i‹@\‚ƃoƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ẳ”\«.
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€4FNO“™‚̃Cƒ[ƒWƒ“ƒO„

  3. “›ˆä³lA‰ºìG–ŸA–öŒŽ‰„ÍA”ö’ҁ@–LFzŠÂŠíEt‘Ÿ•a‚É‚š‚¯‚éNOSsŒn‚Ì•aˆö“I–ðŠ„.
  4. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[1„

  5. ‰ºìG–ŸFŒŒŠÇ“à”ç‹@”\‚ÌŒ€‹†FÅ‹ß‚Ì’mŒ©.
  6. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[3„

  7. ˆÉ“¡Œ’‘ŸF’áo—Í‘ÌŠOÕŒ‚”g‚ð—p‚¢‚œV‚µ‚¢ŒŒŠÇV¶—Ö@.
  8. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[4„

  9. ‰ºìG–ŸFŽ‰Ž¿ˆÙíÇ‚ÉŠÖ‚·‚éÅ‹ß‚Ì’mŒ©.
  10. ƒYIAƒZƒbƒVƒ‡ƒ“„

  11. –ì“cˆêŽ÷A•Ÿ–{‹`OAâV“¡‘åŽ÷A_ŒË–ΗYAƒuƒhƒoƒUƒ‹@ƒGƒ“ƒwƒWƒƒƒ‰ƒJƒ‹A“›ˆä³lA‰ºìG–ŸFŽ‰Ž¿‘ãŽÓ‚É‚š‚¯‚éˆêŽ_‰»’‚‘f‚ÆRho-kinase‚Ì–ðŠ„@\NO‡¬y‘fŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚錟“¢\
  12. ŒÃ–ì—R”üA“à“c‘Ÿ˜YA‰ºìG–ŸA‘剮—S•ãA–öŒŽ‰„ÍA”ö’ҁ@–LA“c‘º‰ëmA“›ˆä³lF‘n–ò‚É—L—p‚ÈŽ©‘R”­Ç‹}«S‹Ø[Çƒ‚ƒfƒ‹‚ÌŠJ”­.
  13. ƒŒû‰‰”­•\„

  14. ŒŽ”ŽŽuA¬‘܉Á“ÞŠGA‰„‰iŠóAX‰ªOŽuA‹vPº“NA‰ºìG–ŸA“›ˆä³lFNOˆË‘¶“I‚Ȑ_Œoƒyƒvƒ`ƒhÜ‚è‚œ‚œ‚Ý•s‘S˜Ži‚É‚æ‚鎋°‰º•”ƒIƒŒƒLƒVƒ“ƒjƒ…[ƒƒ“‚Ì‘I‘ð“I•Ï«.
  15. ƒƒ|ƒXƒ^[”­•\„

  16. ã–ì@WA“›ˆä³lA–L•œ—R”üŽqA“瓇r—²A‰ºìG–ŸA–öŒŽ‰„ÍFNOSŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚é_Œos“®‚ɂ‚¢‚Ä‚ÌŒŸ“¢i1jF•sˆÀŠÖ˜As“®‚Ì”­Œ»‚ÆNOSŒn‚Æ‚ÌŠÖ˜A«‚ɂ‚¢‚Ä.
  17. ã–ì@WA“›ˆä³lA–L•œ—R”üŽqA“瓇r—²A‰ºìG–ŸA–öŒŽ‰„ÍFNOSŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚é_Œos“®‚ɂ‚¢‚Ä‚ÌŒŸ“¢i2jFR‚€‚–ò‚ɑ΂·‚锜‰ž«‚©‚猟“¢‚µ‚œNOSŒn‚Ì–ðŠ„‚É‚Â‚¢‚Ä.
  18. _ŒË–ΗYAƒuƒhƒoƒUƒ‹@ƒGƒ“ƒwƒWƒƒƒ‰ƒJƒ‹AâV“¡‘åŽ÷AàV“cˆŒŽqA–ì“cˆêŽ÷A‰ºìG–ŸF“à”çˆË‘¶«’oŠÉ”œ‰ž‚É‚š‚¯‚éNO/EDHF‚̃oƒ‰ƒ“ƒX‚̏d—v«.
  19. ŒÃ–ì—R”üA–L•œ—R”üŽqAã–ì@WAâ—œ‚Ü‚äŽqAŒèr”ŽA–ìŒûŽ•FA–öŒŽ‰„ÍA‰ºìG–ŸA”ö’ҁ@–LA“c‘º‰ëmA“›ˆä³lFœ‘—R—ˆŒŒŠÇ‘O‹ì×–E‚É”­Œ»‚·‚éNO‡¬y‘fŒn‚̃}ƒEƒXŒŒŠÇ•a•ÏŒ`¬‚ɑ΂·‚é—}§ì—p.
  20. Ô“cŒ›‘Ÿ˜NA–˜a”ŽA‰€@Ž—bA–ìŒû^ŒáAì”g•q‘¥AÎ–{—TŽmA–L•œ—R”üŽqA‰ºìG–ŸA–öŒŽ‰„ÍA“›ˆä³lAŒ}@Š°F‹CŠÇŽxšb‘§‚É‚š‚¯‚éNO‚š‚æ‚ÑŠeNOSƒAƒCƒ\ƒtƒH[ƒ€‚Ì–ðŠ„.
  21. –ìŒû^ŒáA–˜a”ŽA‰€@Ž—bAÔìŒ›‘Ÿ˜NAŽRè@Œ[Aì”g•q‘¥AÎ–{—TŽmA–L•œ—R”üŽqA‰ºìG–ŸA–öŒŽLÍA“›ˆä³lAŒ}@Š°FNO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚ð—p‚¢‚œƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆÛ‰»ƒ‚ƒfƒ‹‚É‚š‚¯‚éNO‚Ì–ðŠ„‚ÌŒŸ“¢.
  22. ƒuƒhƒoƒUƒ‹@ƒGƒ“ƒwƒWƒƒƒ‰ƒJƒ‹A_ŒË–ΗYAâV“¡‘åŽ÷Aà_“cˆŒŽqA–ì“cˆêŽ÷A‰ºìG–ŸFImportant role of endothelial AMPK in endothelium-derived hyperpolarizing factor-mediated relaxations in mouse coronary artery.
  23. X’å’ŒÆA”Ñ“‡ˆêœA‰ºìG–ŸA“›ˆä³lFˆê‘€”AŠÇŒ‹ãFŒã‚̐t•a•ÏŒ`¬‚É‚š‚¯‚éNO‡¬y‘fƒVƒXƒeƒ€‚̐t•ÛŒìì—p.
  24. –î“c–L—²A‰ºìG–ŸA•œŒ@CAŒã“¡^ŒÈA¬Š}ŒŽN•vAŠ’J•¶•FF“œ”A•a«‹}«S‹Ø[ÇŽžŠ¥”÷¬‘€•›ŒŒŠÇ‚É‚š‚¯‚é“à”ç—R—ˆ‰ß•ª‹ÉˆöŽq‚Æ‚µ‚Ẳߎ_‰»…‘f‚ƃAƒ“ƒWƒIƒeƒ“ƒVƒ“ƒ^ƒCƒvIŽó—e‘̝hR–ò‚ÌŒŒŠÇŠg’£Œø‰Ê‚ɂ‚¢‚Ä.
‘æ2‰ñ“ú–{”xzŠÂŠw‰ïŠwpW‰ïi2013”N6ŒŽ22“ú`23“úA“Œ‹žj

ƒƒVƒ“ƒ|ƒWƒEƒ€2@–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚錌ŠÇ“àŽ¡—Â̌»ó‚Æ“W–]„

  1. ™‘ºGˆê˜YC•Ÿ–{‹`OCŽO‰Y —TCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽR–{¹DCŽO‰Y³’šC²“¡Œö—YC‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̐f’f‚ÆŽ¡—Âɂš‚¯‚éŒõŠ±Â’f‘w–@‚Ì—L—p«.
  2. ƒƒXƒ|ƒ“ƒT[ƒhƒVƒ“ƒ|ƒWƒEƒ€2@”x‚ŒŒˆ³”­Ç‚Ì•ªŽq¶•šŠw“IƒAƒvƒ[ƒ`„

  3. Ž… ‹œC•Ÿ–{‹`OC“c’†áÁˆêC²“¡Œö—YC’r“c®•œC‰ºìG–ŸFƒ}ƒEƒX”x‚ŒŒˆ³Çƒ‚ƒfƒ‹‚ð—p‚¢‚œŒŒŠÇ•œŠŠ‹Ø‚É‚š‚¯‚éROCK2‚Ì–ðŠ„‚Ì‰ð–Ÿ.
  4. ƒƒXƒ|ƒ“ƒT[ƒhƒVƒ“ƒ|ƒWƒEƒ€3@¶SŽŸŠ³‚ÉŠÖ˜A‚µ‚œ”x‚ŒŒˆ³Ç„

  5. Œš•”r‰îC•Ÿ–{‹`OC™‘ºGˆê˜YCŒã‰ªL‘Ÿ˜YCŽO‰Y³’šCŽR–{¹DC‰ºìG–ŸF¶SŒnSŽŸŠ³‚É”º‚€”x‚ŒŒˆ³Ç‚ª—\Œã‚É—^‚Š‚é‰e‹¿.
  6. ƒƒXƒ|ƒ“ƒT[ƒhƒVƒ“ƒ|ƒWƒEƒ€4@”x“®–¬«”x‚ŒŒˆ³ÇŽ¡—Â̍őOü„

  7. •Ÿ–{‹`OF”x“®–¬«”x‚ŒŒˆ³Ç‚Ì•a‘Ô‚É‚š‚¯‚éRhoƒLƒi[ƒ[Œo˜H‚ÉŠÖ‚·‚éÅV‚Ì’mŒ©.
  8. ƒÇ—á“O’ê“¢˜_„

  9. ™‘ºGˆê˜YC•Ÿ–{‹`OCŽO‰Y —TCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽO‰Y³’šC²“¡Œö—YC‰ºìG–ŸF’·ŠúƒGƒ|ƒvƒƒXƒeƒm[ƒ‹Ž¡—ÃŒã‚É–å–¬ˆ³˜ŽiÇ‚ð’悵‚œ“«”x‚ŒŒˆ³Ç‚Ì1—á.
  10. ƒˆê”ʉ‰‘èFŒû‰‰”­•\„

  11. Â–Ø—³’jC™‘ºGˆê˜YC•Ÿ–{‹`OCŽO‰Y —TCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽO‰Y³’šC²“¡Œö—YC‰ºìG–ŸF”xŒŒðÇðÇ‚Ì”­Ç‚É‚š‚¯‚é“Œ“ú–{‘åkÐ‚̉e‹¿.
  12. ’r“c®•œC•Ÿ–{‹`OCŽ… ‹œC‰ºìG–ŸFˆ³•‰‰×‚É‚æ‚éS•s‘S‚Ì•a‘Ô‚É‚š‚¯‚éRho-kinase‚Ì–ðŠ„.
  13. ‘å’Î’mLCŒš•”r‰îC•Ÿ–{‹`OC™‘º Gˆê˜YCŽO‰Y—TCŒã‰ªL‘Ÿ˜YCŽO‰Y³’šC‰ºìG–ŸF‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚ɑ΂·‚éƒ_ƒTƒ`ƒjƒuŽ¡—Ã’†‚ɍ‡•¹‚µ‚œ”x“®–¬«”x‚ŒŒˆ³Ç‚Ì1—á.
  14. ²“¡Œö—YC•Ÿ–{‹`OC™‘ºGˆê˜YCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽ… ‹œC–î”ö”M—TC’†‘ºˆê•¶CˆÉ“¡ _C‰ºìG–ŸF”x‚ŒŒˆ³‚̏dÇ“x‚Æ—\Œã—\‘ª‚Ì‚œ‚߂̐V‹KƒoƒCƒIƒ}[ƒJ[¥ƒTƒCƒNƒƒtƒBƒŠƒ“A.
  15. ™‘ºGˆê˜YC•Ÿ–{‹`OCŽO‰Y —TCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽO‰Y³’šC²“¡Œö—YC‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éf’f‚ÆŽ¡—Âɂš‚¯‚éŒõŠ±Â’f‘w–@‚Ì—L—p«.
  16. Œš•”r‰îC•Ÿ–{‹`OC™‘ºGˆê˜YCŽO‰Y —TCŒã‰ªL‘Ÿ˜YCŽO‰Y³’šCŽáŽR”ü“ÞŽqC‰Á‰ê’J –LC‰ºìG–ŸF”x‚ŒŒˆ³Š³ŽÒ‚Ì—\Œã—\‘ª‚ɑ΂·‚éFDG-PET‚Ì—L—p«.
  17. ‘O“c ŒbC”ªŠªd—YCˆÀ“¡‘ŸŽOC•Ÿ–{‹`OC”óŒû‹`˜YC‹àŽq Š®C‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì”x¶ŒŸf’f53—á‚€‚¿Ž€–S3Ç—á‚Ì•a—‘gDŠw“IŒŸ“¢.
  18. –î”ö”M—TC•Ÿ–{‹`OC–x“à‹v“¿C‰ºìG–ŸF”x‚ŒŒˆ³Ç‚É‚š‚¯‚錌¬”“àSmall GTPase‚Ì•]‰¿.
  19. –î”ö”M—TC•Ÿ–{‹`OC–x“à‹v“¿C‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚š‚¯‚錌ðü—n’ïR«|Thrombin activated fibrinolysis inhibitor|‚ÌŠÖ—^.
  20. Md. Elias Al-MamunC²“¡Œö—YC“c’†áÁˆêCŽ… ‹œCSuvd NerguiC•Ÿ–{‹`OC‰ºì –ŸFCombination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension in rats.
  21. Suvd NerguiC•Ÿ–{‹`OCŽì—–‘Ž‘ŽŠiCMd. Elias Al-MamunC‰ºìG–ŸFImpact of endothelial nitric oxide synthase on the development of right ventricular dysfunction caused by pulmonary hypertension.
  22. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[”­•\„

  23. Œš•”r‰îC•Ÿ–{‹`OC™‘ºGˆê˜YCŽO‰Y —TCŒã‰ªL‘Ÿ˜YCŽO‰Y³’šC‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚é”x“®–¬ƒoƒ‹[ƒ“Œ`¬pŽž‚ÌOCT‚Ì—L—p«|IVUS‚Æ‚Ì”äŠr|
  24. ƒƒRƒƒfƒBƒJƒ‹ƒZƒbƒVƒ‡ƒ“„

  25. ŒŽ‹|ŠGC“¡“ˆŒbŽqC‰ºìG–ŸFŽ‘±Ã’—Ö@‚ÌŽ©ŒÈŠÇ—Žw“±’†‚ÌŠ³ŽÒ‚ªŽw“±‚ð’†’f‚µÄŠJ‚ÉŽŠ‚Á‚œ—vˆö
‘æ199‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2013”N6ŒŽ15“úAå‘äj
  1. âV“¡ˆ»ŽqA‚‹Ž@AˆÉ“¡ˆ€„A‰~’J—²Ž¡A”’ŒË@’AŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‰ºìG–ŸAÄ“¡^ˆê˜YF‘å“®–¬‰ŠÇŒóŒQ‚ð”wŒi‚Æ‚µ‚œ¶Š¥“®–¬ŽåŠ²•”‚Ì‹·ó•a•Ï‚É‚æ‚è‹}«S‹Ø[Ç‚𔭏ǂµ‚œ1—á.
  2. £ì«lAŒË“c@’ŒA›Á@Œ³‹gA‚–Ø—S‰îA–©’J@–LAŽR–{‹`lA™@³•¶A‰ºìG–ŸFIsoproterenol“Š—^‚ªelectrical storm‚̃Rƒ“ƒgƒ[ƒ‹‚É—LŒø‚Å‚ ‚Á‚œJ wave syndrome‚Ì1—á.
  3. Œš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‰ºìG–ŸF‰@ŠOS’âŽ~‚©‚ç‘h¶‚³‚ê‚œŠ®‘S–[ŽºƒuƒƒbƒN‡•¹–¢C•œ‹@”\“I’PSŽºiDORVj‚Ì1—á.
  4. ™‘ºGˆê˜YA•Ÿ–{‹`OAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽO‰Y³’šA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éf’f‚ÆŽ¡—Âɂš‚¯‚éŒõŠ±Â’f‘w–@‚Ì—L—p«.
‘æ66‰ñ“ú–{Ž_‰»ƒXƒgƒŒƒXŠw‰ïŠwpW‰ïi2013”N6ŒŽ13`14“úA–ŒŒÃ‰®j
  1. ²“¡Œö—YC•Ÿ–{‹`OC™‘ºGˆê˜YCŽO‰Y@—TCŒã‰ªL‘Ÿ˜YCÂ–Ø—³’jCŒš•”r‰îCŽR–{¹DCŽ…@‹œC–î”ö”M—TC’†‘ºˆê•¶CˆÉ“¡@_C‰ºìG–ŸFŽ_‰»ƒXƒgƒŒƒX•ª”å’`”’FƒTƒCƒNƒƒtƒBƒŠƒ“A ‚É‚æ‚é”x‚ŒŒˆ³‚Ì—\Œã—\‘ª.
‘æ156‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2013”N6ŒŽ1“úA·‰ªj
  1. HŽR³”NAì–{r•ãAÖ–؉ÀŽA•Ÿ“c_“ñA•Ÿ–{‹`OA‰ºìG–ŸFdÇS•s‘S‚ɑ΂·‚é•â•lHS‘ŸAS‘ŸˆÚAŽ¡—Ã.
  2. •Ð•œW‘Ÿ˜YAHŽR³”NA–{‹g’ŒFAì–{r•ãAÖ–؉ÀŽAŽO‰Y³’šAŒã‰ªL‘Ÿ˜YAŽO‰Y@—TA™‘ºGˆê˜YA•Ÿ–{‹`OA‚‹Ž@A•Ÿ“c_“ñA‰ºìG–ŸFŠg’£Œ^S‹ØÇ‹}«‘ˆ«‚ɑ΂µBridge to decision‚ðs‚Á‚œ2Ç—á‚ÌŒoŒ±.
  3. _“cŒj•ãA–{‹g’ŒFAì–{r•ãAÖ–؉ÀŽA•Ÿ–{‹`OA‰ºìG–ŸFŽ©ŒÈ•Ù‰·‘¶Šî•”’uŠ·p‚ÌŽ¡—ЬÑ.
  4. ‹ß“¡³‹PA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@œAì–Œ‹ÅŽqA’·’J•”—Y”òA²’|—m”VAAbdel-Schafee MohamedA‰ºìG–ŸFCARTO SOUND‚ª—L—p‚Å‚ ‚Á‚œ—Œ‘匌ŠÇ‰EŽº‹NŽnÇªŽ¡pŒãSŽº•p”‚̈ê—á.
  5. Ö“¡ˆ»ŽqAŒ–{‘׎¡AˆÉ“¡ˆ€„Aš¢’J—²Ž¡A”’ŒË@’A‰H”öŽ‹MA’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA™‘ºGˆê˜YA‚‹Ž@A‰ºìG–ŸA’†àV‚¿‚ЂëAÎˆä’q“¿A_“cŒj•ãAì–{r•ãA‘å“c‰pŠöA‚£@Œ\FIgG4ŠÖ˜AŽŸŠ³‚ɍ‡•¹‚µ‚œŠ¥¹k«‹·SÇ‚Ì1—á.
  6. ²’|—m”VA•Ÿ“c_“ñA‹ß“¡³‹PA’†–ì@œA’·’J•”—Y”òAAbdel-Schafee MohamedAŽáŽR—TŽiA™‘ºGˆê˜YA‰ºìG–ŸAŽÂè@‹BF–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚鐇–°ŽžŒÄ‹záŠQ‚Æ’vŽ€«•s®–¬ƒCƒxƒ“ƒg‚ÌŒŸ“¢.
  7. ”’ŒË@’A‚‹Ž@AŒ–{‘׎¡AˆÉ“¡ˆ€„Aš¢’J—²Ž¡A“ñ•r‘Ÿ˜YA’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‰ºìG–ŸF•ÂÇ•”‚©‚番Šò‚·‚é‘ΊpŽ}‚ÆŒŒŠÇ“à’Ž‰¹”gŽg—p‚ªƒƒCƒ„[’ʉ߂ɗLŒø‚Å‚ ‚Á‚œ–«Š®‘S•ÂÇ‚Ì1—á.
  8. ™‘ºGˆê˜YA•Ÿ–{‹`OAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽO‰Y³MA²“¡Œö—YA‰ºìG–ŸF–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì––œ”x“®–¬‚É‚š‚¯‚éŒõŠ±Â’f‘w–@‚ð—p‚¢‚œ•]‰¿.
  9. ’†–ì@œA•Ÿ“c_“ñAŽáŽR—TŽiA‹ß“¡³‹PA’·’J•”—Y”òAì–Œ‹ÅŽqA²’|—m”VAAbdel-Schafee MohamedA‰ºìG–ŸF”­ìŽž‚ÉJ wave‚ð”F‚ß‚œŽá”N«SŽº×“®‚̈ê—á.
  10. Œã‰ªL‘Ÿ˜YA•Ÿ–{‹`OA™‘ºL‘Ÿ˜YAŽO‰Y@—TAŒš•”r‰îAŽO‰Y³’šAŽR–{¹DA²“¡Œö—YA‰ºìG–ŸAHŽR³”NAì–{r•ãAÖ–؉ÀŽAHê”ü‹IF—ŒS•â•lHS‘Ÿ‚𓱓ü‚µ‚œ‚ª‹~–œ•s‰Â”\‚Å‚ ‚Á‚œŒ€ÇŒ^S‹Ø‰Š‚Ì1—á.
  11. ’·’J•”—Y”òA’†–ì@œAŽáŽR—TŽiA‹ß“¡³‹PA²’|—m”VAAbdel-Schafee MohamedA•Ÿ“c_“ñA‰ºìG–ŸFŽž_‚ÌŒŽˆö‚Æ‚È‚Á‚œSŽº«ŠúŠOŽûk‹Nˆö«ˆê‰ß«SŽº×“®‚ɑ΂µ‚ăAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—ª—LŒø‚Å‚ ‚Á‚œˆê—á.
  12. ŽO‰Y³’šAâ“c‘וFAŒã‰ªL‘Ÿ˜YA‚“c„ŽjA‹{“c@•qA‚‹Ž@A‰ºìG–ŸFS•s‘SŠ³ŽÒ‚É‚š‚¯‚é‰îŒì—\–h•K—v“x‚Æ—\‘ªˆöŽq‚ÌŒŸ“¢@CHART-2‚©‚ç‚Ì•ñ.
  13. ‰¡ì—T‘åAì–{r•ãAHŽR³”NA‰Í’Á@‘A–{‹g’ŒFAÖ–؉ÀŽA•Ÿ–{‹`OA‰ºìG–ŸFŽûk«S–Œ‰Š‚ÌŠO‰ÈŽ¡—ЬÑ‚ÌŒŸØ.
‘æ35‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwpW‰ïi2013”N5ŒŽ30“úAŽRŒ`j
  1. * ‰ºìG–ŸF“Œ“ú–{‘åkÐ‚ƏzŠÂŠíŽŸŠ³.
‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2013”N3ŒŽ15`17“úA‰¡•lj

ƒPlenary Sessions„

  1. (PL03: To Improve Outcomes of Acute Heart Failure Patients: Lessons from Asian and Western Registries) Miura M, Sakata Y, Takada T, Nochioka K, Miyata S, Takahashi J, Hiramoto T, Inoue K, Tamaki K, Shiba N, Shimokawa H. Prognostic impact of blood urea nitrogen increase during hospitalization in patients with acute decompensated heart failure. Circ J. 77(Suppl. I):I-63,2013.
  2. ƒSymposiums„

  3. (SY01: Progress in Coronary Revascularization: CABG and PCI for Severe Coronary Artery Disease) Takahashi J, Sakata Y, Nochioka K, Miura M, Takada T, Miyata S, Shimokawa H. Prognostic impact of coronary revascularization therapy in patients with ischemic heart failure. Circ J. 77(Suppl. I):I-90,2013.
  4. (SY07: Advances in the Cardiovascular Regenerative Medicine -Lesson from the Clinical Studies-) Ito K, Fukumoto Y, Takahashi J, Hanawa K, Shindo T, Serizawa F, Sato A, Shimokawa H. Development of non-invasive regenerative therapies for cardiovascular disorders -Low-energy shock wave therapy and low-intensity pulsed ultrasound therapy- Circ J. 77(Suppl. I):I-120,2013.
  5. (SY10: New Biomarkers for Cardiovascular Disease Prevention) Satoh K, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimizu T, Takagi Y, Tsuburaya R, Itoh Y, Matsumoto Y, Nakayama M, Takeda M, Takahashi J, Ito K, Yasuda S, Shimokawa H. Plasma cyclophilin A is a novel biomarker for oxidative stress and coronary artery disease. Circ J. 77(Suppl. I):I-139,2013.
  6. (SY14: Establishment of Caring Facilities in Adults with Congenital Heart Disease) Tatebe S, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Yamamaoto S, Satoh K, Shimokawa H. Current status of chronic heart failure with adult congenital heart disease in Japan. Circ J. 77(Suppl. I):I-162,2013.
  7. (SY17: Recent Progress in Pulmonary Hypertension) Fukumoto Y, Sugimura K, Shimizu T, Qiqige Z, Yamamoto S, Tatebe S, Aoki T, Nochioka K, Miura Y, Satoh K, Shimokawa H. Recent research progress on the role of Rho-kinase pathway in the pathogenesis of pulmonary arterial hypertension -From Bench to Bedside- Circ J. 77(Suppl. I):I-180,2013.
  8. (SY23: Disasters and Cardiovascular Diseases) Aoki T, Fukumoto Y, Yasuda S, Ito K, Takahashi J, Miyata S, Shinozaki T, Inoue K, Yagi T, Komaru T, Katahira Y, Shimokawa H. Impact of the Great East Japan Earthquake Disaster on cardiovascular diseases. Circ J. 77(Suppl. I):I-215,2013.
  9. ƒLate Breaking Cohort Studies„

  10. (LBCS2-4) Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Shimokawa H. Different impact of elevated baseline heart rate on outcomes in patients with HFrEF vs. HFpEF: The CHART-2 Study. Circ J. 77(Suppl. I):I-552,2013.
  11. ƒYoung Investigatorfs Award for International Students„

  12. Ellawindy A, Satoh K, Tanaka S, Ikeda S, Shimizu T, Noda K, Fukumoto Y, Kobayashi K, Nakayama K, Shimokawa H. Spontaneous development of arrhythmogenic right ventricular cardiomyopathy in mice overexpressing dominant-negative Rho-kinase in cardiovascular system. Circ J. 77(Suppl. I): I-568,2013.
  13. ƒESC-JCS Joint Symposium„

  14. (Recent Progress in the Understanding, Management and Prevention of Sudden Cardiac Death) Yasuda S, Ogawa H, Shimokawa H. Coronary artery spasm and out-of- hospital cardiac arrest. Circ J. 77(Suppl. I):I-230,2013.
  15. ƒRound Table Discussion„

  16. (RT12: How to Manage Intractable Coronary Artery Spasm) Takagi Y, Takahashi J, Yasuda S, Ogata Y, Sumiyoshi T, Goto T, Ogawa H, Shimokawa H. Nitrates as a concomitant therapy in patients with vasospastic angina -A report from the Japanese Coronary Spasm Association- Circ J. 77(Suppl. I):I-303,2013.
  17. ƒMorning Lecture„

  18. Sugimura K, Fukumoto Y, Shimokawa H. Management of chronic thromboembolic pulmonary hypertension. Circ J. 77(Suppl. I):I-525,2013.
  19. ƒFeatured Research Sessions„

  20. (FRS10: Angina pectoris) Satoh K, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Takagi Y, Tsuburaya R, Itoh Y, Matsumoto Y, Nakayama M, Takeda M, Takahashi J, Ito K, Yasuda S, Shimokawa H. Plasma cyclophilin A level is a novel biomarker of vasospastic angina. Circ J. 77(Suppl. I):I-636,2013.
  21. Nihei T, Jun Takahashi J, Kikuchi Y, Hao K, Takagi Y, Tsuburaya R, Shirato T, Itoh Y, Matsumoto Y, Nakayama M, Ito K, Shimokawa H. Circadian variation of Rho-kinase activity in patients with vasospastic angina. Circ J. 77(Suppl. I):I-637,2013.
  22. (FRS17: Vascular Diseaese) Takagi Y, Takahashi J, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanabe Y, Ogawa H, Shimokawa H. Chronic nitrate therapy in patients with vasospastic angina -Multicenter registry study of the Japanese Coronary Spasm Association- Circ J. 2013;77(Suppl. I):I-679,2013.
  23. (FRS18: Pulmonary Circulation) Satoh K, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimizu T, Nakamura K, Ito H, Shimokawa H. Plasma cyclophilin A as a novel biomarker for pulmonary hypertension in humans. Circ J. 77(Suppl. I):I-686,2013.
  24. (FRS20: Heart Failure) Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Shimokawa H. Factors influencing development of de novo heart failure from Stage-B asymptomatic status -A report from the CHART-2 Study- Circ J. 77(Suppl. I):I-698,2013.
  25. ƒOral presentations„

  26. Abdel-Shafee M, Fukuda K, Wakayama Y, Nakayama M, Nakano M, Kondoh M, Hasebe Y, Kawana A, Shimokawa H. Improved long-term prognosis of patients with cardiac sarcoidosis in the modern era. Circ J. 77(Suppl. I):I-873,2013.
  27. Hao K, Takahashi J, Nihei T, Tsuburaya R, Shirato T, Itoh Y, Matsumoto Y, Nakayama M, Kenta Ito, Yasuda S, Shimokawa H.@Improved emergency care of acute myocardial infarction during the Great East Japan Earthquake Disaster -The Miyagi AMI Registry Study-@Circ J. 77(Suppl. I):I-835,2013.
  28. Miura M, Sakata Y, Nochioka K, Takada T, Miyata S, Takahashi J, Shiba N, Shimokawa H. Stratification of mortality risk according to heart rate and systolic blood pressure in heart failure patients. Circ J. 77(Suppl. I):I-1086,2013.
  29. Nochioka K, Sakata Y, Takahashi J, Miyata S, Miura M, Takada T, Fukumoto Y, Shimokawa H. Psychological impact of the Fukushima Daiichi Nuclear Accident in patients with cardiovascular diseases -An interim analysis from the CHART-2 Study- Circ J. 277(Suppl. I):I-1054,2013.
  30. Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Takahashi J, Fukumoto Y, Shimokawa H. Psychological impact of the Great East Japan Earthquake Disaster in patients with cardiovascular diseases; A report from the CHART-2 Study. Circ J. 77(Suppl. I):I-1055,2013.
  31. Shiroto T, Romero N, Sugiyama T, Sartoretto JL, Kalwa H, Yan Z, Shimokawa H, Michel T, Caveolin-1 plays a key role in the regulation of vascular oxidative stress. Circ J. 77(Suppl. I):I-1024,2013.
  32. Tatebe S, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Yamamoto S, Wakayama M, Kagaya Y, Shimokawa H. Prognostic impact of enhanced [18F]fluorodeoxyglucose accumulation in the right ventricle in patients with pulmonary hypertension. Circ J. 77(Suppl. I):I-1079,2013.
  33. Uchida T, Furuno Y, Tanimoto A, Toyohira Y, Sakanashi M, Matsuzaki T, Noguchi K, Nakasone J, Ohya Y, Yanagihara N, Shimokawa H, Tamura M, Otsuji Y, Tsutsui M. Development of an experimentally useful model of spontaneous myocardial infarction. Circ J. 77(Suppl. I):I-810,2013.
  34. Yada T, Shimokawa H, Hiramatsu O, Goto M, Ogasawara Y, Kajiya F. Beneficial effects of angiotensin type 1 receptor blocker on H2O2-induced vasodilatation of native coronary collateral microvessels in dogs in vivo. Circ J. 77(Suppl. I):I-883,2013.
  35. ƒPoster presentations„

  36. Abe Y, Ito K, Hao K, Shimokawa H. Beneficial effects of low-energy shock wave therapy on inflammatory responses after acute myocardial infarction in rats. Circ J. 77(Suppl. I):I-2013,2013.
  37. Al-Mamun E, Satoh K, Tanaka S, Shimizu T, Nergui S, Fukumoto Y, Shimokawa H. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension in rats. Circ J. 77(Suppl. I):I-1766,2013.
  38. Dai Z, Fukumoto Y, Tatebe S, Sugimura K, Miura Y, Nochioka K, Aoki T, Yamamoto S, Shimokawa H. Pulmonary arterial remodeling occurs in the very early stage of pulmonary hypertension -An optical coherence tomography study- Circ J. 77(Suppl. I):I-1762,2013.
  39. Enkhjargal B, Saito H, Godo S, Sawada A, Noda K, Shimokawa H. Important role of endothelial AMPK in endothelium-derived hyperpolarizing factor-mediated relaxations in mice. Circ J. 77(Suppl. I):I-1640,2013.
  40. Hanawa K, Ito K, Kentaro Aizawa K, Tomohiko Shindo1, Kensuke Nishimiya1, Yuhi Hasebe1, Junyi Gao1, Hideyuki Hasegawa2, Satoshi Yasuda3, Hiroshi Kanai2, Hiroaki Shimokawa1 Low-Intensity Pulsed Ultrasound Induces Angiogenesis and Ameliorates Left Ventricular Dysfunction in a Porcine Model of Chronic Myocardial IschemiaCirculation Journal 2013, 77(Suppl. I):I-2524,2013.
  41. Hao K, Takahashi J, Nihei T, Tsuburaya R, Shirato T, Itoh Y, Matsumoto Y, Nakayama M, Ito K, Yasuda S, Shimokawa H. Characteristics of patients with acute myocardial infarction who did not receive primary PCI -A report from the Miyagi AMI Study- Circ J. 77(Suppl. I):I-2827,2013.
  42. Hasebe Y, Fukuda K, Yamamoto H, Nishimiya K, Hanawa K, Kondoh M, Nakano M, Wakayama Y, Shimokawa H. Development of a novel shock wave catheter ablation system -A feasiblity study for atrioventricular node ablation in pigs in vivo- Circ J. 77(Suppl. I):I-1354,2013.
  43. Ikeda S, Fukumoto Y, Shimizu T, Shimokawa H. Cardiac-specific overexpression of dominant-negative Rho-kinase suppresses pressure overload-induced right and left heart failure in mice. Circ J. 77(Suppl. I) : I-2905 ,2013.
  44. Kawana A, Takahashi J, Takagi Y, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanabe Y, Sueda S, Kubo N, Momomura S, Ogawa H, Shimokawa H. Age-dependent differences in clinical characteristics and outcomes of female patients with vasospastic angina. Circ J. 77(Suppl. I):I-2370,2013.
  45. Kondoh M, Fukuda K, Wakayama Y, Nakano M, Kawana A, Hasebe Y, Abdel-Shafee M, Satake H, Shimokawa H. New Occurrence of ventricular arrhythmias after cardiac resynchronization therapy in patients with severe heart failure. Circ J. 77(Suppl. I):I-2346,2013.
  46. Miura M, Sakata Y, Nochioka K, Takada T, Miyata S, Takahashi J, Shiba N, Shimokawa H. Emerging healthcare issues in the management of chronic heart failure in Japan -An interim analysis of the CHART-2 Study- Circ J. 77(Suppl. I):I-2981,2013.
  47. Miura Y, Fukumoto Y, Sugimura K, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Satoh K, Shimokawa H. Impact of positive myocardial biopsy on ventricular function and prognosis in patients with cardiac sarcoidosis. Circ J. 77(Suppl. I):I-2547,2013.
  48. Nergui S, Fukumoto Y, Qiqige Z, Al Mamun E, Shimokawa H. Impact of endothelial nitric oxide synthase on the development of right ventricular dysfunction caused by pulmonary hypertension. Circ J. 77(Suppl. I):I-1764,2013.
  49. Nishimiya K, Matsumoto Y, Takahashi J, Shindo T, Hanawa K, Hasebe Y, Tsuburaya R, Shirato T, Ito K, Ishibashi-Ueda H, Yasuda S, Shimokawa H. New generation biolimus A9-eluting stent suppresses coronary hyperconstricting responses after stent implantations through Rho-kinase pathway inhibition in pigs in vivo. Circ J. 77(Suppl. I):I-1851,2013.
  50. Qiqige Z, Fukumoto Y, Sugimura K, Miura Y, Tatebe S, Yamamoto S, Aoki T, Nochioka K, Satoh K, Nergui S, Kondoh M, Nakano M, Wakayama Y, Fukuda K, Nihei T, Takahashi J, Shimokawa H. Enhanced Rho-kinase activity in circulating leukocytes in patients with heart failure. Circ J. 77(Suppl. I) : I-1424 ,2013.
  51. Shimizu T, Fukumoto Y, Tanaka S, Satoh K, Shimokawa H. Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice. Circ J. 77(Suppl. I):I-2276,2013.
  52. Sugimura K, Fukumoto Y, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimokawa H. Usefulness of optical coherence tomography for diagnosis and treatment of chronic thromboembolic pulmonary hypertension. Circ J. 77(Suppl. I):I-2575,2013.
  53. Suzuki H, Sumiyoshi A, Taki Y, Matsumoto Y, Fukumoto Y, Kawashima R, Shimokawa H. Usefulness of voxel-based morphometry for in vivo evaluation of hippocampal damage in a rat model of cardiopulmonary resuscitation. Circ J. 77(Suppl. I):I-2073,2013.
  54. Tsuburaya R, Takahashi J, Itoh Y, Shirato T, Yasuharu Matsumoto, Kenta Ito, Masaharu Nakayama, Hiroaki Shimokawa Beneficial Effects of a Single Prophylactic Hemodialysis on Renal Function Worsening after Percutaneous Coronary Intervention in Patients with Severe CKD.Circulation Journal 2013, 77(Suppl. I):I-2395,2013.
  55. Wakayama Y, Fukuda K, Nakano M, Kondoh M, Abdel-Shafee M, Hasebe Y, Kawana A, Satake H, Shimokawa H. Usefulness of quantitative gated SPECT to predict responders of cardiac resynchronization therapy among patients with a relatively narrow QRS. Circ J. 77(Suppl. I):I-1586,2013.
  56. Yaoita N, Fukumoto Y, Horiuchi M, Shimokawa H. Evidence for resistance to fibrinolysis in patients with chronic thromboembolic pulmonary hypertension -Possible involvement of thrombin activated fibrinolysis inhibitor- Circ J. 77(Suppl. I):I-2745,2013.
‘æ15‰ñ“ú–{¬læ“V«SŽŸŠ³Šw‰ï‘‰ïEŠwpW‰ïi2013”N2ŒŽ19`20“úA“Œ‹žj
  1. ‹ß“¡³‹PC•Ÿ“c_“ñCŽáŽR—TŽiC’†–ì@œCì–Œ‹ÅŽqC’·’J•”—Y”òC²’|—m”VCMohamed A. ShafeeC‰ºìG–ŸFæ“V«SŽŸŠ³pŒãS–[•p”‚É‚š‚¯‚é—Տ°“I“Á’¥‚ÌŒŸ“¢.
‘æ198‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2013”N2ŒŽ16“úAå‘äj

ƒ‰Šú—Տ°Œ€CˆãƒvƒŒƒiƒŠ[ƒZƒbƒVƒ‡ƒ“E—DGÜŽóÜ„

  1. ‚“cØ¶ŽqA™‘ºGˆê˜YA•Ÿ–{‹`OAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šAŒš•”r‰îA‰ºìG–ŸA‰Á“¡¹ºF’†«Ž‰–b’~ÏS‹ØŒŒŠÇÇ‚Ì1—á.
  2. ƒˆê”ʉ‰‘聄

  3. ²’|—m”VA‹ß“¡³‹PA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@œAì–Œ‹ÅŽqA’·’J•”—Y”òA‰ºìG–ŸFŠg‘å”xÃ–¬Šu—£pŒã‚ÉŒ°Ý‰»‚µ‚œŽOë•Ù—Ö‹NŒ¹SŽº«ŠúŠOŽûk‚Ì1—á.
  4. ‚“c“NŽjAŒã‰ªL‘Ÿ˜YA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TAŒš•”r‰îAŽO‰Y³’šA²“¡Œö—YAÎˆä’q“¿FCoganÇŒóŒQ‚É‘å“®–¬•Âœ•s‘SÇ‚ð‡•¹‚µS•s‘S‚𗈂µ‚œ1—á.
‘æ33‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï“Œ–k’n•û‰ïi2013”N2ŒŽ9“úAå‘äj
  1. ‚‹Ž@C”’ŒË@’CŒ–{‘׎¡CˆÉ“¡ˆ€„C‰~’J—²Ž¡C“ñ•r‘Ÿ˜YC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‰ºìG–ŸF•ÂÇ•”‚©‚番Šò‚·‚é‘ΊpŽ}‚ÆIVUS ‚ð—˜—p‚·‚邱‚Æ‚Å‘O‰ºsŽ}–{Š²––œ‚ɃƒCƒ„[’ʉ߂ª‰Â”\‚Æ‚È‚Á‚œ1—á.
‘æ42‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïŠwpW‰ïi2013”N2ŒŽ8“ú`9“úA“ޗǁj

ƒŽáŽèŒ€‹†ŽÒÜŽóÜ„

  1. Ž…@‹œA•Ÿ–{‹`OA“c’†^ˆêA²“¡Œö—YA‰ºìG–ŸF”xŒŒŠÇƒŠƒ‚ƒfƒŠƒ“ƒO‚É‚š‚¯‚éROCK2‚Ì–ðŠ„@\”x‚ŒŒˆ³ÇƒƒJƒjƒYƒ€‚̉𖟁\
  2. ƒŽáŽèŒ€‹†ŽÒÜÅIŒó•â„

  3. –ì“cˆêŽ÷A•Ÿ–{‹`OA’†“ˆ‘s‘ŸA‰ºìG–ŸFƒ}ƒEƒX‚É‚š‚¢‚ÄRho-kinase‚ÍAMPKŒo˜H‚ð—}§‚·‚邱‚Æ‚É‚æ‚胁ƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚ðŽä‚«‹N‚·
  4. ƒˆê”ʉ‰‘聄

  5. ²“¡Œö—YA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TAÂ–Ø—³’jAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DAŽ…@‹œA–î”ö”M—TA’†‘ºˆê•¶AˆÉ“¡@_A‰ºìG–ŸF”x‚ŒŒˆ³‚̏dÇ“x‚Æ—\Œã—\‘ª‚Ì‚œ‚߂̐V‹KƒoƒCƒIƒ}[ƒJ[EƒTƒCƒNƒƒtƒBƒŠƒ“A.
“ú–{“®–¬d‰»Šw‰ï@‘æ13‰ñ“®–¬d‰»‹³ˆçƒtƒH[ƒ‰ƒ€i2013”N2ŒŽ3“úA‹ž“sj
  1. ‰ºìG–ŸFŽ‰Ž¿ˆÙíÇf—Â̍ŋ߂̐i•à.
‘æ6‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2013”N2ŒŽ1`2“úAå‘äj

ƒÅ—DG‰‰‘èÜ„

  1. ŽO‰Y³’šAâ“c‘וFAŒã‰ªL‘Ÿ˜YA‚“c„ŽjA‹{“c@•qA‚‹Ž@AŽÄ@MsA‰ºìG–ŸFSŒŒŠÇ•aŠ³ŽÒ‚É‚š‚¯‚é‰îŒì—\–h•K—v“x‚ƉîŒì—\–h‚ª•K—v‚Æ‚È‚é—\‘ªˆöŽq‚ÌŒŸ“¢\CHART-2Œ€‹†‚É‚š‚¯‚é’mŒ©\
  2. ƒÅ—DG‰‰‘èŒû‰‰„

  3. ‚“c„ŽjAâ“c‘וFA‹{“c@•qAŽO‰Y³’šAŒã‰ªL‘Ÿ˜YA‚‹Ž@A‰ºìG–ŸF¶ŽºŽûk”\‚Ì•Û‚œ‚ê‚œ–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚éS””‚Ì—\Œã‚É—^‚Š‚é‰e‹¿‚Æ‚»‚ê‚ÉŠÖ˜A‚·‚éˆöŽq‚ÌŒŸ“¢\«·‚ÌŠÏ“_‚àŠÜ‚߂ā[
  4. ‰H”öŽ‹MA‚‹Ž@A“ñ•r‘Ÿ˜YA‰~’J—²Ž¡A”’ŒË@’AˆÉ“¡ˆ€„AŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸAˆÀ“c@‘A‰ºìG–ŸF‹}«S‹Ø[ÇŠ³ŽÒ‚É‚š‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“–¢Ž{s—á‚̐«·‚ÉŠÖ‚·‚錟“¢\‹{éŒ§S‹Ø[Ç‘΍ô‹Š‹c‰ï‚©‚ç‚Ì•ñ\
  5. ƒƒ|ƒXƒ^[”­•\„

  6. ˆÉ“¡ˆ€„A‚‹Ž@A‰H”öŽ‹MA‰~’J—²Ž¡A”’ŒË@’AŒ–{‘׎¡A“ñ•r‘Ÿ˜YA’†ŽR‰ë°AˆÉ“¡Œ’‘ŸAˆÀ“c@‘A‰ºìG–ŸF‹}«S‹Ø[Ç‚̉@“àŽ€–S—Š‚̐«·‚ÉŠÖ‚·‚éˆöŽq‚ÌŒŸ“¢\‹{éŒ§S‹Ø[Ç‘΍ô‹Š‹c‰ï‚©‚ç‚Ì•ñ\
  7. ì–Œ‹ÅŽqA‚‹Ž@A‚–Ø—S‰îAˆÀ“c@‘AŠp“c—²•ãA•ûN”ŽAŠÖ@“ցAZ‹g“OÆAŒˆäŠ²”VAŒã“¡•q˜aA“c•Ó‹±•FA––“cÍŽOA‹v•Û“TŽjA•S‘ºLˆêA¬ì‹v—YA‰ºìG–ŸFŠ¥¹k«‹·SÇŠ³ŽÒ‚É‚š‚¯‚鐫•ÊE”N‘ã•Ê‚̗Տ°‘œ‚Æ—\Œã‚̈Ⴂ.
  8. ‹ß“¡³‹PA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@œAì–Œ‹ÅŽqA’·’J•”—Y”òA²’|—m”VAAbdel-Schafee MohamedA‰ºìG–ŸFSŽº«ŠúŠOŽûk‚̗Տ°“I“Á’¥‚š‚æ‚уJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚Ì—LŒø«‚É‚š‚¯‚鐫·‚ÉŠÖ‚·‚錟“¢.
  9. Œš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jA²“¡Œö—YA‰ºìG–ŸF¶SŒnSŽŸŠ³‚É‚æ‚é”x‚ŒŒˆ³Ç‚̐«·‚É‚æ‚é—Տ°“IˆÓ‹`.
  10. ’†–ì@œA•Ÿ“c_“ñAŽáŽR—TŽiA‹ß“¡³‹PA’·’J•”—Y”òAAbdel Schafee MohamedA‰ºìG–ŸF“–‰È‚ł̐S‘ŸƒTƒ‹ƒRƒCƒh[ƒVƒXÇ—á‚É‚š‚¯‚鐫·‚ÌŒŸ“¢.
  11. Œã‰ªL‘Ÿ˜YAâ“c‘וFA‹{“c@•qA‚‹Ž@AŽO‰Y³’šA‚“c„ŽjA’A–Ø‘sˆê˜YA•Ÿ–{‹`OA‰ºìG–ŸF“Œ“ú–{‘åkÐ‚É‚æ‚éŠOŒãƒXƒgƒŒƒXáŠQ‚̐SŒŒŠÇ•aŠ³ŽÒ‚É‚š‚¯‚鐫·\CHART-2Œ€‹†ƒRƒz[ƒg‚É‚š‚¯‚é’mŒ©\
  12. ŽO‰Y@—TA•Ÿ–{‹`OA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸFSƒTƒ‹ƒRƒCƒh[ƒVƒX‚̐«·‚ÉŠÖ‚·‚錟“¢.

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2012”N
‘æ155‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2012”N12ŒŽ8“úAå‘äj

ƒYIAÇ—á•”–偄

  1. ‰H”öŽ‹MA‚‹Ž@A“ñ•r‘Ÿ˜YAš¢’J—²Ž¡A”’ŒË@’AˆÉ“¡ˆ€„AŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‰ºìG–ŸF–òÜ—no«ƒXƒeƒ“ƒg—¯’uŠ¥“®–¬‚ɐ¶‚¶‚œ“«Š¥¹k‚ÉRho-kinase‘jŠQ–ò‚ª’˜Œø‚µ‚œ1—á.

ƒYIAŒ€‹†•”–åiÅ—DGÜŽóÜj„

  1. ŽO‰Y³’šAâ“c‘וFAŒã‰ªL‘Ÿ˜YA‚“c„ŽjA‚‹Ž@A‰ºìG–ŸA•œ–{“N–çAˆäãŠ°ˆêA“cŠªŒ’Ž¡F‹}«S•s‘S“ü‰@’†‚ÌBUN‘‰Á‚Í’·Šú—\Œã‚ð—\‘ª‚·‚é.

ƒˆê”ʉ‰‘聄

  1. ™‘ºGˆê˜YAÂ–Ø—³’jA•Ÿ–{‹`OAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DA²“¡Œö—YA‰ºìG–ŸF9”NŠÔ‚̃Gƒ|ƒvƒƒXƒeƒm[ƒ‹Ž¡—ÃŒã‚É–å–¬ˆ³˜ŽiÇ‚ð’悵‚œ“«”x“®–¬«”x‚ŒŒˆ³Ç‚Ì1—á.
  2. ”’ŒË@’A‚‹Ž@Aš¢’J—²Ž¡A‚–Ø—S‰îA‰H”öŽ‹MAˆÉ“¡ˆ€„AŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFƒVƒƒŠƒ€ƒX—noƒXƒeƒ“ƒg—¯’uŒã‚ÉPeri-stent contrast staining (PSS)‚𔺂¢”ÓŠúÄ‹·ó‚𗈂µ‚œ2—á.
  3. ‹ß“¡³‹PA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@œAì–Œ‹ÅŽqA’·’J•”—Y”òA²’|—m”VA‰ºìG–ŸFƒtƒ@ƒ[Žl’¥ÇpŒã‚ɐ¶‚¶‚œL”͈͂Ȓá“dˆÊ—̈悪ŠÖ—^‚µ‚œ”ñ’Ê“dŒ^S–[‘e“®‚̈ê—á.
  4. ‚‹Ž’‰‹vA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@œA‹ß“¡³‹PAì–Œ‹ÅŽqA’·’J•”—Y”òA²’|—m”VA‰ºìG–ŸFICD–„‚ߍž‚Ý7”NŒã‚ɐSŽº×“®‚𔭏ǂµ‚œ–³ÇŒó«ƒuƒ‹ƒKƒ_ÇŒóŒQ‚̈ê—á.
  5. ’†–ì@œA•Ÿ“c_“ñAŽáŽR—TŽiA‹ß“¡³‹PA’·’J•”—Y”òAì–Œ‹ÅŽqAƒ‚ƒnƒƒhƒAƒuƒfƒ‹ƒVƒƒƒtƒB[A‰ºìG–ŸF‰ð–UŠw“IˆÊ’uŠÖŒW‚ð—˜—p‚µA‰ESA¶S‘o•û‚©‚ç‚ÌŽ¡—ª‘tŒ÷‚µ‚œPVC‚̈ê—á.
  6. ‘å’Î’mLAŒš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jA‰ºìG–ŸF¶ŽºS‹Øãk–§‰»áŠQ‚Æ‚ÌŠÓ•Ê‚ª¢“ï‚Å‚ ‚Á‚œC³‘匌ŠÇ“]ˆÊÇ‚Ì1—á.
  7. “–ì—F‘ŸAš¢’J—²Ž¡A‚‹Ž@A‰H”öŽ‹MAˆÉ“¡ˆ€„A”’ŒË@’AŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFƒAƒŒƒ‹ƒM[«“÷‰èŽî«ŒŒŠÇ‰Š‚É‚æ‚éDŽ_‹…«S‹Ø‰Š‚̈ê—á.
  8. ‚‹ŽG“¿AÂ–Ø—³’jA•Ÿ–{‹`OA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŽO‰Y@—TAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸAa’JŽ‹MFŒŽ”­«•›bó‘B‹@”\˜ŽiÇ‚ɍ‡•¹‚µ‚œS•s‘S‚̈ê—á.
The 20th Annual Scientific Meeting of the Japanese Vascular Biology and Medicine Organization (2012”N12ŒŽ5`7“úA“¿“‡)

ƒSymposium 1 : Heart Failure„

  1. Fukumoto Y, Tatebe S, Sugimura K, Shimokawa H. Prognostic impact of elevated pulmonary vascular resistance in patients with chronic heart failure.
  2. Noda K, Nakajima S, Fukumoto Y, Shimokawa H. Rho-kinase causes manifestations of metabolic syndrome through AMPK pathway inhibition in mice in vivo.
  3. Shimozu T, Fukumoto Y, Tanaka S, Satoh K, Shimokawa H. Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice.
‘æ16‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2012”N11ŒŽ30“ú`12ŒŽ2“úAå‘äj

ƒ‰ï’·u‰‰„

  1. ‰ºìG–ŸF‹}‘¬‚ɕω»‚·‚é‚킪‘‚̐S•s‘S‚ÌŽÀ‘Ԃƍ¡Œã‚Ì“W–].
    \“Œ“ú–{‘åkÐ‚©‚ç‚Ì‹³ŒP\

ƒSpecial Symposium 1 : Disaster and Heart Failure„

  1. Aoki T, Fukumoto Y, Yasuda S, Sakata Y, Ito K, Takahashi J, Shimokawa H. Increased incidence of heart failure in the East Japan Earthquake. J Cardiac Failure. 18(Suppl. 1):S123,2012.

ƒSpecial Symposium 2 : Chronic Stress, Radiation Injury and Heart Failure„

  1. Fukuda K, Nakano M, Wakayama Y, Kondo M, Kawana A, Hasebe Y, Shafee MA, Shimokawa H. Adverse impacts of the Great East Japan Earthquake in patients with chronic heart failure treated with cardiac resynchronization therapy. J Cardiac Failure. 18(Suppl. 1):S125,2012.

ƒS1-2 : Present Status of Heart Failure Pandemic -Rapid Aging Society and Heart Failure-„

  1. Sakata Y, Nochioka K, Miura M, Takada T, Miyata S, Takahashi J, Fukumoto Y, Shiba N, Shimokawa H. Clinical presentation of heart failure in the elderly: Insight from the CHART-2 Study- J Cardiac Failure. 18(Suppl. 1):S126,2012.

ƒSymposium 3 : How to Manage Inreasing Risk Factors of Heart Failure„

  1. Sakata Y, Nochioka K, Miura M, Takada T, Miyata S, Takahashi J, Fukumoto Y, Shiba N, Shimokawa H. Etiology of hypertensive heart failure: Insight from the CHART-2 Study. J Cardiac Failure. 18(Suppl. 1):S128,2012.

ƒSymposium 5 : Pulmonary Hypertension and Right Heart Failure„

  1. Sugimura K, Fukumoto Y, Satoh K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimokawa H. Percutaneous transluminal pulmonary angioplasty markedly ameliorates severe right heart failure in patients with distal-type chronic thromboembolic pulmonary hypertension. J Cardiac Failure. 18(Suppl. 1):S131,2012.

ƒSymposium 6 : Pathogenesis and Treatment of Diastolic Heart Failure„

  1. Fukumoto Y, Tatebe S, Sugimura K, Miura Y, Nochioka K, Aoki T, Yamamoto S, Shimokawa H. Prognostic impact of pulmonary circulation in patients with left ventricular diastolic dysfunction.

ƒSymposium 13 : Inceasing Importance of Cardiac Rehabilitation„

  1. Matsumoto Y, Shimokawa H. Primary prevention of heart failure: Potential important role of physical exercise.

ƒYIA Session : Clinical Study„

  1. Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura Y, Shimokawa H. Prognostic impact of increased heart rate on heart failure with preserved ejection fraction.

ƒYIA Session : Co-medical Session„

  1. Ito D, Ito O, Mori N, Suda C, Hao K, Cao P, Muroya Y, Takashima K, Shimokawa H, Kohzuki M. Effect of exercise training on nitric oxide synthase in the cardiovasculture and kidney of rats with chronic heart failure. J Cardiac Failure. 18(Suppl. 1):S147,2012.

ƒˆê”ʉ‰‘è : Œû‰‰”­•\„

  1. Zhulanqiqige Do E, Fukumoto Y, Sugimura K, Miura Y, Tatebe S, Yamamoto S, Aoki T, Nochioka K, Satoh K, Shimokawa H. Rho-kinase activity in circulating leukocytes as a novel biomarker of heart failure. J Cardiac Failure. 18(Suppl. 1):S149,2012.
  2. Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Shimokawa H. Etiology and predictive factors of de novo heart failre in Stage-B asymptomatic patients -Insight from the CHART-2 Study- J Cardiac Failure. 18(Suppl. 1):S149,2012.
  3. Nochioka K, Sakata Y, Miyata S, Miura Y, Takada T, Takahashi J, Fukumoto Y, Shimokawa H. Post-traumatic stress disorder after the Fukushima Daiichi nuclear plant disaster in patients with cardiovascular diseases -The CHART-2 Study- J Cardiac Failure. 18(Suppl. 1):S150,2012.
  4. ŽOŒŽL”üA›’J–ƒ—R”üAâ“c‘וFA‹{“c@•qAŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‚“c„ŽjA‚‹Ž@A‰ºìG–ŸF“Œ–k‘åŠw•a‰@‚É‚š‚¯‚éCHART-2’ǐՒ²ž‚ÌŽæ‚è‘g‚Ý
  5. Nochioka K, Sakata Y, Takahashi J, Miura M, Takada T, Fukumoto Y, Miyata S, Shimokawa H. Prevalence of post-traumatic stress disorder after the Great East Japan Earthquake in patients with cardiovascular diseases -The CHART-2 Study- J Cardiac Failure. 18(Suppl. 1):S154,2012.
  6. Tatebe S, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Yamamoto S, Shimokawa H. Clinical profiles of chronic heart failure with adult congenital heart disease. J Cardiac Failure. 18(Suppl. 1):S156,2012.
  7. Nakayama M, Takahashi J, Ito K, Matsumoto Y, Ito Y, Tsuburaya R, Shiroto T, Takagi Y, Hao K, Shimokawa H. Cessasion of spironolactone worsens long-term prognosis of heart failure patients. J Cardiac Failure. 18(Suppl. 1):S158,2012.
  8. Miura Y, Fukumoto Y, Sugimura K, Sato K, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimokawa H. Effects of corticosterol therapy on long-term survival of patients with cardiac sarcoidosis. J Cardiac Failure. 18(Suppl. 1):S158,2012.
  9. Hasebe S, Fukuda K, Kawana A, Shafee MA, Kondo M, Nakano M, Wakayama Y, Shimokawa H. The characteristics of ventricular tachycardia in familial dilated cardiomyopathy with Lamin A/C gene mutation. J Cardiac Failure. 18(Suppl. 1):S159,2012.
  10. Tatebe S, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Yamamoto S, Oikawa-Wakayama M, Kagaya Y, Shimokawa H. Prognostic impact of enhanced [18F]Fluorodeoxyglucose accumulation in the right ventricular free wall in patients with pulmonary hypertension. J Cardiac Failure. 18(Suppl. 1):S162,2012.
  11. Hao K, Takahashi J, Tsuburaya R, Shiroto T, Ito Y, Matsumoto Y, Nakayama M, Ito K, Yasuda S, Shimokawa H. Influence of coexisting heart failure on non-performance of primary percutaneous coronary intervention in patients with acute myocardial infarction. J Cardiac Failure. 18(Suppl. 1):S163,2012.
  12. Suzuki K, Matsumoto Y, Takahashi J, Tsuburaya R, Ito Y, Sugimura K, Nakayama M, Ito K, Fukumoto Y, Shimokawa H. No increase in the incidence of Takotsubo cardiomyopathy after the Great East Japan Earthquake. J Cardiac Failure. 18(Suppl. 1):S163,2012.
  13. Shafee MA, Fukuda K, Wakayama Y, Nakano M, Kondo M, Hasebe Y, Kawana A, Shimokawa H. Delayed enhancement on cardiac magnetic resonance imaging is a poor prognostic marker in patients with cardiac sarcoidosis. J Cardiac Failure. 18(Suppl. 1):S165,2012.
  14. Wakayama Y, Fukuda K, Nakano M, Kondo M, Shafee AS, Kawana A, Hasebe Y, Shimokawa H. Efficacy of cardiac resynchronization therapy in patients with a relatively narrow QRS complex. J Cardiac Failure. 18(Suppl. 1):S165,2012.
  15. Miura M, Sakata Y, Nochioka K, Takada T, Miyata S, Takahashi J, Shiba N, Shimokawa H. Stratification of the mortality risk according to heart rate and systolic blood pressure in heart failure patients. J Cardiac Failure. 18(Suppl. 1):S165,2012.

ƒˆê”ʉ‰‘è : ƒ|ƒXƒ^[”­•\„

  1. Kondo M, Fukuda K, Wakayama Y, Nakano M, Kawana A, Hasebe Y, Shafee MA, Shimokawa H. Diagnostic usefulness of an implantable loop recorder in a patient with repetitive syncope due to paroxysmal complete atrioventricular block. J Cardiac Failure. 18(Suppl. 1):S167,2012.
  2. Nakano M, Fukuda K, Wakayama Y, Kondo M, Hasebe Y, Shafee MA, Kawana A, Shimokawa H. A case of successful radiofrequency catheter ablation for amiodarone-resistant atrial tachycardia-induced cardiomyopathy. J Cardiac Failure. 18(Suppl. 1):S168,2012.
  3. Tsuburaya R, Takahashi J, Ito Y, Takagi Y, Matsumoto Y, Nakayama M, Ito K, Shimokawa H. Acute heart failure caused by biventricular involvement of Takotsubo cardiomyopathy. J Cardiac Failure. 18(Suppl. 1):S177,2012.
  4. Hanawa K, Ito K, Aizawa K, Shindo T, Nishimiya K, Hasebe Y, Hasegawa H, Yasuda S, Kanai H, Shimokawa H. Low-intesity pulsed ultrasound induces angiogenesis and ameliorates left ventricular dusfunction in a porcine model of chronic myocardial ischemia. J Cardiac Failure. 18(Suppl. 1):S180,2012.
  5. Kawana A, Hasebe Y, Kondo M, Nakano M, Shafee MA, Wakayama Y, Fukuda K, Shimokawa H. Effectiveness of emergent CRT-D treatment in a case with intractable severe ischemic heart failure. J Cardiac Failure. 18(Suppl. 1):S180,2012.
  6. Miura Y, Fukumoto Y, Sugimura K, Sato K, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimokawa H. A rare case with fatal pulmonary tumor thrombotic microangiopathy. J Cardiac Failure. 18(Suppl. 1):S184,2012.
  7. Yaoita N, Fukumoto Y, Shimokawa H. Resistance to fibrinolysis in patients with chronic thromboembolic pulmonary hypertension. J Cardiac Failure. 18(Suppl. 1):S187,2012.
  8. Shimizu T, Tanaka S, Sato K, Fukumoto Y, Shimokawa H. Crucial role of ROCK2 in vascular smooth muscle cells in hypoxia-induced pulmonary hypertension in mice. J Cardiac Failure. 18(Suppl. 1):S189,2012.
‘æ1‰ñ“ú–{”xzŠÂŠw‰ïŠwpW‰ïi2012”N9ŒŽ22“úA“Œ‹žj

ƒƒXƒ|ƒ“ƒT[ƒhƒVƒ“ƒ|ƒWƒEƒ€2F”x‚ŒŒˆ³Ç‚ÌŽ¡—ÁFÅV‚Ì’mŒ©„

  1. •Ÿ–{‹`OAŽì—–‘Ž‘ŽŠiA™‘ºGˆê˜YA‰ºìG–ŸFRhoƒLƒi[ƒ[Œo˜H‚š‚æ‚Ñ”x“®–¬Œ`¬p.

ƒˆê”ʉ‰‘èFŒû‰‰„

  1. Œš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YA²“¡Œö—YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽR–{¹DA‰ºìG–ŸF¶SŒnSŽŸŠ³‚É‚æ‚é”x‚ŒŒˆ³Ç‚̗Տ°“I“Á’¥‚Æ—\Œã.
  2. Â–Ø—³’jA™‘ºGˆê˜YA•Ÿ–{‹`OA²“¡Œö—YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸF”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚œCombined pulmonary fibrosis and emphysema syndrome (CPFE)‚Ì3Ç—á.
  3. ²“¡Œö—YA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TAÂ–Ø—³’jAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DAŽ…@‹œA‰ºìG–ŸFŽ_‰»ƒXƒgƒŒƒX•ª”å’`”’Cyclophylin A‚É‚æ‚é”x‚ŒŒˆ³‘£i‹@\@\Rho-kinaseŒn‚ÌŠÖ—^\
  4. Œš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YA²“¡Œö—YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽR–{¹DA‰ºìG–ŸFŒõ’f‘wŽB‘œ–@‚ð—p‚¢‚œ”x‚ŒŒˆ³Ç‚̊ӕʐf’f‚Ì—L—p«.
  5. ™‘ºGˆê˜YA•Ÿ–{‹`OA²“¡Œö—YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸF––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚Ì—\Œã‚É‚š‚¯‚éŒø‰Ê.
  6. ”ªŠªd—YAˆÀ“¡‘ŸŽOA•Ÿ–{‹`OA”óŒû‹`˜YA‰ºìG–ŸF”x¶ŒŸf’f‚É‚æ‚éCTEPHŒŒð“à–Œ”—£p‚Ì—\Œã”»’è‚ɂ‚¢‚Ä.

ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  1. ŽO‰Y@—TA•Ÿ–{‹`OA™‘ºGˆê˜YA²“¡Œö—YAŒã‰ªL‘Ÿ˜YAŽR–{¹DAŒš•”r‰îA‰ºìG–ŸF”x‚ŒŒˆ³Ç‹}«Šú‚ÉNO‹z“ü‚Å”x…Žî‚ª‹N‚«‚œˆê—á.
  2. ŽO‰Y@—TA•Ÿ–{‹`OA™‘ºGˆê˜YA²“¡Œö—YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸFPCPS“±“ü‚É‚Ä‚à‹~–œo—ˆ‚È‚©‚Á‚œdÇ”x‚ŒŒˆ³ÇFpulmonary tumor trombotic microangiopathy (PTTM)‚̈ê—á.
  3. Œš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YA²“¡Œö—YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽR–{¹DA‰ºìG–ŸF”x“®–¬‹·ó‚ð‡•¹‚µ‚œ‘å“®–¬‰ŠÇŒóŒQ‚É—Œ‘€”x“®–¬ƒoƒCƒpƒXŽ{sŒãAÄ‹·ó‚ɑ΂µ”x“®–¬ƒXƒeƒ“ƒg—¯’u‚ª—LŒø‚Å‚ ‚Á‚œ1—á.

ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  1. •Ÿ–{‹`OA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DAÂ–Ø—³’jAŒã‰ªL‘Ÿ˜YA²“¡Œö—YA‰ºìG–ŸF”x‚ŒŒˆ³Ç‚̉摜f’f‚ÉŠÖ‚·‚éÅ‹ß‚Ì’mŒ©FOCTŠŒ©.
‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2012”N9ŒŽ14`16“úA‹à‘òj

ƒ“Á•ÊŠé‰æFÐŠQ‚ƏzŠÂŠíŽŸŠ³„

  1. ‰ºìG–ŸF‘åŠw•a‰@zŠÂŠí“à‰Èˆã‚Ì—§ê‚©‚ç

ƒYIA‘Il‰ï„

  1. Â–Ø—³’jA•Ÿ–{‹`OAˆÀ“c@‘AˆÉ“¡Œ’‘ŸA‚‹Ž@A’ҁ@ˆê˜YA‰ºìG–ŸFThe Great East Japan Earthquake Disaster and Cardiovascular Diseases.

ƒƒVƒ“ƒ|ƒWƒEƒ€2FƒXƒeƒ“ƒg—¯’uŒã‚Ì’·ŠúŠÇ—„

  1. ˆÀ“c@‘A‚‹Ž@AŒ–{‘׎¡A‰ºìG–ŸF–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚ÌŒŒŠÇ‹@”\.

ƒƒVƒ“ƒ|ƒWƒEƒ€3„

  1. ’·’J•”—Y”òA•Ÿ“c_“ñAŽR–{—T˜NA‹ß“¡³‹PA’†–ì@œAŽáŽR—TŽiA‰ºìG–ŸFÕŒ‚”g‚ð—˜—p‚µ‚œV‹KƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ƒVƒXƒeƒ€‚ÌŠJ”­.

ƒƒVƒ“ƒ|ƒWƒEƒ€6„

  1. Œ–{‘׎¡AVolker AdamsA‰ºìG–ŸFSŒŒŠÇ•a‚É‚š‚¯‚é‰^“®—Ö@‚̐V‚œ‚È—LŒø«‚Æ‚»‚Ì•ªŽq‹@˜FˆêŽŸ—\–h‚ðÅ“_‚É.

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“1Fæ“V«SŽŸŠ³C•œpŒã‚ÌŠÇ—F¬Ž™‚©‚琬l‚܂Ł„

  1. Œš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YA²“¡Œö—YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŽR–{¹DA‰ºìG–ŸFS“àC•œpŒã‚É”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚œ¬læ“V«SŽŸŠ³Š³ŽÒ‚̗Տ°‘œ.

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“3FSŒŒŠÇŽŸŠ³‚ÆCKD„

  1. ŽO‰Y³’šAŽÄ@MsA‚‹Ž@AŒã‰ªL‘Ÿ˜YA‚“c„ŽjAµ‰ãçtA›’J–ƒ—R”üAâ“c‘וFA‰ºìG–ŸFS•s‘S‚É‚š‚¯‚é”AŽŽŒ±Ž†–@‚É‚æ‚éƒAƒ‹ƒuƒ~ƒ“”A„’è‚̈Ӌ`.

ƒˆê”ʉ‰‘èFŒû‰‰„

  1. ‚–Ø—S‰îA‚‹Ž@AˆÀ“c@‘A•ûN”ŽAZ‹g“OÆAŒã“¡•q˜aA“c•Ó‹±•FA––“cÍŽOA¬ì@‘A•S‘ºLˆêA¬ì‹v—YA‰ºìG–ŸFŠ¥¹k«‹·SÇ‚É‚š‚¯‚é—\Œã—\‘ªƒXƒRƒA‚ÌŠJ”­FŠ¥¹kŒ€‹†‰ï‘œŽ{Ý‹€“¯Œ€‹†‚©‚ç.
  2. “ñ•r‘Ÿ˜YA‚‹Ž@A‹e’n@—ƒA‚–Ø—S‰îA‰H”öŽ‹MA‰~’J—²Ž¡A”’ŒË@’AˆÉ“¡ˆ€„AŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸAˆÀ“c@‘A‰ºìG–ŸFŠ¥¹k«‹·SÇŠ³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐ‚̉e‹¿F––œŒŒD’†‹…RhoƒLƒi[ƒ[Šˆ«‚ÉŠî‚­ŽŸŠ³Šˆ“®«‚ÌŒŸ“¢.
  3. ™‘ºGˆê˜YA•Ÿ–{‹`OA²“¡Œö—YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸF––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‘OŒã‚É‚š‚¯‚éŒõŠ±Â’f‘w–@‚É‚æ‚é”x“®–¬•a•Ï‚Ì•]‰¿.
  4. ‚“c„ŽjAŽÄ@MsAâ“c‘וFA‚‹Ž@AŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA›’J–ƒ—R”üA‰ºìG–ŸF–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚鍂”AŽ_ŒŒÇ‚ÆRAAŒn‚ÌŠÖ˜A‚ɂ‚¢‚Ă̍lŽ@.
  5. •Ÿ–{‹`OAÂ–Ø—³’jA™‘ºGˆê˜YA‰ºìG–ŸFŠ¥“®–¬ŒŒ—¬áŠQ‚É‚š‚¯‚é”÷¬Š¥“®–¬ŽüˆÍüˆÛ‰»‚ÌŠÖ—^.
  6. ²“¡Œö—YA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‚–Ø—S‰îA‰~’J—²Ž¡AˆÉ“¡ˆ€„AŒ–{‘׎¡A’†ŽR‰ë°A‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFŒŒŸ÷ƒTƒCƒNƒƒtƒBƒŠƒ“A‚ÌŠ¥“®–¬ŽŸŠ³f’f‚É‚š‚¯‚é—L—p«.
  7. ‰H”öŽ‹MA‚‹Ž@A“ñ•r‘Ÿ˜YA‚–Ø—S‰îA‰~’J—²Ž¡A”’ŒË@’AˆÉ“¡ˆ€„AŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸAˆÀ“c@‘A‰ºìG–ŸF‹}«S‹Ø[ÇŠ³ŽÒ‚É‚š‚¯‚éPrimary PCI–¢Ž{s—á‚ÌŒŸ“¢@|‹{éŒ§S‹Ø[Ç‘΍ô‹Š‹c‰ï‚©‚ç‚Ì•ñ\

ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  1. ’†–ì@œA•Ÿ“c_“ñAŽáŽR—TŽiA‹ß“¡³‹PA’·’J•”—Y”òAì–Œ‹ÅŽqA‰ºìG–ŸFƒuƒ‹ƒKƒ_ÇŒóŒQÇ—á‚Æ“Á”­«SŽº×“®Ç—á‚̐S“d}Šw“I“Á’¥‚È‚ç‚Ñ‚É“d‹C¶—Šw“IŒŸž‚É‚š‚¯‚éSŽº×“®—U”­«‚ÉŠÖ‚·‚錟“¢.
  2. ‹ß“¡³‹PA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@œAì–Œ‹ÅŽqA’·’J•”—Y”òA‰ºìG–ŸFŠ®‘S–[ŽºƒuƒƒbƒN‚©‚çƒVƒ‡ƒbƒNó‘ԂɊׂè‹Ù‹}S‘ŸÄ“¯Šú—Ö@‚ð—v‚µ‚œdÇ‹•ŒŒ«S‹ØÇ‚̈ê—á.
  3. ˆÉ“¡ˆ€„A‚‹Ž@A‰H”öŽ‹MA‚–Ø—S‰îA‰~’J—²Ž¡A”’ŒË@’AŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸAˆÀ“c@‘A‰ºìG–ŸF‹}«S‹Ø[Ç”­Ç‚©‚çÄŸó—¬‚Ü‚Å‚ÌŽžŠÔŒo‰ß‚ÉŠÖ‚·‚鐫•ÊA”N—î•Ê‚Ì”äŠrŒŸ“¢@|‹{éŒ§S‹Ø[Ç‘΍ô‹Š‹c‰ï‚©‚ç‚Ì•ñ\
‘æ197‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2012”N9ŒŽ8“úAå‘äj
  1. ¬—Ñ‹P‘åC•Ÿ“c_“ñCŽáŽR—TŽiC’†–ì@œC‹ß“¡³‹PCì–Œ‹ÅŽqC’·’J•”—Y”òC²’|—m”VC‰ºìG–ŸFŠá•a•Ï‚ɑ΂·‚éƒXƒeƒƒCƒh’†Ž~Œã‚ɐf’f‚³‚ê‚œSƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì1—á
  2. ‚‹ŽG“¿CÂ–Ø—³’jC•Ÿ–{‹`OC™‘ºGˆê˜YCŒã‰ªL‘Ÿ˜YCŽO‰Y@—TCŒš•”r‰îCŽR–{¹DC‰ºìG–ŸFŒŽ”­«•›bó‘B‹@”\˜ŽiÇ‚ɍ‡•¹‚µ‚œS•s‘S‚Ì1—á
‘æ196‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2012”N6ŒŽ16“úAå‘äj
  1. £ì«lA•Ÿ–{‹`OA™‘ºGˆê˜YA²“¡Œö—YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸF‹Ù‹}¶‘Ì”xˆÚA‚ðŽ{s‚µ‚œ”x–э׌ŒŠÇŽîÇ‚Ì1—á.
  2. ™‘ºGˆê˜YA•Ÿ–{‹`OA²“¡Œö—YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸF––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚Ì—\Œã‚É‚š‚¯‚éŒø‰Ê.
‘æ65‰ñ“ú–{Ž_‰»ƒXƒgƒŒƒXŠw‰ïŠwpW‰ïi2012”N6ŒŽ7`8“úA“¿“‡j
  1. ²“¡Œö—YA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‚–Ø—S‰îAš¢’J—²Ž¡AˆÉ“¡ˆ€„A’†ŽR‰ë°A‚‹Ž@AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFV‹KŽ_‰»ƒXƒgƒŒƒXƒ}[ƒJ[‚̃TƒCƒNƒƒtƒBƒŠƒ“A‚ÌŠ¥“®–¬ŽŸŠ³f’f‚É‚š‚¯‚é—L—p«.
  2. –ì“cˆêŽ÷A×’J^‹IA’†“ˆ‘s‘ŸA‰ºìG–ŸFƒIƒ‹ƒƒTƒ‹ƒ^ƒ“‚ƃAƒ[ƒ‹ƒjƒWƒsƒ“‚Ì•¹—p—Ö@‚É‚æ‚é“œ”A•a”­ÇApoEŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚éR“®–¬d‰»ì—p‚ÌŒŸ“¢.
‘æ154‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2012”N6ŒŽ2“úA·‰ªj

ƒYIAÇ—á”­•\•”–偄

  1. Œã‰ªL‘Ÿ˜YA•Ÿ–{‹`OA™‘ºGˆê˜YA²“¡Œö—YAŽO‰Y@—TAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸAŒF’J‹Iˆê˜YAâV–؉ÀŽAŽR–{÷ŽiA•ŸŒŽ‹KŽqAÎàVŒ«ˆêA’£‘֏G˜YFSƒ^ƒ“ƒ|ƒi[ƒf‚Å”­Ç‚µAŠO‰È“IØœ‚ƏpŒã‰»Šw—Ö@‚É‚æ‚è’·Šú¶‘¶’†‚̐S‘ŸŒŽ”­ˆ««ƒŠƒ“ƒpŽî‚Ì1—á.
  2. ƒYIAŒ€‹†”­•\•”–åi—DGÜŽóÜj„

  3. “ñ•r‘Ÿ˜YA‚‹Ž@A‹e’r@—ƒA‚–Ø—S‰îA‰H”öŽ‹MAš¢’J—²Ž¡AˆÉ“¡ˆ€„AŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‰ºìG–ŸAˆÀ“c@‘FŠ¥¹k«‹·SÇŠ³ŽÒ‚É‚š‚¯‚é“Œ“ú–{‘åkÐ‚̉e‹¿@\RhoƒLƒi[ƒ[Šˆ«‚ÉŠî‚­ŽŸŠ³Šˆ“®«‚ÌŒŸ“¢\
  4. ƒˆê”ʉ‰‘聄

  5. ŽO‰Y³’šA‚“c„ŽjAŒã‰ªL‘Ÿ˜YA‚‹Ž@A‰ºìG–ŸAŽÄ@MsFSŒŒŠÇŽŸŠ³‚É‚š‚¯‚éŠà‚ÌŠù‰‚Æ—\Œã‚ÉŠÖ‚·‚錟“¢.
  6. š¢’J—²Ž¡A‚‹Ž@A“ñ•r‘Ÿ˜YA‚–Ø—S‰îAˆÉ“¡ˆ€„AŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‰ºìG–ŸF‘œŽ}Š¥¹k«‹·SÇ‚ð‡•¹‚µ‚œ‚œ‚±‚‚ڐS‹ØÇ‚̈ê—á.
  7. ˆÉ“¡ˆ€„A‚‹Ž@A“ñ•r‘Ÿ˜YA‰H”öŽ‹MA‚–Ø—S‰îAš¢’J—²Ž¡AŒ–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‰ºìG–ŸF“Á”­«Š¥“®–¬‰ð—£‚ª‘œ”­‚µ‘œÊ‚È‘¢‰eŠŒ©‚ð’悵‚œ‹}«S‹Ø[Ç‚̈ê—á.
  8. ì–Œ‹ÅŽqA’·’J•”—Y”òA‹ß“¡³‹PA’†–ì@œAŽáŽR—TŽiA•Ÿ“c_“ñA‰ºìG–ŸF‹Ù‹}S‘ŸÄ“¯Šú—Ö@‚ð—v‚µ‚œ‹•ŒŒ«S‹ØÇ‚̈ê—á.
  9. ‹g‰ªˆê˜NAì–{r•ãAâV–؉ÀŽA‚‹Ž@A‰ºìG–ŸFLerischeÇŒóŒQ‚𔺂Á‚œ‹•ŒŒ«S‹ØÇ‚ɑ΂·‚鍶ŽºŒ`¬p‚Ì1—á.
  10. ‘Ձ@“NAÂ–Ø—³’jA•Ÿ–{‹`OA‰ºìG–ŸF”÷¬Š¥“®–¬ŽüˆÍüˆÛ‰»‚ÌŠ¥“®–¬ŒŒ—¬áŠQ‚Ö‚ÌŠÖ—^.
  11. HŽR³”NAì–{r•ãAâV–؉ÀŽAHê”ü‹IA•Ð‹ËŒõ—tA•Ÿ“c_“ñA•Ÿ–{‹`OA‰ºìG–ŸFAž‚ÝŒ^•â•lHS‘Ÿ‚̏dÇS•s‘SŠO‰ÈŽ¡—Ã.
  12. ‘“cM–çA–{‹g’ŒFAHŽR³”NAì–{r•ãAâV–؉ÀŽA²“¡Œö—YA•Ÿ–{‹`OA‰ºìG–ŸFCalcified amorphous tumor‚̈êŽèp—á.
  13. Â–Ø—³’jA™‘ºGˆê˜YA•Ÿ–{‹`OA²“¡Œö—YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸF”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚œCombined Pulmonary Fibrosis and Emphysema Syndrome (CPFE)‚Ì3Ç—á.
  14. Â–Ø—³’jA²“¡Œö—YA™‘ºGˆê˜YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAŒš•”r‰îAŽR–{¹DA•Ÿ–{‹`OAŠ}“‡“ÖŽqFdÇ”x‚ŒŒˆ³Ç‚𗈂µ‚œpulmonary tumor thrombotic microangiopathy (PTTM)‚̈ê—á.
  15. ™‘ºGˆê˜YA•Ÿ–{‹`OA²“¡Œö—YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸF––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚š‚¯‚éŒo”ç“I”x“®–¬Œ`¬p‚̍œK•a•Ï‚ÌŒŸ“¢.
  16. ‰Í‘ºŒ\ˆê˜YA‹ÚàV@ŒºA²“¡@¬A—¢Œ©@iAˆÉ“¡Œ’‘ŸA‰ºìG–ŸFŠÔŒ‡«æês‚ð—L‚·‚é––œ“®–¬ŽŸŠ³Š³ŽÒ‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Ã.
  17. ‹ß“¡³‹PA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@œAì–Œ‹ÅŽqA’·’J•”—Y”òA‰ºìG–ŸFA‚Šž‚ÝŒ^ƒ‹[ƒvƒŒƒR[ƒ_[‚ŐS’âŽ~ƒCƒxƒ“ƒg‚𓯒肵‚œˆê—á.
  18. ‹ß“¡³‹PA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@œAì–Œ‹ÅŽqA’·’J•”—Y”òA‰ºìG–ŸFŠJSpŒãS–[•p”‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ÌŒŸ“¢.
  19. ’†–ì@œA•Ÿ“c_“ñAŽáŽR—TŽiA‹ß“¡³‹PA’·’J•”—Y”òAì–Œ‹ÅŽqAƒ‚ƒnƒƒhƒVƒƒƒtƒB[A‰ºìG–ŸFƒuƒ‹ƒKƒ_ÇŒóŒQ‚Æ“Á”­«SŽº×“®‚̐S“d}Šw“I“Á’¥‚È‚ç‚тɐSŽº×“®—U”­«‚ÉŠÖ‚·‚錟“¢.
‘æ10‰ñ“ú–{—\–hˆãŠwƒŠƒXƒNƒ}ƒl[ƒWƒƒ“ƒgŠw‰ïŠwp‘‰ïi2012”N4ŒŽ26“úAŽD–yj

ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[FkÐ‚ƏzŠÂŠíŽŸŠ³„

  1. ‰ºìG–ŸF“Œ“ú–{‘åkÐ‚ƏzŠÂŠíŽŸŠ³.
‘æ76‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2012”N3ŒŽ16`18“úC•Ÿ‰ªj

ƒLate Breaking Clinical Trials 3-3„

  1. Shimokawa H, Aoki T, Fukumoto Y. The East Japan Earthquake Disaster and cardiovascular diseases. Circ J 76(Suppl I):I-542,2012.
  2. ƒLuncheon Sminar„

  3. ‰ºìG–ŸFƒXƒeƒ“ƒg—¯’uŒã‚ÌŠ¥¹k‚ð”@‰œ‚É–h‚®‚©@|–òÜ—no«ƒXƒeƒ“ƒg—¯’uÇ—á‚Ì—\Œã‰ü‘P‚ðŒ©˜‚Š‚œŠ¥“®–¬•ÛŒìí—ª|
  4. ƒFireside Seminar : IHE‚Á‚ĉœH@Œ©‚Š‚éA‚‚Ȃª‚éIzŠÂŠí—̈æ‚̈ã—Ïî•ñ„

  5. ’†ŽR‰ë°:—Տ°ˆã‚ªIHE‚ÉŠú‘Ò‚·‚邱‚ƁEEE‰œ‚ª‚Å‚«‚é‚©A‰œ‚ð‚·‚×‚«‚©
  6. ƒFireside Seminar : Š¥¹k‚̐V‚œ‚È“WŠJ„

  7. ‚–Ø—S‰îA‰ºìG–ŸFŠ¥¹k‚ð‡•¹‚µ‚œ‰@ŠOS’âŽ~—á‚É‚š‚¯‚éICD‚Ì—LŒø«‚ÌŒŸ“¢]Š¥¹kŒ€‹†‰ï‚š‚æ‚Ñ“Œ–k‘åŠw‚Ì’mŒ©]
  8. ƒAsian Joint Case-Conference 2 : Malaysia and Japan (AJC2) (CAD)„

  9. Sugimura K, Fukumoto Y, Satoh K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimokawa H. Effects of percutaneous transluminal pulmonary angioplasty in patients with distal-type chromic thromboembolic pulmonary hypertension. Circ J 76(Suppl I):I-100,2012.
  10. ƒSymposium : Recent Progress in the Treatment of Pulmonary Hypertension„

  11. Fukumoto Y, Sugimura K, Zhulan Qiqige, Yamamoto S, Tatebe S, Aoki T, Nochioka K, Miura Y, Satoh K, Shimokawa H. Recent progress in the management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Circ J 76(Suppl I):I-266,2012.
  12. ƒSymposium : Diagnosis of Heart Failure Using Genetic Biomarker„

  13. Zhulan Qiqige, Fukumoto Y, Sugimura K, Miura Y, Yamamoto S, Tatebe S, Aoki T, Nochioka K, Satoh K, Shimokawa H. Rho-kinase activity in circulating leukocytes as a novel biomarker in patients with chronic heart failure. Circ J 76(Suppl I):I-199,2012.
  14. ƒSymposium : Management of Congenital Heart Disease Long-term After Repair„

  15. Tatebe S,Fukumoto Y, Sugimura K, Yamamoto S, Aoki T, Nochioka K, Miura Y, Sato K, Shimokawa H. Clinical characteristics and long-term prognosis of patients with adult congenital heart disease associated with pulmonary arterial hypertension after intra-cardiac repair. Circ J 76(Suppl I):I-238,2012.
  16. ƒSymposium : Gender-specific Medicine in Cardiovascular Disease: Current Status and Future Perspectives„

  17. Kawana A, Yasuda S, Takagi Y, Takahashi J, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanabe Y, Sueda S, Satoh T, Ogawa S, Kubo N, Momomura S, Ogawa H, Shimokawa H. Gender differences in clinical characteristics and outcomes of patients with vasospastic angina -a report from the japanese coronary spasm association-. Circ J 76(Suppl I):I-24,2012.
  18. ƒFeatured Research Session„

  19. Miura M, Shiba N, Takahashi J, Nochioka K, Takada T, Kohno H, Sugaya M, Shimokawa H. Prognostic impact of albuminuria combined with egfr in hrpef patients -an interim analysis of the chart-2 study-. Circ J 76(Suppl I):I-658,2012.
  20. Shimizu T, Tanaka S, Satoh K, Fukumoto Y, Shimokawa H. ROCK2 in vascular smooth muscle cells plays a crucial role for hypoxia-induced pulmonary hypertension in mice. Circ J 76(Suppl I):I-641,2012.
  21. Sugimura K, Fukumoto Y, Satoh K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimokawa H. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with distal-type chronic thromboembolic pulmonary hypertension. Circ J 76(Suppl I):I-644,2012.
  22. Tatebe S, Fukumoto Y, Sugimura K, Satoh K, Miura Y, Nochioka K, Aoki T, Yamamoto S, Shimokawa H. Usefulness of optical coherence tomography in diagnosis of distal-type chronic thromboembolic pulmonary hypertension -comparison with intravascular ultrasound-. Circ J 76(Suppl I):I-625,2012.
  23. Nihei T, Takagi Y, Takahashi J, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanbae Y, Ogawa H, Shimokawa H. Age-dependent differences in clinical characteristics and outcomes of patients with vasospastic angina -a report from the Japanese coronary spasm association-. Circ J 76(Suppl I):I-582,2012.
  24. ƒˆê”ʉ‰‘è : Œû‰‰”­•\„

  25. Aoki T, Fukumoto Y, Sugimura K, Satoh K, Miura Y, Nochioka K, Tatebe S, Yamamoto S, Shimokawa H. Increased incidence of heart failure in the East Japan Earthquake Disaster. Circ J 76(Suppl I):I-907,2012.
  26. Hasebe Y, Fukuda K, Yamamoto H, Kondoh M, Mohamed Abdel-Shafee, Nakano M, Wakayama Y, Shimokawa H. Development of a novel shock wave catheter ablation system. Circ J 76(Suppl I):I-1086,2012.
  27. Matsumoto Y, Volker A, Fukumoto Y, Shimokawa H. Regular exercise prevents the development and rupture of aortic aneurysm by inhibiting oxidative stress and proteolysis in mice. Circ J 76(Suppl I):I-852,2012.
  28. Miura M, Shiba N, Takahashi J, Nochioka K, Takada T, Kohno H, Sugaya M, Shimokawa H. Heart rate control is important even in heart failure patients with low blood pressure. Circ J 76(Suppl I):I-880,2012.
  29. Nakano M, Wakayama Y, Kawana A, Hasebe Y, Mohamed Abdel Shafee, Kondoh M, Fukuda K, Shimokawa H. Deterioration of heart failure after the East Japan Earthquake Disaster in patients with cardiac resynchronization therapy. Circ J 76(Suppl I):I-905,2012.
  30. Nihei T, Takahashi J, Kikuchi Y, Itoh Y, Nakayama M, Tsuburaya R, Ohhashi J, Takagi Y, Itoh K, Yasuda S, Shimokawa H. Increased rho-kinase activity in patients with vasospastic angina after the East Japan Earthquake Disaster. Circ J 76(Suppl I):I-1050,2012.
  31. Nochioka K, Shiba N, Takahashi J, Miura M, Takada T, Shimokawa H. Nutritional status score (CONUTS) is a useful prognostic marker in stage-b heart failure patients; interim analysis of the CHART-2 study. Circ J 76(Suppl I):I-941,2012.
  32. Noda K, Nakajima S, Ohhashi J, Fukumoto Y, Tsutsui M, Shimokawa H. rho-kinase as a novel therapeutic target of metabolic syndrome. Circ J 76(Suppl I):I-1189,2012.
  33. Satoh K, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Osaki S, Takagi Y, Tsuburaya R, Itoh Y, Matsumoto Y, Nakayama M, Takeda M, Takahashi J, Itoh K, Yasuda S, Shimokawa H. Plasma cyclophilin a level is a novel biomarker of coronary artery disease. Circ J 76(Suppl I):I-763,2012.
  34. Satoh K, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimizu T, Nakamura K, Itoh H, Shimokawa H. Cyclophilin A plays an important role in the pathogenesis of pulmonary arterial hypertension in humans -involvement of rho-kinase pathway-. Circ J 76(Suppl I):I-1368,2012.
  35. Suzuki H, Sumiyoshi A, Kawashima R, Shimokawa H. Different brain activation under the left and the right ventricular stimulation: evidence from functional magnetic resonance imaging study in rats. Circ J 76(Suppl I):I-1037,2012.
  36. Takada T, Shiba N, Takahashi J, Nochioka K, Miura M, Shimokawa H. Low systolic blood pressure is associated with poor prognosis of stage-b heart failure patients -a report from the CHART-2 study-. Circ J 76(Suppl I):I-878,2012.
  37. Takada T, Shiba N, Takahashi J, Nochioka K, Miura M, Shimokawa H. Importance of heart rate control in chronic heart failure patients receiving diuretics -an interim analysis of the CHART-2 study-. Circ J 76(Suppl I):I-1203,2012.
  38. Takagi Y, Takahashi J, Nihei T, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanbae Y, Ogawa H, Shimokawa H. Clinical implications of coronary spasm provocation tests -multicenter registry study of the Japanese Coronary Spasm Association-. Circ J 76(Suppl I):I-745,2012.
  39. Takagi Y, Takahashi J, Nihei T, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanbae Y, Ogawa H, Shimokawa H. Novel clinical risk score for prediction of cardiac events in VSA patients -a report from the Japanese Coronary Spasm Association-. Circ J 76(Suppl I):I-1090,2012.
  40. ƒˆê”ʉ‰‘è : ƒ|ƒXƒ^[”­•\„

  41. Abe Y, Itoh K, Hao K, Shimokawa H. Effects of low-energy shock wave therapy on dynamics of inflammatory cells after acute myocardial infarction in rats. Circ J 76(Suppl I):I-2774,2012.
  42. Aoki T, Fukumoto Y, Sugimura K, Satoh K, Miura Y, Nochioka K, Tatebe S, Yamamoto S, Shimokawa H. Increased incidence of infectious endocarditis in the East Japan Earthquake Disaster. Circ J 76(Suppl I):I-2312,2012.
  43. Budbazar Enkhjargal, Noda K, Nakajima S, Ohhashi J, Shimokawa H. Vasoconstrictor-induced relaxation is mediated by endothelium-derived hyperpolarizing factor in the coronary artery in mice. Circ J 76(Suppl I):I-1886,2012.
  44. Hanawa K, Itoh K, Aizawa K, Nishimiya K, Hasebe Y, Junyi Gao, Hasegawa H, Yasuda S, Kanai H, Shimokawa H. Low-intensity pulsed ultrasound induces angiogenesis and ameliorates left ventricular dysfunction in a porcine model of chronic myocardial ischemia. Circ J 76(Suppl I):I-1847,2012.
  45. Hao K, Yasuda S, Takii T, Itoh Y, Takahashi J, Itoh K, Shimokawa H. Different circadian variation in the onset of acute myocardial infarction between urban and rural areas; a report from MIYAGI-AMI registry. Circ J 76(Suppl I):I-1695,2012.
  46. Hao K, Yasuda S, Takii T, Itoh Y, Takahashi J, Itoh K, Shimokawa H. Difference in incidence and risk factors of acute myocardial infarction between the rural and urban areas in the Miyagi prefecture. Circ J 76(Suppl I):I-1698,2012.
  47. Itoh Y, Yasuda S, Takahashi J, Takagi Y, Ohhashi J, Tsuburaya R, Matsumoto Y, Takeda M, Nakayama M, Itoh K, Shimokawa H. Regional difference in emergency medical service and survival; analysis of the utstein data of out-of-hospital cardiac arrest in Miyagi prefecture. Circ J 76(Suppl I):I-2120,2012.
  48. Itoh Y, Yasuda S, Takahashi J, Itoh K, Takeda M, Nakayama M, Tsuburaya R, Ohhashi J, Takagi Y, Shimokawa H. Factors influencing the gender difference in the outcome of reperfusion therapy in patients with acute myocardial infarction. Circ J 76(Suppl I):I-2172,2012.
  49. Miura M, Shiba N, Takada T, Nochioka K, Hiramoto T, Inoue K, Tamaki K, Shimokawa H. Acute heart failure patients without b-type Natriuretic Peptide Evaluation at admission may correlate with higher in-hospital mortality. Circ J 76(Suppl I):I-2830,2012.
  50. Miura Y, Fukumoto Y, Sugimura K, Satoh K, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimokawa H. Current status of the management of cardiac sarcoidosis with a special reference to corticosteroid therapy. Circ J 76(Suppl I):I-2231,2012.
  51. Nakajima S, Ohhashi J, Sawada A, Noda K, Shimokawa H. Evidence for the important role of the bone marrow in modulating microvascular endothelial and metabolic functions in mice. Circ J 76(Suppl I):I-2377,2012.
  52. Nakayama M, Shimokawa H. Clinical factors that impede the accuracy of the seattle heart failure score. Circ J 76(Suppl I):I-2683,2012.
  53. Sugimura K, Fukumoto Y, Satoh K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimokawa H. Optical coherence tomography is useful for evaluation for percutaneous transluminal pulmonary angioplasty in patients with distal-type chronic thromboembolic pulmonary hypertension. Circ J 76(Suppl I):I-1841,2012.
  54. Takagi Y, Takahashi J, Nihei T, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanbae Y, Ogawa H, Shimokawa H. Prognostic impact of long-acting nitrate therapy in patients with vasospastic angina -a report from the Japanese Coronary Spasm Association-. Circ J 76(Suppl I):I-2184,2012.
  55. Tsuburaya R, Takahashi J, Takagi Y, Ohhashi J, Itoh Y, Matsumoto Y, Takeda M, Nakayama M, Itoh K, Yasuda S, Shimokawa H. Beneficial effects of a single prophylactic hemodialysis on renal function worsening after percutaneous coronary intervention in patients with severe CKD. Circ J 76(Suppl I):I-2651,2012.
  56. Wakayama Y, Kawana A, Hasebe Y, Mohamed Abdel Shafee, Kondoh M, Nakano M, Fukuda K, Shimokawa H. Limited effects of cardiac resynchronization therapy in heart failure patients with highly advanced left ventricular remodeling. Circ J 76(Suppl I):I-2578,2012.
‘æ195‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2012”N2ŒŽ18“úAå‘äj
  1. ™‘ºGˆê˜YC•Ÿ–{‹`OC²“¡Œö—YCŽO‰Y@—TCŒã‰ªL‘Ÿ˜YCÂ–Ø—³’jCŒš•”r‰îC‹{“¹¹DC‰ºìG–ŸF––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‘OŒã‚É‚š‚¯‚éŒõŠ±Â’f‘w–@‚É‚æ‚é”x“®–¬•a•Ï‚Ì•]‰¿
  2. —é–؁@•‘A²“¡Œö—Y, ™‘ºGˆê˜Y, ŽO‰Y@—T, Œã‰ªL‘Ÿ˜Y, Â–Ø—³’j, Œš•”r‰î, ŽR–{¹D, •Ÿ–{‹`O, ‰ºìG–ŸFPCPS“±“ü‚É‚Ä‚à‹~–œo—ˆ‚È‚©‚Á‚œdÇ”x‚ŒŒˆ³Ç: pulmonary tumor thrombotic microangiopathyiPTTM) ‚Ì‚P—á
‘æ41‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïŠwpW‰ïi2012”N2ŒŽ10`11“úCH“cj

ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  1. ‰ºìG–Ÿ : “à”ç—R—ˆ’oŠÉˆöŽq|Å‹ß‚Ì’mŒ©|

ƒˆê”ʉ‰‘聄

  1. Ž…@‹œC“c’†^ˆêC•Ÿ–{‹`OC‰ºìG–Ÿ : ”xŒŒŠÇƒŠƒ‚ƒfƒŠƒ“ƒO‚É‚š‚¯‚éROCK2‚Ì–ðŠ„|”x‚ŒŒˆ³ÇƒƒJƒjƒYƒ€‚̉𖟁|
  2. –ì“cˆêŽ÷C×’J^‹IC’†“ˆ‘s‘ŸC‘å‹ŽŽqC‰ºìG–Ÿ : ƒIƒ‹ƒƒTƒ‹ƒ^ƒ“‚ƃAƒ[ƒ‹ƒjƒWƒsƒ“‚Ì•¹—p—Ö@‚É‚æ‚é“œ”A•a”­ÇApoEŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚éR“®–¬d‰»ì—p‚ÌŒŸ“¢
  3. š¢’J—²Ž¡CˆÀ“c@‘C”’ŒË@’C‘ŠàVŒ’‘Ÿ˜YCˆÉ“¡ˆ€„CŒ–{‘׎¡C‚‹Ž@CˆÉ“¡Œ’‘ŸC‰ºìG–Ÿ : ’·ŽžŠÔì—pŒ^CahR–òƒjƒtƒFƒWƒsƒ“‚É‚æ‚é–òÜ—no«ƒXƒeƒ“ƒgA‚Šž‚ÝŒã‚ÌŒŒŠÇ•ÛŒìŒø‰ÊFRhoƒLƒi[ƒ[Œo˜H‚ÌŠÖ—^
  4. ’†“ˆ‘s‘ŸC‘å‹ŽŽqCàV“cˆŒŽqC–ì“cˆêŽ÷C‰ºìG–Ÿ : œ‘—R—ˆ×–E‚̓}ƒEƒX‚Ì”÷¬ŒŒŠÇ“à”ç‹@”\‚š‚æ‚Ñ‘Ï“œ”\§Œä‚É‚š‚¢‚ďd—v‚È–ðŠ„‚ð‰Ê‚œ‚µ‚Ä‚¢‚é
  5. ‚‹ŽŠì‹v‘ãCŒ–{‘׎¡C‹ààV³”́C‰ºìG–Ÿ : ƒXƒ^ƒ`ƒ“‚ƃJƒ‹ƒVƒEƒ€hR–ò‚Ì•¹—p—Ö@‚É‚æ‚é• •”‘å“®–¬áŽ”­Ç‚Ì—}§‚ɂ‚¢‚Ä‚ÌŒŸ“¢
‘æ31‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï“Œ–k’n•û‰ïi2012”N2ŒŽ4“úC·‰ªj
  1. ˆÉ“¡ˆ€„C‚‹Ž@C‚–Ø—S‰îCš¢’J—²Ž¡CŒ–{‘׎¡C’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‰ºìG–Ÿ : “Á”­«Š¥“®–¬‰ð—£‚ª‘œ”­‚µ‘œÊ‚È‘¢‰eŠŒ©‚ð’悵‚œ‹}«S‹Ø[Ç‚̈ê—á
‘æ5‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2012”N2ŒŽ4`5“úC“Œ‹žj
  1. Â–Ø—³’jC•Ÿ–{‹`OC‰ºìG–Ÿ : “Œ“ú–{‘åkÐ‚̐SŒŒŠÇ•a”­Ç‚ւ̉e‹¿F«·‚ÌŠÏ“_‚©‚çiÅ—DG‰‰‘èÜŽóÜj
  2. ‚“c„ŽjCŒã‰ªL‘Ÿ˜YCŽO‰Y³’šC›’J–ƒ—R”üC‚‹Ž@CŽÄ@MsC‰ºìG–Ÿ : –«S•s‘S‚Ì—\Œã‚ɐ«·‚ª‹y‚Ú‚·‰e‹¿
  3. ì–Œ‹ÅŽqC‚‹Ž@CˆÀ“c@‘C‚–Ø—S‰îCŠp“c—²•ãC•ûN”ŽCŠÖ@“ցCZ‹g“OÆCŒˆäŠ²”VCŒã“¡•q˜aC“c•Ó‹±•FC––“cÍŽOC‹v•Û“TŽjC•S‘ºLˆêC¬ì‹v—YC‰ºìG–Ÿ : Š¥¹k«‹·SÇ‚É‚š‚¯‚鐫·FŠ¥¹kŒ€‹†‰ï‚É‚š‚¯‚é’mŒ©
  4. ŽO‰Y³’šCŽÄ@MsC‚‹Ž@CŒã‰ªL‘Ÿ˜YC‚“c„ŽjC›’J–ƒ—R”üC‰ºìG–Ÿ : SŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é‰îŒì—\–h•K—v“x‚Ɛ«·‚ÉŠÖ‚·‚錟“¢@|CHART-2Œ€‹†‚É‚š‚¯‚é’mŒ©|

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2011”N
‘æ19‰ñ“ú–{ŒŒŠÇ¶•šˆãŠw‰ïŠwpW‰ïƒXƒyƒVƒƒƒ‹ƒCƒuƒjƒ“ƒOƒŒƒNƒ`ƒƒ[i2011”N12ŒŽ8“úC“Œ‹žj
  1. ‰ºìG–Ÿ : Ž‰Ž¿ˆÙíÇf—Â̐V‚œ‚È“WŠJ
  2. Nakajima S, Ohashi J, Sawada A, Noda K, Shimokawa H.@Evidence for the important role of the bone marrow in modulating microvascular endothelial responses and metabolic functions in mice.
  3. Noda K, Hosoya M, Nakajima S, Ohashi J, Shimokawa H.@Combination therapy with olmesartan and azelnidipine exerts anti-atherogenic effects in diabetic Apoliprotein E-deficient mice.
  4. Shimizu T, Satoh K, Tanaka S, Fukumoto Y, Shimokawa H.@ROCK2 in vascular smooth muscle cells plays a crucial role for hypoxia-induced pulmonary hypertension in mice.
  5. Satoh K, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Takagi Y, Tsuburaya R, Ito Y, Matsumoto M, Nakayama M, Takahashi J, Shimokawa H.@Plasm cyclophilin A is a novel predictor of coronary artery disease.
‘æ153‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2011”N12ŒŽ3“úCå‘äj

ƒYIAŒ€‹†”­•\•”–åÅ—DGÜ„

  1. ‹e’n@—ƒAˆÀ“c@‘A‘ŠàVŒ’‘Ÿ˜YAš¢’J—²Ž¡AˆÉ“¡ˆ€„A‘å‹ŽŽqA‚–Ø—S‰îA•“cŽç•FA’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‚‹Ž@A‰ºìG–ŸFŠ¥¹k«‹·SÇ‚̐f’f‚ƗՏ°•]‰¿‚É‚š‚¯‚éRhoƒLƒi[ƒ[Šˆ«‚̃oƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ä‚Ì—L—p«.

ƒYIAÇ—á”­•\•”–å—DGÜ„

  1. ‹ß“¡³‹PA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@œAì–Œ‹ÅŽqA’·’J•”—Y”òA‰ºìG–ŸFŽˆ‘ÌŒ^‹ØƒWƒXƒgƒƒtƒB[‚ɍ‡•¹‚µ‚œ”ñ’ʏíŒ^S–[‘e“®‚É‚æ‚èS‹@”\’ቺ‚ð‚«‚œ‚µ‚œˆê—á.

ƒˆê”ʉ‰‘聄

  1. š¢’J—²Ž¡A‚‹Ž@AˆÉ“¡ˆ€„A‚–Ø—S‰îA‘å‹ŽŽqA’†ŽR‰ë°AŒ–{‘׎¡A•“cŽç•FAˆÉ“¡Œ’‘ŸAˆÀ“c@‘A‰ºìG–ŸA–xŒû@‘F—ŒSŽº‚ŕlj^“®ˆÙí‚ª”F‚ß‚ç‚ê‚œƒ^ƒR‚‚ڌ^S‹ØÇ‚̈ê—á.
  2. ‚“c„ŽjA‚‹Ž@AŒã‰ªL‘Ÿ˜YAŽO‰Y³’šA‰ºìG–ŸAŽÄ@MsF—˜”A–ò“Š—^’†‚Ì–«S•s‘SŠ³ŽÒ‚É‚š‚¯‚éS””ŠÇ—‚̈Ӌ`.
  3. Œã‰ªL‘Ÿ˜YA‚‹Ž@AŽO‰Y³’šA‚“c„ŽjA‰ºìG–ŸAŽÄ@MsFCONUTƒXƒRƒAControlling Nutritional Statusj‚ð—p‚¢‚œStage-BS•s‘S‚̃ŠƒXƒN•]‰¿FCHART-2Œ€‹†.
  4. ì–{r•ãA‘“cM–çA‘’ÍKOAâV–؉ÀŽA‚‹Ž@A‰ºìG–ŸF–«“§ÍŠ³ŽÒ‚ɑ΂·‚éŠO‰ÈŽ¡—ЬÑ‰ü‘P‚Ì‚œ‚߂̗Տ°“I‰ðÍ.
  5. ‘å‹ŽŽqAŒ–{‘׎¡A‚‹Ž@A•“cŽç•FAˆÉ“¡Œ’‘ŸA’†ŽR‰ë°AˆÉ“¡ˆ€„Aš¢’J—²Ž¡A‚–Ø—S‰îA“ñ•r‘Ÿ˜YAˆÀ“c@‘A‰ºìG–ŸAì–{r•ãAâV–؉ÀŽA–kŒü@CA”öŒ`Œö•FF‹}«S‹Ø[ÇŒã‚Éblow-outŒ^S”j—ô‚ð‡•¹‚µ‹~–œŒã–«Šú¶Žº‰Œ«áŽŒ`¬‚Ì‚œ‚ߍĎèp‚ð—v‚µ‚œÇ—á.
  6. _ŒË–ΗYAŒ–{‘׎¡A‚‹Ž@Aš¢’J—²Ž¡AˆÉ“¡ˆ€„A‘å‹ŽŽqA‚–Ø—S‰îA•“cŽç•FA’†ŽR‰ë°AˆÉ“¡Œ’‘ŸA‰ºìG–ŸFŠ¥”÷¬ŒŒŠÇ¹k‚ð‡•¹‚µ‚œŠ¥¹k«‹·SÇ‚Ì1—á.
  7. ™‘ºGˆê˜YA•Ÿ–{‹`OA²“¡Œö—YAŽO‰Y@—TAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸA‹{–{‘ì–çA‹v•Û“c@Œ÷FŒo”ç“I”x“®–¬Œ`¬p‚É‚ÄPGI2Ž‘±Ã’—Ö@‚©‚ç—£’E‚µ‚Š‚œ–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̈ê—á.
  8. ŽO‰Y@—TA•Ÿ–{‹`OA™‘ºGˆê˜YA²“¡Œö—YAŒã‰ªL‘Ÿ˜YAÂ–Ø—³’jAŒš•”r‰îAŽR–{¹DA‰ºìG–ŸFNO‹z“ü‚Å‘ˆ«‚µ‚œ”xÃ–¬•ÂÇÇ(PVOD)‹^‚¢‚̈ê—á.
  9. ‘åÎW•œAÂ–Ø—³’jA™‘ºGˆê˜YA•Ÿ–{‹`OAŒã‰ªL‘Ÿ˜YAŽO‰Y@—TAŽR–{¹DAŒš•”r‰îA²“¡Œö—YA‰ºìG–ŸF‹CŽî‡•¹üˆÛÇ‚É”x‚ŒŒˆ³Ç‚𕹔­‚µ‚œˆê—á.
  10. Â–Ø—³’jA•Ÿ–{‹`OA™‘ºGˆê˜YAŒã‰ªL‘Ÿ˜YAŽO‰Y@—TAŽR–{¹DAŒš•”r‰îA²“¡Œö—YA‰ºìG–ŸF“Œ“ú–{‘åkÐ‚É‚š‚¯‚銎õ«S“à–Œ‰Š‚Ì‘‰Á.
  11. ’†–ì@œA•Ÿ“c_“ñAŽáŽR—TŽiA‹ß“¡³‹PA’·’J•”—Y”òAì–Œ‹ÅŽqA‰ºìG–ŸF‰EŽº—¬o˜H‹NŒ¹‚ª‹^‚í‚ê‚œ‚ª‘å“®–¬‰EŠ¥ë‚ł̏Ď܂ª—LŒø‚Å‚ ‚Á‚œSŽº«ŠúŠOŽûk‚̈ê—á.
  12. ì–Œ‹ÅŽqA’·’J•”—Y”òA‹ß“¡³‹PA’†–ì@œAŽáŽR—TŽiA•Ÿ“c_“ñA‰ºìG–ŸF‹NŒ¹EŽ¡—Õ”ˆÊ“¯’è‚ɏp‘OMRI‚ª—L—p‚Å‚ ‚Á‚œ¶Žº‘€•Ç‹NŒ¹SŽº•p”‚̈ê—á.
  13. ‹ß“¡³‹PA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@œAì–Œ‹ÅŽqA’·’J•”—Y”òA‰ºìG–ŸF“Œ“ú–{‘åkÐ‚É‚š‚¯‚éƒfƒoƒCƒXA‚Šž‚ÝŠ³ŽÒ‚Ì•s®–¬”­¶‚ÉŠÖ‚·‚錟“¢.
  14. Œã‰ªL‘Ÿ˜YA•Ÿ–{‹`OA™‘ºGˆê˜YA²“¡Œö—YAŽO‰Y@—TAŽR–{¹DAŒš•”r‰îAÂ–Ø—³’jA‰ºìG–ŸAHŽR³”NAì–{r•ãAâV–؉ÀŽAHê”ü‹IF•ÛŒ¯žŠÒ‚Æ‚È‚Á‚œA‚Šž‚ÝŒ^•â•S‘ŸDuraHeart‚ð‘•’…‚µŒo‰ß—ǍD‚ÈŠg’£Œ^S‹ØÇ‚Ì1—á.
  15. ’J“àˆŸˆßA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@œA‹ß“¡³‹PA’·’J•”—Y”òAì–Œ‹ÅŽqA‰ºìG–ŸFƒAƒ~ƒIƒ_ƒƒ“’ïR«‚̐S–[•p”‚ɑ΂µƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚œ•p–¬—U”­«S‹ØÇ‚̈ê—á.
  16. ŽO‰Y³’šAŒã‰ªL‘Ÿ˜YA‚‹Ž@A‚“c„ŽjAŽÄ@MsA•œ–{“N–çAˆäãŠ°ˆêA“cŠªŒ’Ž¡F‹}«S•s‘S“ü‰@Žž‚É‚š‚¯‚éBNP”ñ‘ª’è‚͉@“àŽ€–S‚ÆŠÖ˜A‚·‚é.
The 28th Annual Meeting of the International Society for Heart Research Japanese Sectioni2011”N12ŒŽ2`3“úC“Œ‹žj

ƒSymposium : Roles of inflammation and immunity in cardiovascular diseases„

  1. Satoh K, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimokawa H.@Cyclophylin A is a novel biomarker for oxidative stress and atherosclerosis.
‘æ99‰ñ“ú–{zŠÂŠíŠw‰ï’†‘’n•û‰ï‹³ˆçu‰‰i2011”N11ŒŽ26“úC‰ºŠÖj
  1. ‰ºìG–Ÿ : “Œ“ú–{‘åkÐ‚ƏzŠÂŠíŽŸŠ³
‘æ48‰ñ“ú–{—Տ°¶—Šw‰ïE‹g‘º³Ž¡µ¿u‰‰i2011”N11ŒŽ4“úC“Œ‹žj
  1. ‰ºìG–Ÿ : ŽŸ•a‚Ì‹€’ÊŠî”Õ‚Æ‚µ‚Ä‚ÌRho-kinase‚̈Ӌ`
‘æ52‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi2011”N10ŒŽ20`22“úCŠò•Œj
  1. ²“¡Œö—YC•Ÿ–{‹`OC™‘ºGˆê˜YCŽO‰Y@—TCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽR–{¹DCÂ–Ø—³’jC‰ºìG–Ÿ : V‹KŽ_‰»ƒXƒgƒŒƒX‘•’`”’ƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚éSŒŒŠÇ•a‘£i‹@\iJCAAÅ—DGÜj
‘æ15‰ñ“ú–{S•s‘SŠw‰ïi2011”N10ŒŽ13`15“úCŽ­Ž™“‡j

ƒSymposium„

  1. Fukumoto Y, Miura Y, Miura T, Shimada K, Daida H, Tsutsui H, Asakura M, Yamada A, Shiba N, Shimokawa H.@The role of metabolic components in heart failure in Japan. J Cardiac Failure. 17(Suppl):S131,2011.

ƒRegular papers„

  1. Ito Y, Yasuda S, Takii T, Hao K, Takahashi J, Ito K, Shiba N, Shimokawa H.@Rural and urban difference in the incidence and in-hospital mortality of acute myocardial infarction -Report from the MIYAGI-AMI registry Study-@J Cardiac Failure. 17(Suppl):S157-158,2011.
  2. Nochioka K, Shiba N, Miura M, Sugaya M, Kohno H, Shimokawa H.@Prognostic impact of statins in patients with ischemic heart failure -Interim analysis of CHART-2 Study-@J Cardiac Failure. 17(Suppl):S158,2011.
  3. Miura M, Shiba N, Nochioka K, Sugaya M, Kohno H, Shimokawa H.@Prognostic impact of malignant tumors in Japanese heart failure patients -An interim analysis of the CHART-2 Study-@J Cardiac Failure. 17(Suppl):S158,2011.
  4. Miura M, Shiba N, Nochioka K, Sugaya M, Kohno H, Shimokawa H.@Current status of patients with cardiovascular disease requiring nursing-care service in Japan -An interim analysis of the CHART-2 Study-@J Cardiac Failure. 17(Suppl):S159,2011.
  5. Takahashi J, Yasuda S, nakayama M, Ito Y, Ito K, Fukuda K, Fukumoto Y, Shiba N, Shimokawa H.@Increased incidence of heart failure in the Tohoku Earthquake -Initial report from the Tohoku University Hospital-@J Cardiac Failure. 17(Suppl):S169,2011.
  6. Aoki T, Fukumoto Y, Sugimura K, Satoh K, Nochioka K, Miura Y, Yamamoto S, Nakayama M, Shimokawa H.@Myocardial interstitial fibrosis as a prognostic factor in non-ischemic heart failure -Usefulness of myocardial biopsy-@J Cardiac Failure. 17(Suppl):S173,2011.
  7. Tatebe S, Fukumoto Y, Sugimura K, Satoh K, Miura Y, Nochioka K, Aoki T, Miyamichi-Yamamoto S, Shimokawa H.@Clinical implication of post-capillary reactive pulmonary hypertension in patients with left heart disease.@J Cardiac Failure. 17(Suppl):S175,2011.
  8. Aoki T, Sugimura K, Fukumoto Y, Saoh K, Miura Y, Nochioka K, Tatebe S, YamamotoS, Shimokawa H.@Percutaneous transluminal pulmonary angioplasty improves pulmonary hemodynamics in patients with distal-type chronic thromboembolic pulmonary hypertension.@J Cardiac Failure. 17(Suppl):S176,2011.
  9. Hasebe Y, Kawana A, Kondo M, Nakano M, Wakayama Y, Fukuda K, Shimokawa H.@A case of tachycardia-induced cardiomyopathy caused by uncommon atrial fluter rotating lower crista terminalis.@J Cardiac Failure. 17(Suppl):S177,2011.
‘æ59‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2011”N9ŒŽ23`25“úC_ŒËj

ƒƒVƒ“ƒ|ƒWƒEƒ€3 : ‹}«Š¥ÇŒóŒQ‚ÌŽ¡—Ð헪„

  1. ˆÀ“c@‘CˆÉ“¡ˆ€„C‘ëˆä@’šCì–Œ‹ÅŽqC‚‹Ž@CˆÉ“¡Œ’‘ŸCŽÄ@MsC‰ºìG–Ÿ : ”­Ç—ŠEŽ€–S—Š‚Ì30”NŠÔ•Ï‘J‚©‚çl‚Š‚é‰ä‚ª‘‚Ì‹}«S‹Ø[Çf—Â̌»‹µ‚Æ–â‘è“_FMIYAGI-AMIƒŒƒWƒXƒgƒŠ[Œ€‹†

ƒƒVƒ“ƒ|ƒWƒEƒ€6„

  1. ŽO‰Y³’šCŽÄ@MsCŒã‰ªL‘Ÿ˜YC‰Í–ìtC›’J–ƒ—R”üC‰ºìG–Ÿ : ƒAƒ‹ƒuƒ~ƒ“”A‚ÍŠg’£•s‘SŠ³ŽÒ‚Ì—\Œã‚ð—\‘ª‚·‚é@-CHART-2Œ€‹†‚©‚ç‚Ì•ñ-

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“9„

  1. Œã‰ªL‘Ÿ˜YCŽÄ@MsCŽO‰Y³’šC•Ÿ–{‹`OC‰ºìG–Ÿ : ƒGƒ[ƒ`ƒ~ƒu‚ÍŽ‰Ž¿‹zŽû‚ð—}§‚µŒŒŠÇ“à”ç‹@”\‚ð‰ü‘P‚·‚é@-RhoƒLƒi[ƒ[—}§‚ð‰î‚µ‚œV‹KR“®–¬d‰»ì—p‚̉”\«-

ƒƒrƒWƒ…ƒAƒ‹ƒ[ƒNƒVƒ‡ƒbƒv4„

  1. ŽáŽR—TŽiC•Ÿ“c_“ñCì–Œ‹ÅŽqC’·’J•”—Y”òCMohamed Abdel ShafeeC‹ß“¡³‹PC’†–ì@œC‰ºìG–Ÿ : CRT“K‰ž‚ƍ¶Žº‹tƒŠƒ‚ƒfƒŠƒ“ƒO•]‰¿‚É‚š‚¯‚éƒ}ƒ‹ƒ`ƒ‚ƒ_ƒŠƒeƒB[Žž‘ã‚̉摜f’f–@‚Ì–ðŠ„

ƒˆê”ʉ‰‘聄

  1. ™‘ºGˆê˜YC•Ÿ–{‹`OC²“¡Œö—YCŽO‰Y@—TCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽR–{¹DC‰ºìG–Ÿ : ––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚Ì’˜–Ÿ‚ÈŽ¡—ÃŒø‰Ê
  2. Œã‰ªL‘Ÿ˜YCŽÄ@MsCŽO‰Y³’šC‰Í–ìtC›’J–ƒ—R”üCX‚ ‚¯‚݁C‰ºìG–Ÿ : ’Ž‚—îŽÐ‰ï‚̂킪‘‚É‚š‚¯‚é•Ù‹@”\áŠQ‚̗Տ°“IˆÓ‹`@-CHART-2Œ€‹†’†ŠÔ‰ðÍ‚æ‚è-
  3. ‰H”öŽ‹MCˆÉ“¡Œ’‘ŸC‹ÚàV@ŒºC•Ÿ–{‹`OC²“¡@¬C‰ºìG–Ÿ : ‹•ŒŒ«SŒŒŠÇŽŸŠ³‚ɑ΂·‚éV‚µ‚¢”ñNP“IŒŒŠÇV¶—Ö@F’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Ã
  4. ŽR–{¹DC•Ÿ–{‹`OC™‘ºGˆê˜YCÎˆä’q“¿C²“¡Œö—YCŒã‰ªL‘Ÿ˜YCŽO‰Y@—TCŒš•”r‰îCÂ–Ø—³’jC‰ºìG–Ÿ : äPŒŽ•a«”x“®–¬«”x‚ŒŒˆ³Ç‚ɑ΂·‚éÏ‹É“I–Ɖu—}§—Ö@‚Ì—LŒø«
  5. ŽO‰Y³’šCŽÄ@MsCŒã‰ªL‘Ÿ˜YC•œ–{“N–çCˆäãŠ°ˆêC“cŠªŒ’ŽiC‰ºìG–Ÿ : ‹}«S•s‘S‚É‚š‚¢‚ÄŒŒˆ³ãž‚̓Jƒ‹ƒyƒŠƒ`ƒh‚̐t•ÛŒìŒø‰Ê‚ð’ቺ‚³‚¹‚é
  6. ‚‹Ž@CˆÀ“c@‘CŽÄ@MsC‰ºìG–Ÿ : StÇŒóŒQ‚ð‡•¹‚µ‚œS•s‘SÇ—á‚É‚š‚¯‚鎝‘±t‘ã‘֗Ö@‚Ì—L—p«

ƒƒ|ƒXƒ^[‰‰‘聄

  1. ’·’J•”—Y”òC•Ÿ“c_“ñCŽáŽR—TŽiC’†–ì@œC‹ß“¡³‹PC‰ºìG–Ÿ : ’˜–Ÿ‚ȐSŠg‘å‚ƐS‹@”\’ቺ‚𗈂œ‚µA•p”Ž¡—ÃŒã‚̐S‹@”\‰ñ•œ‚É’·ŠúŠÔ‚ð—v‚µ‚œ•p”—U”­«S‹ØÇ‚̈ê—á
  2. ‘å‹ŽŽqCŒ–{‘׎¡C‚‹Ž@C•“cŽç•FCˆÉ“¡Œ’‘ŸC’†ŽR‰ë°CˆÉ“¡ˆ€„Cš¢’J—²Ž¡C‚–Ø—S‰îCˆÀ“c@‘C–kŒü@CCì–{r•ãCâV–؉ÀŽC‰ºìG–Ÿ : ‹}«S‹Ø[ÇŒãS”j—ô‚ð‡•¹‚µ‹~–œŒãA–«Šú¶Žº‰Œ«áŽŒ`¬‚Ì‚œ‚ߍĎèp‚ð—v‚µ‚œÇ—á
  3. •“cŽç•FC‚‹Ž@CˆÉ“¡Œ’‘ŸC’†ŽR‰ë°CˆÀ“c@‘C‰ºìG–Ÿ : Optical Coherence Tomography‚ð—p‚¢‚œ¹k‚𐶂¶‚銥“®–¬‚Ì”÷×\‘¢‚̉ðÍF‹ÇŠ«Š¥¹k‚Æ‚Ñ‚Ü‚ñ«Š¥¹k‚̍·ˆÙ
  4. ì–Œ‹ÅŽqCˆÉ“¡ˆ€„C‘ëˆä@’šC‚‹Ž@CˆÉ“¡Œ’‘ŸC•Ÿ–{‹`OCŽÄ@MsCˆÀ“c@‘C‰ºìG–Ÿ : ‹}«S‹Ø[ÇŠ³ŽÒ‚É‚š‚¯‚é“sŽs•”‚ƍxŠO•”‚Å‚Ì’nˆæ·E«·‚ÌŒŸ“¢@-‹{éŒ§S‹Ø[Ç‘΍ô‹Š‹c‰ï‚É‚š‚¯‚錟“¢-
  5. ˆÉ“¡ˆ€„CˆÀ“c@‘C‘ëˆä@’šCì–Œ‹ÅŽqC‰H”öŽ‹MC‚‹Ž@CˆÉ“¡Œ’‘ŸCŽÄ@MsC‰ºìG–Ÿ : ‹}«S‹Ø[Ç”­ÇŽžŠÔ‚Ì“ú“à•Ï“®‚ÉŠÖ‚·‚é“sŽs•”‚ÆŒS•”‚Ì”äŠrŒŸ“¢@-‹{éŒ§S‹Ø[Ç‘΍ô‹Š‹c‰ï‚©‚ç‚Ì•ñ-
‘æ1‰ñ“ú–{”x‚ŒŒˆ³Œ€‹†‰ïi2011”N9ŒŽ17“úC“Œ‹žj
  1. Œš•”r‰îC•Ÿ–{‹`OC‰ºìG–Ÿ : ¶S•s‘S‚É”º‚€”x‚ŒŒˆ³Ç‚̗Տ°‘œ‚Ɛ¶–œ—\Œã
‘æ194‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2011”N9ŒŽ10“úC·‰ªj
  1. –xˆäWˆê—ǁC•Ÿ“c_“ñCŽáŽR—TŽiC’†–ì@œC‹ß“¡³‹PCì–Œ‹ÅŽqC’·’J•”—Y”òCMohamed Abdel-ShafeeC‰ºìG–Ÿ : •p”’âŽ~Žž‚É’˜–Ÿ‚È“Ž’âŽ~‚𔺂€”­ì«S–[×“®‚ɑ΂µ‚ăJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚é”xÃ–¬Šu—£p‚ª—LŒø‚Å‚ ‚Á‚œ‚P—á
  2. ™‘ºGˆê˜YC•Ÿ–{‹`OC²“¡Œö—YCŽO‰Y@—TCŒã‰ªL‘Ÿ˜YCŒš•”r‰îCŽR–{¹DC‰ºìG–Ÿ : ––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚ÌŒø‰Ê
‘æ75‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2011”N8ŒŽ3`4“úC‰¡•lj

ƒSymposium 2 : Š¥¹k‚̍ŐV‚Ì’mŒ©„

  1. Yasuda S, Takagi Y, Ogawa H, Shimokawa H. Clinical characteristics and outcomes of vasospastic angina patients survived from out-of-hospital cardiac arrest -A report from the Japanese Coronary Spasm Association-

ƒSymposium : New Biomarkers for Prediction and Prevention of Cardiovascular Diseases„

  1. Satoh K, Fukumoto Y, Shimizu T, Suzuki H, Sugimura K, Miura Y, Tatebe S, Miyamichi S, Berk BC, Shimokawa H. Cyclophilin A is a novel biomarker for aortic aneurysms and atherosclerotic plaque instability.

ƒSymposium : Management of Cardiovascular Diseases in Patients with End-stage Renal Disease„

  1. Miura M, Shiba N, Nochioka K, Kohno H, Sugaya M, Shimokawa H. Evaluation of albuminuria is important in patients with chronic heart failure. -An interim analysis of the CHART-2 Study-

ƒSymposium : ”x‚ŒŒˆ³Ç‚̍ŐVŽ¡—Á„

  1. Sugimura K, Fukumoto Y, Satoh K, Miura Y, Tatebe S, Miyamichi S, Shimokawa H. New therapeutic strategies for pulmonary hypertension: Rho-kinase inhibitor and balloon pulmonary angioplasty.

ƒLate Breaking Clinical Trial 3„

  1. Shiba N, Miura M, Kohno H, Shimokawa H. A large-scale hospital-based cohort of patients at high risk for heart failure -Primary results of the CHART-2 Study-

ƒFireside Seminar„

  1. ‰ºìG–Ÿ : ‹•ŒŒ«SŽŸŠ³f—Âɂš‚¯‚銥¹k‚̏d—v«

ƒLuncheon Seminar„

  1. ‰ºìG–Ÿ : Œ»‘ã“ú–{l‚Ì•a‘ԂɑΉž‚µ‚œŽ‰Ž¿ˆÙíÇŽ¡—ÃXƒgƒ‰ƒeƒW[

ƒˆê”ʉ‰‘聄

  1. Aizawa K, Yasuda S, Gao J-Y, Tsuburaya R, Kikuchi Y, Kiyotaka Hao K, Ito Y, Ito K, Hasegawa H, Kanai H, Shimokawa H. Low-intensity pulsed ultrasound induces VEGF expression and ameliorates left ventricular dysfunction in a porcine model of chronic myocardial ischemia.
  2. Aoki T, Fukumoto Y, Sugimura K, Satoh K, Miura Y, Tatebe S, Miyamichi S, Nakayama M, Shimokawa H. Gender difference in prognostic impact of myocardial fibrosis in heart failure patients -Usefulness of myocardial biopsy-
  3. Fukuda K, Wakayama Y, Nakano M, Kondo M, Shimokawa H. Clinical predictors of electrical storm in coronary artery disease patients with an implantable cardioverter defibrillator.
  4. Kikuchi Y, Aizawa K, Yasuda S, Tsuburaya R, Ito Y, Matsumoto Y, Takeda M, Nakayama M, Ito K, Takahashi J, Shimokawa H. Rho-kinase activity in circulating neutrophils for diagnosis and disease activity assessment of vasospastic angina.
  5. Gao JY, Yasuda S, Tsuburaya R, Ito Y, Aizawa K, Kikuchi Y, Ito K, Shimokawa H. Long-term treatment with eicosapentaenoic acid ameliorates myocardial ischemia-reperfusion injury in pigs in vivo -Potential involvement of Rho-kinase pathway-
  6. Matsumoto Y, Adams V, Fukumoto Y, Schuler G, Shimokawa H. Regular exercise training prevents the development of angiotensin II-induced aortic aneurysm in mice.
  7. Miura M, Shiba N, Nochioka K, Nakayama M, Hiramoto T, Inoue K, Tamaki K, Shimokawa H. Acute heart failure with preserved ejection fraction may be associated with higher in-hospital mortality.
  8. Miura Y, Fukumoto Y, Shiba N, Miura T, Shimada K, Iwama Y, Takagi A, Matsusaka H, Tsutsumi T, Yamada A, Kinugawa S, Asakura M, Okamatsu S, Tsutsui H, Daida H, Matsuzaki M, Tomoike H, Shimokawa H. Prevalence and clinical implication of metabolic syndrome in chronic heart failure -A nationwide multi-center study-
  9. Miyamichi S, Fukumoto Y, Sugimura K, Satoh K, Nakano M, Miura Y, Tatebe S, Oikawa M, Ishii T, Shimokawa H. Effects of intensive immunosuppressive therapy on pulmonary hemodynamics in patients with pulmonary arterial hypertension associated with connective tissue disease.
  10. Morisada N, Iijima K, Matsuo M, Shimokawa H, Yanagihara N, Tsutsui M. Complete disruption of all nitric oxide synthase genes causes markedly accelerated renal lesion formation in mice in vivo.
  11. Nakajima S, Ohashi J, Sawada A, Noda K, Shimokawa H. Evidence for the important role of the bone marrow in modulating microvascular endothelial functions and glucose tolerance in mice.
  12. Nochioka K, Shiba N, Miura M, Sugaya M, Takahashi J, Kohno H, Shimokawa H. Elevated serum TSH levels are associated with poor prognosis of Japanese patients with chronic heart failure -Interim analysis of the CHART-2 Study-
  13. Nochioka K, Shiba N, Miura M, Sugaya M, Takahashi J, Kohno H, Shimokawa H. Valvular dysfunction is significant burden for Japanese female patients with cardiovascular diseases; Interim analysis of the CHART-2 Study.
  14. Ito K, Kikuchi Y, Ito Y, Tsuburaya R, Aizawa K, Hao K, Takahashi J, Takeda M, Nakayama M, Fukumoto Y, Yasuda S, Shimokawa H. Low-energy extracorporeal shock wave therapy as a new and non-invasive angiogenic strategy for cardiovascular diseases.
  15. Ito Y, Yasuda S, Takii T, Takahashi J, Ito K, Shiba N, Shimokawa H, on behalf of the MIYAGI-AMI Study Investigators. Circadian variation of the onset of acute myocardial infarction in rural and urban district; A report from MIYAGI-AMI Registry Study.
  16. Ito Y, Yasuda S, Takii T, Takahashi J, Ito K, Shiba N, Shimokawa H, on behalf of the MIYAGI-AMI Study Investigators. Comparison of the incidence and in-hospital mortality of acute myocardial infarction between rural and urban district in Miyagi Prefecture.
  17. Serizawa F, Ito K, Sato A, Shimokawa H. Extracorporeal shock wave therapy ameliorates walking ability in patients with peripheral artery disease and intermittent claudication.
  18. Shibata K, Tsutsui M, Yatera Y, Furuno Y, Yanagihara N, Shimokawa H, Otsuji Y. Spontaneous development of left ventricular hypertrophy and diastolic dysfunction in mice lacking all nitric oxide synthases.
  19. Shimizu T, Satoh K, Tanaka S, Fukumoto Y, Shimokawa H. ROCK2 in vascular smooth muscle cells plays a crucial role for hypoxia-induced pulmonary hypertension in mice.
  20. Suzuki H, Satoh K, Miura S, Fukudo S, Shimokawa H. Different brain processing from the right and the left ventricles in humans.
  21. Takagi Y, Yasuda S, Takahashi J, Tsuburaya R, Ito Y, Takeda M, Ito K, Kondo M, Wakayama Y, Fukuda K, Masafumi Sugi M, Shimokawa H. Usefulness of dual induction tests for coronary vasospasm and ventricular fibrillation in the decision-making for the management of out-of-hospital cardiac arrest.
  22. Takagi Y, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Goto T, Tanabe Y, Sueda S, Sato T, Ogawa S, Kubo N, Momomura S, Ogawa H, Shimokawa H, on behalf of the Japanese Coronary Spasm Association. Prognostic impact of organic coronary stenosis in patients with vasospastic angina -A report from the Japanese Coronary Spasm Association-
  23. Takagi Y, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Goto T, Tanabe Y, Sueda S, Sato T, Ogawa S, Kubo N, Momomura S, Teragawa H, Kihara Y, Ogawa H, Shimokawa H, on behalf of the Japanese Coronary Spasm Association. Gender differences in clinical characteristics and prognostic factors of patients with vasospastic angina -A report from the Coronary Spasm Association-
  24. Takahashi J, Yasuda S, Shiba N, Nakayama M, Shimokawa H. Continuous renal replacement therapy in patients with acute decompensated heart failure and cardio-renal syndrome.
  25. Tatebe S, Fukumoto Y, Sugimura K, Satoh K, Miura Y, Miyamichi S, Oikawa M, Shimokawa H. Post-capillary reactive pulmonary hypertension is an adverse prognostic factor in patients with left heart disease.
  26. Tatebe S, Fukumoto Y, Sugimura K, Satoh K, Nakano M, Miura Y, Miyamichi S, Shimokawa H. Optical coherence tomography as a novel diagnostic tool for distal-type chronic thromboembolic pulmonary hypertension.
  27. Takeda M, Takahashi J, Nakayama M, Ito K, Yasuda S, Shimokawa H. Morphological analysis of the coronary arterial wall of patients with vasospastic angina pectoris with optical coherence tomography.
  28. Tsuburaya R, Yasuda S, Aizawa K, Gao JY, Ito Y, Shiroto T, Ito K, Ishibashi-Ueda H, Shimokawa H. Long-term treatment with nifedipine suppresses coronary hyperconstricting responses induced by paclitaxel-eluting stent in pigs in vivo -Possible involvement of Rho-kinase-
  29. Tsuburaya R, Yasuda S, Ito Y, Shiroto T, Gao JY, Ito K, Shimokawa H. Eicosapentaenoic acid suppresses ischemia-induced ventricular fibrillation in pigs in vivo -Possible involvement of Kir6.2-coupled ATP-sensitive potassium (KATP) channel -
  30. Wang W, Kagaya Y, Asaumi Y, Fukui S, Takeda M, Shimokawa H. Molecular mechanisms for the protective effects of recombinant human erythropoietin in pressure overload-induced left ventricular dysfunction in mice in vivo.
‘æ17‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2011”N7ŒŽ16`17“úC‘åãj
  1. Œ–{‘׎¡CƒtƒHƒ‹ƒJ[ƒAƒ_ƒ€ƒXC‰ºìG–Ÿ : ’èŠú“I‰^“®‚ÍŽÀŒ±“I“®–¬áŽƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚š‚¢‚Ä• •”‘å“®–¬áŽŒ`¬‚ð—}§‚·‚éiÅ—DG‰‰‘èÜŽóÜj
  2. ˆÉ“¡ˆ€„CˆÉ“¡Œ’‘ŸC‹e’n@—ƒC‰H”öŽ‹MC‰~’J—²Ž¡C‘ŠàVŒ’‘Ÿ˜YC‚‹Ž@C•“cŽç•FC’†ŽR‰ë°CŒ–{‘׎¡C‚–Ø—S‰îC•Ÿ–{‹`OCˆÀ“c@‘C‰ºìG–Ÿ : ’áo—Í‘ÌŠOÕŒ‚”gŽ¡—ÁFSŒŒŠÇŽŸŠ³‚ɑ΂·‚éV‚µ‚¢”ñNP«ŒŒŠÇV¶—Ö@
  3. ŽO‰Y³’šCŽÄ@MsCŒã‰ªL‘Ÿ˜YC‰Í–ìtC›’J–ƒ—R”üC‰ºìG–Ÿ : SŒŒŠÇŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é‰îŒì—\–h‚Ì•K—v«‚ÆŒ»ó@|CHART-2Œ€‹†‚É‚š‚¯‚é’mŒ©|
‘æ64‰ñ“ú–{Ž_‰»ƒXƒgƒŒƒXŠw‰ïŠwpW‰ïi2011”N7ŒŽ2“úC–kŠC“¹j

ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[1„

  1. ‰ºìG–Ÿ : “ú–{l‚ÆŠ¥¹k

ƒˆê”ʉ‰‘聄

  1. ²“¡Œö—YC•Ÿ–{‹`OC™‘ºGˆê˜YCŽO‰Y@—TCŒã‰ªL‘Ÿ˜YCÂ–Ø—³’jCŒš•”r‰îCŽR–{¹DC‰ºìG–Ÿ : V‹KŽ_‰»ƒXƒgƒŒƒXƒ}[ƒJ[EƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚éSŒŒŠÇ•a‘£i‹@\
‘æ58‰ñ“ú–{–ƒŒ‰ÈŠw‰ïŠwpW‰ïi2011”N5ŒŽ20“úC_ŒËj

ƒµ‘ҍu‰‰„

  1. ‰ºìG–Ÿ : “à”ç—R—ˆ‰ß•ª‹ÉˆöŽqiEDHFj‚̗Տ°“IˆÓ‹`
‘æ11‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2011”N5ŒŽ13`14“úC“Œ‹žj

ƒƒVƒ“ƒ|ƒWƒEƒ€3 : ƒKƒXó•ªŽq‚É‚æ‚錌ŠÇ“à”ç‹@”\’²ß\ŒŒŠÇ“à”ç‹@”\‘ª’è‚̈Ӌ`‚Æ–â‘è“_\„

  1. “c’†áÁˆêC‰ºìG–Ÿ : ŒŒŠÇ“à”ç‚É‚š‚¯‚éƒXƒ^ƒ`ƒ“‚Ì‘œ–Ê“Iì—p‹@˜‚̐V’mŒ©

ƒˆê”ʉ‰‘聄

  1. “›ˆä³lCX’å’ŒÆC–öŒŽ‰„ÍC“팎_ˆêC‰ºìG–Ÿ : ˆê‘€”AŠÇŒ‹ãFŒã‚̐t•a•ÏŒ`¬‚É‚š‚¯‚é‚R‚‚ÌNOSs‚Ì—}§“I–ðŠ„
  2. “›ˆä³lC‹g–ì—R”üC–öŒŽ‰„ÍC”ö’ҁ@–LC“c‘º‰ëmC‰ºìG–Ÿ : ƒ}ƒEƒXèò“®–¬Œ‹ãFƒ‚ƒfƒ‹‚É‚š‚¯‚é‘SNOSsŒn‚ÌŒŒŠÇ•ÛŒìì—pFœ‘—R—ˆ×–E‚ÌŠñ—^
  3. “›ˆä³lCŽÄ“cŽŽqC–öŒŽ‰„ÍC”ö’ҁ@–LC‰ºìG–Ÿ : NOSsŒnŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚ÉŒ©‚ç‚ê‚œŽ©‘R”­ÇŠg’£ŠúS•s‘S
  4. –ì“cˆêŽ÷C×’J^‹IC’†“ˆ‘s‘ŸC‘å‹ŽŽqC‰ºìG–Ÿ : Combination therapy with olmesartan and azelnidipine exerts anti-atherogenic effects in diabetic Apoliporotein E-deficient mice.
  5. –î“c–L—²C‰ºìG–ŸC•œŒ@CCŒã“¡^ŒÈC¬Š}ŒŽN•vCŠ’J•¶•F : ¶‘Ì“àƒCƒkŠ¥”÷¬‘€•ŒŒŠÇ‚É‚š‚¯‚éƒAƒ“ƒMƒIƒeƒ“ƒVƒ“Žó—e‘̝hR–ò‚Ì“àˆö«‰ßŽ_‰»…‘f‚ð‰î‚µ‚œŒŒŠÇŠg’£ì—p‚š‚æ‚Ñ“œ”A•aƒ‚ƒfƒ‹‚̉ü‘PŒø‰Ê
  6. ’†“ˆ‘s‘ŸC‘å‹ŽŽqCàV“cˆŒŽqC–ì“cˆêŽ÷C‰ºìG–Ÿ : œ‘—R—ˆ×–E‚̓}ƒEƒX‚Ì”÷¬ŒŒŠÇ“à”ç‹@”\‚š‚æ‚Ñ‘Ï“œ”\§Œä‚É‚š‚¢‚ďd—v‚È–ðŠ„‚ð‰Ê‚œ‚µ‚Ä‚¢‚é
  7. ‘å‹ŽŽqCàV“cˆŒŽqC‚–؁@•¶C–ì“cˆêŽ÷C’†“ˆ‘s‘ŸC‰ºìG–Ÿ : ”÷¬ŒŒŠÇ‚É‚š‚¢‚Ä“à”ç—R—ˆ‰ß•ª‹ÉˆöŽq(EDHF)”œ‰ž‚ª˜Ži‚µ‚Ä‚¢‚镪Žq‹@˜‚̉ð–Ÿ
‘æ3‰ñ“Œ–k‘åŠw‘ÛŽYŠw˜AŒgƒVƒ“ƒ|ƒWƒEƒ€i2011”N3ŒŽ7“úC“Œ‹žj
  1. ‰ºìG–Ÿ : S‘Ÿ•a‚ɑ΂·‚é‘ÌŠOÕŒ‚”gŽ¡—Â̊J”­
•œ¬22”N“xŒú¶˜J“­‰ÈŠwŒ€‹†¬‰Ê“™•‹yŒ[”­Ž–‹ÆE‡“¯¬‰Ê”­•\‰ïi2011”N2ŒŽ24“úC“Œ‹žj
  1. ‰ºìG–Ÿ : ‘ŽY‹Zp‚ÉŠî‚­•s®–¬Ž¡—×pÕŒ‚”gƒAƒuƒŒ[ƒVƒ‡ƒ“ƒVƒXƒeƒ€‚ÌŠJ”­
  2. ‰ºìG–Ÿ : ’áNP«‘ÌŠOÕŒ‚”gŽ¡—Ö@‚ÌŽÀ—p‰»‚ð–ÚŽw‚µ‚œƒGƒrƒfƒ“ƒXŠm—§‚Ì‚œ‚ß‚Ì‹’“_Œ`¬
‘æ4‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2011”N2ŒŽ5`6“úC‰ºŠÖj
  1. ì–Œ‹ÅŽqCˆÉ“¡ˆ€„C‘ëˆä@’šC‚‹Ž@CˆÉ“¡Œ’‘ŸC•Ÿ–{‹`OCŽÄ@MsCˆÀ“c@‘C‰ºìG–Ÿ : ‹{éŒ§“à‚Ì‹}«S‹Ø[ÇŠ³ŽÒ‚̉@“àŽ€–S—Š‚ÉŠÖ‚·‚é’nˆæ·‚š‚æ‚ѐ«·‚ÉŠÖ‚·‚錟“¢
  2. ì–Œ‹ÅŽqCŽO‰Y@—TC•Ÿ–{‹`OCŽÄ@MsC‰ºìG–ŸCŽO‰Yr˜YC‘ã“c_”VC’©‘q³‹ICŽR“c@–ŸC“›ˆä—T”V : ‚킪‘‚Ì–«S•s‘S‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚̈Ӌ` : «·‚ÌŠÏ“_‚©‚ç
  3. Œã‰ªL‘Ÿ˜YCŽÄ@MsCŽO‰Y³’šC‰Í–ìtC‰ºìG–Ÿ : •Ù‹@”\áŠQ‚͏—«‚̐SŒŒŠÇŽŸŠ³Š³ŽÒ‚Ì—\Œã‚𑝈«‚³‚¹‚é : CHART-2Œ€‹†‚æ‚è
‘æ40‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïi2011”N2ŒŽ4`5“úC‚Œj

ƒŠî’²u‰‰„

  1. ‰ºìG–Ÿ : SŒŒŠÇ•a‚̐V‚œ‚ÈŽ¡—ÕW“I‚Æ‚µ‚Ä‚ÌRho-kinase‚̈Ӌ`.

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2010”N
‘æ26‰ñ—Տ°ƒtƒŠ[ƒ‰ƒWƒJƒ‹‰ï‹ci2010”N1ŒŽ30“úC‘å’Áj
  1. ‰ºìG–Ÿ : “à”ç—R—ˆŠˆ«Ž_‘f‚ƏzŠÂŠíŽŸŠ³
‘æ39‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïi2010”N2ŒŽ5“úC–ŒŒÃ‰®j
  1. ²“¡Œö—YC‰ºìG–Ÿ : Ž_‰»ƒXƒgƒŒƒX‘B’`”’CyclophylinA‚̐SŒŒŠÇ•a‘£i‹@\
  2. ‰ºìG–ŸC‚–؁@•¶CàV“cˆŒŽqC–ì“cˆêŽ÷C×’J^‹IC‰ºìG–Ÿ : “à”çŒ^ˆêŽ_‰»’‚‘f‡¬y‘f‹@”\‚Ì‘œ—l«‚É‚š‚¯‚镪Žq‹@\‚̉𖟠: ƒ}ƒEƒX‚ÌŒŒŠÇ‚ð—p‚¢‚œŒŸ“¢
  3. ‰~’J—²Ž¡CˆÀ“c@‘CˆÉ“¡ˆ€„C‚@ŒR‹BCˆÉ“¡Œ’‘ŸC‰ºìG–Ÿ : ATPŠŽŽó«ƒJƒŠƒEƒ€ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚œ’·ŠúƒGƒCƒRƒTƒyƒ“ƒ^ƒGƒ“Ž_“Š—^‚É‚æ‚éƒuƒ^‹•ŒŒ«SŽº×“®—}§Œø‰Ê
‘æ19‰ñ‘q•~ƒ‰ƒCƒuƒfƒ‚ƒ“ƒXƒgƒŒ[ƒVƒ‡ƒ“ƒR[ƒXi2010”N2ŒŽ25“úC‘q•~j

ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  1. ²“¡^‹ICˆÀ“c@‘C‰ºìG–Ÿ : ƒ\ƒŠƒ…[ƒVƒ‡ƒ“ƒpƒbƒNTM“±“ü‚É‚æ‚é”pŠüì‹Æ‚ÌŒø—Š‰»‚ÆŠŽõƒŠƒXƒNŒž­‚Ö‚ÌŽæ‚è‘g‚Ý
‘æ55‰ñ“ú–{“à‰ÈŠw‰ï“Œ–kŽx•”¶ŠU‹³ˆçu‰‰‰ïi2010”N2ŒŽ20“úCå‘äj
  1. ‰ºìG–Ÿ : ‹•ŒŒ«S‘Ÿ•a‚ɑ΂·‚é”ñNP«‘ÌŠOÕŒ‚”gŽ¡—Ã
‘æ3‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2010”N2ŒŽ20“ú`21“úC“Œ‹žj
  1. ‚–Ø—S‰îCˆÀ“c@‘CŠp“c—²•ãC•ûN”ŽCŠÖ@“ցCZ‹g“OÆCŒˆäŠ²—R”VCŒã“¡•q˜aC¬ì‹v—YC‰ºìG–Ÿ : Š¥¹k«‹·SÇ‚É‚š‚¯‚é’j—‚̗Տ°“I“Á’¥‚̍·ˆÙ„ŸŠ¥¹kŒ€‹†‰ï‘œŽ{Ý‹€“¯Œ€‹†‚©‚ç„Ÿ
  2. Œã‰ªL‘Ÿ˜YCŽÄ@MsCŽO‰Y³’šC‰Í–ìtC–x“c”ü•äC•Ÿ–{‹`OC‰ºìG–Ÿ : Š¥“®–¬ŽŸŠ³”­Ç‚É‚š‚¯‚鐫·„ŸCHART-2Œ€‹†’†ŠÔ‰ðÍ‚æ‚è„Ÿ
  3. ŽO‰Y@—TC•Ÿ–{‹`OC‰ºìG–ŸCŽO‰Yr˜YC“‡“c˜a“TC‘ã“c_”VC’©‘q³‹IC—F’rm’šCŽR“c@–ŸC“›ˆä—T”V : ‚킪‘‚Ì–«S•s‘S‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚̈Ӌ` : ’j—·‚ÌŠÏ“_‚©‚ç
  4. ˆÀ“c@‘C‘ëˆä@’šC‚‹Ž@C‚–Ø—S‰îCˆÉ“¡ˆ€„C’†ŽR‰ë°C•“cŽç•FCˆÉ“¡Œ’‘ŸCŽÄ@MsC‰ºìG–Ÿ : ‹{éŒ§‚É‚š‚¯‚é‹}«S‹Ø[Ç”­Ç—ŠEŽ€–S—Š30”NŠÔ‚Ì•Ï‘J‚Ɛ«· „ŸMIYAGI-AMIŒ€‹†„Ÿ
•œ¬21”N“xŒú¶˜J“­‰ÈŠwŒ€‹†”‰Ê“™•‹yŒ[”­Ž–‹Æˆã—Ë@ŠíŠJ”­„iŒ€‹†@Šˆ“®—̈æŠg’£ˆã—Ë@ŠíŠJ”­Œ€‹†¬‰Ê”­•\‰ïi2009”N2ŒŽ23“úC“Œ‹žj
  1. ‰ºìG–Ÿ : ‘ŽY‹Zp‚ÉŠî‚­•s®–¬Ž¡—×pÕŒ‚”gƒAƒuƒŒ[ƒVƒ‡ƒ“ƒVƒXƒeƒ€‚ÌŠJ”­
‘æ74‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2010”N3ŒŽ5“ú`7“úC‹ž“sj

ƒPlenary Session : Cardiac Sudden Death : Clinical Evidence and Treatment„

  1. Yasuda S, Takagi Y, Tsunoda R, Ogata Y, Satoh T, Ogawa S, Ogawa H, Shimokawa H. Clinical characteristics and prognosis of vasospastic angina patients survived from our-of-hospital cardiac arrest„ŸMulticenter registry study of the Coronary Spasm Association„Ÿ Circ J 74(Suppl I):I-18,2010.

ƒPlenary Session : Cardiovascular Regenerative Medicine„

  1. Ito K, Fukumoto Y, Takahashi J, Yasuda S, Shimokawa H. Extracorporeal shock wave therapy as a new and non-invasive angiogenic strategy. Circ J 74(Suppl I):I-22,2010.

ƒSymposium : Molecular Mechanisms for Diastolic Heart Failure and Remodeling„

  1. Fukumoto Y, Miura Y, Fukui S, Aoki T, Miura T, Matsuzaki M, Shimada K, Iwama Y, Takagi A, Daida H, Tsutsumi T, Yamada A, Kinugawa S, Tsutsui H, Asakura M, Tomoike H, Shiba N, Shimokawa H. Current status and future perspectives of diastolic heart failure in Japan„ŸRho-kinase as a possible therapeutic target„Ÿ Circ J 74(Suppl I):I-32,2010.

ƒSymposium„

  1. Shiba N, Nochioka K, Miura M, Kohno H, Hotta M, Shimokawa H. Accumulating Evidence for Chronic Heart Failure in Japan -The CHART-2 Study and The SUPPORT Trial

ƒSymposium : Theraputic strategy for acute coronary syndrome : Am up-date„

  1. Arakawa K, Yasuda S, Hao H, Kataoka Y, Morii I, Kasahara Y, Kawamura A, Ueda H, Miyazaki S. The clinical significance of the interaction between thrombosis and inflammation : insights from aspirated samples in the culprit lesions of STEMI

ƒAccumulating Evidence of Cardiovascular Disease Prevention and Treatment in Japanese Population„

  1. Shiba N, Nochioka K, Miura M, Kohno H, Hotta M, Shimokawa H. Accumulating evidence for chronic heart failure in Japan „ŸThe CHART-2 Study and The SUPPORT Trial„Ÿ Circ J 74(Suppl I):I-53,2010.

ƒSpecial Session : Perspectives of Acute Coronary Syndrome in Japan : From Cohort Studies in Regions Across the Nation„

  1. Yasuda S, Takii T, Shimokawa H on behalf of MIYAGI-AMI Study investigators. Increasing incidence but decreasing mortality of acute myocardial infarction over 30 years in Japan„Ÿreport from the MIYAGI-AMI Registry Study„Ÿ Circ J 74(Suppl I):I-157,2010.

ƒYIA Finalists Lectures„

  1. Satoh K, Nakano M, Sugimura K, Oikawa M, Fukumoto Y, Shimokawa H. Emerging importance of the erythropoietin/erythropoietin receptor system and cyclophillin A as novel therapeutic targets in cardiovascular medicine. Circ J 74(Suppl I):I-159,2010.

ƒFeatured Research Session„

  1. Miura Y, Fukumoto Y, Miura T, Matsuzaki M, Shimada K, Iwama Y, Takagi A, Daida H, Tsutsumi T, Yamada A, Kinugawa S, Tsutsui H, Asakura M, Tomoike H, Shimokawa H. Current status of chronic heart failure with a special reference to metabolic syndrome in Japan. Circ J 74(Suppl I):I-172,2010.
  2. Satoh K, Fukumoto Y, Berk BC, Shimokawa H. Cyclophillin A as a novel therapeutic target for aortic aneurysms. Circ J 74(Suppl I):I-192,2010.
  3. Takagi Y, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanabe Y, Sue-da S, Ogawa H, Shimokawa H. Clinical characteristics and prognostic factors of vasospastic angina„ŸMulticenter registry study of the Japanese Coronary Spasm Association„Ÿ Circ J 74(Suppl I):I-170,2010.

ƒFireside seiminar : Coronary artery spasm : up-dated, amining at the international colla-borating study„

  1. Yasuda S, Takagi Y, Ogawa H, Shimokawa H. Progress report from the Japanese coronary spasm association

ƒˆê”ʉ‰‘聄

  1. Abe T, Toyohara T, Suzuki T, Akiyama Y, Takeuchi Y, Mishima E, Tanemoto M, Kawano H, Maemura K, Fukumoto Y, Shimokawa H, Ito S, Soga T. Statin-inducible uremic toxin transporter prevents hypertension, renal function and inflammation. Circ J 74(Suppl I):I-485,2010.
  2. Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, Nakayama M, Shimokawa H. Prognositc impact of myocardial fibrosis in heart failure patients„ŸUsefulness of myocardial biopsy„Ÿ Circ J 74(Suppl I):I-336,2010.
  3. Doe Zhulangigige, Fukumoto Y, Takaki A, Tawara S, Ohhashi J, Nakano M, Tada T, Saji K, Sugimura K, Fujita H, Hoshikawa Y, Nawata J, Kondo T, Shimokawa H. Direct evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 74(Suppl I):I-322,2010.
  4. Fukuda K, Wakayama Y, Hirose N, Yamaguchi N, Kondoh M, Shimokawa H. The difference of electrophysiological characteristics between Brugada Syndrome and idiopathic ventricular fibrillation. Circ J 74(Suppl I):I-370,2010.
  5. Hosoya M, Ohashi J, Sawada A, Takaki A, Shimokawa H. Combination therapy with an angiotensin receptor blocker and a calcium channel blocker improves EDHF-mediated responses in diabetic Apolipoprotein E-deficient mice. Circ J 74(Suppl I):I-657,2010.
  6. Kikuchi Y, Ito K, Ito Y, Aizawa K, Tsuburaya R, Hao K, Shiroto T, Fukumoto Y, Takahashi J, Takeda M, Nakayama M, Yasuda S, Shimokawa H. Placebo-controlled study for the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris. Circ J 74(Suppl I):I-388,2010.
  7. Kikuchi Y, Aizawa K, Yasuda S, Ito Y, nakayama M, Takeda M, Ito K, Takahashi J, Shimokawa H. Significance of Rho-kinase activity in circulating neutrophils for diagnosis and disease activity assessment of vasospastic angina. Circ J 74(Suppl I):I-704,2010.
  8. Morishita N, Watanabe S, Nomura M, Sabanai K, Matsumoto T, Shimokawa H, Yanagihara N, Shirahata T, Kusuhara K, Tsutsui M. Protective role of nitric oxide synthase against renal remodeling : Lesson from mice lacking all three nitric oxide synthase isoforms. Circ J 74(Suppl I):I-485,2010.
  9. Nakano M, Fukumoto Y, Satoh K, Itoh Y, Kagaya Y, Shimokawa H. Inhibition of OX40 ligand suppresses the development of atherosclrosis in Apolipoprotein E-deficient mice. Circ J 74(Suppl I):I-563,2010.
  10. Nakayama M, Osaki S, Shimokawa H. Prognostic factors for octogenarians with cardiovascular disease. Circ J 74(Suppl I):I-472,2010.
  11. Nishigaki K, Inoue Y, Yamanouchi Y, Fukumoto Y, Yasuda S, Sueda S, Urata H, Shimokawa H, Minatoguchi S. Effects of calcium channel blockers on majot adverse cardiovascular events in patients with vasospastic angina : A meta-analysis. Circ J 74(Suppl I):I-528,2010.
  12. Nochioka K, Shiba N, Kohno H, Miura M, Shimokawa H. Sick euthyroid syndrome is common in Japanese patients with chronic heart failure„ŸInterim analysis of the CHART-2 Study„Ÿ. Circ J 74(Suppl I):I-289,2010.
  13. Satoh K, Berk BC, Shimokawa H. Cyclophilin A mediates endothelial damage and promotes recruitment of inflammatory cells and atherosclerosis. Circ J 74(Suppl I):I-343,2010.
  14. Satoh K, Fukumoto Y, Berk BC, Shimokawa H. Extracellular cyclophilin A causes cardiac hypertrophy under oxidative stress conditions. Circ J 74(Suppl I):I-404,2010.
  15. Suzuki H, Hirose M, Watanabe S, Miura S, Fukudo S, Shimokawa H. New method to examine the afferent neuronal pathway from the heart to the brain in humans. Circ J 74(Suppl I):I-546,2010.
  16. Takagi Y, Yasuda S, Takahashi J, Takeda M, Nakayama M, Ito K, Hirose M, Wakayama Y, Fukuda K, Shimokawa H. Emerging roles of coronary vasospasm and ventricular fibrillation in the pathogenesis of out-of-hospital cardiac arrest. Circ J 74(Suppl I):I-276,2010.
  17. Takagi Y, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanabe Y, Sueda S, Ogawa H, Shimokawa H. Spontaneous rest attacks with ST-segment elevation (variant angina) associated with higher incidence of MACE in patients with coronary vasospasm. Circ J 74(Suppl I):I-276,2010.
  18. Takagi Y, Yasuda S, Satoh T, Ogawa S, Tsunoda R, Ogata Y, Ogawa H, Shimokawa H. Patients with vasospastic angina survived from our-of-hospital cardiac arrest as a high-risk population of recurrent major adverse cardiac events. Circ J 74(Suppl I):I-367,2010.
  19. Takagi Y, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanabe Y, Sueda S, Ogawa H, Shimokawa H. Safety of the coronary spasm provocation test„ŸMulticenter registry study of the Japanese Coronary Spasm Association„Ÿ Circ J 74(Suppl I):I-747,2010.
  20. Takii T, Yasuda S, Takagi Y, Itoh Y, Takahashi J, Takeda M, Nakayama M, Itoh K, Shiba N. Shimokawa H. Increasing incidence but decreasing mortality of acute myocardial infarction over 30 years in Japan„ŸReport from the MIYAGI-AMI Registry Study„Ÿ Circ J 74(Suppl I):I-632,2010.
  21. Wakayama Y, Fukuda K, Hirose M, Yamaguchi N, Kondoh M, Shimokawa H. Identification of gtrueh responders with left ventricular reverse remodeling after cardiac resynchronization therapy using quantitative gated SPECT. Circ J 74(Suppl I):I-480,2010.
  22. Yada T, Shimokawa H, Hiramatsu O, Satoh M, Kashihara N, Shinozaki Y, Mori H, Takaki A, Gotoh M, Ogasawara Y, Kajiya F. Cardioprotective effects of hydrogen peroxide and erythropoietin during acute coronary occlusion in canine coronary native collateral microcirculation in vivo. Circ J 74(Suppl I):I-635,2010.
  23. Yatera Y, Tsutsui M, Nakata S, Shibata K, Furuno Y, Morishita T, Sabanai K, Tasaki H, Nakashima Y, Yanagihara N, Shimokawa H, Otsuji Y. Critical role of nitric oxide synthase system in the pathogenesis of dyslipidemia : Lessons from mice lacking all nitric oxide synthases. Circ J 74(Suppl I):I-214,2010.
‘æ150‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2010”N6ŒŽ5“úC·‰ªj

ƒYIAÇ—á•”–åÅ—DGÜ„

  1. ‰~’J—²Ž¡C‚‹Ž@CˆÀ“c@‘C•“cŽç•FCˆÉ“¡ˆ€„C‚–Ø—S‰îC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‰ºìG–ŸCì–{r•ãC¬“cŽ•FC‚£@Œ\C“c—ѝæˆê : is«‚Ì‹‘劥“®–¬áŽ‚ɑ΂µŠ¥“®–¬ƒoƒCƒpƒXp‚ƃRƒCƒ‹Çðp‚É‚æ‚éƒnƒCƒuƒŠƒbƒhŽ¡—ÂðŽ{s‚µ‚œDorpŒãÇ—á

ƒYIAŒ€‹†•”–å—DGÜ„

  1. Â–Ø—³’jC•Ÿ–{‹`OC™‘ºGˆê˜YC‹yì”ü“ÞŽqC²“¡Œö—YC’†–ì@œC’†ŽR‰ë°C‰ºìG–Ÿ : S‹Ø‚̐üˆÛ‰»‚ª—\Œã‚É—^‚Š‚é‰e‹¿@\S‹Ø¶ŒŸ‚Ì—L—p«\

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“ : “Œ–k’n‹æ‚̏zŠÂŠí‹~‹}‚ɂ‚¢‚ā„

  1. ˆÀ“c@‘ : ‹{éŒ§‚É‚š‚¯‚é‹}«S‹Ø[Ç‚ÌŽÀ‘Ô : MIYAGI-AMI Registry 30”Nƒf[ƒ^‚æ‚è

ƒˆê”ʉ‰‘聄

  1. ‹ß“¡³‹PC•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°C’†–ì@œC‰ºìG–Ÿ : “ŽŒ‹ß‹ß–T‹NŒ¹‚ÆŠÓ•Ê‚ð—v‚µ‚œRSPV‹NŒ¹AT‚̈ê—á
  2. ‹ß“¡³‹PC•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°C’†–ì@œC‰ºìG–Ÿ : ‰EŽºŽOë•Ù—Ö’†Šu‘€‚©‚ç‚Ì’Ê“d‚ª—LŒø‚Å‚ ‚Á‚œ‰º•Ç[ÇŒãSŽº•p”‚̈ê—á
  3. ™‘ºGˆê˜YC•Ÿ–{‹`OC²“¡Œö—YC‹yì”ü“ÞŽqC’†–ì@œCŒš•”r‰îC‹{“¹¹DC‰ºìG–Ÿ : dÇ–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ÉŒo”ç“I”x“®–¬Œ`¬p‚ª’˜Œø‚µ‚œˆê—á
  4. •“cŽç•FC‚‹Ž@C‰~’J—²Ž¡CˆÉ“¡ˆ€„C‚–Ø—S‰îC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸCˆÀ“c@‘C‰ºìG–Ÿ : CypherƒXƒeƒ“ƒg—¯’u3”NŒã‚É’Ž’x”­«ƒXƒeƒ“ƒgŒŒðÇ‚𔭏ǂµCX‚É‚»‚Ì2”N”ŒŒã‚ɉ@ŠOS’âŽ~‚𗈂µ‚œˆê—á
  5. ‰~’J—²Ž¡C‚‹Ž@CˆÀ“c@‘CˆÉ“¡ˆ€„C‚–Ø—S‰îC•“cŽç•FC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‰ºìG–ŸC’|“à‰ëŽ¡ : ˆ««ƒŠƒ“ƒpŽî‰»Šw—Ö@Œã‚É•sˆÀ’艻‚ðŒJ‚è•Ô‚µ‚œ“«Š¥¹k«‹·SÇ‚Ì1—á
  6. ’†–ì@œCŽáŽR—TŽiC•Ÿ“c_“ñC‹ß“¡³‹PC‰ºìG–Ÿ : ‘œŒ¹«SŽº«ŠúŠOŽûk‚ð’悵‚œSƒTƒ‹ƒRƒCƒh[ƒVƒX‚̈ê—á
  7. ’†–ì@œC•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°C‹ß“¡³‹PC‰ºìG–Ÿ : VT”­ì‚Ì‹NŒ¹‚Æ‚È‚éPVC—}§‚ɃCƒ\ƒvƒƒeƒŒƒm[ƒ‹‚ª—LŒø‚Å‚ ‚Á‚œƒuƒ‹ƒKƒ_ÇŒóŒQÇ—á
  8. Œã‰ªL‘Ÿ˜YCŽO‰Y³’šC‰ºìG–ŸCŽÄ@MsC‰Í–ìtC›’J^—R”ü : «·‚É‚æ‚銥“®–¬ŽŸŠ³”­ÇƒŠƒXƒN‚̈Ⴂ@\CHART-2Œ€‹†’†ŠÔ‰ðÍ‚æ‚è[
  9. ŽO‰Y@—TC•Ÿ–{‹`OC‰ºìG–ŸCŽO‰Yr˜YCŒè‰v“¿C“‡“c˜a“TCŠâŠÔ‹`FC‚–ؓďrC‘ã“c_”VC’ç@FŽ÷CŽR“c@–ŸCŒŠì^‘Ÿ˜YC“›ˆä—T”VC’©‘q³‹IC—F’rm’š : “ú–{l‚Ì–«S•s‘S‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚Ì“Á
  10. ŽO‰Y³’šCŒã‰ªL‘Ÿ˜YC‰ºìG–ŸCŽÄ@MsC‰Í–ìt : –«S•s‘SŠ³ŽÒ‚É‚š‚¯‚é—˜”A–ò“Š—^‚ÌŒ»ó
‘æ191‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2010”N6ŒŽ19“úCå‘äj
  1. ‹àŽqm•FCû‚–{‹`OC™‘ºGˆê˜YC’†–ì@œC‹{“¹¹DCŒš•”r‰îC‹yì”ü“ÞŽqC²“¡Œö—YC‰ºìG–Ÿ : ‹‘劥“®–¬\”x“®–¬á‘/ᎂÌ1—á
‘æ63‰ñ“ú–{Ž_‰»ƒXƒgƒŒƒXŠw‰ïŠwpW‰ïi2010”N6ŒŽ24`25“úC‰¡•lj
  1. ²“¡Œö—YC™‘ºGˆê˜YCŽO‰Y@—TCŒš•”r‰îC‹{“¹¹DCû‚–{‹`OC‰ºìG–Ÿ : ƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚éŽ_‰»ƒXƒgƒŒƒX‘•‹@\‚Æ“®–¬d‰»ƒvƒ‰[ƒN”j’]
‘æ19‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï(CVIT2010)i2010”N8ŒŽ22`24“úCå‘äj

ƒSymposium:Coronary spasm for interventionalist„

  1. * Shimokawa H. Key note lecture: Overview of coronary spasm.
  2. Takeda M, Takahashi J, Ito K, Nakayama M, Yasuda S, Shimokawa H. Life-threatening complications after sirolimus-eluting stent implantation.
  3. Takahashi J, Yasuda S, Takeda M, Ito Y, Tsuburaya R, Takagi Y, Oda K, Kawamoto S, takase B, Tabayashi K, Shimokawa H. A hybrid strategy with percutaneous coil embolization and re-CABG for giant coronary aneurysm in a patient undergone Dor procedure.
‘æ192‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2010”N9ŒŽ4“úAŽRŒ`j
  1. £ì«lC•Ÿ“c_“ñCŽáŽR—TŽiC’†–ì@œC‹ß“¡³‹PC‰ºìG–ŸFŒJ‚è•Ô‚·ãŽº«•p”‚ð‡•¹‚µ‚œ“Á”­«Šg’£Œ^S‹ØÇ‚Ì1—á
  2. ‘O“c@ŒbCˆÉ“¡ˆ€„C•“cŽç•FC‚‹Ž@CˆÉ“¡Œ’‘ŸCˆÀ“c@‘C‰ºìG–ŸFS‘ŸƒJƒe[ƒeƒ‹ŒŸžŒã‚ɃAƒiƒtƒBƒ‰ƒNƒgƒCƒhŽ‡”Á•a‚ð”F‚ß‚œ1—á
‘æ58‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2010”N9ŒŽ17`19“úC“Œ‹žj

ƒƒVƒ“ƒ|ƒWƒEƒ€2 : •s®–¬‚Ì”ñ–ò•šŽ¡—Â̐i•à„

  1. ŽáŽR—TŽiC•Ÿ“c_“ñCL£®“¿CŽRŒû“WŠ°C’†–ì@œC‹ß“¡³‹PC‰ºìG–Ÿ. ’vŽ€«SŽº«•s®–¬‚ɑ΂·‚éƒfƒoƒCƒXŽ¡—Á@\ICD‹y‚ÑCRT-D‚É‚æ‚éˆêŽŸ—\–h‚ÉŠÖ‚·‚錟“¢\@J Cardiol Jpn Ed. 2(Suppl I):I-123,2010.

ƒƒVƒ“ƒ|ƒWƒEƒ€3 : SŽŸŠ³‚̉^“®ƒŠƒnƒrƒŠ„

  1. Œ–{‘׎¡C•Ÿ–{‹`OC‰ºìG–Ÿ : ‰Á—î‚É‚æ‚é•Ï«‘å“®–¬•Ù‹·óÇ‚͉^“®—Ö@‚Å—\–h‰Â”\‚©H : anti-ageing‰î“ü‚Æ‚µ‚Ẳ^“®—Ö@‚̐V‚µ‚¢–ðŠ„. J Cardiol Jpn Ed. 2(Suppl I):I-125,2010.

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“1 : ”x‚ŒŒˆ³Ž¡—Â̐i•à„

  1. •Ÿ–{‹`OC‰ºìG–Ÿ : ”x‚ŒŒˆ³Ç‚É‚š‚¯‚éV‚œ‚È•ªŽqŽ¡—ÕW“I : RhoƒLƒi[ƒ[. J Cardiol Jpn Ed. 2(Suppl I):I-139,2010.

ƒ‚킪‘‚Ì–«S•s‘S‚̐¬ˆö‚É‚š‚¯‚é“œ”A•a‚̈Ӌ`„

  1. •Ÿ–{‹`OCŽO‰Y@—TC•Ÿˆäd•¶CŽÄ@MsCŽO‰Yr˜YCŒè‰v“¿C“‡“c˜a“TC‘ã“c_”VC’©‘q³‹IC—F’rm’šC“›ˆä—T”VC‰ºìG–Ÿ.@J Cardiol Jpn Ed. 2(Suppl I):I-149,2010.

ƒˆê”ʉ‰‘聄

  1. ²“¡Œö—YC•Ÿ–{‹`OC™‘ºGˆê˜YCŽO‰Y@—TCŒš•”r‰îC‹{“¹¹DC‰ºìG–Ÿ : ŒŒð“à–Œ“EœpŒã‚ÌŽc‘¶”x‚ŒŒˆ³‚É”x“®–¬ƒoƒ‹[ƒ“Šg’£p‚ª—LŒø‚Å‚ ‚Á‚œ–«”xŒŒðÇð«”x‚ŒŒˆ³‚̈ê—á. J Cardiol Jpn Ed. 2(Suppl I):I-420,2010./li>
  2. ‚–Ø—S‰îCˆÀ“c@‘C‚‹Ž@C•“cŽç•FC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸCŽáŽR—TŽiC•Ÿ“c_“ñC‰ºìG–Ÿ : ŠíŽ¿“ISŽŸŠ³‚Ì‚È‚¢‰@ŠOS’âŽ~‚Ì•a‘Ô‚Æ—\Œã : Š¥¹k‚ƐSŽº×“®‚Ì“ñd—U”­ŽŽŒ±‚̏d—v«. J Cardiol Jpn Ed. 2(Suppl I):I-219,2010.
  3. ‚‹Ž@CˆÀ“c@‘CŽÄ@MsC’†ŽR‰ë°C‰ºìG–Ÿ : StÇŒóŒQ‚ð‡•¹‚µ‚œ‹}«S•s‘SÇ—á‚É‚š‚¯‚鎝‘±t‘ã‘֗Ö@‚ÌŒŸ“¢. J Cardiol Jpn Ed. 2(Suppl I):I-371, 2010.
  4. ™‘ºGˆê˜YC•Ÿ–{‹`OC²“¡Œö—YCŒš•”r‰îC‹{“¹¹DC’†–ì@œC‹yì”ü“ÞŽqC‰ºìG–Ÿ : ’·Šú“ü‰@‰Á—Âð•K—v‚Æ‚µ‚œdÇ–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ÉŒo”ç“I”x“®–¬Œ`¬p‚ª‘tŒ÷‚µ‚œˆê—á. J Cardiol Jpn Ed. 2(Suppl I):I-390,2010.
  5. Œš•”r‰îC•Ÿ–{‹`OC™‘ºGˆê˜YC²“¡Œö—YC’†–ì@œCŽO‰Y@—TC‹{“¹¹DC‰ºìG–Ÿ : ‘å“®–¬‰ŠÇŒóŒQ‚É‚æ‚é”x“®–¬‹·ó‚É—Œ‘€”x“®–¬ƒoƒCƒpƒXŽ{sŒãCÄ‹·ó‚ɑ΂·‚é”x“®–¬ƒoƒ‹[ƒ“Œ`¬p‚ª—LŒø‚Å‚ ‚Á‚œ1—á. J Cardiol Jpn Ed. 2(Suppl I):I-230,2010.
  6. •“cŽç•FC‚‹Ž@CˆÉ“¡Œ’‘ŸC’†ŽR‰ë°CˆÀ“c@‘C‰ºìG–Ÿ : • •”‘å“®–¬áŽŠ³ŽÒ‚É‚š‚¯‚ép‘OŠ¥“®–¬‘¢‰e‹y‚ÑŠ¥ŒŒsÄŒšp‚Ì—L—p«. J Cardiol Jpn Ed. 2(Suppl I):I-325,2010.
  7. Œã‰ªL‘Ÿ˜YCŽÄ@MsCŽO‰Y³’šC‰Í–ìtC›’J^—R”üC‰ºìG–Ÿ. –«S•s‘S‚É‚š‚¯‚éÅ“KBMI’l‚ÌŒŸ“¢ : CHART-1Œ€‹†‚æ‚è. J Cardiol Jpn Ed. 2(Suppl I):I-220,2010.
  8. •Ÿ“c_“ñCŽáŽR—TŽiC’†–ì@œC‹ß“¡³‹PC‰ºìG–Ÿ : ‹•ŒŒ«SŽŸŠ³Š³ŽÒ‚É‚š‚¯‚éSŽº«•s®–¬dÇ‰»‚Ì”wŒi. J Cardiol Jpn Ed. 2(Suppl I):I-478,2010.
  9. ŽO‰Y³’šCŽÄ@MsCŒã‰ªL‘Ÿ˜YC‰Í–ìtC‰ºìG–Ÿ : ‹•ŒŒ«S•s‘S‚ɑ΂·‚éƒXƒ^ƒ`ƒ““Š—^‚ÌŒ»ó‚ÆŒø‰Ê@\‘æ“ñŽŸ“Œ–k–«S•s‘S“o˜^Œ€‹†‚©‚ç‚Ì•ñ\J Cardiol Jpn Ed. 2(Suppl I):I-371,2010.
‘æ14‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2010”N10ŒŽ7“ú`9“úC“Œ‹žj
  1. Fukumoto Y, Fukui S, Aoki T, Shimokawa H. Rho-kinase as a possible therapeutic target on diastolic heart failure. J Cardiac Failure. 16(Suppl 1):S135,2010.
  2. Miura M, Shiba N, Nochioka K, Kohno H, Shimokawa H. What is the determinant for beta-blocker use in Japanese heart failure patients? J Cardiac Failure. 16(Suppl 1):S163,2010.
  3. Nochioka K, Shiba N, Miura M, Hotta M, Sugaya M, Kohno H, Shimokawa H. Prevalence and characteristics of Japanese patients with valvular heart diseases -Interim analysis of CHART-2 Study- J Cardiac Failure. 16(Suppl 1):S167,2010.
  4. Wakayama Y, Kondo M, Nakano M, Fukuda K, Shimokawa H. Efficacy of ICD and CRT-d on primary prevention of sudden cardiac death. J Cardiac Failure. 16(Suppl 1):S170,2010.
  5. Wang W, Kagaya Y, Asaumi Y, Fukui S, Shimokawa H. Cardioprotective effects of human recombinant erythropoietin in pressure overload-induced left ventricular dysfunction in mice. J Cardiac Failure. 16(Suppl 1):S173,2010.
  6. ›’J^—R”üCŽÄ@MsC‰Í–ìtC–x“c”ü•äC‚‹ŽŠì‹vŽqCX‚ ‚¯‚݁C²“¡^‹IŽqC’†“ˆ‰ÀŽqC•Ÿ“cŽu”TC‰ºìG–Ÿ : ‘å‹K–Í–ò•š‰î“üŽŽŒ± : SUPPORTŽŽŒ±‚É‚š‚¯‚é—Տ°Œ€‹†ƒR[ƒaƒBƒl[ƒ^[‚É‚æ‚éV‹K“o˜^‘‰Á‚ÌŽæ‚è‘g‚Ý
‘æ30‰ñ“ú–{ìè•aŠw‰ï‘‰ïEŠwpW‰ïi2010”N10ŒŽ11“úC‹ž“sj

ƒ“Á•Êu‰‰„

  1. * ‰ºìG–Ÿ : ŒŒŠÇ¶•šŠw‚̍ŋ߂̒mŒ©@\ìè•a‚ÉŠÖ˜A‚µ‚ā\
‘æ18‰ñ“ú–{ŒŒŠÇ¶•šˆãŠw‰ïi2010”N12ŒŽ1`3“úC‘åãj

ƒÅ—DGŒûq”­•\„

  1. ²“¡Œö—YC•Ÿ–{‹`OCŽ…@‹œC—é–؏G–ŸC™‘ºGˆê˜YCŽO‰Y@—TCŒš•”r‰îC‹{“¹¹DC‚‹Ž@C•“cŽç•FCˆÀ“c@‘CBradford BerkC‰ºìG–Ÿ : Cyclophilin A is a novel biomarker for cardiovascular diseases.

ƒˆê”ʉ‰‘聄

  1. ‘å‹ŽŽqCàV“cˆŒŽqC‚–؁@•¶C–ì“cˆêŽ÷C’†“ˆ‘s‘ŸC×’J^‹IC‰ºìG–Ÿ : CaMKKb plays a key role for the diverse functions of eNOS between conduit and resistance arteries in mice.
‘æ151‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2010”N12ŒŽ4“úCå‘äj

ƒYIAÇ—á”­•\•”–åiÅ—DGÜŽóÜj„

  1. ‘O“c@ŒbCˆÉ“¡ˆ€„C‰~’J—²Ž¡CŒ–{‘׎¡C•“cŽç•FC‚‹Ž@C’†ŽR‰ë°CˆÉ“¡Œ’‘ŸCˆÀ“c@‘C‰ºìG–ŸC‚àV“¿•FC‰““¡ŽÆC¬ì‰pì : S‘ŸƒJƒe[ƒeƒ‹ŒŸžŒã‚ɃAƒiƒtƒBƒ‰ƒNƒgƒCƒhŽ‡”Á•a‚ð‹}«”­Ç‚µ‚œ1—á

ƒYIAŒ€‹†”­•\•”–åi—DGÜŽóÜj„

  1. ‹{“¹¹DC•Ÿ–{‹`OC™‘ºGˆê˜YC²“¡Œö—YC’†–ì@œCŽO‰Y@—TCŒš•”r‰îC‰ºìG–ŸCÎˆä’q“¿ : äPŒŽ•a«”x“®–¬«”x‚ŒŒˆ³Ç‚ɑ΂·‚é–Ɖu—}§—Ö@‚Ì—LŒø«

ƒˆê”ʉ‰‘聄

  1. ˆÉ“¡ˆ€„C‚‹Ž@CˆÀ“c@‘C‰~’J—²Ž¡C‚–Ø—S‰îC•“cŽç•FC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‰ºìG–Ÿ : XienceƒXƒeƒ“ƒg—¯’u3ƒ–ŒŽŒã‚ɍċ·óE•sˆÀ’è‹·SÇ‚𔭏ǂµ‚œˆÛŽ“§ÍÇ—á
  2. ì–Œ‹ÅŽqC‚‹Ž@CˆÀ“c@‘CˆÉ“¡ˆ€„C‰~’J—²Ž¡C‚–Ø—S‰îC•“cŽç•FC’†ŽR‰ë°CŒ–{‘׎¡CˆÉ“¡Œ’‘ŸC‰ºìG–Ÿ : Š¥“®–¬áŽŽc‘¶EƒoƒCƒpƒXpŒã‚Å”DPEoŽY‚µ‚œìè•a‚Ì1—á
  3. ‹ß“¡³‹PC’†–ì@œCŽáŽR—TŽiC•Ÿ“c_“ñC‰ºìG–Ÿ : Ž¡—Âɓïa‚µ‚œICDƒŠ[ƒhŠŽõÇ‚Ì1—á
  4. ™‘ºGˆê˜YC•Ÿ–{‹`OC²“¡Œö—YCŽO‰Y@—TCŒš•”r‰îC‹{“¹¹DC‰ºìG–Ÿ : ––œŒ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç(CTEPH)‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p(PTPA)‚É—LŒø«
  5. £ì«lC•Ÿ“c_“ñCŽáŽR—TŽiC’†–ì@œC‹ß“¡³‹PC’·’J•”—Y”òC‰ºìG–Ÿ : ŒJ‚è•Ô‚·ãŽº«•p”‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ªS‹@”\‰ü‘P‚É—LŒø‚Å‚ ‚Á‚œŠg’£Œ^S‹ØÇ‚Ì1—á
  6. •“cŽç•FC‚‹Ž@CˆÉ“¡Œ’‘ŸC’†ŽR‰ë°CˆÀ“c@‘C‰ºìG–Ÿ : • •”‘å“®–¬áŽ‚ÌŠO‰ÈŽ¡—×\’芳ŽÒ‚É‚š‚¯‚ép‘OŠ¥“®–¬‘¢‰e‚Ì—L—p«
  7. Œš•”r‰îC•Ÿ–{‹`OC™‘ºGˆê˜YC²“¡Œö—YC’†–ì@œCŽO‰Y@—TC‹{“¹¹DC‰ºìG–Ÿ : ‘å“®–¬‰ŠÇŒóŒQ‚É‚æ‚é”x“®–¬‹·ó‚É”x“®–¬ƒoƒCƒpƒXŽ{sŒãCÄ‹·ó‚ɑ΂µƒXƒeƒ“ƒg—¯’u‚ª—LŒø‚Å‚ ‚Á‚œ1—á
  8. ’†–ì@œC•Ÿ“c_“ñCŽáŽR—TŽiC‹ß“¡³‹PC’·’J•”—Y”òC‰ºìG–Ÿ : ¶Žº“û“ª‹Ø‹NŒ¹‚ƍl‚Š‚ç‚ê‚œ•p”­«SŽº«ŠúŠOŽûk‚ɑ΂µ‚ÄRECA‚ðŽ{s‚µ‚œ1—á
  9. ŽO‰Y³’šCŽÄ@MsCŒã‰ªL‘Ÿ˜YC‰Í–ìtC›’J–ƒ—R”üC‰ºìG–Ÿ : –«S•s‘SŠ³ŽÒ‚É‚š‚¯‚éƒAƒ‹ƒuƒ~ƒ“”A‚Ì‘ª’èˆÓ‹`@\‘æ“ñŽŸ“Œ–k–«S•s‘S“o˜^Œ€‹†‚©‚ç‚Ì•ñ\
  10. ŽáŽR—TŽiC•Ÿ“c_“ñC‹ß“¡³‹PC’†–ì@œC‰ºìG–Ÿ : f’f‚É‹ê—¶‚µ‚œ’ʏíŒ^S–[‘e“®ƒAƒuƒŒ[ƒVƒ‡ƒ“ŒãÄ”­‚Ì1—á

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2009”N
zŠÂŠí•aŒ€‹†ˆÏ‘õ”ïi20Œö-3j•œ¬20”N“x”ljï‹ci2009”N1ŒŽ9“úC‘—§zŠÂŠí•aƒZƒ“ƒ^[C‘åãj
  1. ‰ºìG–Ÿ : ƒXƒ^ƒ`ƒ“‚Ì‘œ–Ê“Iì—p‚ÉŠÖ‚·‚éƒVƒOƒiƒ[ƒ€‰ðÍ
‘æ38‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïi2009”N2ŒŽ6“úC‰ªŽRj
  1. ‘å‹ŽŽqC‚–Ø •¶CXìŒhŽqC‘ºŽR‰À”́CŽRŠÝ•¶lC×’J^‹IC‰ºìG–Ÿ : “à”ç—R—ˆ‰ß•ª‹ÉˆöŽq‚Ì”œ‰ž‚É‚š‚¯‚é“à”çƒIƒLƒVƒ_[ƒ[‚ÌŠÖ—^
  2. ’†–ì œC•Ÿ–{‹`OC²“¡Œö—YCˆÉ“¡ˆ€„C‰Á‰ê’J –LCÎˆä’ŒlC›‘º˜a•vC‰ºìG–Ÿ : ŠŸó“®–¬d‰»•a•Ï‚É‚š‚¯‚錌ŠÇV¶‚Ì—}§‚ðƒ^[ƒQƒbƒg‚Æ‚µ‚œOX40/OX40LŒn‚ð‰î‚·‚é“®–¬d‰»Ž¡—Ð헪
‘æ2‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2009”N2ŒŽ7“ú`8“úC“Œ‹žj
  1. Œã‰ªL‘Ÿ˜YCŽÄ MsC‰Í–ìtC‚‹Ž C‰ºìG–Ÿ : “ú–{l—«‚Ì–«S•s‘S‚͏«—ˆ‘‰Á‚·‚é
zŠÂŠíŽŸŠ³“™¶ŠˆKŠµ•a‘΍ô‘‡Œ€‹†E“œ”A•aí—ª“™Œ€‹†¬‰Ê”­•\‰ïi2009”N2ŒŽ10“úC“Œ‹žj
  1. ‰ºìG–Ÿ : –«S•s‘S‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚̈Ӌ`‚ÉŠÖ‚·‚錀‹†
‘æ147‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2009”N2ŒŽ14“új
  1. ˆÉ“¡ˆ€„CˆÉ“¡Œ’‘ŸC”’ŒË ’C‰~’J—²Ž¡C‚ ŒR‹BC•“cŽç•FC•Ÿ–{‹`OCˆÀ“c ‘C‰ºìG–Ÿ: ƒuƒ^S‹Ø‹•ŒŒÄŸó—¬ŠQŒã‚̍¶ŽºƒŠƒ‚ƒfƒŠƒ“ƒO‚ɑ΂·‚é‘ÌŠOÕŒ‚”gŽ¡—Â̗}§Œø‰ÊiYIAÅ—DGÜŽóÜj
  2. ‹ß“¡³‹PC•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°C‰ºìG–Ÿ : œœ‰ºÃ–¬ƒAƒvƒ[ƒ`‚ª—L—p‚Å‚ ‚Á‚œMahaimüˆÛ‚ð‰î‚µ‚œwide QRS•p”‚ð’悵‚œˆê—á
  3. Žì—“‘Ž‘ŽŠiiƒWƒ‡ƒ‰ƒ“Eƒ`ƒ`ƒSjC•Ÿ–{‹`OC‚–Ø •¶C“cŒŽr‰îC’†–ì œC“ê“c ~C‰ºìG–Ÿ : ”x‚ŒŒˆ³Š³ŽÒ‚É‚š‚¯‚éRhoƒLƒi[ƒ[Šˆ«‚̘Ži
  4. Œã‰ªL‘Ÿ˜YC‚‹Ž CŽÄ MsC‰Í–ìtCL£®“¿C‰ºìG–Ÿ : –«t‘Ÿ•a‚ð‡•¹‚µ‚œ–«S•s‘S‚É‚š‚¯‚郌ƒjƒ“EƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Œn‘jŠQ–ò‚ÌŒø‰Ê
  5. “¡àV‰ÄsC•Ÿ–{‹`OC‹yì”ü“ÞŽqC™‘ºGˆê˜YC²“¡Œö—YC’†–ì œC‰ºìG–Ÿ : DŽ_‹…‘‘œÇ‚ɍ‡•¹‚µ‚œSŽºáŽ‚̈ê—á
  6. .áÁ–ì —BC•“cŽç•FC‹ß“¡³‹PC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‚‹Ž CˆÀ“c ‘C‰ºìG–Ÿ : Š¥¹k—U”­ŽŽŒ±Žž‚Ƀuƒ‹ƒKƒ_—lS“d}‚ð’悵‚œŠ¥¹k«‹·SÇ‚̈ê—á
  7. ŽO‰Y —TC•Ÿ–{‹`OC•Ÿˆäd•¶C²“¡Œö—YC™‘ºGˆê˜YC‹yì”ü“ÞŽqC‰ºìG–Ÿ : ”x‚ŒŒˆ³‚̐V‚œ‚È—\Œã‹K’èˆöŽq‚ÌŒŸõ
  8. ŽR“c—F—¢ŒbC‚‹Ž CˆÀ“c ‘C‘ëˆä ’šC’†–ì œC‚‹Ž‹M‹v‘ãC•“cŽç•FC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‰ºìG–Ÿ: ‘œŽ}¹k‚É”º‚€‘œ—l‚ȐS“d}•Ï‰»‚Æ“ÁˆÙ‚ÈMRIŠŒ©‚ð’悵‚œ‹}«S‹Ø[ÇÇ—á
  9. ŽR“c—F—¢ŒbC‚‹Ž CˆÀ“c ‘C‘ëˆä ’šC‚–Ø—S‰îC•“cŽç•FC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‰ºìG–Ÿ: ƒwƒpƒŠƒ“‹Nˆö«ŒŒ¬”ÂŒž­ÇEŒŒðÇ‚É‚æ‚é‚ÆŽv‚í‚ê‚é‹}«S‹Ø[Ç‚ðPCI’Œ‘O‚É”­Ç‚µ‚œ1—á
  10. ŽáŽR—TŽiC•Ÿ“c_“ñCL£®“¿CŽRŒû“WŠ°C‹ß“¡³‹PC‰ºìG–Ÿ: Š®‘S–[ŽºƒuƒƒbƒN‚𔺂€S‹ØŽŸŠ³‚É‚š‚¯‚éSŽº•p”ƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ÌŒoŒ±
“Œ–k‘åŠwƒOƒ[ƒoƒ‹COE/Network Medicine‘n¬‹’“_ “~‚̍‡hinH•Ûi2009”N2ŒŽ14“ú`15“úCH•Ûj
  1. ‰ºìG–Ÿ : Šˆ«Ž_‘fEŒŒŠÇ“à”ç‚ð‰î‚·‚é‘ŸŠíŠÔƒlƒbƒgƒ[ƒN
  2. ’†–ì œC•Ÿ–{‹`OC²“¡Œö—YCˆÉ“¡ˆ€„C‰Á‰ê’J –LCÎˆä’ŒlC›‘º˜a•vC‰ºìG–Ÿ : Genetic deletion of OX40 ligand suppresses the development of atherosclerosis in apoprotein E-deficient mice
‘æ187‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2009”N2ŒŽ21“úCå‘äj
  1. Œã‰ªL‘Ÿ˜YC‚‹Ž CŽÄ MsC‰Í–ìtCL£®“¿C‰ºìG–Ÿ : –«S•s‘S‚É‚š‚¯‚éŽg—p–òÜ‚Ì•]‰¿ \ CHART2’†ŠÔ•]‰¿‚æ‚è \
  2. ‰H”öŽ‹MC•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°C‹ß“¡³‹PC‰ºìG–Ÿ : ¶ŽºŒ`¬pŒã‚ɐ¶‚¶‚œŽ¡—Ã’ïR«SŽº•p”‚ɃJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚œ’‹Œ«S‹Ø[Ç‚̈ê—á
  3. “¡àV‰ÄsC™‘ºGˆê˜YC•Ÿ–{‹`OC‹yì”ü“ÞŽqC²“¡Œö—YC’†–ì œC‰ºìG–Ÿ : DŽ_‹…‘‘œÇ‚ɍ‡•¹‚µ‚œSŽºáŽ‚̈ê—á
  4. áÁ–ì —BC•“cŽç•FC‹ß“¡³‹PC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‚‹Ž CˆÀ“c ‘C‰ºìG–Ÿ : ƒuƒ‹ƒKƒ_—lS“d}‚ð’悵‚œŠ¥¹k«‹·SÇ‚̈ê—á
•¶•”‰ÈŠwÈVŠwp‘n¬—̈挀‹†uŠˆ«Ž_‘f‚̃VƒOƒiƒ‹“`’B‹@”\v‘æ2‰ñ”ljï‹ci2009”N2ŒŽ22“úCŒF–{j
  1. ‰ºìG–Ÿ : “à”ç—R—ˆ’oŠÉˆöŽq‚Æ‚µ‚Ä‚ÌŠˆ«Ž_‘f–ðŠ„‚Æì—p‹@\‚̉ð–Ÿ
•œ¬20”N“xŒú¶˜J“­‰ÈŠwŒ€‹†”‹†¬‰Ê“™•‹yŒ[”­Ž–‹Æ ˆã—Ë@ŠíŠJ”­„iŒ€‹† Šˆ“®—̈æŠg’£ˆã—Ë@ŠíŠJ”­Œ€‹†¬‰Ê”­•\‰ïi2009”N2ŒŽ24“úC“Œ‹žj
  1. ‰ºìG–Ÿ : ‘ŽY‹Zp‚ÉŠî‚­•s®–¬Ž¡—×pƒAƒuƒŒ[ƒVƒ‡ƒ“ƒVƒXƒeƒ€‚ÌŠJ”­
‘æ82‰ñ“ú–{–ò—Šw‰ï”N‰ïi2009”N3ŒŽ16“ú`18“úC‰¡•lj

ƒƒVƒ“ƒ|ƒWƒEƒ€ : ˆâ“`Žq‰ü•Ï“®•š‚É‚š‚¯‚é•a‘Ԑ¶—‚Æ‚»‚ÌŽ¡—Öòí—ª : “Á‚ɏzŠÂŠíŒn‹y‚ѐž__ŒoŒnŽŸŠ³‚©‚ç‚ÌŽ‹“_‚Æ‚»‚̐ړ_‚ð’T‚遄

  1. “›ˆä³lCã–ì WC–L•œ—R”üŽqC‹g‘º—掙C’†‘º ƒC”ö’Ò –LC‰ºìG–ŸC–öŒŽ‰„Í: SŒŒŠÇ•a‹y‚Ñ‚€‚•a‚̐¬ˆö‚É‚š‚¯‚éˆêŽ_‰»’‚‘f‡¬y‘fƒVƒXƒeƒ€‚̈Ӌ`

ƒƒVƒ“ƒ|ƒWƒEƒ€ : SŒŒŠÇŒnGƒ^ƒ“ƒpƒNŽ¿‹€–ðŒ^Žó—e‘̂̍זE“à“®‘ԂƐV‚µ‚¢ƒVƒOƒiƒ‹“`’BŒn‚ð‚ß‚®‚éÅ‹ß‚̘b‘聄

  1. ‰ºìG–Ÿ : SŒŒŠÇ•a‚ɑ΂·‚éRho-kinase‘jŠQ–ò‚ÌŠJ”­
‘æ73‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2009”N3ŒŽ20“ú`22“úC‘åãj

ƒPlenary session : Pathophysiology and therapeutic strategy of diastolic dysfunction in heart failure„

  1. Fukumoto Y, Miura Y, Fukui S, Miura T, Matsuzaki M, Shimada K, Iwama Y, Takagi A, Daida H, Tsutsumi T, Yamada A, Asakura M, Tomoike H, Shimokawa H. Current status and future perspectives of diastolic heart failure in Japan.@„Ÿpossible importance of metabolic syndrome„Ÿ. Circ J 73(Suppl. I):I-20,2009.

ƒSymposium : Therapeutic decision making for coronary artery disease among PCI, CABG, and medication„

  1. Shimokawa H, Sakata R. An overview. Circ J 73(Suppl. I):I-28,2009.
  2. Yasuda S, Takagi Y, Ogawa H, Shimokawa H. Importance of medical treatment for vasospastic angina. „ŸLessons from multicenter registry by coronary spasm association of Japan„Ÿ.@Circ J 73(Suppl. I):I-28,2009.

ƒSymposium : Key players of metabolic syndrome„

  1. Shiba N, Nochioka K, Kouno H, Shimokawa H. Central obesity is a significant risk independent of insulin resistance in the development. Circ J 73(Suppl. I):I-30,2009.

ƒRoundtable discussion : The mechanism and management of cardio-renal risk„

  1. Kagaya Y, Asaumi Y, Takeda M, Minegishi N, Shimokawa H. Protective role of endogenous erythropoietin-erythropoietin receptor system in the development of heart failure. Circ J 73(Suppl. I):I-104,2009.

ƒRoundtable discussion : The drug of choice for idiopathic pulmonary arterial hyper-tension„

  1. Fukumoto Y, Shimokawa H. New therapeutic strategy for pulmonary arterial hyper-ten-sion : Rho-kinase inhibitors. Circ J 73(Suppl. I):I-107,2009.
Meet the Experts
  1. Shimokawa H.@Microvascular angina.@„ŸInvisible but important player in cardiovascular gen-der medicine„Ÿ.@Circ J . 73(Suppl. I):I-96,2009.
  2. Yasuda S, Ogawa H, Shimokawa H.@Current status of vasospastic angina in Japan : An interim-report of the multicenter registry of the coronary spasm association of Japan. Circ J 73(Suppl. I):I-98,2009.

ƒYoung Investigator's Award competition„

  1. Nakano M, Fukumoto Y, Satoh K, Ito Y, Kagaya Y, Shimokawa H. Differential role of progenitor cells in the arterial development of the abnormal vasculature. Circ J 73(Suppl. I):I-72,2009.

ƒYoung Investigator's Award competition, International„

  1. Doe Zhulanqiqige, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, Tada T, Saji K, Sugimura K, Fujita H, Hoshikawa Y, Nawata J, Kondo T, Shimokawa H.@Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension.@Circ J 73(Suppl. I):I-73,2009.

ƒFeatured Research Sessions„

  1. Oikawa M, Kerwin W, Underhill H, Yuan C, Shimokawa H, Hatsukami T. Association between adventitial vasa vasorum and fibrous cap rupture: A prospective, longitudinal dynamic contrast-enhanced MRI study. Circ J 73(Suppl. I):I-142,2009.
  2. Satoh K, Nigro P, OfDell MR, Blaxall BC, Shimokawa H, Berk BC.@Cyclophyllin A promote angiotensin II-induced inflammation and cardiovascular hypertrophy in mice.@Circ J 73(Suppl. I):I-161,2009.
  3. Takagi Y, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanabe Y, Sato T, Ogawa S, Ogawa H, Shimokawa H. Features and preliminary results of the multicenter registry of the coronary spasm association. Circ J 73(Suppl. I):I-158,2009.

ƒˆê”ʉ‰‘聄

  1. Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, Nakayama M, Shimokawa H. Prognostic impact of myocardial fibrosis in systolic heart failure. „ŸNew aspect of usefulness of myocardial biopsy„Ÿ. Circ J 73(Suppl. I):I-511,2009.
  2. Fukuda K, Wakayama Y, Hirose M, Yamaguchi N, Kondo M, Shimokawa H. Inhibition of sodium channels enhances arrhythmogenic regional endocardial substrate in patients with Brugada syndrome.@Circ J 73(Suppl. I):I-693,2009.
  3. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Sugimura K, Miura Y, Kagaya Y, Shimokawa H.@Renin-angiotensin system plays an important role in diabetes mellitus-induced diastolic dysfunction in hypertensive rats.@Circ J 73(Suppl. I):I-511,2009.
  4. Hosoya M, Takaki A, Sawada A, Ohashi J, Shimokawa H.@Combination therapy with an angiotensin receptor blocker and a calcium channel blocker improves EDHF-mediated responses in diabetic Apolipoprotein E-deficient mice.@Circ J 73(Suppl. I):I-593,2009.
  5. Ito Y, Ito K, Shiroto T, Tsuburaya R, Gao JY, Kikuchi Y, Aizawa K, Takeda M, Yasuda S, Shimokawa H.@Extracorporeal cardiac shock wave therapy ameliorates left ventricular remodeling after myocardial ischemia-reperfusion injury in pigs in vivo.@Circ J 73(Suppl. I):I-513,2009.
  6. Miura Y, Fukumoto Y, Fukui S, Satoh K, Sugimura K, Oikawa M, Shimokawa H.@New additional prognostic factors of pulmonary hypertension. „ŸLessons from long-term follow-up study„Ÿ. Circ J 73(Suppl. I):I-202,2009.
  7. Morishita N, Tsutsui M, Nomura M, Sabanai K, Watanabe S, Matsumoto T, Shimokawa H, Shirahata A, Yanagihara N.@Genetic disruption of all nitric oxide synthase isoforms causes accerelated renal lesion formation in mive in vivo. Circ J 73(Suppl. I):I-730,2009.
  8. Nakata S, Tsutsui M, Shimokawa H, Shibata K, Yatera Y, Suda O, Tasaki H, Nakashima Y, Yanagisawa N, Otsuji Y.@Genetic disruption of entire nitric oxide synthase system causes activation of renin-angiotensin-aldosterone axis in mice in vivo. Circ J 73(Suppl. I):I-176,2009.
  9. Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Shimokawa H.@Genetic deletion of OX40 ligand suppresses the development of atherosclerosis in Apolipoprotein E-deficient mice. Circ J 73(Suppl. I):I-431,2009.
  10. Nakayama M, Osaki S, Kato T, Sugimura K, Oikawa M, Fukumoto Y, Shimokawa H.@Gender difference in the responsiveness to corticosteroid therapy in patients with cardiac sarcoidosis.@ Circ J. 73(Suppl. I):I-487,2009.
  11. Nochioka K, Shiba N, Takahashi J, Hirose M, Shimokawa H.@Penetration rate of standard treatment in Japanese patients with chronic heart failure : Interim analysis of the CHART-2 Study.@Circ J 73(Suppl. I):I-346,2009.
  12. Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Shimokawa H.@Genetic deletion of OX40 ligand suppresses the development of atherosclerosis in Apolipoprotein E-deficient mice. Circ J 73(Suppl. I) : 464.
  13. Satoh K, Nigro P, OfDell MR, Shimokawa H, Berk BC. Cyclophillin A is a novel pro- inflammatory cytokine that accerelates development of atherosclerosis. Circ J 73(Suppl. I):I-233,2009.
  14. Satoh K, Nigro P, Matoba T, Shimokawa H, Berk BC. Cyclophillin A promotes vascular oxidative stress and accerelates development of angiotensin II-induced aortic aneurysm. Circ J 73(Suppl. I):I-250,2009.
  15. Shibata K, Tsutsui M, Shimokawa H, Yatera Y, Nakata S, Morishita T, Tasaki H, Nakashima Y, Yanagihara N, Otsuji Y, Furuno Y, Sabanai K. Left ventricular hypertrophy and diastolic dysfunction in mice lacking all nitric synthase isoforms. Circ J 73(Suppl. I):I-222,2009.
  16. Shiroto T, Yasuda S, Tsuburaya R, Ito Y, Takahashi J, Ito K, Ueda H, Shimokawa H. Role of Rho-kinase in the pathogenesis of coronary hyperconstricting responses induced by pacritaxel-eluting stent. Circ J 73(Suppl. I):I-199,2009.
  17. Suda O, Tsutsui M, Shimokawa H, Nakata S, Morishita T, Sabanai K, Tasaki H, Nakashina Y, Yanagihara N, Otsuji Y. Characterization of vascular function in mice lacking entire nitric oxide synthase system. Circ J 73(Suppl. I):I-446,2009.
  18. Sugimura K, Fukumoto Y, Oikawa M, Satoh K, Nakano M, Miura Y, Shimokawa H. Diagnostic usefulness of vasodilator test with inhaled nitric oxide in patients with pulmonary veno-occlusive disease. Circ J 73(Suppl. I):I-666,2009.
  19. Takahashi J, Yasuda S, Takagi Y, Nakayama M, Ito K, Takeda M, Hirose M, Wakayama Y, Fukuda K, Shimokawa H. Co-existance of coronary vasospasm and ventricular fibrillation in patients survived from out-of-hospital cardiac arrest. Circ J 73(Suppl. I):I-442,2009.
  20. Takeda M, Shimokawa H, Kasahara H. Postnatal deletion of Nkx2-5 causes slowly progressive impairment of cardiac conduction and contraction in mice. Circ J 73(Suppl. I):I-223,2009.
  21. Tsuburaya R, Yasuda S, Ito Y, Shiroto T, Gao JY, Ito K, Shimokawa H. Long-term treatment with eicosapentaenoic acid suppresses ischemia-induced ventricular fibrillation in pigs in vivo. „ŸPossible involvement of ATP-sensitive potassium (Katp) channel„Ÿ. Circ J 73(Suppl. I):I-450,2009.
  22. Wakayama Y, Fukuda K, Hirose M, Yamaguchi N, Oikawa M, Ichinose A, Takahashi S, Shi-mokawa H. Usefulness of cardiac magnetic resonance imaging to evaluate cardiac dys-synchrony in patients with chronic heart failure. Circ J 73(Suppl. I):I-604,2009.
  23. Yada T, Shimokawa H, Hiramatsu O, Shinozaki Y, Mori H, Goto M, Ogasawara Y, Kajiya F. Role of H2O2 as an endogenous EDHF during coronary occlusion and injection of erythropoietin in canine coronary native collateral microvessels. Circ J 73(Suppl. I):I-681,2009.
  24. Yasuda S, Sawano H, Hazui H, Ukai I, Yokoyama H, Ohashi J, Sase K, Kada A, Nonogi H. High rates of survival to hospital admission in patients with shock-resistant out-of-hospital ventricular fibrillation treated with nifekalant hydrochloride, a novel and pure class-III agent: report from J-PULSE registry. J-PULSE Investigators. Cic J. 73(Suppl. I) : 442.
  25. Yatera Y, Tsutsui M, Shimokawa H, Nakata S, Shibata K, Furuno Y, Morishita T, Sabanai K, Tasaki H, Nakashima Y, Yanagihara N, Otsuji Y. Severe dyslipidemia and lipid-rich atherosclerotic lesion formation in mice lacking all nitric oxide synthases fed a high-cholesterol diet. Circ J 73(Suppl. I):I-265,2009.
  26. Doe Zhulanqiqige, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, Tada T, Saji K, Sugimura K, Fujita H, Hoshikawa Y, Nawata J, Kondo T, Shimokawa H. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 73(Suppl. I):I-297,2009.
‘æ106‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ïi2009”N4ŒŽ10-12“úC“Œ‹žj
  1. ™‘ºGˆê˜YC•Ÿ–{‹`OC‹yì”ü“ÞŽqC²“¡Œö—YC’†–ì@œCŽO‰Y@—TC‰ºìG–Ÿ : ”xÃ–¬•ÂÇÇ‚̐f’f‚É‚š‚¯‚éˆêŽ_‰»’‚‘f‹z“üŽŽŒ±‚Ì—L—p«
‘æ46‰ñ“ú–{—Տ°•ªŽqˆãŠw‰ïŠwpW‰ïi2009”N4ŒŽ12-13“úC“Œ‹žj

ƒƒVƒ“ƒ|ƒWƒEƒ€ : ˆãH˜AŒg„

  1. ˆÉ“¡Œ’‘ŸCˆÉ“¡ˆ€„C•Ÿ–{‹`OCˆÀ“c@‘C‰ºìG–Ÿ : ’áo—Í‘ÌŠOÕŒ‚”g‚ð—p‚¢‚œ”ñNP«ŒŒŠÇV¶—Ö@‚ÌŠJ”­
‘æ106‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïi2009”N4ŒŽ12“úC“Œ‹žj

ƒu‰‰‰ï@ƒVƒ“ƒ|ƒWƒEƒ€3„

  1. •Ð‰ª@—LC‹{–{ŒbGC‹g­N’ŒCˆÀ“c@‘C¬›‰ë”üC–Ø‘ºˆê—YC‹{èrˆê : “œ”A•a‚ÌŒŒŠÇ‡•¹Ç‚̃g[ƒ^ƒ‹ƒPƒA : ‘Šúf’fC‚»‚µ‚Ä—\–h‚ցCŒyÇ“œ”A•a‚ɑ΂·‚é–ò•š‰î“ü‚É‚æ‚é Š¥“®–¬•a•Ïi“W—\–hŒø‰Ê : DIANA (DIAbetes and diffuse coronary Narrowing Analysis) Œ€‹†‚©‚ç
‘æ48‰ñ“ú–{¶‘̈ãHŠw‰ï‘å‰ïi2009”N4ŒŽ23-25“úC“Œ‹žj

ƒƒI[ƒKƒiƒCƒYƒhƒZƒbƒVƒ‡ƒ“ : ÕŒ‚”gˆã—Á„

  1. ˆÉ“¡Œ’‘ŸCˆÉ“¡ˆ€„C‰ºìG–Ÿ : ’áo—Í‘ÌŠOÕŒ‚”g‚ð—p‚¢‚œV‚µ‚¢ŒŒŠÇV¶—Ö@
‘æ9‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2009”N5ŒŽ8-9“úCÃ‰ªj

ƒ’|‰ºæ¶‚ðŽÃ‚ԁ„

  1. ‰ºìG–Ÿ : ŽŠœ‚Ì‹³ˆçŽÒ‚Æ‚µ‚Ä‚Ì’|‰º²æ¶

ƒƒVƒ“ƒ|ƒWƒEƒ€@¶–œ‰ÈŠw‚É‚š‚¯‚éNOŒ€‹†‚̐V“WŠJ„

  1. “›ˆä³lC’†“c@–õC‰ºìG–ŸC”ö’ҁ@–LC–öŒŽ‰„Í : ˆêŽ_‰»’‚‘f‡¬y‘fŒn‚̈Ӌ`‚ÉŠÖ‚·‚éV’mŒ©

ƒˆê”ʉ‰‘聄

  1. ‘å‹ŽŽqC‚–؁@•¶CXìŒhŽqC‘ºŽR‰À”́CŽRŠÝ•¶lC×’J^‹IC‰ºìG–Ÿ : “à”ç—R—ˆ‰ß•ª‹ÉˆöŽq‚Ì”œ‰ž‚É‚š‚¯‚é“à”çƒIƒLƒVƒ_[ƒ[‚ÌŠÖ—^
  2. –î“c–L—²C‰ºìG–ŸC•œŒ@CCŒã“¡^ŒÈC¬Š}ŒŽN•vCŠ’J•¶•F : ‹}«S‹Ø‹•ŒŒŽžŠ¥”÷¬ŒŒŠÇ‘€•›ŒŒs˜H‚É‚š‚¯‚éƒGƒŠƒXƒƒ|ƒCƒGƒ`ƒ“‚Æ“àˆö«‰ßŽ_‰»…‘f‚Ì–ðŠ„
‘æ148‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2009”N6ŒŽ6“úC·‰ªj
  1. ˆÉ“¡ˆ€„C‚‹Ž@C’†ŽR‰ë°C•“cŽç•FCˆÉ“¡Œ’‘ŸCˆÀ“c@‘C‰ºìG–Ÿ : ƒNƒ‚–Œ‰ºoŒŒ”­Ç’ŒŒã‚ɐ¶‚¶‚œ‹¹’É”­ì‚̊ӕʂɐS‘ŸMSCT‚ª—L—p‚Å‚ ‚Á‚œ1—á
  2. ‘Ÿ“c@~C²“¡Œö—YC•Ÿ–{‹`OC™‘ºGˆê˜YC‹yì”ü“ÞŽqC’†–ì@œCŽO‰Y@—TC‰ºìG–Ÿ : “SÜ‚ÆErythropoietin‚É‚æ‚è‰ES•s‘S‚̉ü‘P‚ð‚Ý‚œ–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì1—á
  3. ‹ß“¡³‹PC•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°C‰ºìG–Ÿ : •p”’†‚ÉPVC‚̛Ɠü‚ð”F‚ߏ㎺«•p”‚ÆŠÓ•Ê‚ð—v‚µ‚œ“Á”­«¶Žº‹NŒ¹SŽº•p”‚̈ê—á
  4. —é–؏G–ŸCŽRŒû“WŠ°C‹ß“¡³‹PCL£®“¿CŽáŽR—TŽiC•Ÿ“c_“ñC‰ºìG–Ÿ : ƒAƒ~ƒIƒ_ƒƒ““à•ž’†‚ɏdÇ‹}«ŠÔŽ¿«”x‰Š‚𔭏ǂµ‚œSŽº•p”‚Ì1—á
  5. ‘ëˆä@’šC•“cŽç•FCˆÉ“¡ˆ€„C’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‚‹Ž@CˆÀ“c@‘C‰ºìG–Ÿ : OCTƒKƒCƒh‰ºPCI‚̍¢“ï‚ðŠŽ‚¶‚œ‹}«S‹Ø[Ç‚̈ê—á
  6. Œã‰ªL‘Ÿ˜YCŽO‰Y³’šC‚‹Ž@C‰ºìG–ŸCŽÄ@MsC‰Í–ìt : ‘Šú‚ÌŽ‘±“IŒŒ‰tàh‰ß“§Í“±“ü‚ª—LŒø‚ÆŽv‚í‚ê‚œ–«S•s‘S‹}«‘ˆ«‚̈ê—á
  7. L£®“¿C‹ß“¡³‹PCŽRŒû“WŠ°CŽáŽR—TŽiC•Ÿ“c_“ñC‰ºìG–Ÿ : ƒy[ƒXƒ[ƒJ[S–[ƒŠ[ƒh‚Ì—¯’u‚ÉCARTOƒVƒXƒeƒ€‚ÌŽg—p‚ª—L—p‚Å‚ ‚Á‚œ“Ž•s‘SÇŒóŒQ‚̈ê—á
  8. •Ÿˆäd•¶C•Ÿ–{‹`OC™‘ºGˆê˜YC“ê“c@~C’†–ì@œCˆÀ“c@‘C‰Á‰ê’J@–LC‰ºìG–ŸCˆ¢•”—Ï–ŸCŽí–{‰ë”VCˆ¢•”‚–ŸCˆÉ“¡’å‰ÃCŠÖŒû@Œå : ‘å“®–¬“àƒoƒ‹[ƒ“ƒpƒ“ƒsƒ“ƒO(IABP)‚Ì’·ŠúŽ¡—Âɂæ‚è‹~ –œ‚µ“Ÿ‚œŠŒF×–EŽî‚É‚æ‚édÇS•s‘S‚̈ê—á
  9. ŽO‰Y@—TC•Ÿ–{‹`OC’†–ì@œC²“¡Œö—YC™‘ºGˆê˜YC‹yì”ü“ÞŽqC‰ºìG–Ÿ : ”x‚ŒŒˆ³Ç‚̐V‚œ‚È—\Œã‹K’èˆöŽq‚ÌŒŸõ
  10. ‹{“¹¹DC‚‹Ž@CˆÀ“c@‘C•“cŽç•FC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸCˆÉ“¡ˆ€„C‘ëˆä@’šC‚–Ø—S‰îC‰ºìG–Ÿ : •ÂŒo‘O—«‚É”F‚ß‚ç‚ê‚œŠ¥”÷¬ŒŒŠÇ«‹·SÇ‚Ì1—á
  11. ŽRŒû“WŠ°C•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿C‹ß“¡³‹PC‰ºìG–Ÿ : ICDƒŠ[ƒh—¯’u‚̍H•v‚ð—v‚µ‚œ’˜–Ÿ‚ȉEŽºŠg‘å‚𔺂€•s®–¬Œ¹«‰EŽºS‹ØÇ‚̈ê—á
‘æ188‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2009”N6ŒŽ20“úCå‘äj
  1. —é–؏G–ŸC•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°C‹ß“¡³‹PC‰ºìG–Ÿ : ƒAƒ~ƒIƒ_ƒƒ““à•ž’†‚ɏdÇ‹}«ŠÔŽ¿«”x‰Š‚𔭏ǂµ‚œSŽº•p”‚Ì1—á
‘æ24‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi2009”N7ŒŽ2-4“úC‹ž“sj
  1. ‹ß“¡³‹PCŽáŽR—TŽiCŽRŒû“WŠ°CL£®“¿C•Ÿ“c_“ñCŠ¡•”–Ÿ•FC‰ºìG–Ÿ : –[ŽºƒuƒƒbƒN‚𔺂€‰Æ‘°«Šg’£Œ^S‹ØÇ‚É‚š‚¯‚éSŽº•p”ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ÌŒoŒ±
  2. •Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°C‹ß“¡³‹PC—é–ؐ³–ŸC‰ºìG–Ÿ : S’âŽ~‘h¶‚ÌŠù‰‚ð‚à‚“Á”­«SŽº×“®‚Ì“d‹C¶—Šw“Á’¥‚Æ‚»‚Ì—\Œã
  3. ŽRŒû“WŠ°C•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿C‹ß“¡³‹PC‰ºìG–Ÿ : “–‰@‚É‚š‚¯‚é–³ÇŒó«BrugadaÇŒóŒQ‚ÌVF—U”­«‚ÉŠÖ‚·‚錟“¢
  4. ŽáŽR—TŽiC‹ß“¡³‹PCŽRŒû“WŠ°CL£®“¿C•Ÿ“c_“ñC‰ºìG–Ÿ : S‘ŸÄ“¯Šú—Ö@Œã‚ÌQGS–@‚É‚æ‚鍶ŽºƒŠƒ‚ƒfƒŠƒ“ƒO‚Ì•]‰¿„Ÿ^‚Ì—LŒø—á‚ÌŒŸ“¢„Ÿ
‘æ41‰ñ“ú–{“®–¬d‰»Šw‰ï‘‰ïEŠwpW‰ïi2009”N7ŒŽ17-18“úC‰ºŠÖj

ƒƒVƒ“ƒ|ƒWƒEƒ€ : ‘å“®–¬áŽ‚ÌŠî‘b‚ƗՏ°„

  1. Nakano M, Fukumoto Y, Satoh K, Ito Y, Kagaya Y, Ishii N, Sugamura K, Shimokawa H. Genetic deletion of OX40 ligand suppresses the development of atherosclerosis in Apolipoprotein E-deficient mice.
  2. Satoh K, Patrizia N, Matoba T, Berk B, Shimokawa H. Cyclophillin A promotes vascular oxidative stress and acclerates development of angiotensin II-induced aortic aneurysms.
ŠâŽèŒ§—§•a‰@ˆãŠw‰ï zŠÂŠí•ª‰È‰ï Šwpu‰‰‰ïi2009”N9ŒŽ9“úC·‰ªj

ƒ“Á•Êu‰‰„

  1. ˆÉ“¡Œ’‘Ÿ : ’áo—Í‘ÌŠOÕŒ‚”g‚ð—p‚¢‚œV‚µ‚¢ŒŒŠÇV¶—Ö@
‘æ57‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2009”N9ŒŽ18-20“úCŽD–yj

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“1 : –«S•s‘S‚ÌŽ¡—Ð헪„

  1. ŽÄ@MsCŒã‰ªL‘Ÿ˜YC‚‹Ž@C’†ŽR‰ë°C‰ºìG–Ÿ : ‹}«S•s‘S‚̉uŠw : “–‰Èƒf[ƒ^ƒx[ƒX‚̉ðÍŒ‹‰Ê‚©‚ç

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“2 : Š¥zŠÂ‚É”—‚遄

  1. ‰ºìG–Ÿ : Š¥zŠÂ§Œä‚̐V’mŒ©

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“4 : uSŒŽ«S’âŽ~‚ÌŽÀ‘ԂƑ΍ô : ‹~‹}‘h¶‘ÛƒKƒCƒhƒ‰ƒCƒ“2010‚ÉŒü‚¯‚āv„

  1. ˆÀ“c@‘ : “d‹C“Iœ×“®’ïR«‰@ŠOS’âŽ~—á‚ɑ΂·‚éIIIŒQÃ’–ò‚̈ʒu•t‚¯ : ƒjƒtƒFƒJƒ‰ƒ“ƒgCƒAƒ~ƒƒ_ƒƒ“‚Ì“Á«‚ð—‰ð‚·‚é

ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[21 : Š¥¹k‚ð‹á–¡‚·‚遄

  1. ‰ºìG–Ÿ : Š¥¹k‚ÉŠÖ‚·‚éÅV‚Ì’mŒ©

ƒPCI‹³ˆçƒZƒbƒVƒ‡ƒ“„

  1. ˆÀ“c@‘ : PCIƒrƒfƒIƒ‰ƒCƒu

ƒˆê”ʉ‰‘聄

  1. ‹ß“¡³‹PCŽRŒû“WŠ°CL£®“¿CŽáŽR—TŽiC•Ÿ“c_“ñC‰ºìG–Ÿ : S–[×“®‚ɑ΂·‚éIcŒQR•s®–¬–ò‚ÅŒ°Ý‰»‚µ‚È‚©‚Á‚œ—LÇŒó«ƒuƒ‹ƒKƒ_ÇŒóŒQ‚̈ê—á
  2. ²“¡’Œ”üC‚‹Ž@C‘ëˆä@’šC•“cŽç•FC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‚–Ø—S‰îCˆÀ“c@‘C‰ºìG–Ÿ : ‘œŽ}¹k‚É”º‚€‘œ—l‚ȐS“d}•Ï‰»‚Æ“ÁˆÙ‚ÈMRIŠŒ©‚𔺂Á‚œ‹}«S‹Ø[ÇÇ—á
  3. Ž…@‹œC™‘ºGˆê˜YC•Ÿ–{‹`OC‹yì”ü“ÞŽqC²“¡Œö—YC’†–ì@œC‰ºìG–Ÿ : ¶–[‚ւ̃Vƒƒƒ“ƒg‚ð”F‚ß‚œ”x“®–¬ŒŽ”­ŒŒŠÇ“÷Žî‚Ì1—á
  4. ™‘ºGˆê˜YC•Ÿ–{‹`OC‹yì”ü“ÞŽqC²“¡Œö—YC’†–ì@œCŽO‰Y@—TC‰ºìG–Ÿ : ”x‚ŒŒˆ³Ç‚̐f’f‚É‚š‚¯‚éˆêŽ_‰»’‚‘f‹z“üŽŽŒ±‚̈Ӌ`
  5. ‘ëˆä@’šC‚‹Ž@CˆÀ“c@‘C‚–Ø—S‰îCˆÉ“¡ˆ€„C’†ŽR‰ë°C•“cŽç•FCˆÉ“¡Œ’‘ŸC‰ºìG–Ÿ : ‹{éŒ§‚É‚š‚¯‚é‹}«S‹Ø[Ç”­Ç30”NŠÔ‚Ì•Ï‘J : MIYAGI-AMIŒ€‹†‚©‚ç
  6. Œã‰ªL‘Ÿ˜YCŽÄ@MsCŽO‰Y³’šC‰Í–ìtC‰ºìG–Ÿ : bó‘B‹@”\áŠQ‚ð‡•¹‚µ‚œSŒŒŠÇŽŸŠ³‚Ì“Á’¥@„ŸCHART-2Œ€‹†’†ŠÔ‰ðÍ‚æ‚è\
  7. L£®“¿C‹ß“¡³‹PCŽRŒû“WŠ°CŽáŽR—TŽiC•Ÿ“c_“ñC‰ºìG–Ÿ : S–[ƒŠ[ƒh‚Ì—¯’u‚ÉCARTOƒVƒXƒeƒ€‚ÌŽg—p‚ª—L—p‚Å‚ ‚Á‚œ“Ž•s‘SÇŒóŒQ‚̈ê—á
  8. ŽO‰Y³’šCŽÄ@MsCŒã‰ªL‘Ÿ˜YC‰Í–ìtC‰ºìG–Ÿ : —˜”A–ò‚Í–«S•s‘SŠ³ŽÒ‚Ì’·Šú—\Œã‚𑝈«‚³‚¹‚é‚©„Ÿ“Œ–k–«S•s‘S“o˜^Œ€‹†‚©‚ç‚Ì•ñ„Ÿ
  9. ŽO‰Y@—TC•Ÿ–{‹`OC’†–ì@œC²“¡Œö—YC‹yì”ü“ÞŽqC™‘ºGˆê˜YC‰ºìG–Ÿ : ”x‚ŒŒˆ³Ç‚̐V‚œ‚È—\Œã‹K’èˆöŽq‚ÌŒŸõ : “–‰@ƒf[ƒ^ƒx[ƒX‰ðÍ‚©‚ç\
‘æ8‰ñŒ§“싹•”ŽŸŠ³Œ€‹†‰ïi2009”N9ŒŽ24“úC‰¡Žèj

ƒŠî’²u‰‰„

  1. ‰ºìG–Ÿ : ‹•ŒŒ«S‘Ÿ•a‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Â̊J”­

ƒ“Á•Êu‰‰„

  1. ˆÉ“¡Œ’‘Ÿ : ’áo—Í‘ÌŠOÕŒ‚”g‚ð—p‚¢‚œV‚µ‚¢ŒŒŠÇV¶—Ö@
‘æ17‰ñ“ú–{ŒŒŠÇ¶•šˆãŠw‰ïi2009”N10ŒŽ8-9“úC“Œ‹žj

ƒYIAiYIAÅ—DGÜŽóÜj„

  1. ²“¡Œö—YC‰ºìG–Ÿ : Cyclophyllin A promotes vascular oxidative stress and accelerates deve-lop-ment of angiotensin II-induced aortic naeurysms.

ƒˆê”ʉ‰‘聄

  1. Žì—–‘Ž‘ŽŠiiƒWƒ‡ƒ‰ƒ“Eƒ`ƒ`ƒSjC•Ÿ–{‹`OC‚–؁@•¶C“cŒŽr‰îC‘å‹ŽŽqC’†–ì@œC‘œ“c’q—mC²Ž¡Œ«ÆC™‘ºGˆê˜YC“¡“c@‰›C¯ì@NC“ê“c@~C‹ß“¡@‹uC‰ºìG–Ÿ : ”x‚ŒŒˆ³Š³ŽÒ‚É‚š‚¯‚éRhoƒLƒi[ƒ[Šˆ«‰»‚̃Gƒrƒfƒ“ƒX
  2. ’†–ì@œC•Ÿ–{‹`OC²“¡Œö—YCˆÉ“¡ˆ€„C‰Á‰ê‰®@–LCÎˆä’ŒlC›‘º˜a•vC‰ºìG–Ÿ : ŠŸó“®–¬d‰»•a•Ï‚É‚š‚¯‚錌ŠÇV¶‚Ì—}§‚ðƒ^[ƒQƒbƒg‚Æ‚µ‚œOX40/OX40LŒn‚ð‰î‚·‚é“®–¬d‰»Ž¡—Ð헪
“Œ–k‘åŠwƒCƒmƒx[ƒVƒ‡ƒ“ƒtƒFƒA2009 in å‘äi2009”N10ŒŽ14“úCå‘äj
  1. ˆÉ“¡Œ’‘ŸC‰ºìG–Ÿ : ’áo—Í‘ÌŠOÕŒ‚”g‚ð—p‚¢‚œV‚µ‚¢ŒŒŠÇV¶—Ö@‚ÌŠJ”­
‘æ46‰ñ“ú–{—Տ°¶—Šw‰ï‘‰ïi2009”N10ŒŽ22-23“úC·‰ªj

ƒ“Á•Êu‰‰„

  1. ‰ºìG–Ÿ : ŒŒŠÇ“à”çNO‡¬y‘fŒn‚̐¶•šŠw“I‘œ—l«‚ɂ‚¢‚Ä

ƒˆê”ʉ‰‘聄

  1. Žì—–‘Ž‘ŽŠiiƒWƒ‡ƒ‰ƒ“Eƒ`ƒ`ƒSjC•Ÿ–{‹`OC‚–؁@•¶C“cŒŽr‰îC‘å‹ŽŽqC’†–ì@œC‘œ“c’q—mC²Ž¡Œ«ÆC™‘ºGˆê˜YC“¡“c@‰›C¯ì@NC“ê“c@~C‹ß“¡@‹uC‰ºìG–Ÿ : ”x‚ŒŒˆ³Š³ŽÒ‚É‚š‚¯‚éRhoƒLƒi[ƒ[Šˆ«‰»‚̃Gƒrƒfƒ“ƒX
  2. ŽO‰Y@—TC•Ÿ–{‹`OC’†–ì@œC²“¡Œö—YC™‘ºGˆê˜YC‹yì”ü“ÞŽqC‰ºìG–Ÿ : ”x‚ŒŒˆ³‚̐V‚œ‚È—\Œã‹K’èˆöŽq‚ÌŒŸõ@„Ÿ—Տ°“I’mŒ©‚©‚ç„Ÿ
‘æ63‰ñ‘—§•a‰@‘‡ˆãŠw‰ïi2009”N10ŒŽ24“úCå‘äj

ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  1. ‰ºìG–Ÿ : S•s‘Sf—Â̍ŋ߂̐i•à
‘æ50‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi2009”N10ŒŽ29-31“úC“Œ‹žj
  1. ‹ÚàV@ŒºC²“¡@¬CˆÉ“¡Œ’‘ŸCŒã“¡@‹ÏC‹Ž–{@ŒhCÔŒ‘å“ñ˜YC›ŒŽG•¶CŒc——“wCŽO‰Y’õŽiCà_“c@—fC‰ºìG–ŸC—¢Œ©@i : ––œ“®–¬ŽŸŠ³(PAD)Š³ŽÒ‚ɑ΂·‚é’áo—Í‘ÌŠOÕŒ‚”g‚ð—p‚¢‚œŽ¡—Â̌Ÿ“¢
‘æ13‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi10ŒŽ30“ú`11ŒŽ1“úC•Ÿ‰ªj

ƒƒVƒ“ƒ|ƒWƒEƒ€ : S•s‘SŠ³ŽÒ‚Æ“Ë‘RŽ€@„Ÿ‚»‚Ì—\–h‚Ƒ΍ô„Ÿ„

  1. Shiba N, Nochioka K, Watanabe J, Tada T, Kohno H, Miura M, Shimokawa H. Sudden cardiac death in patients with chronic heart failure„ŸEpidemiological findings from the CHART Study„Ÿ. J Cardiac Failure. 15(Suppl 1):S141,2009.

ƒˆê”ʉ‰‘聄

  1. Fukuda K, Wakayama Y, Hirose M, Yamaguchi N, Kondo M, Shimokawa H. Inappropriate ICD shocks due to the recovery of AV conduction by prednisolone in a patient with cardiac sarcoidosis. J Cardiac Failure. 15(Suppl 1):S178,2009.
  2. Fukui S, Fukumoto Y, Sugimura K, Nawata J, Nakano M, Miura Y, Yasuda S, Kagaya Y, Shi-mokawa H. A successful case of long-term treatment with intraaortic balloon pumping in severe catecholamine-induced cardiomyopathy due to pheochromocytoma. J Cardiac Failure. 15(Suppl 1):S173,2009.
  3. Miura M, Shiba N, Nochioka K, Takahashi J, Nakayama M, Tatebe S, Kohno H, Osaki S, Fuku-moto Y, Shimokawa H. Characteristics of Japanese patients with acute heart failure ; Risks of in-hospital mortality. J Cardiac Failure. 15(Suppl 1):S154,2009.
  4. Miura Y, Fukumoto Y, Nakano M, Satoh K, Sugimura K, Oikawa M, Shimokawa H. New addi-tional prognostic factors of pulmonary hypertension. „ŸLessons from long-term folloe-up study„Ÿ . J Cardiac Failure. 15(Suppl 1):S156,2009.
  5. Nochioka K, Shiba N, Miura M, Kohno H, Shimokawa H. Characteristics of subclinical hypo-thyroid disease in patients with cardiovascular diseases. „ŸInterim analysis of the CHART-2 Study„Ÿ. J Cardiac Failure. 15(Suppl 1):S158,2009.
  6. Oikawa M, Takii T, Miyamichi S, Sugimura K, Fukumoto Y, Shimokawa H. Usefulness of car-diac magnetic resonance imaging in the clinical risk stratification in patients with hypertrophic cardiomyopathy. J Cardiac Failure. 15(Suppl 1):S163,2009.
  7. Shiba N, Nochioka K, Kohno H, Takahashi J, Miura M, Shimokawa H. Long-term use of diure-tics may be associated with increased cardiac events in patients with chronic heart failure. J Cardiac Failure. 15(Suppl 1):S167,2009.
  8. Takahashi J, Yasuda S, Sato T, Shimokawa H. Continous renal replacement therapy in patients with acute decompensated heart failure and cardiorenal syndrome. J Cardiac Failure. 15(Suppl 1):S171,2009.
  9. Wakayama Y, Kondo M, Yamaguchi N, Hirose M, Fukuda K, Shimokawa H. Characteristics of gtrueh responders with left ventricular reverse remodeling after cardiac resynchronization therapy. J Cardiac Failure. 15(Suppl 1):S165,2009.
‘æ149‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2009”N12ŒŽ12“úCå‘äj

ƒYIAÇ—á”­•\•”–åiYIA—DGÜŽóÜj„

  1. Ž…@‹œC™‘ºGˆê˜YC•Ÿ–{‹`OC‹yì”ü“ÞŽqC²“¡Œö—YC’†–ì@œC‰ºìG–ŸC‚£@Œ\CˆÉ“¡‚µ‚°‚݁C’†‘º•ÛG : ”xÇðÇ‚ð‡•¹‚µ‚œ”x“®–¬ŒŽ”­ŒŒŠÇ“÷Žî‚Ì1–UŒŸ—á

ƒYIAŒ€‹†”­•\•”–åiYIAÅ—DGÜŽóÜj„

  1. ‚–Ø—S‰îCˆÀ“c@‘C‚‹Ž@C•“cŽç•FC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸCL£®“¿CŽáŽR—TŽiC•Ÿ“c_“ñC‰ºìG–Ÿ : ‰@ŠOS’âŽ~‚̐¬ˆö‚š‚æ‚Ñ—\Œã : Š¥¹k‚ƐSŽº×“®‚Ì“ñd—U”­ŽŽŒ±‚̏d—v«

ƒˆê”ʉ‰‘聄

  1. ‹àŽqm•FC•Ÿ–{‹`OC™‘ºGˆê˜YC’†–ì@œC‹{“¹¹DCŒš•”r‰îC‹yì”ü“ÞŽqC²“¡Œö—YC‰ºìG–Ÿ : ‹‘劥“®–¬„Ÿ”x“®–¬˜KEᎂ̈ê—á
  2. ‹àŽqm•FC•Ÿ–{‹`OC™‘ºGˆê˜YC’†–ì@œC‹{“¹¹DCŒš•”r‰îC‹yì”ü“ÞŽqC²“¡Œö—YC‰ºìG–Ÿ : ‘O–э׌ŒŠÇ«‚š‚æ‚ÑŒã–э׌ŒŠÇ«”x‚ŒŒˆ³Ç‚ð—L‚µ‚œ‰Ì•‘ŠêÇŒóŒQ‚̈ê—á
  3. ‹ß“¡³‹PC•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°C‰ºìG–Ÿ : ƒXƒeƒƒCƒh‚É‚æ‚è–[Žº“`“±‚ª‰ñ•œ‚µ“Ž«•p–¬‚ɑ΂µ‚ÄICDŒëì“®‚ð”F‚ß‚œSƒTƒ‹ƒRƒCƒh[ƒVƒX‚̈ê—á
  4. ‚‹Ž@CˆÀ“c@‘C‘ëˆä@’šC•“cŽç•FCˆÉ“¡ˆ€„C’†ŽR‰ë°C‚–Ø—S‰îCˆÉ“¡Œ’‘ŸC‰ºìG–Ÿ : ’·Šúƒ~ƒ‹ƒŠƒmƒ““Š—^‚ª—LŒø‚Å‚ ‚Á‚œ‹•ŒŒ«dÇ‘m–X•Ù•Âœ•s‘SÇ‚̈ê—á
  5. Œã‰ªL‘Ÿ˜YC‰ºìG–ŸCŽÄ@MsC‰Í–ìtCŽO‰Y³’š : –«S•s‘SÇ—á‚É‚š‚¯‚é’áT3ÇŒóŒQ‚Ì“Á’¥‚Æ‚»‚Ì•p“x@„ŸCHART-2Œ€‹†’†ŠÔ‰ðÍ„Ÿ
  6. ‹{“¹¹DC‹yì”ü“ÞŽqC•Ÿ–{‹`OC™‘ºGˆê˜YC²“¡Œö—YC’†–ì@œC‰ºìG–Ÿ : ”ì‘åŒ^S‹ØÇŠ³ŽÒ‚É‚š‚¯‚é’x‰„‘¢‰eMRI‚Ì—\Œã—\‘ªˆöŽq‚Æ‚µ‚Ä‚Ì—L—p«‚ɂ‚¢‚Ä
  7. ‹g“c’ŒŽ÷C‚‹Ž@CˆÀ“c@‘C•“cŽç•FCˆÉ“¡ˆ€„C’†ŽR‰ë°C‚–Ø—S‰îC‘ëˆä@’šCˆÉ“¡Œ’‘ŸCŽÄ@MsC‰ºìG–Ÿ : ˆÚASŠ¥“®–¬‚É‚š‚¯‚éOCTŽg—p‚ÌŒoŒ±
  8. ŽáŽR—TŽiC•Ÿ“c_“ñCL£®“¿CŽRŒû“WŠ°C‹ß“¡³‹PC‰ºìG–Ÿ : “–‰@‚É‚š‚¯‚éS‘ŸÄ“¯Šú—Ö@‚̍¶Žº‹tƒŠƒ‚ƒfƒŠƒ“ƒOŒø‰Ê‚ÌŒŸ“¢
zŠÂŠí•aŒ€‹†ˆÏ‘õ”ï20Œö-3@•œ¬21”N“x”ljï‹ci2009”N12ŒŽ18“úC‘åãj
  1. ‰ºìG–Ÿ : ƒXƒ^ƒ`ƒ“‚Ì‘œ–Ê“Iì—p‚ÉŠÖ‚·‚éƒVƒOƒiƒ[ƒ€‰ðÍ

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2008”N
‘æ37‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïi2008”N2ŒŽ2“úCå‘äj

ƒƒVƒ“ƒ|ƒWƒEƒ€ : ŒŒŠÇ“à”ç—R—ˆS–¬ŠÇì“®•šŽ¿‚̍ŐV‚Ì’mŒ©„

  1. “›ˆä³lC‰ºìG–ŸC’†“c –õC––õŽqCŽÄ“cŽŽqCŽç‰º ŠžC”ö’Ò –LC–öŒŽ‰„Í : SŒŒŠÇ•a‚ÆNO : NO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚©‚ç“Ÿ‚ç‚ê‚œV’mŒ©
  2. ŽÄ“cŽŽqC“›ˆä³lC‰ºìG–ŸC”ö’Ò –LC’†“c –õC²‰H“à Œ€C––õŽqCL£‹ÅŽqCŒÃ–ì—R”üC‘Ÿè”Ž”üC–öŒŽ‰„Í : NO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚ÉŒ©‚ç‚ê‚œ¶Žº”ì‘å‚ƐSŠg’£‹@”\áŠQ
  3. ‚–Ø •¶CXìŒhŽqCŽRŠÝ•¶lC‘ºŽR‰À”́CƒeƒPƒXƒGƒ“ƒ_[C“›ˆä³lC–öŒŽ‰„ÍC‰ºìG–Ÿ : “à”ç—R—ˆ‰ß•ª‹ÉˆöŽq (EDHF) ”œ‰ž‚ÍNO‡¬y‘fŒn‚ÉŠ®‘S‚Ɉˑ¶‚·‚é \ NO‡¬y‘fŒnŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚錟“¢ \
  4. ‘œ“c’q—mC“ê“c ~C‰€ Š©C”öã‹IŽqCƒWƒ‡ƒ‰ƒ“ƒ`ƒ`ƒSCˆÉ“¡Œ’‘ŸC™‘ºGˆê˜YC•Ÿ–{‹`OC‰ºìG–Ÿ : –¬ˆ³‚É‚æ‚é•œŠŠ‹Ø×–E‚É‚š‚¯‚é—V‘–”\‚̕ω»‚ÌŒŸ“¢
  5. “›ˆä³lC’†“c –õC‰ºìG–ŸC²‰H“à Œ€C–öŒŽ‰„Í : ƒAƒgƒ‹ƒoƒXƒ^ƒ`ƒ“‚ÍŒŒŠÇ‚̐_ŒoŒ^NO‡¬y‘f‚Ì”­Œ»‚ðAkt/NF-kBŒo˜H‚ð‰î‚µ‚ĘŽi‚³‚¹‚é
  6. ‰~’J—²Ž¡CˆÀ“c ‘CˆÉ“¡ˆ€„C”’ŒË ’C‚ ŒR‹BCˆÉ“¡Œ’‘ŸC‰ºìG–Ÿ : ’·ŠúƒGƒCƒRƒTƒyƒ“ƒ^ƒGƒ“Ž_“Š—^‚Ì‹•ŒŒÄŸó—¬áŠQ‚ɑ΂·‚éŒø‰Ê \ ƒuƒ^‹}«‹•ŒŒÄŸó—¬‚ð—p‚¢‚œŒŸ“¢ \
  7. ’†–ì œC•Ÿ–{‹`OC²“¡Œö—YCˆÉ“¡ˆ€„C‰ºìG–Ÿ : ŒŒŠÇ‹ÇŠ‚ÌOX40ƒŠƒKƒ“ƒh‚Í“®–¬d‰»•a•ÏŒ`¬‚ɏd—v‚È“­‚«‚ð’S‚Á‚Ä‚¢‚é
  8. ’†–ì œC•Ÿ–{‹`OC²“¡Œö—YCˆÉ“¡ˆ€„C‰ºìG–Ÿ : ƒvƒ‰ƒoƒXƒ^ƒ`ƒ“‚ÍStromal Cell-Derived Factor-1‚Ì—}§‚ð‰î‚µ‚ă}ƒEƒX‚É‚š‚¯‚é’áŽ_‘f«”x‚ŒŒˆ³‚ð‰ü‘P‚·‚é
  9. •Ÿˆäd•¶C•Ÿ–{‹`OC—é–Ø C²Ž¡Œ«ÆC“cŒŽr‰îC™‘ºGˆê˜YC“ê“c ~C‰Á‰ê’J –LC‰ºìG–Ÿ : Rho-kinase‚Ì’·Šú‘jŠQ‚͍‚ŒŒˆ³ƒ‰ƒbƒg‚É‚š‚¯‚éŠg’£•s‘S‚ð‰ü‘P‚³‚¹‚é
  10. •Ÿˆäd•¶C•Ÿ–{‹`OC—é–Ø C²Ž¡Œ«ÆC™‘ºGˆê˜YC“ê“c ~C‰Á‰ê’J –LC‰ºìG–Ÿ : “œ”A•a‚ª¶ŽºŠg’£‹@”\áŠQ‚ðˆ«‰»‚³‚¹‚郁ƒJƒjƒYƒ€‚ɂ‚¢‚Ä : ƒ_[ƒ‹H‰–ŠŽŽó«‚ŒŒˆ³ƒ‰ƒbƒg‚É‚š‚¯‚錟“¢
  11. Rashid MC“cŒŽr‰îC•Ÿ–{‹`OC‰ºìG–Ÿ : Molecular mechanisms of the pleiotropic effects of HMG-CoA reductase inhibitors \ Different inhibitory effects on Rho GTPases \
zŠÂŠíŽŸŠ³“™¶ŠˆKŠµ•a‘΍ô‘‡Œ€‹†E“œ”A•aí—ª“™Œ€‹†¬‰Ê”­•\‰ïi2008”N2ŒŽ7“úC“Œ‹žj
  1. ‰ºìG–Ÿ : –«S•s‘S‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚̈Ӌ`‚ÉŠÖ‚·‚錀‹†
‘æ1‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2008”N2ŒŽ9“úC“Œ‹žj

ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  1. ‰ºìG–Ÿ : ‹•ŒŒ«S‘Ÿ•a‚É‚š‚¯‚鐫·‚ɂ‚¢‚čl‚Š‚é
‘æ145‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2008”N2ŒŽ23“úCå‘äj
  1. ˆÉ“¡Œ’‘ŸCˆÀ“c ‘C‚‹Ž C‰z“c—ºŽiC’†ŽR‰ë°C‘¶‘ה́C‘œ“c’q—mC‰Á‰ê’J –LC‰ºìG–Ÿ : ƒˆ[ƒhƒAƒŒƒ‹ƒM[Ç—á‚ɑ΂·‚éƒKƒhƒŠƒjƒEƒ€‘¢‰eÜ‚ð—p‚¢‚œŠ¥“®–¬‘¢‰e
  2. —é–؏G–ŸC‰z“c—ºŽiCˆÉ“¡Œ’‘ŸC’†ŽR‰ë°C‘œ“c’q—mC‘¶‘ה́C‚‹Ž CˆÀ“c ‘C‰Á‰ê’J –LC‰ºìG–Ÿ : ƒTƒCƒtƒ@[—¯’uŒã‚Éincomplete stent apposition‚ð‡•¹‚µlate stent thrombosis‚𗈂µ‚œ2Ç—á‚ÌŒoŒ±
  3. ‚‹Ž CˆÀ“c ‘C‰z“c—ºŽiC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‘¶‘ה́C‘œ“c’q—mC‰Á‰ê’J –LC‰ºìG–Ÿ : ”ñS‘ŸŽèp‘O‚É’á”x‹@”\‚Ì‚œ‚ßPCIEOPCAB‚É‚æ‚éƒnƒCƒuƒŠƒbƒhŠ®‘SŠ¥ŒŒsÄŒš‚ðŽ{s‚µ‚œ1—á
  4. ‘œ“c’q—mCŽÄ MsCŒ–Ø”üC‚‹Ž C‰ºìG–Ÿ : “ú–{l‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€f’f‚ÌŽŠ“KƒEƒGƒXƒgŽüˆÍŒa‚Æ‚Í ? \ CHART-2Œ€‹†‚©‚ç‚Ì’†ŠÔ•ñ \
  5. L£®“¿CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiCŽRŒû“WŠ°C‰ºìG–Ÿ : Ensite system‚ðŽg—p‚µ‚ăAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚œ‰EŽº—¬o˜H‹NŒ¹SŽº«ŠúŠOŽûk‚̈ê—á
  6. •Ÿˆäd•¶C•Ÿ–{‹`OC™‘ºGˆê˜YC“ê“c ~C²Ž¡Œ«ÆCŽO‰Y —TC‰Á‰ê’J –LC‰ºìG–Ÿ : ŒŒ«S”X‰t‚ð”F‚ß‚œeffusive constrictive pericarditis‚̈ê—á
  7. •Ÿ“c_“ñCŒF’J_ŽiCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°C›ˆä‹`®C‰ºìG–ŸC˜Q‘Ő¬l : VF’âŽ~Œã‚Ì‘€•Ç—U“±‚É‚ÄSTãž‚ð”F‚ß‚œŠ¥¹k‡•¹BrugadaÇŒóŒQ‚Ì1—á
  8. ŽO‰Y —TC•Ÿ–{‹`OC•Ÿˆäd•¶C™‘ºGˆê˜YC“ê“c ~C‰ºìG–Ÿ : ŠŽ–`—lÇó‚É‘±”­‚µ‚œbó‘B‹@”\˜ŽiÇ‚ðŒ_‹@‚É‘ˆ«‚µ‚œ”x‚ŒŒˆ³Ç‚̈ê—á
  9. ŽRŒû“WŠ°CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CL£®“¿C‰ºìG–Ÿ : ’ʏíŒ^S–[‘e“®‚É‚š‚¯‚é‰ES–[“`“±‘¬“x‚ÌŒŸ“¢
  10. ŽáŽR—TŽiCŒF’J_ŽiC•Ÿ“c_“ñCL£®“¿CŽRŒû“WŠ°C‰ºìG–Ÿ : ¶Žºãk–§‰»áŠQ—l‚̏ŠŒ©‚ð’悵‚œŠg’£‘Š”ì‘åŒ^S‹ØÇ‚̈ê—á
‘æ72‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2008”N3ŒŽ28“ú`30“úC•Ÿ‰ªj

ƒSymposium : Coronary spasm revisited„

  1. Yasuda S, Ogawa H, Shimokawa H. Coronary spasm association : Nationwide multicenter study. Circ J 72(Suppl. I):I-27,2008.

ƒSymposium : Update in cardiomyopathy \ Novel approaches; novel targets \„

  1. Karibe A, Saga A, Otomo J, Shinozaki T, Shimokawa H. Molecular genetics of cardiomyopathy with conduction disturbance and arrhythmia. A revision of the gelectric disturbance type of cardiomyopathyh. Circ J 72(Suppl. I):I-44,2008.

ƒSymposium : Stroke and cardiorenal complications in hypertension„

  1. Kagaya Y, Tada T, Asaumi Y, Nakano M, Satoh K, Shiba N, Fukumoto Y, Minegishi N, Shimokawa H. Potential roles of anemia and endogenous erythropoietin-mediated signaling in cardiorenal syndrome with hypertension. Circ J 72(Suppl. I):I-46,2008.

ƒSymposium : How can we make the best use of Japanese evidence for future guidelines„

  1. Shiba N, Matsuki M, Takahashi J, Hirose M, Fukumoto Y, Kagaya Y, Shimokawa H. Large cohort studies for the establishment of guidelines of chronic heart failure in Japan. Circ J 72(Suppl. I):I-62,2008.

ƒƒVƒ“ƒ|ƒWƒEƒ€11 : Stroke and cardiorenal complications in hypertension„

  1. Kagaya Y, Tada T, Asaumi Y, Nakano M, Satoh K, Shiba N, Fukumoto Y, Minegishi N, Shimokawa H. Potential roles of anemia and endogenous erythropoietin-mediated signaling in cardiorenal syndrome with hypertension. Circ J. 72(Suppl. I):46,2008.

ƒƒVƒ“ƒ|ƒWƒEƒ€10 : Update in cardiomyopathy\Novel approaches; novel targets\„

  1. Karibe A, Saga A, Otomo J, Shinozaki T, Shimokawa H. Molecular genetics of cardiomyopathy with conduction disturbance and arrhythmia. A revision of the gelectric disturbance type of cardiomyopathyh. Circ J. 72(Suppl. I):44,2008.

ƒƒVƒ“ƒ|ƒWƒEƒ€18 : How can we make the best use of Japanese evidence for future guidelines„

  1. Shiba N, Matsuki M, Takahashi J, Hirose M, Fukumoto Y, Kagaya Y, Shimokawa H. Large cohort studies for the establishment of guidelines of chronic heart failure in Japan. Circ J. 72(Suppl. I):62,2008.

ƒƒVƒ“ƒ|ƒWƒEƒ€2 : Coronary spasm revisited„

  1. Yasuda S, Ogawa H, Shimokawa H. Coronary spasm association : Nationwide multicenter study. Circ J. 72(Suppl. I):27,2008.

ƒFRS-36„

  1. Nakata S, Tsutsui M, Shimokawa H, Morishita T, Suda O, Sabanai K, TYatera Y, Shibata K, Tasaki H, Nakashima Y, Yanagihara N, Otsuji Y. Gender difference of arteriosclerotic cardiovascular diseases in mice lacking all nitric oxide synthase isoforms. Circ J. 72(Suppl. I):151,2008.

ƒˆê”ʉ‰‘聄

  1. Doe Z, Nawata J, Tawara S, Tada T, Sugimura K, Saji K, Fujita H, Fukumoto Y, Shimokawa H. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 72(Suppl. I):I-699,2008.
  2. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Kagaya Y, Shimokawa H. Diabetes mellitus accelerates left ventricular diastolic dysfunction through activation of rennin-angiotensin system in hypertensive rats. Circ J 72(Suppl. I):I-214,2008.
  3. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Tawara S, Kagaya Y, Shimokawa H. Inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. Circ J 72(Suppl. I):I-444,2008.
  4. Fukumoto Y, Fujita H, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Circ J 72(Suppl. I):I-501,2008.
  5. Hirose M, Endoh H, Sugai Y, Wakayama Y, Miura M, Shimokawa H. JTV-519 reverses abnormal Ca2+ release and Ca2+ waves in Purkinje cells from the infarcted canine heart. Circ J 72(Suppl. I):I-304,2008.
  6. Miura M, Wakayama Y, Shimokawa H. Spatial non-uniformity of excitation-contraction coupling enhances delayed afterdepolarizations in rat cardiac traveculae \ Possible arrhythmogenic effects of non-uniform myocardial contraction \. Circ J 72(Suppl. I):I-217,2008.
  7. Nakano M, Fukumoto Y, Satoh K, Ito Y, Shimokawa H. Genetic deletion of OX40 ligand suppresses the development of atherosclerosis in apoprotein E-deficient mice. Circ J 72(Suppl. I):I-228,2008.
  8. Nakano M, Satoh K, Fukumoto Y, Sugimura K, Nawata J, Demachi J, Karibe A, Kagaya Y, Watanabe J, Shirato K, Shimokawa H. Pravastatin ameliorates hypoxia-induced pulmonary arterial hypertension through down-regulation of stromal cell-derived factor-1 in mice. Circ J 72(Suppl. I):I-554,2008.
  9. Nakata S, Tsutsui M, Shimokawa H, Morishita T, Suda O, Sabanai K, Yatera Y, Shibata K, Tasaki H, Nakashima Y, Yanagihara N, Otsuji Y. Gender difference of arteriosclerotic cardiovascular diseases in mice lacking all nitric oxide synthase isoforms. Circ J 72(Suppl. I):I-151,2008.
  10. Nakata S, Tsutsui M, Shimokawa H, Suda O, Sabanai K, Yatera Y, Shibata K, Morishita T, Tasaki H, Nakashima Y, Yanagihara N, Otsuji Y. Statin treatment ameliorates metabolic syndrome in mice lacking all nitric oxide synthase isoforms. Circ J 72(Suppl. I):I-203,2008.
  11. Nakata S, Tsutsui M, Shimokawa H, Morishita T, Sabanai K, Suda O, Yatera Y, Shibata K, Tasaki H, Nakashima Y, Yanagihara N, Otsuji Y. Important role of the renin-angiotensin system in the pathogenesis of myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circ J 72(Suppl. I):I-248,2008.
  12. Nakata S, Tsutsui M, Shimokawa H, Yatera Y, Shibata K, Morishita T, Sabanai K, Suda O, Tasaki H, Nakashima Y, Yanagihara N, Otsuji Y. Abnormal low-density lipoprotein metabolisms in mice lacking all nitric oxide synthase isoforms. Circ J 72(Suppl. I):I-310,2008.
  13. Rashid M, Tawara S, Fukumoto Y, Shimokawa H. Molecular mechanisms of the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J 72(Suppl. I):I-457,2008.
  14. Sugai Y, Ichinose A, Kumagai K, Fukuda K, Wakayama Y, Hirose M, Yamaguchi N, Shimokawa H. Assessment of delayed enhancement scoring on MRI in patients with cardiac sarcoidosis with implantable cardioverter defibrillator. Circ J. 72(Suppl. I):671,2008.
  15. Sugimura K, Fukumoto Y, Nawata J, Saji K, Fukui S, Miura Y, Shimokawa H. Prognostic impact of main pulmonary artery remodeling in patients with pulmonary arterial hypertension. Circ J 72(Suppl. I):I-502,2008.
  16. Tada T, Shiba N, Matsuki M, Takahashi J, Shimokawa H. What is the optimal circumference cut-point to diagnose metabolic syndrome in Japanese population ? \ Interim analysis from the CHART-2 Study \ . Circ J 72(Suppl. I):I-166,2008.
  17. Tada T, Shiba N, Matsuki M, Takahashi J, Hirose M, Shimokawa H. What is the optimal therapeutic target of hemoglobin level in patients with chronic heart failure ? \ Lessons from the CHART Study \. Circ J 72(Suppl. I):I-211,2008.
  18. Tada T, Shiba N, Matsuki M, Takahashi J, Shimokawa H. Long-term mortality of Japanese patients with diastolic heart failure. Circ J 72(Suppl. I):I-234,2008.
  19. Tada T, Nawata J, Wang H, Onoue N, Doe Z, Ito K, Sugimura K, Fukumoto Y, Shimokawa H. Enhanced pulsatile pressure accelerates vascular smooth muscle migration \ Implication for atherogensis of hypertension \ Circ J 72(Suppl. I):I-254,2008.
  20. Takahashi J, Koshida R, Kokusho Y, Tada T, Nakayama M, Ito K, Shimokawa H. Importance of dual induction test for coronary vasospasm and ventricular fibrillation in patients survived from out-of-hospital cardiac arrest. Circ J 72(Suppl. I):I-279,2008.
  21. Takahashi J, Yasuda S, Koshida R, Ito K, Nakayama M, Tada T, Kokusho Y, Shimokawa H. Significance of basal coronary artery tone in patients with vasospastic angina : Analysis by using quantitative coronary angiography. Circ J 72(Suppl. I):I-361,2008.
  22. Takahashi J, Shiba N, Tada T, Matsuki M, Shimokawa H. Undernutrition is an important prognostic factor of cardiac death in patients with diastolic heart failure. Circ J 72(Suppl. I):I-496,2008.
  23. Takaki A, Morikawa K, Murayama Y, Tekes E, Ohashi J, Tsutsui M, Yanagihara N, Shimokawa H. Endothelium-dependent hyperpolarizations are totally dependent on endothelial nitric oxide synthases system \ Lessons from mice lacking all nitric oxide synthase isoforms \ . Circ J 72(Suppl. I):I-535,2008.
  24. Tsuburaya R, Yasuda S, Ito Y, Shiroto T, Ito K, Shimokawa H. Long-term treatment with eicosapentaenoic acid suppresses ventricular fibrillation in acute myocardial infarction in pigs \ Evaluation with monophasic action potential \. Circ J 72(Suppl. I):I-518,2008.
  25. Wakayama Y, Kumagai K, Fukuda K, Sugai Y, Hirose M, Yamaguchi N, Shimokawa H. Cardiac resynchronization therapy reduces premature ventricular contractions but not ventricular tachyarrhythias in patients with chronic heart failure. Circ J 72(Suppl. I):I-337,2008.
  26. Yada T, Shimokawa H, Hiramatsu O, Shinozaki Y, Mori H, Goto M, Ogasawara Y, Kajiya F. Crucial role of H2O2 as an endogenous EDHF and erythropoietin during acute coronary occlusion in canine collateral microvessels in vivo. Circ J 72(Suppl. I):I-574,2008.
  27. Yamaguchi N, Kumagai K, Fukuda K, Wakayama Y, Sugai Y, Hirose M, Shimokawa H. Properties of the substrates in the right atrial septum in patients with typical atrial flutter. Circ J 72(Suppl. I):I-481,2008.

ƒƒ‰ƒCƒuƒfƒ‚ƒ“ƒXƒgƒŒ[ƒVƒ‡ƒ“„

  1. ŒF’J_Ži : •s®–¬ƒrƒfƒIƒ‰ƒCƒu1PSVT¶–[‹NŒ¹‚ÌPSVT
‘æ105‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ïi2008”N4ŒŽ11“úC“Œ‹žj

ƒˆê”ʉ‰‘èƒvƒŒƒiƒŠ[„

  1. ‘œ“c’q—mCŽÄ MsCŒ–Ø”üC‚‹Ž C‰ºìG–Ÿ : “ú–{l‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€f’f‚ÌŽŠ“KƒEƒGƒXƒgŽüˆÍŒa‚Æ‚Í ? \ CHART-2Œ€‹†‚©‚ç‚Ì’†ŠÔ•ñ \ “ú–{“à‰ÈŠw‰ïŽGŽ97i—ÕŽž‘Š§†) : 137, 2008.
‘æ36‰ñ“ú–{ŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[i2008”N4ŒŽ17“úC“Œ‹žj
  1. ‰ºìG–Ÿ : ’áo—Í‘ÌŠOÕŒ‚”g‚ð—p‚¢‚œ”ñNP«ŒŒŠÇV¶—Ö@‚ÌŠJ”­
‘æ8‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2008”N5ŒŽ9“ú`10“úCå‘äj

ƒƒVƒ“ƒ|ƒWƒEƒ€ : Šˆ«Ž_‘fŽí‚̏zŠÂŠíŒn‚É‚š‚¯‚鐶—“I–ðŠ„„

  1. ‚–Ø •¶CXìŒhŽqC‘ºŽR‰À”́CEnder TekesCŽRŠÝ•¶lC‘å‹ŽŽqC“›ˆä³lC–öŒŽ‰„ÍC‰ºìG–Ÿ : “à”ç—R—ˆ‰ß•ª‹ÉˆöŽq (EDHF) ”œ‰ž‚ÍNO‡¬y‘fŒn‚ÉŠ®‘S‚Ɉˑ¶‚·‚é
  2. “›ˆä³lC‰ºìG–ŸC–öŒŽ‰„ÍC”ö’Ò –L : zŠÂŠíŽŸŠ³‚É‚š‚¯‚éNOSƒVƒXƒeƒ€—R—ˆNO‚Ì–ðŠ„ : NOSƒVƒXƒeƒ€Š®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚錟“¢
  3. –î“c–L—²C‰ºìG–Ÿ : “à”ç—R—ˆ‰ß•ª‹ÉˆöŽq‚Æ‚µ‚Ẳߎ_‰»…‘f‚̐¶‘Ì“à”÷¬zŠÂ‚É‚š‚¯‚é–ðŠ„

ƒYIA„

  1. ‚–Ø •¶CXìŒhŽqC‘ºŽR‰À”́CƒeƒPƒXƒGƒ“ƒ_[CŽRŠÝ•¶lC‘å‹ŽŽqC“›ˆä³lC–öŒŽ‰„ÍC‰ºìG–Ÿ : “à”çˆË‘¶«‰ß•ª‹É”œ‰ž‚É‚š‚¯‚éˆêŽ_‰»’‚‘f‡¬y‘fŒn‚̏d—v‚È–ðŠ„

ƒˆê”ʉ‰‘聄

  1. ²”g“à Œ€C“›ˆä³lCŽðˆäº“TC•œàV‰pKC“c’†LÆC’†‘º‰pˆê˜YCˆÈ“Œ¹ŽqC‰ºìG–ŸC–öŒŽ‰„ÍC’†‘º—˜K : NO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚鍜‘ãŽÓ‰ñ“]‚̘Ži‚ƍœ–§“x‚Ì‘‰Á : ƒŒƒjƒ“EƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Œn‚ÌŠÖ—^
  2. ’†“c –õC“›ˆä³lC‰ºìG–ŸC²”g“à Œ€C–öŒŽ‰„Í : ƒAƒgƒ‹ƒoƒXƒ^ƒ`ƒ“‚ÍŒŒŠÇ‚̐_ŒoŒ^NO‡¬y‘f‚Ì”­Œ»‚ðAkt/NF-kB‚ð‰î‚µ‚ĘŽi‚³‚¹‚é
  3. •Ÿˆäd•¶C•Ÿ–{‹`OC—é–Ø C²Ž¡Œ«ÆC“cŒŽr‰îC™‘ºGˆê˜YC“ê“c ~C‰Á‰ê’J –LC‰ºìG–Ÿ : Rho-kinase‚Ì’·Šú‘jŠQ‚͍‚ŒŒˆ³ƒ‰ƒbƒg‚É‚š‚¯‚éŠg’£•s‘S‚ð‰ü‘P‚³‚¹‚é
  4. •Ÿˆäd•¶C•Ÿ–{‹`OC—é–Ø C²Ž¡Œ«ÆC™‘ºGˆê˜YC“ê“c ~C‰Á‰ê’J –LC‰ºìG–Ÿ : “œ”A•a‚͍‚ŒŒˆ³ƒ‰ƒbƒg‚É‚š‚¢‚ăŒƒjƒ“[ƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Œn‚ÌŠˆ«‰»‚ð‰î‚µ‚趎ºŠg’£”\áŠQ‚ðˆ«‰»‚³‚¹‚é
  5. •Ÿ–{‹`OC“¡“c ‰›C²Ž¡Œ«ÆC™‘ºGˆê˜YCo’¬ ‡C“ê“c ~C‰ºìG–Ÿ : ”x‚ŒŒˆ³Š³ŽÒ‚ɑ΂·‚éRhoƒLƒi[ƒ[‘jŠQ–ò‹z“ü—Ö@‚Ì‹}«Œø‰Ê
  6. X’å’ŒÆC“›ˆä³lC–쑺³—ǁC²”g“à Œ€C’J–{º‰pCŒ–{“N˜NCùŒI–õ”VC‰ºìG–ŸC–öŒŽ‰„ÍC”’”Š ‘ : ”AŠÇŒ‹ãFŒã‚̐t•a•ÏŒ`¬‚É‚š‚¯‚éNO‡¬y‘fƒVƒXƒeƒ€‚̐t•ÛŒìì—p : NO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚錟“¢
  7. ––õŽqC“›ˆä³lC‰ºìG–ŸC’†“c –õCŽÄ“cŽŽqCŽç‰º ŠžC²‰H“à Œ€C’†“‡NGC–öŒŽ‰„ÍC”ö’Ò –L : ‚Ž‰–bH•‰‰×‚É‚æ‚èŽä‹N‚³‚ê‚œƒgƒŠƒvƒ‹n/i/eNOSŒ‡‘¹ƒ}ƒEƒX‚̏dÇ‚Ž‰ŒŒÇ‚ÆŠŸód‰»•a•ÏŒ`¬
‘æ5‰ñ“Œ–k‘åŠwƒoƒCƒIƒTƒCƒGƒ“ƒXƒVƒ“ƒ|ƒWƒEƒ€i2008”N5ŒŽ19“úC“Œ‹žj
  1. ’†–ì œC•Ÿ–{‹`OC²“¡Œö—YCˆÉ“¡ˆ€„C‰Á‰ê’J –LCÎˆä’ŒlC›‘º˜a•vC‰ºìG–Ÿ : Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in hindlimb ischemia in mice.
‘æ146‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2008”N6ŒŽ7“úC·‰ªj
  1. ìŒû“T•FC‰z“c—ºŽiC‚‹Ž C’†ŽR‰ë°C•“cŽç•FCˆÉ“¡Œ’‘ŸC‘œ“c’q—mCˆÀ“c ‘C‰Á‰ê’J –LC‰ºìG–Ÿ : dÇ•nŒŒ‚É”º‚¢•sˆÀ’è‹·SÇ‚ð’悵‚œ1—á
  2. ‚‹Ž CˆÀ“c ‘C‰z“c—ºŽiC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‘œ“c’q—mC‰Á‰ê’J –LC‰ºìG–Ÿ : PCI‚ɍ‡•¹‚µ‚œŠ¥“®–¬úE‚ɑ΂·‚鎡—Õûj‚ÌŒˆ’è‚ɐS‘ŸMDCT‚ª—LŒø‚Ÿ‚Á‚œˆê—á
‘æ61‰ñ“ú–{Ž_‰»ƒXƒgƒŒƒXŠw‰ïŠwpW‰ïi2008”N6ŒŽ19“ú`20“úC‹ž“sj
  1. •Ÿˆäd•¶C•Ÿ–{‹`OC—é–Ø C²Ž¡Œ«ÆC™‘ºGˆê˜YC“ê“c ~CŽO‰Y —TC‰Á‰ê’J –LC‰ºìG–Ÿ : “œ”A•a‚͍‚ŒŒˆ³ƒ‰ƒbƒg‚É‚š‚¢‚ăŒƒjƒ“[ƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Œn‚ÌŠˆ«‰»‚ð‰î‚µ‚趎ºŠg’£‹@”\áŠQ‚𑝈«‚³‚¹‚é
‘æ185‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2008”N6ŒŽ21“úCå‘äj
  1. ‰z“c—ºŽiC™‘ºGˆê˜YCˆê£‚ ‚ž‚³C‰ºìG–Ÿ : “–‰@‚É‚š‚¯‚éS‘ŸMRI‚ÌŒ»ó
  2. Œ›ž‘א¶C•Ÿˆäd•¶C™‘ºGˆê˜YC“ê“c ~C•Ÿ–{‹`OC‰ºìG–Ÿ : dÇ‘m–X•Ù•Âœ•s‘SÇ‚𔺂Á‚œ¬lƒŠƒEƒ}ƒ`”M‚Ì1—á
  3. ŽRŒû“WŠ°C•Ÿ“c_“ñCŽáŽR—TŽiCœA£®“¿C‰ºìG–Ÿ : WPWÇŒóŒQ‚ɍ‡•¹‚µ‚œSŽº×“®‚É‚æ‚éS”x’âŽ~‚Ì1—á
‘æ40‰ñ“ú–{“®–¬d‰»Šw‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[i2008”N7ŒŽ10“úC‚‚­‚΁j
  1. ‰ºìG–Ÿ : ARB‚̍R“®–¬d‰»ì—p
‘æ56‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2008”N9ŒŽ8“ú`10“úC“Œ‹žj

ƒƒVƒ“ƒ|ƒWƒEƒ€ : SŒŒŠÇÄ¶ˆã—Â̌»ó‚Æ“W–]„

  1. ˆÉ“¡Œ’‘ŸC•Ÿ–{‹`OCˆÀ“c ‘C‰ºìG–Ÿ : ’áo—Í‘ÌŠOÕŒ‚”g‚ð—p‚¢‚œ”ñNP«ŒŒŠÇV¶—Ö@‚ÌŠJ”­

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“ : ”x‚ŒŒˆ³‚̐f’f‚ÆŽ¡—Â̐i•à„

  1. •Ÿ–{‹`OC‰ºìG–Ÿ : ”x‚ŒŒˆ³‚É‚š‚¯‚éV‚œ‚È•ªŽqŽ¡—ÕW“I : RhoƒLƒi[ƒ[‚̏d—v«

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“ : dÇS•s‘S‚Ì”ñ–ò•š—Ö@„

  1. ŽáŽR—TŽiC•Ÿ“c_“ñCL£®“¿CŽRŒû“WŠ°CŒF’J_ŽiC›ˆä‹`®C™‘ºGˆê˜YC‰z“c—ºŽiCˆê£‚ ‚ž‚³C‹à“c•ü—mC‚£ Œ\C•Ÿ“c Š°C‰Á‰ê’J –LC‰ºìG–Ÿ : dÇS•s‘S‚ɑ΂·‚éS‘ŸÄ“¯Šú—Ö@ : Quantitative Gated SPECT–@‚ð—p‚¢‚œ¶Žº‹tƒŠƒ‚ƒfƒŠƒ“ƒO‚ÌŒŸ“¢

ƒƒtƒ@ƒCƒ„ƒTƒCƒhƒZƒ~ƒi[ : Š¥¹k«‹·SÇƒKƒCƒhƒ‰ƒCƒ“‚ð“Ç‚Ý‰ð‚­„

  1. ‰ºìG–Ÿ : ŒŒŠÇ‹@”\‚ÆŠ¥¹k

ƒˆê”ʉ‰‘聄

  1. ŽÄ MsCŒ–Ø”üCL£®“¿C‚‹Ž C‰ºìG–Ÿ : •nŒŒ‚Æ–«t‘Ÿ•a‚̍‡•¹‚Í–«S•s‘SŠ³ŽÒ‚ÌŽ€–SƒŠƒXƒN‚ð2”{‚É‚·‚é
  2. ™‘ºGˆê˜YC•Ÿ–{‹`OCo’¬ ‡C“ê“c ~C²Ž¡Œ«ÆC•Ÿˆäd•¶C’†–ì œC‰ºìG–ŸC‹ß“¡ ‹u : ¶‘Ì”xˆÚA‚É‚æ‚è‹~–œ‚Å‚«‚œ”xÃ–¬•ÂÇ‚𔺂€”x“®–¬«”x‚ŒŒˆ³Ç‚̈ê—á
  3. “¹Šz Žì—–‘Ž‘ŽŠiC•Ÿ–{‹`OC“ê“c ~C“cŒŽr‰îC’†–ì œC‘œ“c’q—mC²Ž¡Œ«ÆC“¡“c ‰›C¯ì NC‹ß“¡ ‹uC‰ºìG–Ÿ : ”x‚ŒŒˆ³Š³ŽÒ‚É‚š‚¯‚éRhoƒLƒi[ƒ[Šˆ«‚̘Ži
  4. L£®“¿CŽRŒû“WŠ°CŽáŽR—TŽiC•Ÿ“c_“ñC‰ºìG–Ÿ : ICD-twiddler's syndrome‚̈ê—á
  5. •Ÿˆäd•¶C•Ÿ–{‹`OC™‘ºGˆê˜YC“ê“c ~C²Ž¡Œ«ÆCŽO‰Y —TC’†–ì œC‰Á‰ê’J –LC‰ºìG–Ÿ : dÇ‘m–[•Ù•Âœ•s‘SÇ‚𔺂Á‚œ¬lƒŠƒEƒ}ƒ`”M‚̈ê—á
  6. •Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°C‰ºìG–Ÿ : ‰EŽº—¬o˜H‹NŒ¹SŽº«ŠúŠOŽûk‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª”­ì—}§‚É—LŒø‚Å‚ ‚Á‚œ“Á”­«SŽº×“®‚Ì1—á
  7. ŽO‰Y —TC•Ÿ–{‹`OC’†–ì œC•Ÿˆäd•¶C™‘ºGˆê˜YC‰ºìG–Ÿ : ”x‚ŒŒˆ³‚ɍ‡•¹‚·‚ébó‘B‹@”\áŠQ‚Ì“Á’¥
  8. ŽRŒû“WŠ°C•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿C‰ºìG–Ÿ : ICDA‚Šž‚ÝŽž‚̍‚œ×“®è‡’l‚ɑ΂µC’†SÃ–¬‚ւ̃Š[ƒh—¯’u‚ª—LŒø‚Å‚ ‚Á‚œ’‹Œ«S‹Ø[Ç‚̈ê—á
‘æ186‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2008”N9ŒŽ20“úCH“cj
  1. Îì—z“ñ˜YC‹yì”ü“ÞŽqC‚–Ø—S‰îC‹ß“¡³‹PC•Ÿˆäd•¶C™‘ºGˆê˜YC•Ÿ–{‹`OC‰ºìG–Ÿ : ‰æ‘œf’f‚ª—L—p‚Å‚ ‚Á‚œDŽ_‹…«S‹Ø‰Š‚Ì1—á
  2. ŽR“c—F—¢ŒbC‚‹Ž CˆÀ“c ‘C‘ëˆä ’šC’†–ì œC‚‹Ž‹M‹v‘ãC•“cŽç•FC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‰ºìG–Ÿ : ‘œŽ}¹k‚É”º‚€‘œ—l‚ȐS“d}•Ï‰»‚Æ“ÁˆÙ‚ÈMRIŠŒ©‚𔺂Á‚œ‹}«S‹Ø[ÇÇ—á
‘æ31‰ñ“ú–{‚ŒŒˆ³Šw‰ï‘‰ïi2008”N10ŒŽ9“ú`11“úCŽD–yj

ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[ : Š¥¹k«‹·SÇ‚̐f’f‚ÆŽ¡—Á„

  1. ‰ºìG–Ÿ : Š¥¹k‚Ì”­¶‹@˜‚ÆŒŒŠÇ‹@”\

ƒˆê”ʉ‰‘聄

  1. Œã‰ªL‘Ÿ˜YCŽÄ MsCœA£®“¿C‰ºìG–Ÿ : ƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚É‚š‚¯‚鍂ŒŒˆ³Ç‚̈Ӌ` \ ‘æ“ñŽŸ“Œ–k–«S•s‘S“o˜^‚Ì’†ŠÔ•ñ‚©‚ç \
  2. •Ÿˆäd•¶C•Ÿ–{‹`OC—é–Ø C²Ž¡Œ«ÆC™‘ºGˆê˜YC“ê“c ~C‰Á‰ê’J –LC‰ºìG–Ÿ : “œ”A•a‚͍‚ŒŒˆ³ƒ‰ƒbƒg‚É‚š‚¢‚ăŒƒjƒ“[ƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Œn‚ÌŠˆ«‰»‚ð‰î‚µ‚趎ºŠg’£‹@”\áŠQ‚ðˆ«‰»‚³‚¹‚é
‘æ12‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2008”N10ŒŽ16“ú`18“úC“Œ‹žj

ƒƒVƒ“ƒ|ƒWƒEƒ€ : ‚킪‘‚É‚š‚¯‚éˆãŽtŽå“±Œ^—Տ°ŽŽŒ±„

  1. Shiba N, Hirose M, Nochioka K, Shimokawa H. The CHART Study and SUPPORT Trial \ One of realistic solutions to fight chronic heart failure in Japan \ . J Cardiac Failure 14(Suppl 1):S133,2008.

ƒƒVƒ“ƒ|ƒWƒEƒ€ : S•s‘S‚Ì”ñ–ò•šŽ¡—Á„

  1. Shinozaki T, Sugimura K, Shimokawa H. Sleep apnea in chronic heart failure. J Cardiac Failure 14(Suppl 1):S139,2008.

ƒƒVƒ“ƒ|ƒWƒEƒ€ : S‹ØŽûk•s‘S‚ÆŠg’£•s‘S„

  1. Shiba N, Hirose M, Nochioka K, Shimokawa H. Systolic heart failure and diastolic heart failure \ Evidence from the epidemiological studies \ . J Cardiac Failure 14(Suppl 1):S142,2008.

ƒƒVƒ“ƒ|ƒWƒEƒ€ : ˆâ“`Žq‰ü•Ïƒ}ƒEƒX‚ð—p‚¢‚œS•s‘SES”ì‘å‚Ì•a‘ԉ𖟁„

  1. Kagaya Y, Asaumi Y, Takeda M, Minegishi N, Shimokawa H. Protective role of erythropoietin-receptor mediated signaling in non-hematopoietic cells against pressure overloaded left ventricular dysfunction in mice. J Cardiac Failure 14(Suppl 1):S146,2008.

ƒˆê”ʉ‰‘聄

  1. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Sugimura K, Miura Y, Shinozaki T, Kagaya Y, Shimokawa H. Diabetes mellitus exacerbates diastolic dysfunction through activation of renin-angiotensin system in hypertensive rats. J Cardiac Failure 14(Suppl 1):S151,2008.
  2. Miura Y, Fukumoto Y, Sugimura K, Fukui S, Nawata J, Oikawa M, Shimokawa H. The incidence and characteristics of thyroid dysfunction in patients with pulmonary hypertension. J Cardiac Failure 14(Suppl 1):S85,2008.
  3. Nochioka K, Shiba N, Kohno H, Takahashi J, Hirose M, Shimokawa H. Underuse of renin-angiotensin ststem inhibitors is associated with poor prognosis of heart failure patients with chronic kidnely disease. J Cardiac Failure 14(Suppl 1):S159,2008.
  4. Wakayama Y, Fukuda K, Hirose M, Yamaguchi N, Oikawa M, Ichinose A, Takase K, Kagaya Y, Shimokawa H. Evaluation of cardic dyssynchrony in patients with chronic heart failure using cardiomagnetic resonance imaging. J Cardiac Failure 14(Suppl 1):S164,2008.
‘æ25‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi2008”N11ŒŽ1“ú`2“úCVŠƒj
  1. ‚–Ø—S‰îC•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°C‰ºìG–Ÿ : ‰@ŠOS’âŽ~‘h¶—á‚É‚š‚¯‚é“Á”­«SŽº×“®‚ÆŠ¥“®–¬¹k‚Ì–ðŠ„ \ “d‹C¶—Šw“IŠíŽ¿‚Æ‹•ŒŒ”­ì‚ÌŠÖ˜A \ S“d} 28:510,2008.
The 25‚”‚ˆ Annual Meeting of International Society for Heart Research Japanese Section (2008”N11ŒŽ5“ú`6“úC‰¡•l)
  1. Doe Zhulanqiqige, Fukumoto Y, Takaki A, Hoshikawa Y, Kondo T, Shimokawa H. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension.
  2. Fukui S, Fukumoto Y, Kagaya Y, Shimokawa H. Diabetes mellitus exacerbates diastolic dysfunction via activation of renin-angiotensin system in hypertensive rats.
  3. Miura Y, Fukumoto Y, Sugimura K, Fukui S, Oikawa M, Shimokawa H. Prevalance and characteristics of thyroid dysfunction in patinets with pulmonary hypertension.
ŽY‹Æˆã‰È‘åŠwŠJŠw30Žü”N‹L”OŽ–‹ÆCŽY‹Æˆã‰È‘åŠw‘åŠw‰@ƒVƒ“ƒ|ƒWƒEƒ€u¢ŠE‚ðƒŠ[ƒh‚·‚é‰ÈŠwŽÒ‚œ‚¿‚©‚çŠw‚Ô \ _Œo‰ÈŠwES‘ŸŒŒŠÇŒ€‹†‚̃tƒƒ“ƒeƒBƒAvi2008”N11ŒŽ25“úC–k‹ãBj
  1. ‰ºìG–Ÿ : ƒIƒŠƒWƒiƒ‹‚ÈŒ€‹†‚ð‚·‚é‚±‚Æ‚ÌŠì‚Ñ

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2007”N
å‘ä—Տ°“d‹C¶—Œ€‹†‰ïi2007”N11ŒŽ21“úCå‘äj
  1. Hirose M, Kumagai K, Yamaguchi N, Wakayama Y, Fukuda K, Shimokawa H. Ensite‚ðŽg—p‚µ‚ăAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚œ‰EŽº—¬o˜H‹NŒ¹SŽº«ŠúŠOŽûk‚̈ê—á
‘æ24‰ñ“ú–{S“dŠw‰ïŠwpW‰ïi2007”N10ŒŽ5“ú`6“úC–ŒŒÃ‰®j
  1. Hirose M, Endo H, Sugai Y, Wakayama Y, Miura M, Shimokawa H. Characteristics change of Ca2+ waves during the development from cardiac hypertrophy to heart failure in monocrotaline treated rats.
  2. •Ÿ“c_“ñCŒF’J_ŽiCŽáŽR—TŽiC›ˆä‹`®CL£®“¿CŽRŒû“WŠ°C‰ºìG–Ÿ : H“¹ŠàpŒã‚ɏoŒ»‚µ‚œƒuƒ‹ƒKƒ_Œ^S“d}‚ð‚à‚ÂŽž_Ç—á
  3. ŽRŒû“WŠ°CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CL£®“¿C‰ºìG–Ÿ : ’ʏíŒ^S–[‘e“®‚É‚š‚¯‚é‰ES–[“`“±‘¬“x‚ÌŒŸ“¢
‘æ55‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2007”N9ŒŽ10“ú`12“úC‰YˆÀj

ƒƒVƒ“ƒ|ƒWƒEƒ€4 : dÇS•s‘S‚ÌŽ¡—Ð헪„

  1. ŽÄ MsCŒ–Ø”üC‘œ“c’q—mC‚‹Ž C‰ºìG–Ÿ : —]–œˆê”NˆÈ“à‚̏dÇS•s‘SÇ—á‚Ì“Á’¥ : “Œ–k–«S•s‘S“o˜^iCHARTj‚É‚š‚¯‚錟“¢

ƒƒVƒ“ƒ|ƒWƒEƒ€7 : Coronary spasmÅV‚Ì’mŒ©„

  1. ˆÀ“c ‘C¬ì‹v—YC‰ºìG–Ÿ : ‰ä‚ª‘‚ÌŠ¥¹k«‹·SÇf—Â̌»óuŠ¥¹kŒ€‹†‰ïv‚ÌŠú‘Ò‚³‚ê‚é–ðŠ„

ƒƒRƒ“ƒgƒƒo[ƒV[ : ‚·‚ׂĂ̕a•Ï‚ɑ΂µ‚ÄDES‚ð—¯’u‚·‚é‚©„

  1. ‚‹Ž CˆÀ“c ‘C‰ºìG–Ÿ : Large lumen vessel‚ɑ΂µ‚Ä–òÜ—no«ƒXƒeƒ“ƒg‚Í•K—v‚©? : ƒxƒAƒƒ^ƒ‹ƒXƒeƒ“ƒg‚Ƃ̍ċ·ó—\–hŒø‰Ê‚ÉŠÖ‚·‚é”äŠrŒŸ“¢

ƒƒRƒƒfƒBƒJƒ‹ƒZƒbƒVƒ‡ƒ“ : zŠÂŠíf—Âɂš‚¯‚éˆãŽtEŠÅŒìŽt‚̘AŒg‚ɂ‚¢‚Ä : Ž¿‚̍‚‚¢f—Ñ̐§‚ð–ÚŽw‚µ‚ā„

  1. ²“¡’qŽqCŒš‹{ŽÀ˜aC‹{•ƒ~ƒhƒŠC–ì“c^‹MŽqC—é–ØŒhŽiC‚‹Ž “wC¯Žq—R”üCˆÀ“c ‘C‹{“c „C‰ºìG–Ÿ : ˆãŽtEŠÅŒìŽtENST˜AŒg‚É‹}«zŠÂŠíŽŸŠ³Ç—á‰h—{ŠÇ—‚̈Ӌ`

ƒˆê”ʉ‰‘聄

  1. ‘œ“c’q—mCŽÄ MsCŒ–Ø”üC‚‹Ž C‰ºìG–Ÿ : Time-dependent alteration in the mortality of heart failure patients with preserved ejection frcation.
  2. •Ÿˆäd•¶C•Ÿ–{‹`OC—é–Ø C²Ž¡Œ«ÆC“ê“c ~C“cŒŽr‰îCŽÂè ‹BC‰Á‰ê’J –LC‰ºìG–Ÿ : ¶ŽºŠg’£‹@”\áŠQ‚É—^‚Š‚é“œ”A•a‚̉e‹¿ : ƒ_[ƒ‹H‰–ŠŽŽó«‚ŒŒˆ³ƒ‰ƒbƒg‚É‚š‚¯‚錟“¢
  3. á‰º‹ËŽqCŒ–Ø”üCŽÄ MsC‘åèÃCéŒËŒû—TŽqC—é–Ø—R”üC‰ºìG–Ÿ : “–‰ÈÇ—á‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚Ì•p“x‚Æ“Á’¥
‘æ11‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2007”N9ŒŽ9“ú`10“úC‰YˆÀj

ƒƒVƒ“ƒ|ƒWƒEƒ€9 : ƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚ƐS•s‘S : V‚µ‚¢S•s‘SŽ¡—Ẩ”\«„

  1. Shimokawa H. Role of metabolic syndrome in the pathogenesis of chronic heart failure. J Cardiac Failure. 13 isuppl 1): S14, 2007.

ƒˆê”ʉ‰‘聄

  1. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Tawara S, Shinozaki T, Kagaya Y, Shimokawa H. The important role of Rho-kinase in the pathogenesis of diastolic heart failure in rats. J Cardiac Failure. 13isuppl 1): S28, 2007.
  2. Kagaya Y, Asaumi Y, Tada T, Shiba N, Shirato K, Minegishi N, Shimokawa H. Erythropietin-mediated signaling in the heart as a potential therapeutic target in chronic heart failure. J Cardiac Failure. 13 isuppl 1): S22, 2007.
  3. Shiba N, Matsuki M, Kidoguchi Y, Shimokawa H. Hyponatremia is associated with the mortality of patients with chronic heart failure. J Cardiac Failure. 13 isuppl 1): S34
  4. Takahashi J, Shiba N, Tada T, Shimokawa H. Prognostic impact of angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker in patients with diastolic heart failure. J Cardiac Failure. 13 isuppl 1): S47, 2007.
  5. Wakayama Y, Kumagai K, Fukuda K, Sugai Y, Hirose M, Yamaguchi N, Kagaya Y, Shimokawa H. Effects of cardiac resynchronization therapy on premature ventricular contractions and ventricular tachyarrhythmias in patients with chronic heart failure. J Cardiac Failure. 13 isuppl 1): S61, 2007.

ƒƒVƒ“ƒ|ƒWƒEƒ€14 : S•s‘S‚É‚š‚¯‚é–òÜ‚ÌŠî‘b“I•]‰¿„

  1. Kagaya Y, Asaumi Y, Tada T, Shiba N, Shirato K, Minegishi N, Shimokawa H. Erythropoietin-mediated signaling in the heart as a potential therapeutic target in chronic heart failure.
  2. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Twara S, Shinozaki T, Kagaya Y, Shimokawa H. The important role of Rho-kinase pathway in the pathogenesis of diastolic heart failure in rats.
  3. Takahashi J, Shiba N, Tada T, Shimokawa H. Prognostic impact of angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker in patients with diastolic heart failure.
  4. Shiba N, Matsuki M, Kidoguchi Y, Shimokawa H. Hyponatremia is associated with the mortality of patients with chronic heart failure.
‘æ183‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2007”N9ŒŽ1“úCÂXj
  1. ‰Á‹v—Y“ñC‚‹Ž C‘å‹ŽŽqC‘¶‘ה́C‰z“c—ºŽiC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‘œ“c’q—mCˆÀ“c ‘C‰ºìG–Ÿ : Šà‰»Šw—Ö@Œã‚ÌŽá”N’j«‚É”­Ç‚µ‚œ‹}«S‹Ø[Ç‚̈ê—á
‘æ39‰ñ“ú–{“®–¬d‰»Šw‰ï‘‰ïŠwpW‰ïi2007”N7ŒŽ13“ú`14“úC‘åãj

ƒƒVƒ“ƒ|ƒWƒEƒ€9 : ‰ä‚ª‘‚É‚š‚¯‚錌ŠÇV¶EÄ¶ˆã—à : Œ»ó‚Æ“W–]„

  1. ’†–ì œC²“¡Œö—YC•Ÿ–{‹`OCˆÉ“¡ˆ€„C‰Á‰ê’J –LC‰ºìG–Ÿ: ‹•ŒŒŒãŒŒŠÇV¶‚É‚š‚¯‚éƒGƒŠƒXƒƒ|ƒCƒGƒ`ƒ“EƒGƒŠƒXƒƒ|ƒCƒGƒ`ƒ“Žó—e‘̃VƒXƒeƒ€‚Ì–ðŠ„
  2. ‘œ“c’q—mC“ê“c ~C‰€ Š©CƒWƒ‡ƒ‰ƒ“ƒ`ƒ`ƒSC”öã‹IŽqCˆÉ“¡Œ’‘ŸC™‘ºGˆê˜YC•Ÿ–{‹`OC‰ºìG–Ÿ : Pulsatile pressure‚ÍIP3ƒŒƒZƒvƒ^[‚ð‰î‚µ‚Ä•œŠŠ‹Ø×–E‚Ì—V‘–”\‚𘎐i‚³‚¹‚é
‘æ13‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïi2007”N7ŒŽ13“ú`14“úC“Œ‹žj

ƒ“Á•Êu‰‰„

  1. ‰ºìG–Ÿ : S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì—L—p«‚ðl‚Š‚é\ŒŒŠÇ¶•šŠw‚Ì—§ê‚©‚ç\
‘æ182‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2007”N6ŒŽ16“úCå‘äj
  1. ²Ž¡Œ«ÆC•Ÿ–{‹`OC“ê“c ~C“¡“c ‰›C‰ºìG–ŸCo’¬ ‡ : ‘ˆ«‚µ‚œŽOë•Ù•Âœ•s‘S‚ª—ˆ‚µ‚œ’áŽ_‘fŒŒÇ‚Ì1—á
‘æ144‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2007”N6ŒŽ9“úC·‰ªj
  1. ŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CL£®“¿CŽRŒû“WŠ°C‰ºìG–Ÿ : Ž‘±«S–[×“®‚ɑ΂·‚éL”͈͔xÃ–¬Šu—£pŒã‚̍Ĕ­—\‘ªˆöŽq‚ÌŒŸ“¢
  2. ‘¶‘ה́C‚‹Ž C›ˆä‹`®CˆÉ“¡Œ’‘ŸC’†ŽR‰ë°C‰z“c—ºŽiCóŠC‘׉hCˆÀ“c ‘C‰ºìG–Ÿ : Bystander CPR‚É‚æ‚è‹~–œ‚³‚êCŽ¡—Ã’ïR«‚ð’悵‚œŠ¥¹k«‹·SÇ‚̈ê—á
  3. ‰z“c—ºŽiC™‘ºGˆê˜YCŽ…ˆŸŠóŽqC‰ºìG–ŸCˆê£‚ ‚ž‚³ : ‘œŽ}•a•Ï‚É‚š‚¯‚éS‹Ø‹•ŒŒ‚̐f’f\S‘ŸMRI‚ƐS‹ØƒVƒ“ƒ`ƒOƒ‰ƒ€‚Ì”äŠrŒŸ“¢\
  4. ²Ž¡Œ«ÆC•Ÿ–{‹`OC“ê“c ~Co’¬ ‡C“¡“c ‰›C‰ºìG–Ÿ : ‘ˆ«‚µ‚œŽOë•Ù•Âœ•s‘S‚ª—ˆ‚µ‚œ’áŽ_‘fŒŒÇ‚̈ê—á
  5. ²Ž¡Œ«ÆC•Ÿ–{‹`OC“ê“c ~Co’¬ ‡C“¡“c ‰›C‰ºìG–Ÿ : ”DP‚ðŒ_‹@‚É‘å“®–¬•Ù•Âœ•s‘S‚É‚æ‚éS•s‘S‚𔭏ǂµ‚œ‰E‹¹S‚̈ê—á
  6. ŽÄ MsCá‰º‹ËŽqCŒ–Ø”üC‘åèÃCéŒËŒû—TŽqC‰ºìG–Ÿ : “–‰ÈÇ—á‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚Ì•p“x‚Æ“Á’¥
  7. ›ˆä‹`®CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°C‰ºìG–Ÿ : Až‚ÝŒ^œ×“®ŠíiICDj‚ªì“®‚µ“d‹C“IƒŠƒZƒbƒg‚𔭐¶‚µ‚œ”ì‘åŒ^S‹ØÇ‚̈êÇ—á
  8. ‚‹Ž CŽÄ MsC‘œ“c’q—mC‰ºìG–Ÿ : Šg’£•s‘SÇ—á‚É‚š‚¢‚ĉh—{ó‘Ô‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿
  9. L£®“¿CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CŽRŒû“WŠ°C‰ºìG–Ÿ : EbsteinŠïŒ`‚ÆWPWÇŒóŒQ‚ð‡•¹‚µ‚œˆê—á
  10. •Ÿ“c_“ñCŒF’J_ŽiCŽáŽR—TŽiC›ˆä‹`®CL£®“¿CŽRŒû“WŠ°C‰ºìG–Ÿ : ƒuƒ‹ƒKƒ_ÇŒóŒQ‚É‚š‚¯‚鉺•û—U“±S”g‚̐f’f“IˆÓ‹`
  11. ŽRŒû“WŠ°CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CL£®“¿C‰ºìG–Ÿ : L”͈͔xÃ–¬“d‹C“IŠu—£pŒã—U”­‚³‚ê‚œ¶–[‹NŒ¹S–[‘e“®‚̈ê—á
  12. ŽáŽR—TŽiCŒF’J_ŽiC•Ÿ“c_“ñC›ˆä‹`®CL£®“¿CŽRŒû“WŠ°C‰Á‰ê’J –LC‰ºìG–Ÿ : S‘ŸÄ“¯Šú—Ö@ iCRTj Œã‚̐SŽº«•s®–¬”­¶‚ÌŒŸ“¢
‘æ22‰ñ“ú–{•s®–¬Šw‰ïŠwp‘å‰ïi2007”N5ŒŽ31“ú`6ŒŽ2“úCL“‡j

ƒƒVƒ“ƒ|ƒWƒEƒ€4 : CRT-P‚ÆCRT-DAž‚Ý‚ÌŒ»ó‚ƍ¡Œã‚̉ۑ聄

  1. ŽáŽR—TŽiCŒF’J_ŽiC•Ÿ“c_“ñC›ˆä‹`®CL£®“¿CŽRŒû“WŠ°C‹yì”ü“ÞŽqC™‘ºGˆê˜YC‰Á‰ê’J–LC‰ºìG–ŸCˆê£‚ ‚ž‚³C‹à“c•ü—mC•Ÿ“c Š° : ƒ}ƒ‹ƒ`ƒ‚ƒ_ƒŠƒeƒB[Žž‘ã‚̐S‘Ÿ‰æ‘œf’f–@‚ð—p‚¢‚œS‘ŸÄ“¯Šú—Ö@‚Ì•]‰¿\Quantitative Gated SPECT–@‚ð—p‚¢‚œŒŸ“¢\

ƒˆê”ʉ‰‘聄

  1. ŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CL£®‹`CŽRŒû“WŠ°C‰ºìG–Ÿ : Ž‘±«S–[×“®‚ɑ΂·‚éL”͈͔xÃ–¬Šu—£pŒã‚̍Ĕ­—\‘ªˆöŽq‚ÌŒŸ“¢
  2. ŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CL£®“¿CŽRŒû“WŠ°C‰ºìG–Ÿ : ’†Šu‹ß–T‹NŒ¹SŽº«•s®–¬‚̐S“d}Šw“I“Á’¥‚ÌŒŸ“¢
  3. L£®“¿CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CŽRŒû“WŠ°C‰ºìG–Ÿ : ICD-twiddler's syndrome‚Ì1—á
  4. ŽRŒû“WŠ°CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CL£®“¿C‰ºìG–Ÿ : –òÜ‚É‚æ‚é“ñŽŸ«QT‰„’·‚É‚æ‚è‘œŒ`«SŽº•p”‚ð‚«‚œ‚µ‚œ•p–¬«S–[×“®‚Ì1—á
  5. •Ÿ“c_“ñCŒF’J_ŽiCŽáŽR—TŽiC›ˆä‹`®CL£®“¿CŽRŒû“WŠ°C‰ºìG–Ÿ : ‰–Ž_ƒsƒ‹ƒWƒJƒCƒjƒh‚É‚æ‚éƒuƒ‹ƒKƒ_ÇŒóŒQ‰EŽºS“à–Œ‘€‚Ì•s®–¬ŠíŽ¿‚ÌŒŸ“¢
‘æ7‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2007”N5ŒŽ17“ú`18“úC‘å’Áj

ƒƒVƒ“ƒ|ƒWƒEƒ€1 : NO‚ƃƒ^ƒ{ƒŠƒbƒNÇŒóŒQ„

  1. “›ˆä³lC‰ºìG–ŸC’†“c –õCŽç‰º ŠžC²‰H“àŒ€C’†“‡NGC”ö’Ò –LC–öŒŽ‰„Í : NO‡¬y‘fŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚郁ƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€

ƒˆê”ʉ‰‘聄

  1. ‚–Ø •¶CXìŒhŽqC‘ºŽR‰À”́CEnder TekesC“›ˆä³lC–öŒŽ‰„ÍC‰ºìG–Ÿ : “à”ç—R—ˆ‰ß•ª‹ÉˆöŽqiEDHFj”œ‰ž‚ÍNO‡¬y‘fŒn‚ÉŠ®‘S‚Ɉˑ¶‚·‚é\NO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚錟“¢\
‘æ46‰ñ“ú–{¶‘̈ãHŠw‰ï‘å‰ïi2007”N4ŒŽ25“ú`27“úCå‘äj

ƒê–å•ÊŒ€‹†‰ïuÕŒ‚”gˆã—Ö@Œ€‹†‰ïv„

  1. ˆÉ“¡Œ’‘ŸC•Ÿ–{‹`OC‰ºìG–Ÿ : ‹•ŒŒ«SŽŸŠ³‚ɑ΂·‚é”ñNP«‘ÌŠOÕŒ‚”gŽ¡—Ã

ƒˆê”ʉ‰‘聄

  1. ˆÉ“¡Œ’‘ŸCã“¿–L˜aC‰ºìG–Ÿ : ‹}«S‹Ø[Ç‚ɑ΂·‚é”ñNP«‘ÌŠOÕŒ‚”gŽ¡—Ã
  2. ˆÀ“c ‘C¶“cŒ’ŽŸ˜YCã“¿–L˜aC•ÐŽR‰ÀŽ÷C‰ºìG–Ÿ : ŒŒŠÇáŠQ•”ˆÊ‚ð”FŽ¯‚·‚éV‚µ‚¢ŠjŽ¥‹C‹€––@—p‹@”\‰»‘¢‰eÜ‚ÌŠJ”­
  3. –î“c–L—²C‰ºìG–ŸC•œŒ CCŒã“¡^ŒÈC¬Š}ŒŽN•vCŠ’J•¶•F : ƒy[ƒVƒ“ƒO‚É‚æ‚éƒCƒk‘ãŽÓ«Š¥”÷¬ŒŒŠÇŠg’£Žž‚Ì“àˆö«‰ßŽ_‰»…‘f‚Ì–ðŠ„
‘æ71‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïi2007”N3ŒŽ15`17“úC_ŒËj

ƒPlenary Session : Clinical Trials Update in Japan and Future Perspective„

  1. Shiba N, Matsuki M, Kagaya Y, Shimokawa H. A new approach with a combined cohort study and randomized controlled trials \ Lessons from the CHART Study \. Circ J. 71 iSuppl. I:23,2007.

ƒPlenary Session : Cardiorenal Syndrome and Hypertensive Heart Diseases„

  1. Kagaya Y, Asaumi Y, Tada T, Shiba N, Tada H, Minegishi N, Shimokawa H. Roles of anemia and erythropoietin in the development of heart failure; Important aspects of cardiorenal syndrome. Circ J. 71(Suppl. I):18,2007.

ƒSymposium 5 : Clinical Trials of Regeneration Therapy in Japan„

  1. Ito K, Fukumoto Y, Shimokawa H. Extracorporeal cardiac shock wave therapy as a new, non-invasive angiogenic strategy for end-stage coronary artery disease. Circ J. 71(Suppl. I):35,2007.

ƒTopics : Coronary Artery Spasm„

  1. Fukumoto Y, Shimokawa H. Important role of Rho-kinase in the pathogenesis of coronary artery spasm. Circ J. 71(Suppl. I):73,2007.
  2. Yasuda S, Shimokawa H. Cronary spasm association : Its mission and goals. Circ J. 71(Suppl. I):73,2007.

ƒFireside Seminar 4„

  1. Fukumoto Y, Shimokawa H. Experience with bosentan therapy for the treatment of pulmonary arterial hypertension.

ƒˆê”ʉ‰‘聄

  1. Arakawa K, Yasuda S, Hao H, Kataoka Y, Morii I, Kasahara Y, Kawamura A, Ueda H, Miyazaki S. Significant association between neutrophil aggregation in aspirated thrombus and myocardial damage in patients with ST-segment elevation acute myocardial infarction. Circ J. 71(Suppl. I):351,2007.
  2. Asaumi Y, Kagaya Y, Takeda M, Yamaguchi N, Tada H, Ito K, Ohta J, Shiroto T, Minegishi N, Shimokawa H. Deletion of endogenous erythropoietin system in non-hematopoietic cells impairs development of coronary angiogenesis and enhances susceptibility to pressure overload-induced heart failure. Circ J. 71(Suppl. I):135,2007.
  3. Demachi J, Fukumoto Y, Nawata J, Sugimura K, Saji K, Fujita H, Sakuma M, Shimokawa H. Characteristics of the responders to epoprostenol infusion therapy in patients with severe pulmonary arterial hypertension. Circ J. 71(Suppl. I):679,2007.
  4. Fukuda K, Kumagai K, Wakayama Y, Sugai Y, Hirose M, Shimokawa H. The diagnostic significance of a notch in S wave of inferior leads for the diagnosis of Brugada syndrome. Circ J. 71(Suppl. I):362,2007.
  5. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Shinozaki T, Kagaya Y, Shimokawa H. Impact of diabetes mellitus on left ventricular diastolic dysfunction in Dahl salt-sensitive hypertensive rats. Circ J. 71(Suppl. I):139,2007.
  6. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Shinozaki T, Kagaya Y, Shimokawa H. Rho-kinase pathway plays an important role in the pathogenesis of diastolic heart failure in Dahl salt-sensitive hypertensive rats. Circ J. 71(Suppl. I):434,2007.
  7. Hirose M, Endoh H, Sugai Y, Wakayama Y, Miura M, Shimokawa H. Increased spontaneous Ca2+ release in Purkinje cells that survive in the infarcted heart. Circ J. 71(Suppl. I):329,2007.
  8. Ichinose A, Kumagai K, Takase K, Morita Y, Kagaya Y, Takahashi S, Shimokawa H. Usefulness of three-dimensional analysis with multi-detector row computed tomography in the treatment of atrial fibrillation. Circ J. 71(Suppl. I):404,2007.
  9. Koiwa Y, Katoh T, Shimokawa H, Kanai H, Hasegawa H. High-resolution measurement of carotid artery wall elasticity for clinical tailor-made risk management of atherosclerosis. Circ J. 71(Suppl. I):547,2007.
  10. Kumagai K, Wakayama Y, Fukuda K, Sugai Y, Hirose M, Ichinose A, Aonuma K, Shimokawa H. Left atrial ablation for atrial fibrillation induces structural reverse remodeling of the left atrium. Circ J. 71(Suppl. I):371,2007.
  11. Kumagai K, Wakayama Y, Fukuda K, Sugai Y, Hirose M, Ichinose A, Shimokawa H. Predictors of recurrence of persistent atrial fibrillation after left atrial ablation. Circ J. 71(Suppl. I):167,2007.
  12. Kumagai K, Fukuda K, Wakayama Y, Sugai Y, Hirose M, Aonuma K, Shimokawa H. The approach from the left side of anteroseptum is useful for repetitive monomorphic ventricular tachycardia originating near His-bundle region. Circ J. 71(Suppl. I):212,2007.
  13. Miura M, Hirose M, Shimokawa H. Cytosolic Ca2+ rather than Ca2+ inside sarcoplasmic reticulum can determine the velocity of Ca2+ waves in monocrotaline-induced failing hearts. Circ J. 71(Suppl. I):290,2007.
  14. Miura M, Wakayama Y, Shimokawa H. Non-uniform excitation-contraction coupling augmented by transient stretch can accelerate Ca2+ waves in intact rat trabeculae. Circ J. 71(Suppl. I):329,2007.
  15. Morishita T, Tsutsui M, Shimokawa H, Nakata S, Sabanai K, Yatera Y, Shibata K, Tasaki H, Yanagihara N, Nakashima Y, Otsuiji Y. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circ J. 71(Suppl. I):140,2007.
  16. Nakata S, Tsutsui M, Shimokawa H, Yatera Y, Morishita T, Sabanai K, Tasaki H, Yanagihara N, Nakashima Y, Itsuji Y. Hyper-low-densitiy-lipoproteinemia in mice lacking all nitric oxide synthases. Circ J. 71(Suppl. I):221,2007.
  17. Nakata S, Tsutsui M, Shimokawa H, Morishita T, Sabanai K, Yatera Y, Tasaki H, Hanagihara N, Nakashima Y, Otsuji Y. Long-term treatment with an angiotensin II type 1 receptor blocker ameliorates metabolic syndrome in mice lacking all nitric oxide synthases. Circ J. 71(Suppl. I):117,2007.
  18. Nakayama M, Asaumi Y, Komaru T, Shimokawa H. Successful in vivo imaging of enhanced cardiac transcriptional activity of GATA during progression of angiotensin II-induced hypertrophy in mice. Circ J. 71(Suppl. I):164,2007.
  19. Onoue N, Nawata J, Tada T, Qiqige Z, Wang H, Sugimura K, Fukumoto Y, Shimokawa H. Increased static pressure promotes migration of vascular smooth muscle cells \ Involvement of Rho-kinase pathway \. Circ J. 71(Suppl. I):196,2007.
  20. Rashid M, Tawara S, Fukumoto Y, Shimokawa H. Molecular mechanisms of the pleiotropic effects of HMG-CoA reductase inhibitors \ Different inhibitory effects on RhoA/Rho-kinase and Rac1 \. Circ J. 71(Suppl. I):139,2007.
  21. Saji K, Fukumoto Y, Suzuki J, Nawata J, Fukui S, Shimokawa H. Microtubule polymerization plays an important role in the pathogenesis of cardiomyocyte apoptosis. Circ J. 71(Suppl. I):135,2007.
  22. Sawano H, Mukainaka S, Yasuda S, Hazui H, Ukai I, Morita H, Nonogi H. Effect of nifekalant for out-of-hospital shock-resistant ventricular fibrillation: J-pulse 2 nifekalant multicenter registry. Circ J. 71(Suppl. I):294,2007.
  23. Shiba N, Matsuki M, Takahashi J, Fukumoto Y, Kagaya Y, Shimokawa H. Prognostic importance of estimated glomerular filtration rate in patients with chronic heart failure. Circ J. 71(Suppl. I):122,2007.
  24. Shinozaki T, Fukui S, Sugimura K, Ogawa H, Okabe S, Shimokawa H. Sleep apnea predicts lethal arrhythmic events in patients with chronic heart failure. Circ J. 71(Suppl. I):566,2007.
  25. Sugai Y, Wakayama Y, Hirose M, Endoh H, Nakano M, Miura M, Stuyvers B, ter Keurs H, Shimokawa H. Initiation mechanism of Ca2+ waves and triggered propagated contractions in non-uniform excitation-contraction coupling: Effect of transient stretch. Circ J. 71(Suppl. I):497,2007.
  26. Sugimura K, Fukumoto Y, Demachi J, Nawata J, Oikawa M, Kagaya Y, Shimokawa H. Identification of non-invasive predictors of high-risk patients with pulmonary arterial hypertension. Circ J. 71(Suppl. I):680,2007.
  27. Tada T, Nawata J, Wang H, Onoue N, Qiqige Z, Ito K, Sugimura K, Fukumoto Y, Shimokawa H. Hemodynamic factors accelerate vascular smooth muscle migration through IP3-receptor \ Implication for atherogenesis of hypertenstion \. Circ J. 71(Suppl. I):335,2007.
  28. Takahashi J, Yasuda S, Koshida R, Nakayama M, Tada H, Ito K, Shimokawa H. Equivalent inhibitory effects of 4.0-mm-diameter bare metal stent with 3.5-mm-diameter drug-eluting stent to prevent restenosis after percutaneous coronary intervention. Circ J. 71(Suppl. I):662,2007.
  29. Takaki A, Morikawa K, Murayama Y, Tekes E, Tsutsui M, Yamagihara N, Shimokawa H. Endothelium-dependent hyperpolarizations are totally dependent on endothelial nitric oxide syntase system \ Lessons from mice lacking all nitric oxide synthase isoforms \. Circ J. 71(Suppl. I):240,2007.
  30. Takaki A, Morikawa K, Murayama Y, Shimokawa H. Intracellular mechanisms and sources for superoxide anion production responsible for endothelium-derived hyperpolarizing factor responses in mice. Circ J. 71(Suppl. I):669,2007.
  31. Tawara S, Abe K, Morikawa K, Fukumoto Y, Shimokawa H. Prostacyclin lacks inhibitory effects on Rho-kinase \ Possible benefits of combined therapy with prostacyclin and a Rho-kinase inhibitor in pulmonary hypertension \. Circ J. 71(Suppl. I):232,2007.
  32. Tsuburaya R, Yasuda S, Hizume T, Ito Y, Shirato T, Ito K, Shimokawa H. Long-term treatment with eicosapentaenoic acid suppresses coronary vasoconstriction and ventricular fibrillation in a porcine model of acute myocardial infarction. Circ J. 71(Suppl. I):346,2007.
  33. Wakayama Y, Kumagai K, Fukuda K, Sugai Y, Hirose M, Oikawa M, Sugimura K, Kagaya Y, Kaneta T, Fukuda H, Shimokawa H. Determinants of left ventricular reverse remodeling after cardiac resynchronization therapy: Evaluation using quantitative gated myocardial perfusion SPECT. Circ J. 71(Suppl. I):237,2007.
  34. Wakayama Y, Kumagai K, Fukuda K, Sugai Y, Hirose M, Oikawa M, Sugimura K, Kagaya Y, Kaneta T, Fukuda H, Shimokawa H. Reverse remodeling after cardiac resynchronization therapy influences cardiac events due to heart failure but not ventricular arrhythmias. Circ J. 71(Suppl. I):238,2007.
  35. Yada T, Shimokawa H, Morikawa K, Takaki A, Shinozaki Y, Mori H, Goto M, Ogasawara Y, Kajiya F. Role of Cu, Zn-SOD in the synthesis of endothelium-derived hyperpolarizing factor iEDHFj during reactive hyperemia in mouse mesenteric microcirculation in vivo. Circ J. 71(Suppl. I):268,2007.
  36. Yada T, Shimokawa H, Hiramatsu O, Shinozaki Y, Mori H, Goto M, Ogasawara Y, Kajiya F. Role of endogenous hydrogen peroxide in tachypacing-induced metabolic coronary vasodilatation in canine coronary microcirculation in vivo. Circ J. 71(Suppl. I):187,2007.
  37. Yamamoto K, Tsutsui M, Tasaki H, Shimokawa H, Nakano Y, Nakata S, Morishita T, Sabanai K, Yanagihara N, Nakashima Y, Otsuji Y. Left ventricular hypertrophy and diastolic dysfunction in mice lacking all nitric oxide synthases. Circ J. 71(Suppl. I):376,2007.
  38. Yatera Y, Tsutsui M, Shimokawa H, Nakata S, Sabanai K, Shibata K, Morishita T, Tasaki H, Yanagihara N, Nakashima Y, Otsuji Y. Dyslipidemia, lipid-rich atherosclerotic lesion formation and sudden death in mice lacking all nitric oxide synthases fed a high-cholesterol diet. Circ J. 71(Suppl. I):335,2007.
  39. ‘åèÃC‘œ“c’q—mCŒ–Ø”üCˆÉ“¡‘å•ãC—é–Ø—R”üC”’»‚œ‚ÜŽqCŽÄ MsC‰ºìG–Ÿ : –«S•s‘SŠ³ŽÒŠÅŒì‚É‚š‚¯‚é‰h—{ó‘ԁEƒŠƒXƒN•]‰¿‚̏d—v« ƒRƒƒfƒBƒJƒ‹ƒZƒbƒVƒ‡ƒ“ : 61, 2007.
  40. Œ–Ø”üCˆÉ“¡‘å•ãC‘åèÃCá‰º‹ËŽqCŽÄ MsC”’»‚œ‚ÜŽqC—é–Ø—R”üC‰ºìG–Ÿ : zŠÂŠíŽŸŠ³‚Æ‚€‚ó‘ԁE‡–°áŠQ‚Æ‚ÌŠÖŒW ƒRƒƒfƒBƒJƒ‹ƒZƒbƒVƒ‡ƒ“ : 79, 2007.
“ú–{–òŠw‰ï‘æ126”N‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[ i2007”N3ŒŽ30“úCå‘äj
  1. ‰ºìG–Ÿ : ‘n–ò‚Ì•W“I‚Æ‚µ‚Ä‚ÌRho/Rho-kinaseŒo˜H‚̏d—v«
“ú–{–òŠw‰ïi2007”N3ŒŽ29“úC•xŽRj
  1. “›ˆä³lC‰ºìG–ŸC’†“c ŽCŽç‰º ŠžC²‰H“à Œ€C’†“‡NGC”ö’Ò –LC–öŒŽ‰„Í : SŒŒŠÇŒn‚É‚š‚¯‚éNO‡¬y‘fƒVƒXƒeƒ€‚̈Ӌ` : NO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚éV’mŒ©
‘æ80‰ñ“ú–{–ò—Šw‰ï”N‰ï i2007”N3ŒŽ14“úC–ŒŒÃ‰®j

ƒƒVƒ“ƒ|ƒWƒEƒ€ : ‘n–òƒ^[ƒQƒbƒg‚Æ‚µ‚ẴvƒƒeƒCƒ“ƒLƒi[ƒ[„

  1. ‰ºìG–Ÿ : Rho-kinase‘jŠQ–òŠJ”­‚ÉŒü‚¯‚Ä‚Ì“WŠJŒ€‹†

ƒƒVƒ“ƒ|ƒWƒEƒ€ : ¶‘Ì“K‰ž’²ß‚É‚š‚¯‚é”]‚š‚æ‚ÑŽ©—¥_Œo‚Ì–ðŠ„ : V‹K’²ßˆöŽq‚ƗՏ°‚ւ̉ž—p„

  1. “›ˆä³lC‰ºìG–ŸCã–ì WC–L•œ—R”üŽqC–öŒŽ‰„Í : ˆêŽ_‰»’‚‘f‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚鐶‘Ì“K‰ž’²ß‚̏áŠQ
‘æ6‰ñŒQ”nŒŒŠÇˆãŠwŒ€‹†‰ïi2007”N3ŒŽ10“úC‘O‹Žj
  1. ‰ºìG–Ÿ : zŠÂŠíŽŸŠ³‚̐V‚œ‚ÈŽ¡—ÕW“I‚Æ‚µ‚Ä‚ÌRho-kinase‚̈Ӌ`
‘æ47‰ñ“Œ–k•s®–¬Œ€‹†‰ï i2007”N3ŒŽ10“úCå‘äj
  1. ŽRŒû“WŠ°CŒF’J_ŽiC‰ºìG–Ÿ : –òÜ‚É‚æ‚é“ñŽŸ«QT‰„’·‚É‚æ‚è‘œŒ`«SŽº•p”‚ð‚«‚œ‚µ‚œ•p–¬«S–[×“®‚̈ê—á
‘æ9‰ñŒ€CˆãƒXƒeƒbƒvƒAƒbƒvƒZƒ~ƒi[ i2007”N3ŒŽ1“új
  1. ŒF’J_Ži : •s®–¬‚Æ‚»‚ÌŽ¡—Ã
‘æ181‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ï i2007”N2ŒŽ17“úCå‘äj
  1. óŠC‘׉hC‚‹Ž C‰z“c—ºŽiC‘¶‘ה́C’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‘œ“c”ŽŽqCˆÀ“c ‘CŽÄ MsC‰ºìG–Ÿ : ŒŒs“®‘Ԃ̈«‰»‚µ‚œŽá”NŽÒŠg’£Œ^S‹ØÇ‚ɑ΂µ‚ÄPDE‘jŠQÜ‚ª’˜Œø‚µ‚œ1Ç—á
‘æ36‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïi2007”N2ŒŽ9“úC“¿“‡j
  1. ‘œ“c’q—mC“ê“c ~C‰€ Š©CŽì—–‘Ž‘ŽŠiC”öã‹IŽqCˆÉ“¡Œ’‘ŸC™‘ºGˆê˜YC•Ÿ–{‹`OC‰ºìG–Ÿ : ƒ‰ƒbƒg‘å“®–¬•œŠŠ‹Ø×–E‚ւ̈³•‰‰×‚É‚æ‚é—V‘–”\‚ÌŒŸ“¢
  2. “cŒŽr‰îCˆ¢•”O‘Ÿ˜YCXìŒhŽqC•Ÿ–{‹`OC‰ºìG–Ÿ : ƒvƒƒXƒ^ƒTƒCƒNƒŠƒ“‚Ì”x‚ŒŒˆ³Ç‚ÌŽ¡—ÃŒø‰Ê‚ÉRho-kinase—}§ì—p‚ÍŠÜ‚Ü‚ê‚Ä‚¢‚È‚¢ \ Rho-kinase‘jŠQ–ò‚Æ‚Ì•¹—p—Ö@‚̉”\« \
  3. ’†–ì œC²“¡Œö—YC•Ÿ–{‹`OCˆÉ“¡ˆ€„C‰Á‰ê’J –LC‰ºìG–Ÿ : ‰ºŽˆ‹•ŒŒŒã‚ÌŒŒŠÇV¶‚É‚š‚¯‚éEpo/EpoRŒn‚Ì–ðŠ„ \ EpoR KO rescuedƒ}ƒEƒX‚É‚š‚¯‚錟“¢ \
‘æ143‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2007”N2ŒŽ3“úCå‘äj
  1. óŠC‘׉hC‚‹Ž C‰z“c—ºŽiC‘¶‘ה́C’†ŽR‰ë°CˆÉ“¡Œ’‘ŸC‘œ“c”ŽŽqCˆÀ“c ‘CŽÄ MsC‰ºìG–Ÿ : ŒŒs“®‘Ԃ̈«‰»‚µ‚œŽá”N«Šg’£Œ^S‹ØÇ—á‚ɑ΂µ‚ÄPDE‘jŠQÜ‚ª’˜Œø‚µ‚œ1—á
  2. ‘Ÿ“c—L—[”üC‚‹Ž C‘œ“c”ŽŽqC‰z“c—ºŽiC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸCˆÀ“c ‘CŽÄ MsC¬ŠÛ’B–çC‰Á‰ê’J –LC‰ºìG–Ÿ : ‹·SÇó‚ð’悵‚œ¶Š¥“®–¬ÄŒšpŒã20”NˆÈãŒo‰ß‚µ‚œBland White GarlandÇŒóŒQ‚Ì2—á
  3. ‘å—F ~C™‘º²•FC•Ÿ’n–ž³C•Ÿ“c_“ñCŒF’J_ŽiC‰ºìG–Ÿ : SŽº«ŠúŠOŽûk‚ւ̃AƒuƒŒ[ƒVƒ‡ƒ“‚ª—LŒø‚Ÿ‚Á‚œŒŽŒoŽüŠú‚ÉŠÖ˜A‚µ‚Ä‘ˆ«‚·‚é”ñŽ‘±«SŽº•p”‚Ì1—á
  4. ‘¶‘ה́C‚‹Ž C‰z“c—ºŽiC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸCóŠC‘׉hCˆÀ“c ‘CŽÄ MsC¬ŠÛ’B–çC‰Á‰ê’J –LC‰ºìG–Ÿ : ŒŒðÇð‚É‚æ‚é‹}«S‹Ø[Ç‚𔭏ǂµ‚œæ“V«SŽŸŠ³pŒã‚Ì2—á
  5. ‰z“c—ºŽiC™‘ºGˆê˜YCŽ…ˆŸŠóŽqC‰ºìG–ŸCˆê£‚ ‚ž‚³ : ‹•ŒŒ«SŽŸŠ³‚̐f’f‚É‚š‚¯‚éS‘ŸMRI‚Ì—L—p«
  6. ›ˆä‹`®CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°CˆäŒû“ÄŽuC“c—ѝæˆêC‰ºìG–Ÿ : ƒŠ[ƒh’fü‚É‚æ‚éAž‚ÝŒ^œ×“®ŠíiICDj‚ÌŒëì“®‚ð‚«‚œ‚µ‚œŠg’£Œ^S‹ØÇiDCMj‚̏Ǘá
  7. ™‘ºGˆê˜YC•Ÿ–{‹`OCo’¬ ‡C“ê“c ~CŽ…ˆŸŠóŽqC²Ž¡Œ«ÆC“¡“c ‰›C‰ºìG–Ÿ : ¬lƒXƒeƒBƒ‹•a‚É‚æ‚éS‹Ø‰Š‚̈êÇ—á
  8. L£®“¿CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CŽRŒû“WŠ°C‰ºìG–Ÿ : ã‘åÃ–¬‹NŒ¹‚̍ד®‚ª•ªŠE—Ë’†•”‚Ìexit‚©‚ç‚Ìbreakthrough‚É‚æ‚èS–[•p”‚ð’悵‚œ1—á
  9. L£®“¿CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CŽRŒû“WŠ°C‰ºìG–Ÿ : ‘å“®–¬•Ù’uŠ·pŒãCICD•p‰ñì“®‚·‚é–òÜ’ïR«‚̍¶SŽºáŽ‹NŒ¹SŽº•p”‚ɃAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚œ1—á
  10. •Ÿ“c_“ñCŒF’J_ŽiCŽáŽR—TŽiC›ˆä‹`®CL£®“¿CŽRŒû“WŠ°CŽÂè ‹BC‰ºìG–Ÿ : ƒuƒ‹ƒKƒ_Œ^S“d}‚ð‡•¹‚µ‚œ’PŒ`«SŽº«ŠúŠOŽûk‚ðŒ_‹@‚Æ‚·‚é“Á”­«SŽº×“®Ç—á
  11. “¡“c ‰›C•Ÿ–{‹`OCo’¬ ‡C“ê“c ~Cµ‰ãˆŸŠóŽqC²Ž¡Œ«ÆC™‘ºGˆê˜YC‰ºìG–Ÿ : AEDƒŒƒ“ƒ^ƒ‹‚ÍICD‚Ì‘ã—p‚Æ‚È‚è“Ÿ‚é‚© ? \ S’âŽ~‚𗈂µ‚œSƒAƒ~ƒƒCƒh[ƒVƒX‚Ì1Ç—á \
  12. “¡“c ‰›C•Ÿ–{‹`OCo’¬ ‡C“ê“c ~CŽ…ˆŸŠóŽqC²Ž¡Œ«ÆC™‘ºGˆê˜YC‰ºìG–Ÿ : æ“V«SŽŸŠ³‚É”º‚€”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒ{ƒZƒ“ƒ^ƒ“‚ÌŽg—pŒoŒ±
  13. ŽRŒû“WŠ°CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CL£®“¿C‰ºìG–Ÿ : –òÜ‚É‚æ‚é“ñŽŸ«QT‰„’·‚É‚æ‚è‘œŒ`«SŽº•p”‚ð‚«‚œ‚µ‚œ•p–¬«S–[×“®‚̈ê—á
  14. ŽáŽR—TŽiCŒF’J_ŽiC•Ÿ“c_“ñC›ˆä‹`®CL£®“¿CŽRŒû“WŠ°C™‘ºGˆê˜YC‰z“c—ºŽiCµ‰ãˆŸŠóŽqCˆê£‚ ‚ž‚³C‰Á‰ê’J –LC‰ºìG–Ÿ : MRI‚ªS‘ŸÄ“¯Šú—Ö@iCRT-Dj‚É—LŒø‚Å‚ ‚Á‚œŠg’£Œ^S‹ØÇ‚̈ê—á
‘æ35‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïi2007”N1ŒŽ28“úC‰F“s‹{j
  1. ‘¶‘ה́C¬ŠÛ’B–çC•“c ’qC‚‹ŽŽ–ŸC‹à’Ë Š®C‰z“c—ºŽiC‰ºìG–Ÿ : ”“®S—R—ˆ‚̉ߎ_‰»…‘f‚Í•p”‚É‚æ‚é‘ãŽÓ«Š¥”÷¬ŒŒŠÇŠg’£‚ðŽi‚Á‚Ä‚¢‚é
  2. ²“¡Œö—YC’†–ì œCˆÉ“¡ˆ€„C‰Á‰ê’J –LC‰ºìG–Ÿ : ƒGƒŠƒXƒƒ|ƒCƒGƒ`ƒ“‚É‚æ‚é“à”ç‘O‹ì×–E“®ˆõ‚Æ”x“®–¬ƒŠƒ‚ƒfƒŠƒ“ƒO‚Ì—}§ \ ’áŽ_‘f«”x‚ŒŒˆ³ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚š‚¯‚錟“¢ \
  3. ²“¡Œö—YC’†–ì œCˆÉ“¡ˆ€„C‰Á‰ê’J –LC‰ºìG–Ÿ : ŒŒŠÇV¶‚É‚š‚¯‚éEpo/EpoŽó—e‘ÌŒn‚̏d—v« \ EpoŽó—e‘ÌŒ‡‘¹ƒ}ƒEƒX‚ð—p‚¢‚œ‰ºŽˆ‹•ŒŒƒ‚ƒfƒ‹‚É‚š‚¯‚錟“¢ \
  4. ‚–Ø •¶CXìŒhŽqC‘ºŽR‰À”́C»ìŒ«“ñC‰ºìG–Ÿ : Angiotensin II–«“Š—^ƒ}ƒEƒX‚É‚š‚¢‚ÄNADiPjH oxidase‚É‚æ‚èŽY¶‚³‚ê‚ésuperoxide‚ÍH2O2 ‚É‚æ‚é“à”çˆË‘¶«‰ß•ª‹É”œ‰ž‚É‚ÍŠÖ—^‚µ‚È‚¢
  5. ‚–Ø •¶CXìŒhŽqC‘ºŽR‰À”́CEnder TekesC“›ˆä³lC–öŒŽ‰„ÍC»ìŒ«“ñC‰ºìG–Ÿ : “à”ç—R—ˆ‰ß•ª‹ÉˆöŽqiEDHFj”œ‰ž‚ÍNO‡¬y‘fŒn‚ÉŠ®‘S‚Ɉˑ¶‚·‚é \ NO‡¬y‘fŒnŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É’u‚¯‚錟“¢ \
‘æ33‰ñ“ú–{“à‰ÈŠw‰ï‹ãB’n•û‰ï¶ŠU‹³ˆçu‰‰‰ïi2007”N1ŒŽ28“úC•Ÿ‰ªj
  1. ‰ºìG–Ÿ : ‹•ŒŒ«SŽŸŠ³‚̐f—à : Å‹ß‚̐i•à
‘æ21‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ï“Œ–k’n•û‰ïi2007”N1ŒŽ27“úCå‘äj
  1. ‚‹Ž CˆÀ“c ‘C‰z“c—ºŽiC’†ŽR‰ë°CˆÉ“¡Œ’‘ŸCóŠC‘׉hCš ¶‘ה́CŽÄ MsC¬ŠÛ’B–çC‰Á‰ê’J –LC‰ºìG–Ÿ : 4.0 mmƒxƒAƒƒ^ƒ‹ƒXƒeƒ“ƒg‚Æ3.5 mm–òÜ—no«ƒXƒeƒ“ƒg‚̍ċ·ó—\–hŒø‰Ê‚Ì”äŠrŒŸ“¢

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2006”N
‘æ5‰ñEDHF Symposium (2006”N1ŒŽ21“úC“Œ‹ž)
  1. ‚–Ø •¶CXìŒhŽqC‘ºŽR‰À”́CTekes EC“›ˆä³lC–öŒŽ‰„ÍC‰ºìG–Ÿ : “à”ç—R—ˆ‰ß•ª‹ÉˆöŽqiEDHFj”œ‰ž‚ÍNO‡¬y‘fŒn‚ÉŠ®‘S‚Ɉˑ¶‚·‚é\NO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚錟“¢\
‘æ141‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2006”N2ŒŽ4“úCå‘ä)
  1. “ê“c ~CŠ¡•”–Ÿ•FC–îì_ˆêC‰ºìG–Ÿ : Sƒtƒ@ƒuƒŠ[•a‚ɑ΂µ‚Ä y‘f•â[—Ö@‚ðŽ{s‚µ‚œ1—á\‚»‚ÌŒø‰Ê‚ƍ¡Œã‚̉ۑè‚ɂ‚¢‚ā\
  2. ŒF’J_ŽiCŽáŽR—TŽiC•Ÿ“c_“ñC›ˆä‹`®C‰ºìG–Ÿ : QRS”gŒ`‚ª—ÞŽ—‚·‚éaorto-mitral continuity‚Æ‘å“®–¬•ÙŠ¥ë•”‹NŒ¹‚Ì“Á”­«¶Žº—¬o˜HŒ¹«ŠúŠOŽûk‚Ì2—á
  3. ‚‹Ž CŽÂè ‹BCŽÄ MsC‘œ“c’q—mC‰ºìG–Ÿ : ƒAƒ“ƒWƒIƒeƒ“ƒVƒ“•ÏŠ·y‘f‘jŠQ–ò ƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Žó—e‘̝hR–ò‚ÍŠg’£•s‘S‚Ì—\Œã‚ð‰ü‘P‚·‚é
  4. •Ÿ“c_“ñCŒF’J_ŽiCŽáŽR—TŽiC›ˆä‹`®C‰““¡GWC‰ºìG–Ÿ : ‰EŽº—¬o˜H‚É‹»•±“`”d’x‰„‚ð”F‚ß‚œƒuƒ‹ƒKƒ_Œ^S“d}Ç—á
  5. ‘œ“c”ŽŽqCŠ¡•”–Ÿ•FC•Ÿ“c_“ñCŒF’J_ŽiCŽ…ˆŸŠóŽqC‘œ“c’q—mC¬ŠÛ’B–çC‰Á‰ê’J–LC‰ºìG–ŸC“n•Ó‚Ý‚©CŠ}“‡“ÖŽqCˆÀ“¡—RŠì•v : S•a•Ï‚ª’˜–Ÿ‚Å‚ ‚Á‚œ‰Æ‘°«SƒAƒ~ƒƒCƒh[ƒVƒX‚̈ê—á
  6. –©’J –LCˆÉ“¡Œ’‘ŸC‰Á‰ê’J–LCóŠC‘׉hC’†ŽR‰ë°C‚‹Ž C–îì_ˆêC•“cŽç•FC”’“y–M’jC‰ºìG–Ÿ : ”÷—ʂ̍bó‘Bƒzƒ‹ƒ‚ƒ“—Ö@‚́C–«Œž•‰‰×ŠÂ‹«‚É‚š‚¯‚éS‹@”\‚š‚æ‚уJƒ‹ƒVƒEƒ€’²ß‹@”\‚̒ቺ‚ð—}§‚·‚é
  7. ŽáŽR—TŽiCŒF’J_ŽiC‘å—F ~C›ˆä‹`®C•Ÿ“c_“ñC‰““¡GWCŽÂè ‹BCˆäŒû“ÄŽuC“c—ѝæˆêC‰ºìG–Ÿ : A‚Šž‚ÝŒ^œ×“®Ší‚ð—p‚¢‚Ä—ŒSŽºƒy[ƒVƒ“ƒO‚ðŽ{s‚µ‚œ‰Æ‘°«Šg’£Œ^S‹ØÇ‚̈êÇ—á
‘æ178‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ï (2006”N2ŒŽ18“úCå‘ä)
  1. ‰ºìG–Ÿ : ‹³ˆçu‰‰ : ‹•ŒŒ«SŽŸŠ³‚ÌŽ¡—à : Å‹ß‚̐i•à
  2. ›ˆä‹`®CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC‰““¡GWCŽÂè ‹BC‰ºìG–ŸCˆäŒû“ÄŽuC“c—ѝæˆê : A‚Šž‚ÝŒ^œ×“®ŠíiICDjÄAž‚ÝŽž‚ÉŽc‘¶ƒŠ[ƒh‚ÌŠ±Â‚É‚æ‚èarray lead‚ðA‚Šž‚ñ‚Ÿ‰E‹¹S‚̏Ǘá
  3. ŒF’J_ŽiCŽáŽR—TŽiC•Ÿ“c_“ñC›ˆä‹`®C‰ºìG–Ÿ : ‘å“®–¬•Ù’uŠ·pŒãCICD•p‰ñì“®‚·‚é–òÜ’ïR«‚̍¶SŽºáŽ‹NŒ¹SŽº•p”‚ɃAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚œ1—á
  4. ‚‹Ž CŽÄ MsC‰z“c—ºŽiC’†ŽR‰ë°C‰ºìG–Ÿ : ƒTƒCƒtƒ@[ƒXƒeƒ“ƒg—¯’uŒãCˆŸ‹}«Šú‚ɃXƒeƒ“ƒg“àŒŒð‚ð”F‚߁C–«Šú‚ÉŠ¥“®–¬áŽ‚ðŒ`¬‚µ‚œ–«•ÂÇ«•a•Ï‚Ì1—á
‘æ35‰ñ“ú–{S–¬ŠÇì“®•šŽ¿Šw‰ïi2006”N2ŒŽ18“úC‰F“s‹{)
  1. ‚–Ø •¶CXìŒhŽqC‘ºŽR‰À”́CTekes EC“›ˆä³lC–öŒŽ‰„ÍC»ìŒ«“ñC‰ºìG–Ÿ : “à”ç—R—ˆ‰ß•ª‹ÉˆöŽqiEDHFj”œ‰ž‚ÍNO‡¬y‘fŒn‚ÉŠ®‘S‚Ɉˑ¶‚·‚é\NO‡¬y‘fŒnŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É’u‚¯‚錟“¢\
  2. ‚–Ø •¶CXìŒhŽqC‘ºŽR‰À”́C»ìŒ«“ñC‰ºìG–Ÿ : Angiotensin II–«“Š—^ƒ}ƒEƒX‚É‚š‚¢‚ÄNAD(P)H oxidase‚É‚æ‚èŽY¶‚³‚ê‚ésuperoxide‚ÍH2O2‚É‚æ‚é“à”çˆË‘¶«‰ß•ª‹É”œ‰ž‚É‚ÍŠÖ—^‚µ‚È‚¢
  3. ²“¡Œö—YC’†–ì œCˆÉ“¡ˆ€„C‰Á‰ê’J–LC‰ºìG–Ÿ : ŒŒŠÇV¶‚É‚š‚¯‚éEpo/EpoŽó—e‘ÌŒn‚̏d—v«\EpoŽó—e‘ÌŒ‡‘¹ƒ}ƒEƒX‚ð—p‚¢‚œ‰ºŽˆ‹•ŒŒƒ‚ƒfƒ‹‚É‚š‚¯‚錟“¢\
  4. ²“¡Œö—YC’†–ì œCˆÉ“¡ˆ€„C‰Á‰ê’J–LC‰ºìG–Ÿ : ƒGƒŠƒXƒƒ|ƒGƒ`ƒ“‚É‚æ‚é“à”ç‘O‹ì×–E“®ˆõ‚Æ”x“®–¬ƒŠƒ‚ƒfƒŠƒ“ƒO‚Ì—}§\’áŽ_‘f«”x‚ŒŒˆ³ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚š‚¯‚錟“¢\
  5. ‘¶‘ה́C¬ŠÛ’B–çC•“c ’qC‚‹ŽŽ–ŸC‹à’Ë Š®C‰z“c—ºŽiC‰ºìG–Ÿ : ”“®S—R—ˆ‚̉ߎ_‰»…‘f‚Í•p”‚É‚æ‚é‘ãŽÓ«Š¥”÷¬ŒŒŠÇŠg’£‚ðŽi‚Á‚Ä‚¢‚é
‘æ5‰ñ“ú–{Ä¶ˆã—Êw‰ï‘‰ïi2006”N3ŒŽ8“úC‰ªŽR)
  1. ²“¡Œö—YC’†–ì œCˆÉ“¡ˆ€„C‰Á‰ê’J–LC‰ºìG–Ÿ : ŒŒŠÇV¶‚É‚š‚¯‚éEpo/EpoŽó—e‘ÌŒn‚̏d—v«\EpoŽó—e‘ÌŒ‡‘¹ƒ}ƒEƒX‚ð—p‚¢‚œ‰ºŽˆ‹•ŒŒƒ‚ƒfƒ‹‚É‚š‚¯‚錟“¢\
  2. ’†–ì œC²“¡Œö—YCˆÉ“¡ˆ€„C‰Á‰ê’J–LC‰ºìG–Ÿ : ƒGƒŠƒXƒƒ|ƒGƒ`ƒ“‚É‚æ‚é“à”ç‘O‹ì×–E“®ˆõ‚Æ”x“®–¬ƒŠƒ‚ƒfƒŠƒ“ƒO‚Ì—}§\’áŽ_‘f«”x‚ŒŒˆ³ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚š‚¯‚錟“¢\
  3. ˆÉ“¡ˆ€„C²“¡Œö—YC’†–ì œC‰Á‰ê’J–LC‰ºìG–Ÿ : ‹•ŒŒ«‘gDáŠQ‚Æ‘O‹ì×–E“®ˆõ‚É‚æ‚鐶‘Ì–hŒä”œ‰ž\SŒŒŠÇ‘gD‚É‚š‚¯‚éEpoŽó—e‘Ì‚Ì–ðŠ„\
‘æ15‰ñ“ú–{S‘ŸŠjˆãŠw‰ï‘‰ï Šwp‘å‰ïi2006”N3ŒŽ23“úC–ŒŒÃ‰®)
  1. ŽáŽR—TŽiC‹yì”ü“ÞŽqC‰Á‰ê’J–LCŒF’J_ŽiC•Ÿ“c_“ñC›ˆä‹`®C™‘ºGˆê˜YC‰““¡GWC‹à“c•üGC•Ÿ“c Š°C‰ºìG–Ÿ : dÇS•s‘S‚ɑ΂·‚éS‘ŸÄ“¯Šú—Ö@‚̐S“d}“¯ŠúS‹ØŒŒ—¬SPECT–@‚ð—p‚¢‚œV‚µ‚¢•]‰¿–@‚ÌŒŸ“¢
‘æ70‰ñ“ú–{zŠÂŠíŠw‰ï‘‰ïi2006”N3ŒŽ24-26“úC–ŒŒÃ‰®)
  1. Kagaya Y, Asaumi Y, Takeda M, Ohta J, Tada H, Minegishi N, Suzuki N, Yamamoto M, Shirato K, Shimokawa H. ƒVƒ“ƒ|ƒWƒEƒ€u‚ŒŒˆ³«S‘Ÿ•a‚ƐS•s‘S”­Ç‹@˜vDeficiency of erythropoietin receptor gene in non-hematopoietic lineage deteriorates cardiac function and survival in ventricular pressure overload in mice. Circ J 70(Suppl I):I-29,2006.
  2. Shiba N, Tada T, Watanabe J, Shinozaki T, Kagaya Y, Shirato K, Shimokawa H. ƒVƒ“ƒ|ƒWƒEƒ€u“ú–{l‚Ì–«S•s‘S‚Ì“Á’¥‚Æ‚»‚ê‚ÉŠî‚­Ž¡—Ð헪vAccumulated risks and non-optimal medical treatment in Japanese older patients with chronic heart failure: results from the CHART study. Circ J 70(Suppl I):I-40,2006.
  3. Asaumi Y, Kagaya Y, Takeda M, Ohata J, Tada H, Yamaguchi N, Minegishi N, Shirato K, Shimokawa H. Important protective role of endogenous erythropoietin system against pressure overload-induced left ventricular dysfunction in mice in vivo. Circ J 70(Suppl I):I-181,2006.
  4. Fukui S, Shinozak T, Sugimura K, Ogawa H, Kagaya Y, Shimokawa H. Prognostic impact of central sleep apnea in patients with chronic heart failure. Circ J 70(Suppl I):I-454,2006.
  5. Jiang BH, Tawara S, Abe K, Takaki A, Shimokawa H. Acute vasodilator effect of fasudill, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. Circ J 70(Suppl I):I-406,2006.
  6. Ito Y, Satoh K, Nakano M, Tada H, Ohta J, Kagaya K, Shimokawa H. Impaired mobilization and incorporation of progenitor cells into the ischemic/hypoxic tissues in erythropoietin receptor-knockout mice. Circ J 70(Suppl I):I-280,2006.
  7. Kokusho Y, Komaru K, Takeda S, Takahashi K, Kanatsuka H, Koshida R, Shimokawa H. Hydrogen peroxide derived from beating heart mediates coronary microvascular dilatation during tachycardia in dogs in vivo. Circ J 70(Suppl I):I-299,2006.
  8. Kumagai K, Wakayama Y, Fukuda K, Sugai Y, Shimokawa H. Characteristics of idiopathic repetitive monomorphic ventricular tachycardia originating from the aorto-mitral continuity. Circ J 70(Suppl I):I-255,2006.
  9. Kumagai K, Wakayama Y, Fukuda K, Sugai Y, Shimokawa H. New approach of radiofrequency catheter ablation with intracoronary and venous mapping for the treatment of refractory ventricular tachycardia. Circ J 70(Suppl I):I-568,2006.
  10. Kumagai K, Wakayama Y, Fukuda K, Sugai Y, Shimokawa H. Different diagnosis of idiopathic ventricular tachycardia with aorto-mitral continuity origin from that with aortic sinus cusps origin. Circ J 70(Suppl I):I-640,2006.
  11. Minatoya Y, Ito K, Kagaya Y, Asaumi Y, Nakayama M, Takahashi J, Yahagi H, Takeda M, Shirato K, Shimokawa H. Low-dose of thyroid hormone restores depressed contractility and impaired calcium handling in chronically unloaded heart in rats. Circ J 70(Suppl I): I-571,2006.
  12. Morishita T, Tsutsui M, Shimokawa H, Nakata S, Sabanai K, Nakano Y, Nagasaki M, Tasaki H, Yanagihara N, Nakashima Y. Vasculoprotective role of the nitric oxide synthases system against vascular lesion formation in mice in vivo. Circ J 70(Suppl I):I-182,2006.
  13. Morishita T, Tsutsui M, Shimokawa H, Sabanai K, Nakano Y, Tasaki H, Yanagihara N, Nakashima Y. Genetic disruption of all nitric oxide synthase isoforms markedly reduces survival in mice. Circ J 70(Suppl I): I-198,2006.
  14. Nakano M, Satoh K, Ito Y, Kagaya Y, Shimokawa H. Chronic hypoxia mobilizes smooth muscle progenitors in mice. Circ J 70(Suppl I):I-296,2006.
  15. Nakano M, Satoh K, Zhulanqiqige D, Nawata J, Ito Y, Sugimura K, Kagaya Y, Shimokawa H. Evidence for mobilization of vascular progenitor cells in patients with pulmonary hypertension. Circ J 70(Suppl I): I-467,2006.
  16. Nakata S, Tsutsui M, Shimokawa H, Morishita T, Sabanai K, Nakano Y, Tasaki H, Yanagihara N, Nakashima Y. Metabolic syndrome in mice lacking all nitric oxide synthase isoforms. Circ J 70(Suppl I): I-441,2006.
  17. Oikawa M, Kagaya Y, Itoh K, Otani H, Takahashi J, Shinozaki T, Ichinose A, Kaneta T, Fukuda H, Takahashi S, Shirato K, Shimokawa H. Diagnostic usefulness of delayed contrast magnetic resonance and FDG-PET for cardiac sarcoidosis. Circ J 70(Suppl I):I-219,2006.
  18. Saji K, Suzuki J, Nawata J, Demachi J, Sugimura K, Oikawa M, Fukui S, Sakuma M, Shirato K, Shimokawa H. Pathogenetic link between microtubule polymerization and cardiomyocyte apoptosis: implication for heart failure. Circ J 70(Suppl I):I-166,2006.
  19. Satoh K, Nakano M, Ito Y, Miura M, Kagaya Y, Shimokawa H. Impaired angiogenic response to acute hindlimb ischemia in erythropoietin receptor-knockout mice. Circ J 70(Suppl I):I-182,2006.
  20. Satoh K, Namiuchi S, Nakano M, Ito Y, Ohta J, Tada H, Kagaya Y, Shimokawa H. Important protective role of endogenous erythropoietin system in ischemic cardiovascular disease. Circ J 70(Suppl I):I-276,2006.
  21. Satoh K, Nakano M, Ito Y, Shimizu A, Karibe A, Kagaya Y, Shimokawa H. High-dose statin therapy ameliorates hypoxia-induced pulmonary hypertension through suppression of the SDF-1/CXCR4 axis. Circ J 70(Suppl I):I-278,2006.
  22. Satoh K, Nakano M, Ito Y, Ohta J, Kagaya Y, Shimokawa H. Important role of endogenous erythropoietin system to recruit endothelial cells in hypoxia-induced pulmonary hypertension in mice. Circ J 70(Suppl I): I-313,2006.
  23. Shimizu A, Karibe A, Otomo J, Takahashi T, Iwabuchi K, Kikuchi J, Shinozaki T, Shimokawa H. Prevalence of lamin A/C gene mutations in the familial DCM with AV block in northern Japan. Circ J 70(Suppl I):I-612,2006.
  24. Sugimura K, Shinozaki T, Fukui S, Ogawa H, Watanabe J, Shirato K, Shimokawa H. End-tidal carbon dioxide predicts the responsiveness of patients with chronic heart failure associated with central sleep apnea to oxygen therapy. Circ J 70(Suppl I):I-330,2006.
  25. Sugimura K, Sakuma M, Shirato K, Shimokawa H. Risk factors and incidence of pulmonary embolism in Japan 2004. Circ J 70(Suppl I):I-203,2006.
  26. Tada H, Kagaya Y, Takeda M, Ohta J, Asaumi Y, Ito K, Satoh K, Karibe A, Shirato K, Shimokawa H. Molecular mechanism for the protective effect of endogenous erythropoietin-erythropoietin receptor system against myocardial reperfusion injury. Circ J 70(Suppl I):I-295,2006.
  27. Tada T, Shiba N, Shinozaki T, Takahashi J, Watanabe J, Shimokawa H. Anemia predicts sudden death in heart failure patients with preserved systolic function. Circ J 70(Suppl I):I-190,2006.
  28. Takahashi J, Shinozaki T, Shiba N, Tada T, Watanabe J, Shirato K, Shimokawa H. Therapeutic importance of angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker in patients with diastolic heart failure. Circ J 70(Suppl I):I-259,2006.
  29. Takaki A, Morikawa K, Murayama Y, Tsutsui M, Yanagihara N, Sunagawa K, Shimokawa H. Genetic disruption of all nitric oxide synthase isoforms abolishes EDHF-mediated responses in mice. Circ J 70(Suppl I):I-275,2006.
  30. Tawara S, Higashi M, Sunagawa K, Shimokawa H. Comparison of the inhibitory effects of HMG-CoA Reductase inhibitors and rho-kinase inhibitor on angiotensin II-induced cardiovascular lesion formation in rats. Circ J 70(Suppl I):I-574,2006.
  31. Tsutsui M, Shimokawa H, Morishita T, Nagasaki M, Sabanai K, Nakata S, Nakashima Y. Spontaneous development of systemic arteriosclerosis in mice lacking all nitric oxide synthase isoforms. Circ J 70(Suppl I):I-164,2006.
  32. Wakayama Y, Kumagai K, Oikawa M, Fukuda K, Sugai Y, Otomo J, Shinozaki T, Kagaya Y, Iguchi A, Tabayashi T, Kaneda T, Fukuda H, Shirato K, Shimokawa H. Cardiac resynchronization therapy improves non-uniform regional left ventricular wall thickening: evaluation by quantitative gated myocardial perfusion SPECT. Circ J 70(Suppl I):I-503,2006.
  33. Wakayama Y, Kumagai K, Oikawa M, Fukuda K, Sugai Y, Otomo J, Shinozaki T, Kagaya Y, Iguchi A, Tabayashi T, Kaneda T, Fukuda H, Shirato K, Shimokawa H. Usefulness of quantitative gated myocardial perfusion SPECT to predict left ventricular reverse remodeling after cardiac resynchronization therapy. Circ J 70(Suppl I):I-252,2006.
  34. Yada T, Shimokawa H, Morikawa K, Takaki A, Goto M, Ogasawara Y, Kajiya F. Important role of Cu/Zn-SOD in the synthesis of endothelium-derived hyperpolarizing factor during reactive hyperemia in mouse mesenteric microvesseis in vivo. Circ J 70(Suppl I):I-199,2006.
  35. Yada T, Shimokawa H, Hiramatsu O, Shinozaki Y, Mori H, Goto M, Ogasawara Y, Kajiya F. Crucial role of hydrogen peroxide as an endogenous EDHF during pacing-induced metabolic dilatation in canine coronary microvessels in vovo. Circ J 70(Suppl I):I-201,2006.
  36. Yada T, Shimokawa H, Hiramatsu O, Shinozaki Y, Mori H, Goto M, Ogasawara Y, Kajiya F. Cardioprotective role of hydrogen peroxide as an endogenous EDHF during ischemia-reperfusion injury in canine coronary microvessels in vivo. Circ J 70(Suppl I):I-472,2006.
‘æ33‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïi2006”N3ŒŽ2-4“úC‘åã)
  1. ‘å‹ŽŽqCˆÀ“c ‘CXˆä Œ÷CŒI“c—²ŽuCŠ™‘qŽj˜YC–ìX–Ø GC‹{èrˆê : “«SŽº«•s®–¬‚ɑ΂·‚éƒjƒtƒFƒJƒ‰ƒ“ƒg‚Ì‹}«—\–hŒø‰Ê : QTŽžŠÔƒRƒ“ƒgƒ[ƒ‹‚̏d—v«
  2. Xˆä Œ÷CˆÀ“c ‘C•Ð‰ª —LCì‘º ~C‹{èrˆê : ‹}«S‹Ø[ÇƒNƒŠƒeƒBƒJƒ‹ƒpƒX“K‰ž‚ÌŒ»ó‚Æ–â‘è
EPC Biology Conference (2006”N3ŒŽ23“úC_ŒË)
  1. ²“¡Œö—YC’†–ì œCˆÉ“¡ˆ€„C‰Á‰ê’J –LC‰ºìG–Ÿ : Impaired angiogenic response to acute hindlimb ischemia in erythropoietin receptor-knockout mice.
‘æ103‰ñ“ú–{“à‰ÈŠw‰ï (2006”N4ŒŽ14-16“úC‰¡•lj
  1. ˆÀ“c ‘C‘å‹ŽŽqCXˆä Œ÷CŽ… ÂCŒI“c—²ŽuCŠ™‘qŽj˜YC–ìX–Ø GC‹{èrˆê : ’vŽ€“ISŽº«•s®–¬‚ɑ΂·‚éƒjƒtƒFƒJƒ‰ƒ“ƒg‚Ì—L—p«‚ƍÕs®–¬ì—p
‘æ6‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2006”N5ŒŽ25-26“úC“Œ‹žj
  1. ‚–Ø •¶CXìŒhŽqC‘ºŽR‰À”́C‰ºìG–Ÿ : NAD(P)H oxidase‚É‚æ‚èŽY¶‚³‚ê‚ésuperoxide‚ÍH2O2‚É‚æ‚é“à”çˆË‘¶«‰ß•ª‹É”œ‰ž‚É‚ÍŠÖ—^‚µ‚È‚¢ \ Angiotensn II–«“Š—^ƒ}ƒEƒX‚É‚š‚¯‚錟“¢ \
  2. “›ˆä³lC‰ºìG–ŸCŽç‰º ŠžC’†“‡NGC–öŒŽ‰„Í : NO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚ézŠÂŠí•a•\Œ»Œ^
  3. Žç‰º ŠžC“›ˆä³lC‰ºìG–ŸC–öŒŽ‰„ÍC’†“‡NG : NO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚ÌŠJ”­‚Æ‹@”\‰ðÍ
  4. ’†“c –õC“›ˆä³lC‰ºìG–ŸCŽç‰º ŠžC{“c Ž¡C’†“‡NGC–öŒŽ‰„Í : ŒŒ¬”—R—ˆ‘BˆöŽq‚ÍMEK/ERKŒo˜H‚ð‰î‚µ‚ÄŒŒŠÇ•ÇnNOS”­Œ»‚𑝉Á‚³‚¹‚é
  5. ‚–Ø •¶CXìŒhŽqC‘ºŽR‰À”́CƒeƒPƒXƒGƒ“ƒ_[C“›ˆä³lC–öŒŽ‰„ÍC‰ºìG–Ÿ : “à”ç—R—ˆ‰ß•ª‹ÉˆöŽq(EDHF)”œ‰ž‚ÍNO‡¬y‘fŒn‚ÉŠ®‘S‚Ɉˑ¶‚·‚é \ NO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚š‚¯‚錟“¢ \
‘æ76‰ñ“ú–{’Ž‰¹”gˆãŠw‰ïi2006”N5ŒŽ26“úC‘åãj
  1. ŽRŠÝr•vCŽR’JˆêLC‰Á“¡ ^C¬ŠâŠì˜YC’·’Jì‰p”VC‹àˆä _C‘å’Ώ¹•v : ˆÊ‘Š·ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚éŒz“®–¬‰ð—£—á‚Ì‹Uo“àŒŒð‚Ì•]‰¿
‘æ27‰ñS‘ŸŠjˆãŠwŒ€‹†‰ï (2006”N5ŒŽ27“úCÃ‰ªj
  1. ‰Á‰ê’J –L : S•s‘S‚ւ̃Aƒvƒ[ƒ`
‘æ142‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2006”N6ŒŽ10“úC·‰ªj

ƒ“Á•Êu‰‰„

  1. ‰ºìG–Ÿ : SŒŒŠÇ•a‚ɑ΂·‚éæiˆã—Â̊J”­

ƒˆê”ʉ‰‘聄

  1. ‘å—F ~C™‘º²•FC•Ÿ’n–ž³CŽáŽR—TŽiCŒF’J_ŽiC‰ºìG–Ÿ : ‘åSÃ–¬‘OSŽº’†ŠuŽ}‚Ö‘}“ü‚µ‚œ‘œ“d‹ÉƒJƒe[ƒeƒ‹‚ª‹NŒ¹‚̐„’è‚É—L—p‚Ÿ‚Á‚œÇŒó«SŽº«ŠúŠOŽûk‚Ì1—á
  2. ŒF’J_ŽiCŽáŽR—TŽiC•Ÿ“c_“ñC›ˆä‹`®C‰ºìG–Ÿ : –òÜ’ïR«‚̍¶SŽºáŽ‹NŒ¹SŽº•p”‚ɃAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚œ1—á
  3. ™‘ºGˆê˜YC‹yì”ü“ÞŽqCo’¬ ‡C•Ÿ–{‹`OC“ê“c ~C²“¡Œö—YC²‹vŠÔ¹mC‰ºì G–Ÿ : ”x‚ŒŒˆ³Ç‚𔺂Á‚œ•Ð‘€”x“®–¬–³Œ`¬Ç‚̈êÇ—á
  4. š¢’J—²Ž¡C‰z“c—ºŽiC‚‹Ž C’†ŽR‰ë°C‘œ“c”ŽŽqCˆÉ“¡Œ’‘ŸCˆÀ“c ‘CŽÄ MsC¬ŠÛ’B–çC‰Á‰ê’J –LC‰ºìG–Ÿ : “–‰È‚É‚š‚¯‚éCypher Stent‚ÌŽg—p¬Ñ‚ƍċ·ó—á‚ÌŒŸ“¢
  5. o’¬ ‡C“ê“c ~C™‘ºGˆê˜YC—é–Ø C•Ÿ ‹`OC²“¡Œö—YC²‹vŠÔ¹mC”’“y–M’jC‰ºìG–Ÿ : ‹ßˆÊ•””x“®–¬áŽ‚𔺂€‘œ”­«”x“®–¬«”x‚ŒŒˆ³Ç‚Ì3—á
  6. “ê“c ~Co’¬ ‡C™‘ºGˆê˜YC²“¡Œö—YC—é–Ø C²‹vŠÔ¹mC•Ÿ–{‹`OC‰ºìG–Ÿ : ”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒ{ƒZƒ“ƒ^ƒ“‚ÌŽg—p¬Ñ
  7. •Ÿ“c_“ñCŒF’J_ŽiCŽáŽR—TŽiC›ˆä‹`®C‰““¡GWC‰ºìG–Ÿ : ƒuƒ‹ƒKƒ_Œ^S“d}‚É‚š‚¯‚éSŽº×“®—U”­«‚ÌŒŸ“¢ \ ‰ÁŽZ•œ‹ÏS“d}’x‰„“dˆÊ‚Æ–ò•š•‰‰×ŽŽŒ±‚Ì—L—p« \
  8. “¡“c ‰›CŽáŽR—TŽiCŒF’J_ŽiC•Ÿ“c_“ñC›ˆä‹`®CŠ¡•”–Ÿ•FC‰ºìG–Ÿ : —ŒSŽºƒy[ƒVƒ“ƒO‚ª—LŒø‚Å‚ ‚Á‚œŠg’£‘Š”ì‘åŒ^S‹ØÇ‚̈ê—á
  9. –©’J –LC‚‹Ž C’†ŽR‰ë°C‰““¡GWC›ˆä‹`®CŽáŽR—TŽiCŽÄ MsC‰ºìG–Ÿ : ‹}«Š¥ÇŒóŒQ‚É”­Ç‚µ‚œDŽ_‹…«S‹Ø‰Š‚̈ê—á
‘æ179‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2006”N6ŒŽ17“úC·‰ªj
  1. Š¡•”–Ÿ•FCÎˆä’q“¿C’GŽR^‹KC—é–Ø C¬ŠÛ’B–çC‰ºìG–Ÿ : ‘œ”­«‹Ø‰Š‚ɍ‡•¹‚µ‚œS•s‘S‚ɖƉu—}§—Ö@‚ª—LŒø‚Å‚ ‚Á‚œ1—á
‘æ21‰ñ“ú–{•s®–¬Šw‰ï/‘æ23‰ñ“ú–{S“dŠw‰ï ‡“¯ŠwpW‰ïi2006”N7ŒŽ7-9“úC“Œ‹žj
  1. ‘å—F ~C•Ÿ’n–ž³CŽÂè ‹BC”nêŒb•vC”ª–Ø“N•vCŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CŠ¡•”–Ÿ•FCŽO‰Y¹lC‰ºìG–Ÿ : ÇŒó«SŽº«•s®–¬Š³ŽÒ‚ɑ΂·‚é—U”­«SŽº×“®‚͐SŽº×“®‚ð—\’m‚µ‚È‚¢
  2. ŒF’J_ŽiCŽáŽR—TŽiC•Ÿ“c_“ñC›ˆä‹`®C‰ºìG–Ÿ : Aorto-mitral continuity‚ð‹NŒ¹‚Æ‚·‚éSŽº«•s®–¬‚ÌŒŸ“¢
  3. ŽÂè ‹BC”nêŒb•vC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CŒF’J_“ñC‰ºìG–ŸC“n•Ó ~ : ’†•Œ^‡–°Žž–³ŒÄ‹zÇŒóŒQ‚Æ’v–œ“I•s®–¬
  4. ›ˆä‹`®CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiCL£®“¿CŽRŒû“WŠ°CˆäŒû“ÄŽuC“c—ѝæˆêC‰ºìG–Ÿ : ICDAž‚ÝŽž‚à‚µ‚­‚͐Až‚ÝŒã‚ɔ牺ƒAƒŒƒCƒŠ[ƒh‚̒ljÁ‚ð—v‚µ‚œ3Ç—á
  5. ”nêŒb•vCŽÂè ‹BC•Ÿ“c_“ñCŽáŽR—TŽiC›ˆä‹`®CŒF’J_ŽiC‰ºìG–ŸC“n•Ó ~ : ¶Žº‹ìo—Š‚͐S‹Ø[ÇŒãS•s‘SŠ³ŽÒ‚Ì“Ë‘RŽ€‚ð—\’m‚·‚é
  6. •Ÿ“c_“ñCŒF’J_ŽiCŽáŽR—TŽiC›ˆä‹`®C‰““¡GWC‰ºìG–Ÿ : –³ÇŒó«ƒuƒ‹ƒKƒ_Œ^S“d}‚Ì“d‹C¶—Šw“IŒŸž‚É‚š‚¯‚éSŽº×“®—U”­—\‘ªˆöŽq‚ÌŒŸ“¢
  7. ŽáŽR—TŽiCŒF’J_ŽiC•Ÿ“c_“ñC›ˆä‹`®C‰““¡GWC™‘ºGˆê˜YC‰Á‰ê’J –LC‰ºìG–Ÿ : S“d}“¯ŠúS‹ØŒŒ—¬SPECT‚ð—p‚¢‚œdÇS•s‘S‚ɑ΂·‚éS‘ŸÄ“¯Šú—Ö@‚Ì’·ŠúŒø‰Ê‚ÌŒŸ“¢
‘æ38‰ñ“ú–{“®–¬d‰»Šw‰ïi2006”N7ŒŽ13“úC“Œ‹žj
  1. ‘œ“c’q—mC“ê“c ~C‰€ ŠœCŽì—–‘Ž‘ŽŠiC”öã‹IŽqC™‘ºGˆê˜YC•Ÿ–{‹`OC‰ºìG–Ÿ : The influence of pulsatile and static pressure on vascular smooth muscle cell migration.
  2. ŽRŠÝr•vC‰Á“¡ ^C¬ŠâŠì˜YC’·’Jì‰p”VC‹àˆä _C‘å’Ώ¹•v : ˆÊ‘Š·ƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚œŒŒŠÇ’e«—Š•ª•z‚É‚æ‚éèò“®–¬ƒvƒ‰[ƒN‚Ì•]‰¿
  3. ŽRŠÝr•vC‰Á“¡ ^C‹àˆä _C’·’Jì‰p”VC”öŒÒ Œ’C¬ŠâŠì˜YC‘å’Ώ¹•v : èò“®–¬ƒvƒ‰[ƒN‚ɑ΂·‚éƒXƒ^ƒ`ƒ“‚̍R“®–¬d‰»ì—p‚ÆŒŒŠÇ’e«—ŠƒqƒXƒgƒOƒ‰ƒ€•ªÍ
‘æ5‰ñƒjƒtƒFƒJƒ‰ƒ“ƒgŒ€‹†‰ïi2006”N7ŒŽ15“úC“Œ‹žj
  1. Ž… ÂCˆÀ“c ‘C‘å‹ŽŽqCŠ™‘qŽj˜Y : –ò—ì—p‚©‚ç‚Ý‚œSŽº«•s®–¬‚ɑ΂·‚éƒjƒtƒFƒJƒ‰ƒ“ƒg‚̈ʒu•t‚¯
‘æ180‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2006”N9ŒŽ16“úAå‘äj
  1. ‘œ“c”ŽŽqC‰z“c—ºŽiC‚‹Ž@C’†ŽR‰ë°CˆÉ“¡Œ’‘ŸCˆÀ“c@‘CŽÄ@MsC¬ŠÛ’B–çC‰Á‰ê’J–LC‰ºìG–ŸF¶Š¥“®–¬ÄŒšpŒã20”N‚Å‹‘劥“®–¬áŽ‚ðŒ`¬‚µ‚œ¶Š¥“®–¬”x“®–¬‹NŽnÇ‚Ì1—á
‘æ54‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï (2006”N9ŒŽ25-27“úCŽ­Ž™“‡)

ƒƒVƒ“ƒ|ƒWƒEƒ€2 : SŒŒŠÇŽŸŠ³‚É‚š‚¯‚éGender Specific Medicine„

  1. ŽÄ MsC‚‹Ž CŒ–Ø”üC‘œ“c’q—mCŽÂè ‹BC“n•Ó ~C‰Á‰ê’J –LC‰ºìG–Ÿ : “ú–{l—«‚É‚š‚¯‚閝«S•s‘S‚Ì“Á’¥‚Æ—\Œã
  2. ŽÂè ‹BC“n•Ó ~CŽÄ MsC‘œ“c’q—mC‚‹Ž C‰Á‰ê’J –LC‰ºìG–Ÿ : S‹Ø[ÇŒãS•s‘SŠ³ŽÒ“Ë‘RŽ€‚̈ꎟ—\–hí—ª : ChronicHeart Failure Analysis and Registry in Tohoku District (CHARTj‚©‚çŠw‚Ô

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“2 : ŒŒŠÇ‹@”\‚ÆŒŒŠÇ•s‘S„

  1. ¬ŠÛ’B–çC‰ºìG–Ÿ : ŒŒŠÇ‹@”\•s‘S‚ƐS‹Ø‹•ŒŒ : Š¥”÷¬ŒŒŠÇ‚ƐS‹Ø‚Ì‘ŠŒÝì—p‚̈Ӌ`

ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  1. ‰ºìG–Ÿ : ƒZƒƒgƒjƒ“‚Æ‹•ŒŒ«SŽŸŠ³

ƒ“ú–{S‘Ÿ•aŠw‰ïC“ú–{S‘ŸŠjˆãŠw‰ïƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€ : S•s‘Sf—Âւ̊jˆãŠw‚̉ž—p„

  1. ‰Á‰ê’J –L : S‹Ø‘ãŽÓƒCƒ[ƒWƒ“ƒOi18F-FDG PET) : ‰EŽºˆ³•‰‰×ŒyŒž—Ö@‚ւ̉ž—p

ƒˆê”ʉ‰‘聄

  1. Š¡•”–Ÿ•FCŽ…ˆŸŠóŽqC‘å—F ~CŽáŽR—TŽiC›ˆä‹`®C•Ÿ“c_“ñCŒF’J_ŽiC‰ºìG–Ÿ : ‚“x–[Žº“`“±áŠQ‚ð‡•¹‚·‚éS‹ØÇ‚Ì•ªŽqˆâ“`Šw“IŒŸ“¢
  2. ŒF’J_ŽiCŽáŽR—TŽiC•Ÿ“c_“ñC›ˆä‹`®C‰ºìG–Ÿ : Ž‘±«S–[×“®‚ɑ΂·‚éL”͈͔xÃ–¬Šu—£p‚É‚æ‚éstructural reverse remodeling‚ÌŒŸ“¢
  3. ¬ŠâŠì˜YC‰Á“¡ ‹Cç—tŒ«Ž¡C‘å•œ”ü‰ÀCÎˆä’q“¿C@‘œ–õ•FC²X–Ø ‹BC‰ºìG–Ÿ : ‚ž“xƒhƒvƒ‰–@‚É‚æ‚茌ŠÇ•Ç‚̉ŠÇ‚ÌŒo‰ß‚ð”cˆ¬‚µ‚Š‚œ‚ˆÀ“®–¬‰Š‚̈ê—á
  4. ¬ŠâŠì˜YCÎˆä’q“¿C@‘œ–õ•FC‰Á“¡ ‹Cç—tŒ«Ž¡C‘å•œ”üŒjC²X–Ø ‹BC‰ºìG–Ÿ : ‚ž“xƒhƒvƒ‰Œv‘ª gˆÊ‘Š·ƒgƒ‰ƒbƒLƒ“ƒO–@h‚Í“®–¬•Ç“à‰ŠÇ•a•Ï‚Ì’è—Ê”cˆ¬‚ð‰Â”\‚Æ‚·‚é
  5. ™‘ºGˆê˜YC‹yì”ü“ÞŽqCµ‰ãˆŸŠóŽqC‰ºìG–Ÿ : S‘ŸƒTƒ‹ƒRƒCƒh[ƒVƒX‚ÌPETEMRI‚É‚æ‚éf’fEŽ¡—ÃŒø‰Ê”»’è
  6. ‚‹Ž CŽÄ MsCŽÂè ‹BC‰ºìG–Ÿ : –«S•s‘S—á‚É‚š‚¯‚éƒAƒ“ƒWƒIƒeƒ“ƒVƒ“•ÏŠ·y‘f‘jŠQ–òEƒAƒ“ƒWƒIƒeƒ“ƒVƒ“Žó—e‘̝hR–ò‚Ì—\Œã‰ü‘PŒø‰Ê\CHARTŒ€‹†‚É‚š‚¯‚錟“¢\
  7. o’¬ ‡C“ê“c ~C™‘ºGˆê˜YC—é–Ø C•Ÿ–{‹`OC²“¡Œö—YC²‹vŠÔ¹mC”’“y–M’jC‰ºìG–Ÿ : ’˜–Ÿ‚ȋ߈ʕ””x“®–¬Šg‘å‚ð”F‚ß‚é“Á”­«”x“®–¬«”x‚ŒŒˆ³Ç‚Ì3—á
  8. “ê“c ~Co’¬ ‡C•Ÿ–{‹`OC™‘ºGˆê˜YC²“¡Œö—YC²‹vŠÔ¹mC‰ºìG–Ÿ : ”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒ{ƒZƒ“ƒ^ƒ“‚ÌŒø‰Ê‚ƈÀ‘S«
  9. Œ–Ø”üCŽÄ MsC‘œ“c’q—mC‚‹Ž C‰Á‰ê’J –LC‰ºìG–Ÿ : ‰h—{•s—Ç‚Í–«S•s‘SŠ³ŽÒ‚Ì—\Œã‚ð—\‘ª‚Å‚«‚é
  10. ŽáŽR—TŽiCŒF’J_ŽiC•Ÿ“c_“ñC›ˆä‹`®C™‘ºGˆê˜YC‹yì”ü“ÞŽqC‰Á‰ê’J –LC‹à“c•ü—mCA“c Š°C‰ºìG–Ÿ : S‘ŸÄ“¯Šú—Ö@‚Í•s‹Ïˆê‚ȍ¶Žº‹ÇŠ•ÇŒú•Ï‰»‚ð‰ü‘P‚·‚é : S“d}“¯ŠúS‹ØŒŒ—¬SPECT–@‚ð—p‚¢‚œŒŸ“¢
‘æ11‰ñLa Jolla-Capri-Yamaguchi-Seoul Research Conferences (2006”N10ŒŽ7“úC”‹Žs)
  1. óŠC‘׉hC‰Á‰ê’J –LC•“cŽç•FCŽRŒû“WŠ°C‘œ“c”ŽŽqCˆÉ“¡Œ’‘ŸC‘Ÿ“c C”’ŒË ’C•õŠÝ’ŒŽqC‰ºìG–Ÿ : Protective role of endogenous erythropoietin/erythropoietin-receptor system against pressure overload-induced heart failure in mice.
‘æ10‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2006”N10ŒŽ13-15“úC“Œ‹žj
  1. Asaumi Y, Kagaya Y, Yamaguchi N, Takeda M, Ito K, Ohta J, Tada H, Minegishi N, Shimokawa H. Protective role of endogenous erythropoietin/erythropoietin-receptor system against pressure overload-induced left ventricular dysfunction in mice in vivo.
  2. Fukui S, Shinozaki T, Sugimura K, Ogawa H, Fukumoto Y, Shimokawa H. Chronic effects of home oxygen therapy on brain-natriuretic peptide in chronic heart failure complicated with central sleep apnea.
  3. Shiba N, Tada T, Matsuki M, Watanabe J, Kagaya Y, Shimokawa H. Prognostic impact of metabolic syndrome in patients with diastolic heart failure.
  4. Shiba N, Matsuki M, Takahashi J, Watanabe J, Kagaya Y, Shimokawa H. Moderate reduction in blood pressure may be associated with reduced survival in non-hypertensive patients with chronic heart failure.
  5. Takahashi J, Shiba N, Tada T, Matsuki M, Shimokawa H. Undernutrition is a significant prognostic factor in patients with diastolic heart failure.
  6. Wakayama Y, Kumagai K, Fukuda K, Sugai Y, Sugimura K, Kaneta T, Fukuda H, Kagaya Y, Shimokawa H. CRT improves abnormal left ventricular wall thickening and remodeling evaluated by quantitative gated myocardial perfusion SPECT.
  7. ™‘ºGˆê˜YC•Ÿ–{‹`OCo’¬ ‡C“ê“c ~C²“¡Œö—YC‰ºìG–Ÿ : ”x‚ŒŒˆ³Ç‚𔺂Á‚œ•Ð‘€”x“®–¬–³Œ`¬Ç‚̈êÇ—á
  8. Œ–Ø”üCˆÉ“¡‘å•ãC‘åèÃCŽÄ MsC”’»‚œ‚ÜŽqC—é–Ø—R”üC‰ºìG–Ÿ : “–‰È“ü‰@’†‚̐SŽŸŠ³Š³ŽÒ‚É‚š‚¯‚é—}‚€‚ó‘ԂƐ‡–°áŠQ‚Ì•p“x‚Æ“Á’¥
‘æ25‰ñS‘ŸˆÚAŒ€‹†‰ï (2006”N10ŒŽ14“úC“Œ‹ž)
  1. š¢’J—²Ž¡CŽáŽR—TŽiCŒF’J_ŽiC•Ÿ“c_“ñC›ˆä‹`®CŽÄ MsCˆäŒû“ÄŽuC“c—ѝæˆêC‰ºìG–Ÿ : ƒJƒeƒRƒ‰ƒ~ƒ“—£’E¢“ï‚ȏdÇS•s‘SÇ—á‚ɑ΂·‚éS‘ŸÄ“¯Šú—Ö@‚ÌŒoŒ±
‘æ47‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi2006”N10ŒŽ20-22“úC_ŒËj
  1. ‘¶‘ה́C¬ŠÛ’B–çC‚‹ŽŽ–ŸCŽRŒû“WŠ°C’†ŽR‰ë°C‰z“c—ºŽiC”’“y–M’jC‰ºìG–Ÿ : ƒCƒ“ƒXƒŠƒ“’ïR«ƒ‰ƒbƒg‚Ìèò“®–¬V¶“à–Œ‚Å‚ÌŠˆ«Ž_‘f‚ÆŠˆ«’‚‘f‚É‹y‚Ú‚·ƒÁ-ƒgƒRƒtƒFƒ[ƒ‹‚ÌŒø‰Ê : ƒ¿-ƒgƒRƒtƒFƒ[ƒ‹‚Æ‚Ì”äŠr
  2. o’¬ ‡C•Ÿ–{‹`OC“ê“c ~C™‘ºGˆê˜YC²‹vŠÔ¹mC‰ºìG–Ÿ : “–‰@‚É‚š‚¯‚éƒGƒ|ƒvƒƒXƒeƒm[ƒ‹Ž‘±Ã’—Ö@Š³ŽÒ‚Ì—\Œã‚ÆŒŒs“®‘Ô
  3. •Ÿ–{‹`OC‰ºìG–Ÿ : ”x‚ŒŒˆ³‚É‚š‚¯‚éRhoƒLƒi[ƒ[‚Ì•ªŽqŽ¡—ÕW“I‚Æ‚µ‚Ă̏d—v«
‘æ18‰ñƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“ˆÏˆõ‰ïŒöŠJŒ€‹†‰ï (2006”N11ŒŽ4“ú)
  1. ŒF’J_ŽiCŽáŽR—TŽiC•Ÿ“c_“ñC›ˆä‹`®C‰ºìG–Ÿ : ”xÃ–¬Šu—£pŽ{sŒã—U”­‚³‚ê‚œS–[•p”‚Ì‹@˜‚ªã‘åÃ–¬‹NŒ¹‚̍ד®‚Ì•ªŠE—Å’†•”‹ß–T‚©‚ç‚Ìbreakthrough‚É‚æ‚é‘e“®‰»‚Å‚ ‚Á‚œˆê—á
‘æ16‰ñ“ú–{S‘ŸŠjˆãŠw‰ïŠwp‘å‰ïi2006”N11ŒŽ11“úCŽ­Ž™“‡j
  1. ‰Á‰ê’J –L : ŠjˆãŠw“IŽè–@‚É‚æ‚éƒqƒg•‰‰×S‹Ø‚̃Gƒlƒ‹ƒM[ŠîŽ¿‘ãŽÓ‚ƍזE“àî•ñ“`’BŒn‚Ì•]‰¿
‘æ40‰ñ“ú–{¶‘̈ãHŠw‰ï“Œ–kŽx•”‘å‰ïi2006”N11ŒŽ25“úCå‘äj
  1. ˆÉ“¡Œ’‘ŸCã“¿–L˜aC‰ºìG–Ÿ : ”ñNP«‘ÌŠOÕŒ‚”gŽ¡—Â͋}«S‹Ø[ÇŒã‚̍¶ŽºƒŠƒ‚ƒfƒŠƒ“ƒO‚ð—}§‚·‚é
  2. ˆÀ“c ‘Cã“¿–L˜aC•ÐŽR‰ÀŽ÷C‰ºìG–Ÿ : ŒŒŠÇáŠQ•”ˆÊ‚ð”FŽ¯‚·‚éV‚µ‚¢ŠjŽ¥‹C‹€–‘•’u‹@”\‰»‘¢‰eÜ‚ÌŠJ”­
2006”N12ŒŽ2“úCThe 23rd Annual Meeting of International Society for Heart Research Japanese Section (Chiba, Japan)
  1. Kagaya Y, Tada H, Asaumi Y, Ohta J, Minegishi N, Shimokawa H. Important protective roles of endogenous erythropoietin-mediated signaling in myocardial ischemia and pressure overload-induced cardiac hypertrophy.
‘æ14‰ñ“ú–{ŒŒŠÇ¶•šˆãŠw‰ï (2006”N12ŒŽ13“úC“Œ‹ž)
  1. ‘œ“c’q—mC“ê“c ~C‰€ ŠœCŽì—–‘Ž‘ŽŠiC”öã‹IŽqCˆÉ“¡Œ’‘ŸC™‘ºGˆê˜YC•Ÿ–{‹`OC‰ºìG–Ÿ : ƒ‰ƒbƒg‘å“®–¬•œŠŠ‹Ø×–E‚ւ̈³•‰‰×‚É‚æ‚é—V‘–”\‚̕ω»
  2. ’†–ì œC²“¡Œö—YC•Ÿ–{‹`OCˆÉ“¡ˆ€„C‰Á‰ê’J –LC‰ºìG–Ÿ : ŒŒŠÇV¶‚É‚š‚¯‚éEpo/EpoRŒn‚Ì–ðŠ„ \ EpoR KOƒ}ƒEƒX‚É‚š‚¯‚錟“¢ \

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2005”N
‘æ37‰ñ“ú–{“®–¬d‰»Šw‰ï‘‰ïi2005”N7ŒŽ14“úC“Œ‹ž)
  1. ”ó‹l‹M“oŽmC‰ºìG–ŸCXìŒhŽqCã“¿–L˜aC‘åˆäŒ[ŽiCˆ¢•”O‘Ÿ˜YC»ìŒ«“ñ : ŒŒŽƒRƒ‹ƒ`ƒ][ƒ‹‚ÌŽ‘±‚’l‚É‚æ‚éƒuƒ^Š¥“®–¬‰ßŽûk”œ‰ž‚ÌŽä‹N\Rho-kinaseŒo˜H‚ÌŠÖ—^\
  2. ‘åˆäŒ[ŽiC‰ºìG–ŸCœA–؏ŽqC•Žs‘•cC’†“ˆŽsC’|‰º ² : ƒ|ƒbƒNƒŠ•aŠ³ŽÒ—R—ˆ‚̃Œƒ€ƒiƒ“ƒgƒŠƒ|’`”’•ª‰æ‚Ì–«ŽhŒƒ‚ÍŠ¥“®–¬‚̝¹k«”œ‰ž‚ðŽä‹N‚·‚é
  3. ŽRŠÝr•vC‚â “oC‰Á“¡ ^C¬ŠâŠì˜YC‹àˆä _C’·’Jì‰p”VC‘å’Ώ¹•v : Š¥“®–¬ŠëŒ¯ˆöŽq‚̐”‚ÆŒz“®–¬•Ç’e«—Š‚ÌŠÖŒW
  4. ‰«–{‹vŽuCÎŠ_ ‘ׁC‰ª –F’mC¬ŠâŠì˜Y : V‹K“®–¬d‰»f’f–@iŒŒŠÇ•Ç’e«“Á«‘ª’èj‚ÌŒŸ“¢ : ]—ˆ‚Ì“®–¬d‰»f’f
‘æ5‰ñSŒŒŠÇÄ¶æ’[Ž¡—ÃtƒH[ƒ‰ƒ€ (2005”N7ŒŽ9“úC“Œ‹ž)
  1. ã“¿–L˜aC‰ºìG–ŸC‘åˆäŒ[ŽiCˆ¢•”O‘Ÿ˜YC”ó‹l‹M“oŽmC»ìŒ«“ñ : ’áo—Í‘ÌŠOÕŒ‚”gŽ¡—Â͋}«S‹Ø[ÇŒã‚̐SŽºƒŠƒ‚ƒfƒŠƒ“ƒO‚ÌŒ`¬‚ð—}§‚·‚é
‘æ7‰ñŽžŠÔzŠÂŒŒˆ³Œ€‹†‰ï (2005”N7ŒŽ16“úC“Œ‹ž)
  1. ŠÝ ‘ñ–íCœA‰ª—Ç—²C‰ºìG–ŸC’|‰º ²C»ìŒ«“ñ : ƒZƒbƒVƒ‡ƒ“ III : Šî‘b Œz“®–¬•a•Ï ”]‘²’†ˆÕ”­Ç«Ž©‘R”­Ç‚ŒŒˆ³ƒ‰ƒbƒg‚Ö‚ÌHMG-CoAŠÒŒ³y‘f‘jŠQÜ’·ŠúŒoŒû“Š—^‚É‚æ‚éŒðŠŽ_ŒoŠˆ“®—}§ì—p‚É‚š‚¯‚铪‘€‰„‘• ŠO‘€–ì‚ł̍RŽ_‰»ì—p‚ɂ‚¢‚Ä
‘æ18‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Šw‰ï“Œ–k’n•û‰ïi2005”N7ŒŽ23“úCÂX)
  1. ‚‹Ž CŠâŸº ŒOCŽÄ MsC‰z“c—ºŽiC‚‹ŽŽ–ŸCˆÉ“¡Œ’‘ŸC’†ŽR‰ë°C‘¶‘ה́C¬ŠÛ’B–çC‰Á‰ê’J–L : CYPHER—¯’u1TŠÔŒã‚ɃXƒeƒ“ƒg“àŒŒð‚ð”F‚ß‚œ1—á
¶‘Ì ¶—HŠwƒVƒ“ƒ|ƒWƒEƒ€ (2005”N9ŒŽ5-7“úC“Œ‹ž)
  1. ‰Á“¡ ^C”‹ŒŽ ®C”œ’†—R’ŒC—é–Ø—²•vC»ì˜aGCì•£³ŒÈC‹àˆä _C’·’Jì‰p”VC¬ŠâŠì˜Y : ’Ž‰¹”g‚ð—p‚¢‚œ“®–¬ŒŒŠÇ‚Ì’e«—Š•ª•zƒŠƒAƒ‹ƒ^ƒCƒ€Œv‘ªƒVƒXƒeƒ€iƒVƒ“ƒ|ƒWƒEƒ€ˆã—p‰æ‘œ‹Zp‚̐V“WŠJjReal-Time Measurement System of Arterial Wall Elasticity Distribution using Ultrasound
‘æ177‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ï (2005”N9ŒŽ10“úC·‰ª)
  1. ”’ŒË ’C‚‹Ž C™‘ºGˆê˜YC‚‹ŽŽ–ŸC›ˆä‹`®CˆÉ“¡ˆ€„C•Ÿ“c_“ñCŽÄ Ms : SƒGƒR[ŠŒ©‚É–R‚µ‚­“à‰ÈŽ¡—Ã’ïR«‚ðŽŠ‚µ‚œlH•ÙS“à–Œ‰Š‚Ì1—á
‘æ53‰ñ“ú–{S‘Ÿ•aŠw‰ïi2005”N9ŒŽ19-21“úC‘åã)
  1. ŽÂè ‹B : ƒ‚[ƒjƒ“ƒOƒZƒ~ƒi[ : S•s‘SÇ—á‚ÌŽ¡—ÃŒø‰Ê‚ðŒüã‚³‚¹‚é‚œ‚߂Ƀ`ƒFƒbƒN‚µ‚È‚­‚Ä‚Í‚¢‚¯‚È‚¢€–Ú‚Æ‚»‚̑΍ô
  2. ’双Œ€“ñC‰ºìG–ŸC“c‘ã‰pŽ÷C^‰h•œ’Œ–çCŽR–{–M•F : Š¥“®–¬ŽŸŠ³Š³ŽÒ‚ÌM-CSF, TGF-ƒÀŒŒ’†”Z“x‚ɑ΂·‚éƒVƒ“ƒoƒXƒ^ƒ`ƒ“CƒƒTƒ‹ƒ^ƒ“‚ÌŒø‰Ê
  3. ‚‹Ž CŽÂè ‹BC“n•Ó ~CŽÄ MsC•Ÿ“c_“ñC”’“y–M’j : SƒTƒ‹ƒRƒCƒh[ƒVƒXÇ‚É‚æ‚éS•s‘S‚̓XƒeƒƒCƒh—Ö@‚É‚æ‚è‰ü‘P‚·‚é‚©H
  4. ŽÄ MsCŽÂè ‹BC‚‹Ž C•Ÿ“c_“ñC‘œ“c’q—mC“n•Ó ~ : ƒVƒ“ƒ|ƒWƒEƒ€7 “ú–{l‚Ì–«S•s‘S‚Ì—\Œã‚Æmetabolic syndrome : Šg’£•s‘S‚É‚š‚¯‚鍂ŒŒˆ³Ç‚̈Ӌ`
‘æ22‰ñ“ú–{S“dŠw‰ï (2005”N10ŒŽ6“úC•xŽR)
  1. ŒF’J_ŽiCŽáŽR—TŽiC•Ÿ“c_“ñC›ˆä‹`®C‰ºìG–Ÿ : 1. L”͈͓¯‘€”xÃ–¬Šu—£p‚ðŽ{s’†œ×“®’ïR«‚̐S–[×“®‚ª’âŽ~‚µ‚Š‚œ1Ç—á
  2. ŒF’J_ŽiCŽáŽR—TŽiC•Ÿ“c_“ñC›ˆä‹`®C‰ºìG–Ÿ : 2. S–[‘e“®Ç—á‚É‚š‚¯‚éÃ–¬“ŽCCrista terminalis‚ÉŠÖ˜A‚µ‚œ‰ES–[“à‹»•±“`“±‚ÌŒŸ“¢
  3. •Ÿ“c_“ñC›ˆä‹`®CŒF’J_ŽiC‘å—F ~CŽáŽR—TŽiC”nêŒb•vCŽÂè ‹BC“n•Ó ~C”’“y–M’jC‰ºìG–Ÿ : ¶‘€•›“`“±˜H‚ªƒuƒ‹ƒKƒ_Œ^S“d}‚𑝈«‚³‚¹‚œˆê—á
‘æ22‰ñ“ú–{S“dŠw‰ï (2005”N10ŒŽ7“úC•xŽR)
  1. ŽáŽR—TŽiCŒF’J_ŽiC‘å—F ~C›ˆä‹`®C•Ÿ“c_“ñCŽÂè ‹BC“n•Ó ~CˆäŒû“ÄŽuC“c—ѝæˆêC”’“y–M’jC‰ºìG–Ÿ : A‚Šž‚ÝŒ^œ×“®Ší‚ð—p‚¢‚Ä—ŒSŽºƒy[ƒVƒ“ƒO‚ðŽ{s‚µ‚œ‰Æ‘°«Šg’£Œ^S‹ØÇ‚Ì2Ç—á
  2. ›ˆä‹`®CŒF’J_ŽiC•Ÿ“c_“ñCŽáŽR—TŽiCŽÂè ‹BC“n•Ó ~CˆäŒû“ÄŽuC“c—ѝæˆêC‰ºìG–Ÿ : ICDÄAž‚݂̍ۂɗ¯’uÏ‚ݐSŽºƒŠ[ƒh‚Ƃ̐ڐGŠ±Â‚É‚æ‚èV‹KSŽºƒŠ[ƒh‚Ì—¯’u‚ª•s”\‚Åarray lead‚ðSë•””牺‚É—¯’u‚µ‚œˆê—á
‘æ42‰ñ“ú–{—Տ°¶—Šw‰ïi2005”N10ŒŽ14-15“úC“Œ‹ž)
  1. ŽÂè ‹B : ‡–°Žž–³ŒÄ‹zÇŒóŒQ‚ƏzŠÂ¶—
‘æ9‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ï (2005”N10ŒŽ20-22“úC‰ºŠÖ)
  1. Uwatoku T, Shimokawa H, Abe K, Oi K, Hizume T, Sunagawa K. Extracorporeal cardiac shock wave therapy suppresses left ventricular remodeling after myocardial infarction in pigs.
  2. Kishi T, Hirooka Y, Masumoto A, Inokuchi K, Tagawa T, Shimokawa H, Takeshita A, Sunagawa K. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilatation of the forearm in patients with heart failure.
  3. Shinozaki T. Profile of diastolic heart failure in Japan.
  4. Shiba N, Tada T, Shinozaki T, Fukuda K, Takahashi T, Watanabe J. Beta-blocker is effective in reducing cardiovascular events in patients with chronic heart failure complicated by atrial fibrillation.
  5. Tada T, Shiba N, Shinozaki T, Takahashi J, Watanabe J, Shimokawa H. Anemia predicts sudden death in heart failure patients with preserved systolic function.
  6. Tada H, Kagaya Y, Takeda M, Ohta J, Asaumi Y, Ito K, Satoh K, Karibe A, Shirato K, Shimokawa H. Endogenous erythropoietin-erythropoietin receptor signals in non-erythroid lineage elicits cardio protective effects by preventing apoptosis after myocardial ischemia and reperfusion.
  7. Ž…ˆŸŠóŽqCŠ¡•”–Ÿ•FC‘å—F ~C²“¡Œö—YCŠâŸº ŒOC“n•Ó ~C”’“y–M’jC‰ºìG–Ÿ : Effective screening of lamin A/C Gene mutation in the familial dilated cardiomyopathy.
‘æ13‰ñ“ú–{ŒŒŠÇ¶•šˆãŠw‰ïi2005”N10ŒŽ25“úCå‘ä)
  1. ‰ºìG–Ÿ : ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[ : zŠÂŠíŽŸŠ³‚ɑ΂·‚é’áNP«æ’[ˆã—Â̊J”­
  2. ‘¶‘ה́C¬ŠÛ’B–çC•“c ’qC‚‹ŽŽ–ŸC‹à’Ë Š®C‰z“c—ºŽiC‰ºìG–Ÿ : S‹Ø—R—ˆ‚̉ߎ_‰»…‘f‚Í•p”‚É‚æ‚銥”÷¬ŒŒŠÇŠg’£‚ðŽi‚Á‚Ä‚¢‚é
  3. ‚–Ø •¶CXìŒhŽqCƒeƒPƒXƒGƒ“ƒ_[C‘ºŽR‰À”́C»ìŒ«“ñC‰ºìG–ŸCAngiotensin II–«“Š—^ƒ}ƒEƒX‚É‚š‚¢‚ÄNAD(P)H oxidase‚É‚æ‚èŽY¶‚³‚ê‚ésuperoxide‚ÍH2O2‚É‚æ‚é“à”çˆË‘¶«‰ß•ª‹É”œ‰ž‚É‚ÍŠÖ—^‚µ‚È‚¢
  4. ƒe[ƒPƒXƒGƒ“ƒ_[CXìŒhŽqC‚–Ø •¶C‘ºŽR‰À”́C“›ˆä³lC–öŒŽ‰„ÍC»ìŒ«“ñC‰ºìG–Ÿ : Genetic disruption of all nitric oxide synthase isoforms abolishes EDHF-medietaed responses in mice.
  5. ‚‹ŽŽ–ŸC¬ŠÛ’B–çC•“c ’qC•“cŽç•FC‰z“c—ºŽiC’†ŽR‰ë°Cš ¶‘ה́C‰ºìG–Ÿ : ƒÁƒgƒRƒtƒFƒ[ƒ‹‚͍‚ƒCƒ“ƒXƒŠƒ“ŒŒÇ‚É‚š‚¯‚鏝ŠQŒŒŠÇV¶“à–Œ‘B‚ð—}§‚·‚é : ƒ¿ƒgƒRƒtƒFƒ[ƒ‹‚Æ‚Ì”äŠr
‘æ9‰ñ“ú–{SŒŒŠÇ“à•ª”å‘ãŽÓŠw‰ïŠwp‘‰ï (2005”N11ŒŽ18“úC“Œ‹ž)
  1. ‚–Ø •¶Cƒe[ƒPƒXƒGƒ“ƒ_[CXìŒhŽqC‘ºŽR‰À”́C“›ˆä³lC–öŒŽ‰„ÍC‰ºìG–Ÿ : Genetic disruption of all nitric oxide synthase isoforms abolishes EDHF-mediated responses in mice.
  2. ‚–Ø •¶CXìŒhŽqCƒe[ƒPƒXƒGƒ“ƒ_[C‘ºŽR‰À”́C»ìŒ«“ñC‰ºìG–Ÿ : ƒAƒ“ƒWƒIƒeƒ“ƒVƒ“II“Š—^ƒ}ƒEƒX‚É‚š‚¯‚éNAD(P)H oxidase—R—ˆ‚Ìsuperoxide‚͉ߎ_‰»…‘f‚É‚æ‚é“à”çˆË‘¶«‰ß•ª‹É”œ‰ž‚É‚ÍŠÖ—^‚µ‚È‚¢
‘æ46‰ñ“ú–{–¬ŠÇŠw‰ïi2005”N12ŒŽ1“úC‘åã)
  1. ”ó‹l‹M“oŽmC‰ºìG–Ÿ : ŒŒŽƒRƒ‹ƒ`ƒ][ƒ‹Ž‘±‚’l‚É‚æ‚èŽä‹N‚³‚ê‚œƒuƒ^Š¥“®–¬‰ßŽûk”œ‰ž\Rho-kinaseŒo˜H‚ÌŠÖ—^\
  2. ‘¶‘ה́C¬ŠÛ’B–çC•“c ’qC‚‹ŽŽ–ŸC‹à’Ë Š®C‰z“c—ºŽiC‰ºìG–Ÿ : S‹Ø—R—ˆ‚̉ߎ_‰»…‘f‚Í•p”‚É‚æ‚銥”÷¬ŒŒŠÇŠg’£‚ðŽi‚Á‚Ä‚¢‚é
  3. ²‹vŠÔ¹mC’†‘º^ŒÎC’†Œé•¶C‹{ŒŽ‰Ã”VC“c粐MGCŽR“c“TˆêCŒIŽR‹ª”VC‘Ž}•‹`C™–{P–ŸC’†–ì æàC”’“y–M’j : ”xÇðÇf’f‚̉ۑè
  4. ²‹vŠÔ¹m : –å–¬”x‚ŒŒˆ³Ç‚̉uŠw

Œ€‹†‹ÆÑˆê——‚ց@b‚±‚̃y[ƒW‚ÌTOP‚Ö